Chr	Start	ID	Ref	Alt	#Variation	ClinVar Variation Id	Allele Registry Id	HGVS Expressions	HGNC Gene Symbol	Disease	Mondo Id	Mode of Inheritance	Assertion	Applied Evidence Codes	Summary of interpretation	PubMed Articles	Expert Panel	Guideline	Approval Date	Published Date	Retracted	Evidence Repo Link	Probability_Path	Prediction_ACMG_tapes	InterVar	 InterVar: InterVar and Evidence 	CharGer_Score	CharGer_Classification
12	103234177	576	C	T	NM_000277.2(PAH):c.1315+1G>A	576	CA251522	NM_000277.2:c.1315+1G>A, NC_000012.12:g.102840399C>T, CM000674.2:g.102840399C>T, NC_000012.11:g.103234177C>T, CM000674.1:g.103234177C>T, NC_000012.10:g.101758307C>T, NG_008690.1:g.82204G>A, NG_008690.2:g.123012G>A, NM_000277.1:c.1315+1G>A, XM_011538422.1:c.1258+1G>A, NM_001354304.1:c.1315+1G>A, NM_000277.3:c.1315+1G>A, ENST00000307000.7:c.1300+1G>A, ENST00000551114.2:n.977+1G>A, ENST00000553106.5:c.1315+1G>A, ENST00000635477.1:n.419+1G>A, ENST00000635528.1:n.830+1G>A, NM_000277.2(PAH):c.1315+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PP4-Moderate [MET], PM3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PS3: abolishes PAH activity due to protein instability (PMID:17935162; PMID:3615198); PM3: (PMID:24941924); PP4_Moderate: Reported in Galician PAH deficiency population. BH4 deficiency ruled out. (PMID:23500595); PVS1: Canonical +1 splice site. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PM3, PP4_Moderate, PVS1)."	23500595, 24941924, 17935162, 3615198	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251522/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234271	577	G	A	NM_000277.1(PAH):c.1222C>T (p.Arg408Trp)	577	CA251523	NM_000277.1:c.1222C>T, XM_011538422.1:c.1165C>T, NM_000277.2:c.1222C>T, NM_001354304.1:c.1222C>T, NM_000277.3:c.1222C>T, ENST00000307000.7:c.1207C>T, ENST00000551114.2:n.884C>T, ENST00000553106.5:c.1222C>T, ENST00000635477.1:n.326C>T, ENST00000635528.1:n.737C>T, NC_000012.12:g.102840493G>A, CM000674.2:g.102840493G>A, NC_000012.11:g.103234271G>A, CM000674.1:g.103234271G>A, NC_000012.10:g.101758401G>A, NG_008690.1:g.82110C>T, NG_008690.2:g.122918C>T, NM_000277.1(PAH):c.1222C>T (p.Arg408Trp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP3: ; PS3: PMID 17935162: Table 1: p.Arg408Trp 1.85% WT activity PMID 25596310: 1.3% activity of WT (Table S4) (PMID:25596310; PMID:17935162); PP4_Moderate: most common PAH mutation in cohort; exclude BH4 deficiency. (PMID:25596310; PMID:9634518); PM3_Strong: Detected with IVS12+1G>A, M1V (Pathogenic/LP) (PMID:9634518; PMID:1971147; PMID:1609797). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PP4_Moderate, PM3_Strong)."	9634518, 25596310, 1971147, 1609797, 9634518, 17935162, 25596310	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	6/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251523/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288534	581	G	A	NM_000277.2(PAH):c.331C>T (p.Arg111Ter)	581	CA251526	NM_000277.2:c.331C>T, NC_000012.12:g.102894756G>A, CM000674.2:g.102894756G>A, NC_000012.11:g.103288534G>A, CM000674.1:g.103288534G>A, NC_000012.10:g.101812664G>A, NG_008690.1:g.27847C>T, NG_008690.2:g.68655C>T, NM_000277.1:c.331C>T, XM_011538422.1:c.331C>T, NM_001354304.1:c.331C>T, XM_017019370.2:c.331C>T, NM_000277.3:c.331C>T, ENST00000307000.7:c.316C>T, ENST00000546844.1:c.331C>T, ENST00000548928.1:n.253C>T, ENST00000549111.5:n.427C>T, ENST00000550978.6:n.315C>T, ENST00000551337.5:c.331C>T, ENST00000551988.5:n.420C>T, ENST00000553106.5:c.331C>T, NM_000277.2(PAH):c.331C>T (p.Arg111Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PP4-Moderate [MET], PVS1 [MET], PM2 [Unmet], PM3-Very Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PP4_Moderate: Seen in multiple Chinese PKU patients. BH4 deficiency excluded. (PMID:1301187; PMID:2816939; PMID:9860305); PM3_very-strong: Detected in trans with 6 known pathogenic variants: p.R158Q; p.R241C; p.R243Q; p.E280K; p.Y356*; p.R413P (PMID:15503242, 26322415). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PP4_Moderate, PM3_very-strong)."	1301187, 9860305, 2816939, 15503242, 26322415	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251526/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246653	582	C	T	NM_000277.1(PAH):c.782G>A (p.Arg261Gln)	582	CA251528	NM_000277.1:c.782G>A, XM_011538422.1:c.782G>A, NM_000277.2:c.782G>A, NM_001354304.1:c.782G>A, NM_000277.3:c.782G>A, ENST00000307000.7:c.767G>A, ENST00000549247.6:n.541G>A, ENST00000553106.5:c.782G>A, NC_000012.12:g.102852875C>T, CM000674.2:g.102852875C>T, NC_000012.11:g.103246653C>T, CM000674.1:g.103246653C>T, NC_000012.10:g.101770783C>T, NG_008690.1:g.69728G>A, NG_008690.2:g.110536G>A, NM_000277.1(PAH):c.782G>A (p.Arg261Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM3-Very Strong [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP3: tools predict damaging; PS3: 15.5-30% activity (PMID:2014036; PMID:25596310); PM3_VeryStrong: L48S, R408W, S349P, R243X (PMID:25596310; PMID:17935162); PP4_Moderate: (PMID:25596310). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PM3_VeryStrong, PP4_Moderate)."	25596310, 17935162, 25596310, 25596310, 2014036	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251528/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
12	103246681	584	G	A	NM_000277.1(PAH):c.754C>T (p.Arg252Trp)	584	CA251529	NM_000277.1:c.754C>T, XM_011538422.1:c.754C>T, NM_000277.2:c.754C>T, NM_001354304.1:c.754C>T, NM_000277.3:c.754C>T, ENST00000307000.7:c.739C>T, ENST00000549247.6:n.513C>T, ENST00000553106.5:c.754C>T, NC_000012.12:g.102852903G>A, CM000674.2:g.102852903G>A, NC_000012.11:g.103246681G>A, CM000674.1:g.103246681G>A, NC_000012.10:g.101770811G>A, NG_008690.1:g.69700C>T, NG_008690.2:g.110508C>T, NM_000277.1(PAH):c.754C>T (p.Arg252Trp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PP4 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: gnomAD MAF: 0.00006; PP3: tools predict damaging ; PS3: 1% residual activity (PMID:25596310; PMID:17935162); PP4: Detection of codon 252arg>trp in a patient with PAH deficiency (PMID:2574153); PM3: Detected with IVS10-11G>A, R261Q, IVS12+1, R68S (all P/LP). (PMID:18299955; PMID:11524738). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4, PM3)."	11524738, 18299955, 2574153, 17935162, 25596310	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251529/MONDO:0009861/006	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310908	586	T	C	NM_000277.2(PAH):c.1A>G (p.Met1Val)	586	CA114360	NM_000277.2:c.1A>G, NC_000012.12:g.102917130T>C, CM000674.2:g.102917130T>C, NC_000012.11:g.103310908T>C, CM000674.1:g.103310908T>C, NC_000012.10:g.101835038T>C, NG_008690.1:g.5473A>G, NG_008690.2:g.46281A>G, NM_000277.1:c.1A>G, XM_011538422.1:c.1A>G, NM_001354304.1:c.1A>G, XM_017019370.2:c.1A>G, NM_000277.3:c.1A>G, ENST00000307000.7:c.-147A>G, ENST00000546844.1:c.1A>G, ENST00000547319.1:n.312A>G, ENST00000549111.5:n.97A>G, ENST00000551337.5:c.1A>G, ENST00000551988.5:n.90A>G, ENST00000553106.5:c.1A>G, ENST00000635500.1:n.29-4232A>G, NM_000277.2(PAH):c.1A>G (p.Met1Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [Unmet], PM2 [MET], PP4-Moderate [MET], PM3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: gnomAD MAF=0.00002; PP4_Moderate: Seen in PKU patients. BH4 disorders ruled out. (PMID:2574002); PS3: <3% (PMID:9450897). PM3: Detected in trans with known pathogenic variants. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM3, PP4_Moderate, PS3). Updated to reflect new PVS1 recommendations."	2574002, 2574002, 9450897	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	7/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114360/MONDO:0009861/006	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260410	587	C	T	NM_000277.2(PAH):c.473G>A (p.Arg158Gln)	587	CA251530	NM_000277.2:c.473G>A, NM_000277.1:c.473G>A, XM_011538422.1:c.473G>A, NM_001354304.1:c.473G>A, XM_017019370.2:c.473G>A, NM_000277.3:c.473G>A, ENST00000307000.7:c.458G>A, ENST00000549111.5:n.569G>A, ENST00000551988.5:n.530+10830G>A, ENST00000553106.5:c.473G>A, NC_000012.12:g.102866632C>T, CM000674.2:g.102866632C>T, NC_000012.11:g.103260410C>T, CM000674.1:g.103260410C>T, NC_000012.10:g.101784540C>T, NG_008690.1:g.55971G>A, NG_008690.2:g.96779G>A, NM_000277.2(PAH):c.473G>A (p.Arg158Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM3-Very Strong [MET], PP3 [MET], PS3 [MET], PS2 [Unmet]	"PAH-specific ACMG/AMP criteria applied: PS3: R158Q is associated with very low levels (0.2-1.8%) of pah enzyme activity compared to wild-type. (PMID:2014036; PMID:19036622); PP3: tools predict damaging ; PP4_Moderate: BH4 testing showed responsive in a pt, pretreatment 1065uM (PMID:23500595); PM3_VeryStrong: in trans with 4 pathogenic variants: I48S, c.1315+1G>A, P281L, R261Ter. (PMID:23500595; PMID:10479481; PMID:24368688). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PP3, PP4_Moderate, PM3_VeryStrong)."	23500595, 10479481, 23500595, 24368688, 19036622, 2014036	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251530/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246708	588	G	A	NM_000277.2(PAH):c.727C>T (p.Arg243Ter)	588	CA220585	NM_000277.2:c.727C>T, NM_000277.1:c.727C>T, XM_011538422.1:c.727C>T, NM_001354304.1:c.727C>T, NM_000277.3:c.727C>T, ENST00000307000.7:c.712C>T, ENST00000549247.6:n.486C>T, ENST00000553106.5:c.727C>T, NC_000012.12:g.102852930G>A, CM000674.2:g.102852930G>A, NC_000012.11:g.103246708G>A, CM000674.1:g.103246708G>A, NC_000012.10:g.101770838G>A, NG_008690.1:g.69673C>T, NG_008690.2:g.110481C>T, NM_000277.2(PAH):c.727C>T (p.Arg243Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: nonsense variant; PS3: <1% of normal PAH activity (PMID:2014036). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PS3)."	2014036	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	7/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220585/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246593	589	G	A	NM_000277.1(PAH):c.842C>T (p.Pro281Leu)	589	CA220589	NM_000277.1:c.842C>T, NC_000012.12:g.102852815G>A, CM000674.2:g.102852815G>A, NC_000012.11:g.103246593G>A, CM000674.1:g.103246593G>A, NC_000012.10:g.101770723G>A, NG_008690.1:g.69788C>T, NG_008690.2:g.110596C>T, XM_011538422.1:c.842C>T, NM_000277.2:c.842C>T, NM_001354304.1:c.842C>T, NM_000277.3:c.842C>T, ENST00000307000.7:c.827C>T, ENST00000549247.6:n.601C>T, ENST00000553106.5:c.842C>T, ENST00000635477.1:n.3C>T, NM_000277.1(PAH):c.842C>T (p.Pro281Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP3: ; PS3: 2% activity in bioPKU (PAH0309) (PMID:25596310; PMID:17935162); PP4_Moderate: 2 patients with moderate or classical PKU; patients with severe PKU. BH4 deficiency ruled out. (PMID:15503242; PMID:12655553); PM3: IVS4-1G>A (P/LP) (PMID:15503242). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PP4_Moderate, PM3)."	12655553, 15503242, 15503242, 17935162, 25596310	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	27/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220589/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234255	592	C	G	NM_000277.1(PAH):c.1238G>C (p.Arg413Pro)	592	CA229414	NM_000277.1:c.1238G>C, NC_000012.12:g.102840477C>G, CM000674.2:g.102840477C>G, NC_000012.11:g.103234255C>G, CM000674.1:g.103234255C>G, NC_000012.10:g.101758385C>G, NG_008690.1:g.82126G>C, NG_008690.2:g.122934G>C, XM_011538422.1:c.1181G>C, NM_000277.2:c.1238G>C, NM_001354304.1:c.1238G>C, NM_000277.3:c.1238G>C, ENST00000307000.7:c.1223G>C, ENST00000551114.2:n.900G>C, ENST00000553106.5:c.1238G>C, ENST00000635477.1:n.342G>C, ENST00000635528.1:n.753G>C, NM_000277.1(PAH):c.1238G>C (p.Arg413Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PS3: In vitro expression of altered protein in COS cells produces severe decrease of PAH activity (<3%); PM2: Extremely low frequency. ExAC MAF=0.00012; PP4_Moderate: Detected in PKU patients, BH4 deficiency excluded; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.895; PM3: Detected with V388M (pathogenic) in 2 patients (PMID:9860305; PMID:21307867). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PM2, PP4_Moderate, PP3, PM3)."	21307867, 9860305	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229414/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234252	593	T	C	NM_000277.1(PAH):c.1241A>G (p.Tyr414Cys)	593	CA114362	NM_000277.1:c.1241A>G, XM_011538422.1:c.1184A>G, NM_000277.2:c.1241A>G, NM_001354304.1:c.1241A>G, NM_000277.3:c.1241A>G, ENST00000307000.7:c.1226A>G, ENST00000551114.2:n.903A>G, ENST00000553106.5:c.1241A>G, ENST00000635477.1:n.345A>G, ENST00000635528.1:n.756A>G, NC_000012.12:g.102840474T>C, CM000674.2:g.102840474T>C, NC_000012.11:g.103234252T>C, CM000674.1:g.103234252T>C, NC_000012.10:g.101758382T>C, NG_008690.1:g.82129A>G, NG_008690.2:g.122937A>G, NM_000277.1(PAH):c.1241A>G (p.Tyr414Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [MET], PM3-Very Strong [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM5: c.1240T>C likely pathogenic in ClinVar; PP3: All computational evidence supports deleterious effect. REVEL=0.982; PS3: 50% activity, 50% immunoreactivity (PMID:2044609); PM3_VeryStrong: Patient #41 p.R408W / p.Y414C, Phe 744 @dx and two homozygous individuals. Total of 9 patients with this variant (PMID:22526846; PMID:17935162; PMID:9399896; PMID:21871829; PMID:26542770); PP4_Moderate: BH4 defect excluded in all patients (PMID:22526846). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP3, PS3, PM3_VeryStrong, PP4_Moderate)."	22526846, 22526846, 17935162, 9399896, 26542770, 21871829, 2044609	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	27/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114362/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260442	594	C	T	NM_000277.1(PAH):c.442-1G>A	594	CA229550	NM_000277.1:c.442-1G>A, NC_000012.12:g.102866664C>T, CM000674.2:g.102866664C>T, NC_000012.11:g.103260442C>T, CM000674.1:g.103260442C>T, NC_000012.10:g.101784572C>T, NG_008690.1:g.55939G>A, NG_008690.2:g.96747G>A, XM_011538422.1:c.442-1G>A, NM_000277.2:c.442-1G>A, NM_001354304.1:c.442-1G>A, XM_017019370.2:c.442-1G>A, NM_000277.3:c.442-1G>A, ENST00000307000.7:c.427-1G>A, ENST00000549111.5:n.538-1G>A, ENST00000551988.5:n.530+10798G>A, ENST00000553106.5:c.442-1G>A, NM_000277.1(PAH):c.442-1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4-Moderate [MET], PM3 [Unmet], PS3 [Unmet]	"PAH-specific ACMG/AMP criteria applied: PM2: Not present in ExAC or 1000 genomes (PMID:9860305); PVS1: Canonical -1 splice site where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 5 is present in biologically-relevant transcript. PP4_Moderate: Reported in a mild PKU patient. BH4 deficiency assessed. (PMID:14681498). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4_Moderate)."	9860305, 14681498, 14681498, 21307867, 14681498	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229550/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237555	595	G	C	NM_000277.2(PAH):c.1068C>G (p.Tyr356Ter)	595	CA229327	NM_000277.2:c.1068C>G, NC_000012.12:g.102843777G>C, CM000674.2:g.102843777G>C, NC_000012.11:g.103237555G>C, CM000674.1:g.103237555G>C, NC_000012.10:g.101761685G>C, NG_008690.1:g.78826C>G, NG_008690.2:g.119634C>G, NM_000277.1:c.1068C>G, XM_011538422.1:c.1011C>G, NM_001354304.1:c.1068C>G, NM_000277.3:c.1068C>G, ENST00000307000.7:c.1053C>G, ENST00000549247.6:n.827C>G, ENST00000551114.2:n.730C>G, ENST00000553106.5:c.1068C>G, ENST00000635477.1:n.172C>G, ENST00000635528.1:n.583C>G, NM_000277.2(PAH):c.1068C>G (p.Tyr356Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4-Moderate [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: ExAC MAF:0.00006.; PP4_Moderate: seen in classic and mild PKU patients. BH4 deficiency excluded.. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	7/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229327/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246621	596	C	A	NM_000277.1(PAH):c.814G>T (p.Gly272Ter)	596	CA251532	NM_000277.1:c.814G>T, XM_011538422.1:c.814G>T, NM_000277.2:c.814G>T, NM_001354304.1:c.814G>T, NM_000277.3:c.814G>T, ENST00000307000.7:c.799G>T, ENST00000549247.6:n.573G>T, ENST00000553106.5:c.814G>T, NC_000012.12:g.102852843C>A, CM000674.2:g.102852843C>A, NC_000012.11:g.103246621C>A, CM000674.1:g.103246621C>A, NC_000012.10:g.101770751C>A, NG_008690.1:g.69760G>T, NG_008690.2:g.110568G>T, NM_000277.1(PAH):c.814G>T (p.Gly272Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extrememly low frequency in ExAC, gnomAD (MAF= 0.00006, 0.0003093); PVS1: Nonsense variant. Predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay.; PP4: G272X found on one allele of a patient with classic PKU (PMID:1975559). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4)."	1975559	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251532/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237528	597	GAGA	G	NM_000277.2(PAH):c.1092_1094del (p.Leu365del)	597	CA229337	NM_000277.2:c.1092_1094del, NC_000012.12:g.102843753_102843755del, CM000674.2:g.102843753_102843755del, NC_000012.11:g.103237531_103237533del, CM000674.1:g.103237531_103237533del, NC_000012.10:g.101761661_101761663del, NG_008690.1:g.78850_78852del, NG_008690.2:g.119658_119660del, NM_000277.1:c.1092_1094del, XM_011538422.1:c.1035_1037del, NM_001354304.1:c.1092_1094del, NM_000277.3:c.1092_1094del, ENST00000307000.7:c.1077_1079del, ENST00000549247.6:n.851_853del, ENST00000551114.2:n.754_756del, ENST00000553106.5:c.1092_1094del, ENST00000635477.1:n.196_198del, ENST00000635528.1:n.607_609del, NM_000277.2(PAH):c.1092_1094del (p.Leu365del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM4 [MET], PM3 [MET], PP4 [MET]	"The c.1092_1094delTCT variant in PAH has been previously reported as a single variant, found in trans with the Pathogenic variant (per internal PAH ClinGen Working Group classification, see ClinVar allele ID 15635) p.Gly272Ter in one proband with classic PKU (PMID: 1975559); phase was confirmed via parental testing (PM3). Apart from stating that the proband was identified via newborn screening further detail is provided regarding the probandâ€™s phenotype, including whether BH4 deficiency was formally excluded (PP4?). The variant is a protein-length changing variant in a non-repeat region (PM4). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2)."	1975559, 1975559	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229337/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246617	598	G	A	NM_000277.2(PAH):c.818C>T (p.Ser273Phe)	598	CA229785	NM_000277.2:c.818C>T, NM_000277.1:c.818C>T, XM_011538422.1:c.818C>T, NM_001354304.1:c.818C>T, NM_000277.3:c.818C>T, ENST00000307000.7:c.803C>T, ENST00000549247.6:n.577C>T, ENST00000553106.5:c.818C>T, NC_000012.12:g.102852839G>A, CM000674.2:g.102852839G>A, NC_000012.11:g.103246617G>A, CM000674.1:g.103246617G>A, NC_000012.10:g.101770747G>A, NG_008690.1:g.69764C>T, NG_008690.2:g.110572C>T, NM_000277.2(PAH):c.818C>T (p.Ser273Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC and gnomAD (1 allele); PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.978; PP4_Moderate: S273F was detected in in Northern Ireland, Belgium/French, Western Scotland, and New South Wales PKU patients. BH4 deficiency was assessed in 1 study. Upgraded per ClinGen Metabolic workgroup. (PMID:1671881; PMID:8533759; PMID:9012412; PMID:24368688); PM3_Strong: Seen with 2 known pathogenic mutations: I65T, R408W. Upgraded based on SVI worgroup recommendations and approved PAH guidelines (PMID:24368688). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong)."	1671881, 24368688, 9012412, 8533759, 24368688	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229785/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246592	599	C	T	NM_000277.2(PAH):c.842+1G>A	599	CA229811	NM_000277.2:c.842+1G>A, NM_000277.1:c.842+1G>A, XM_011538422.1:c.842+1G>A, NM_001354304.1:c.842+1G>A, NM_000277.3:c.842+1G>A, ENST00000307000.7:c.827+1G>A, ENST00000549247.6:n.601+1G>A, ENST00000553106.5:c.842+1G>A, ENST00000635477.1:n.3+1G>A, NC_000012.12:g.102852814C>T, CM000674.2:g.102852814C>T, NC_000012.11:g.103246592C>T, CM000674.1:g.103246592C>T, NC_000012.10:g.101770722C>T, NG_008690.1:g.69789G>A, NG_008690.2:g.110597G>A, NM_000277.2(PAH):c.842+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Canonical +1 splice site; PM2: gnomAD MAF 0.00008; PP4: Reported in 3 PKU populations: Slovak, Germany, Italy (PMID:1671810; PMID:10394930; PMID:23764561); PM3: (PMID:20188615; PMID:24941924). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4, PM3)."	24941924, 20188615, 10394930, 23764561, 1671810	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229811/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237426	601	T	A	NM_000277.1(PAH):c.1197A>T (p.Val399=)	601	CA229379	NM_000277.1:c.1197A>T, XM_011538422.1:c.1140A>T, NM_000277.2:c.1197A>T, NM_001354304.1:c.1197A>T, NM_000277.3:c.1197A>T, ENST00000307000.7:c.1182A>T, ENST00000549247.6:n.956A>T, ENST00000551114.2:n.859A>T, ENST00000553106.5:c.1197A>T, ENST00000635477.1:n.301A>T, ENST00000635528.1:n.712A>T, NC_000012.12:g.102843648T>A, CM000674.2:g.102843648T>A, NC_000012.11:g.103237426T>A, CM000674.1:g.103237426T>A, NC_000012.10:g.101761556T>A, NG_008690.1:g.78955A>T, NG_008690.2:g.119763A>T, NM_000277.1(PAH):c.1197A>T (p.Val399=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PS3 [MET]	"The c.1197A>T (p.Val399=) variant in PAH has been reported on 7 alleles of PKU patients (BH4 deficiency excluded). (PP4_Moderate; PMID: 23271928; PMID: 11214902). This variant has an extremely low allele frequency (0.000004064) in gnomAD (PM2; http://gnomAD.broadinstitute.org). This variant induces post-transcriptional skipping of exon 11 (PS3; PMID: 11214902). This variant was detected in trans with R408W (Pathogenic in ClinVar) (PM3; PMID: 11214902). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate"	23271928, 11214902, 11214902, 11214902	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	28/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229379/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246606	603	A	C	NM_000277.2(PAH):c.829T>G (p.Tyr277Asp)	603	CA251534	NM_000277.2:c.829T>G, NM_000277.1:c.829T>G, XM_011538422.1:c.829T>G, NM_001354304.1:c.829T>G, NM_000277.3:c.829T>G, ENST00000307000.7:c.814T>G, ENST00000549247.6:n.588T>G, ENST00000553106.5:c.829T>G, NC_000012.12:g.102852828A>C, CM000674.2:g.102852828A>C, NC_000012.11:g.103246606A>C, CM000674.1:g.103246606A>C, NC_000012.10:g.101770736A>C, NG_008690.1:g.69775T>G, NG_008690.2:g.110583T>G, NM_000277.2(PAH):c.829T>G (p.Tyr277Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PS3 [MET]	"The c.829T>G (p.Tyr277Asp) variant in PAH has been reported in 2 individuals with Classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 8268925; PMID: 23500595). This variant has an extremely low allele frequency (1/121400) in ExAC (PM2; http://exac.broadinstitute.org). This variant has 0% enzyme activity (PS3; http://www.biopku.org/centralStore/biopku/PAH%20activity.pdf). This variant was detected in trans with L48S (Pathogenic in ClinVar) (PM3; PMID: 23500595). Computational prediction tools and conservation analysis suggest that the c.829T>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3"	23500595, 8268925, 23500595	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251534/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237568	607	C	T	NM_000277.1(PAH):c.1066-11G>A	607	CA251538	NM_000277.1:c.1066-11G>A, XM_011538422.1:c.1009-11G>A, NM_000277.2:c.1066-11G>A, NM_001354304.1:c.1066-11G>A, NM_000277.3:c.1066-11G>A, ENST00000307000.7:c.1051-11G>A, ENST00000549247.6:n.825-11G>A, ENST00000551114.2:n.728-11G>A, ENST00000553106.5:c.1066-11G>A, ENST00000635477.1:n.170-11G>A, ENST00000635528.1:n.581-11G>A, NC_000012.12:g.102843790C>T, CM000674.2:g.102843790C>T, NC_000012.11:g.103237568C>T, CM000674.1:g.103237568C>T, NC_000012.10:g.101761698C>T, NG_008690.1:g.78813G>A, NG_008690.2:g.119621G>A, NM_000277.1(PAH):c.1066-11G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PM3-Strong [MET], PS3 [MET]	"The c.1066-11G>A variant in PAH has been reported in > 76 PKU alleles (BH4 deficiency excluded). (PP4_Moderate; PMID: 23500595; PMID: 8990013). This variant has 0% enzyme activity (PS3; http://www.biopku.org/centralStore/biopku/PAH%20activity.pdf). This variant was detected in trans with multiple known pathogenic variants: p.R243Q, p.R243X, p.R261Q, p.R270K, p.I65T. (PM3_Strong; PMID: 23500595; PMID: 8990013). Computational prediction tools and conservation analysis suggest that the c.1066-11G>A variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Strong"	8990013, 23500595, 8990013, 23500595, 1769645	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	1/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251538/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306594	608	A	G	NM_000277.2(PAH):c.143T>C (p.Leu48Ser)	608	CA251539	NM_000277.2:c.143T>C, NM_000277.1:c.143T>C, XM_011538422.1:c.143T>C, NM_001354304.1:c.143T>C, XM_017019370.2:c.143T>C, NM_000277.3:c.143T>C, ENST00000307000.7:c.128T>C, ENST00000546844.1:c.143T>C, ENST00000548677.2:n.230T>C, ENST00000548928.1:n.65T>C, ENST00000549111.5:n.239T>C, ENST00000550978.6:n.127T>C, ENST00000551337.5:c.143T>C, ENST00000551988.5:n.232T>C, ENST00000553106.5:c.143T>C, ENST00000635500.1:n.111T>C, NC_000012.12:g.102912816A>G, CM000674.2:g.102912816A>G, NC_000012.11:g.103306594A>G, CM000674.1:g.103306594A>G, NC_000012.10:g.101830724A>G, NG_008690.1:g.9787T>C, NG_008690.2:g.50595T>C, NM_000277.2(PAH):c.143T>C (p.Leu48Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PP1 [MET], PS3 [MET]	"The c.143T>C (p.Leu48Ser) variant in PAH has been reported multiple individuals with mild and classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 26322415, 16879198, 1679030). This variant has a frequency that is higher than the suggested cutoff for PM2 by the PAH VCEP (MAF=0.00026). This variant has 39% residual activity (PS3, PMID: 17935162). This variant was detected in trans with p.G247R (LP, 2 submitters) PM3, PMID: 26322415). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). Cosegregation with PKU in 2 siblings for 2 unrelated families was reported ( PMID: 23430547). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3, PP1, PP3."	26322415, 1679030, 16879198, 26322415, 23430547, 17935162	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251539/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246654	610	G	A	NM_000277.1(PAH):c.781C>T (p.Arg261Ter)	610	CA229757	NM_000277.1:c.781C>T, XM_011538422.1:c.781C>T, NM_000277.2:c.781C>T, NM_001354304.1:c.781C>T, NM_000277.3:c.781C>T, ENST00000307000.7:c.766C>T, ENST00000549247.6:n.540C>T, ENST00000553106.5:c.781C>T, NC_000012.12:g.102852876G>A, CM000674.2:g.102852876G>A, NC_000012.11:g.103246654G>A, CM000674.1:g.103246654G>A, NC_000012.10:g.101770784G>A, NG_008690.1:g.69727C>T, NG_008690.2:g.110535C>T, NM_000277.1(PAH):c.781C>T (p.Arg261Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PM3 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PP4: Detected in 2 unrelated patients (PMID:1682234); PM3: Detected with H170D, pathogenic (PMID:11385716). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PP4, PM3)."	11385716, 1682234	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229757/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306571	611	CA	C	NM_000277.2(PAH):c.165delT (p.Phe55Leufs)	611	CA251540	NC_000012.12:g.102912796del, CM000674.2:g.102912796del, NC_000012.11:g.103306574del, CM000674.1:g.103306574del, NC_000012.10:g.101830704del, NG_008690.1:g.9809del, NG_008690.2:g.50617del, NM_000277.1:c.165del, XM_011538422.1:c.165del, NM_000277.2:c.165del, NM_001354304.1:c.165del, XM_017019370.2:c.165del, NM_000277.3:c.165del, ENST00000307000.7:c.150del, ENST00000546844.1:c.165del, ENST00000548677.2:n.252del, ENST00000548928.1:n.87del, ENST00000549111.5:n.261del, ENST00000550978.6:n.149del, ENST00000551337.5:c.165del, ENST00000551988.5:n.254del, ENST00000553106.5:c.165del, ENST00000635500.1:n.133del, NM_000277.2(PAH):c.165delT (p.Phe55Leufs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	The c.165delT (p.F55Lfs*6) is a frameshift variant in exon 2 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in compound heterozygote state in multiple patients with PKU (BH4 deficiency not excluded) (PMID: 1682235 & 23500595). The variants in trans include: R408W, and R261Q, both confirmed pathogenic.This variant has an extremely low allele frequency in the Genome Aggregation database (3/251384) (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria: PM2, PP4, PVS1.	1682235, 23500595	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251540/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234270	612	C	T	NM_000277.1(PAH):c.1223G>A (p.Arg408Gln)	612	CA229404	NM_000277.1:c.1223G>A, NC_000012.12:g.102840492C>T, CM000674.2:g.102840492C>T, NC_000012.11:g.103234270C>T, CM000674.1:g.103234270C>T, NC_000012.10:g.101758400C>T, NG_008690.1:g.82111G>A, NG_008690.2:g.122919G>A, XM_011538422.1:c.1166G>A, NM_000277.2:c.1223G>A, NM_001354304.1:c.1223G>A, NM_000277.3:c.1223G>A, ENST00000307000.7:c.1208G>A, ENST00000551114.2:n.885G>A, ENST00000553106.5:c.1223G>A, ENST00000635477.1:n.327G>A, ENST00000635528.1:n.738G>A, NM_000277.1(PAH):c.1223G>A (p.Arg408Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PP3 [MET], PS3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM3_Strong: In trans with R408W, IVS4-1G>A, R241C (ClinGen, P) (PMID:1312992; PMID:14722928); PP3: ; PS3: Mutant enzyme activity of 46% in BioPKU (PMID:9860305); PP4_Moderate: ~830 uml/L w/o BH4 deficiency & 823 umol/L, BH4 status unknown (PMID:9860305; PMID:1312992). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM3_Strong, PP3, PS3, PP4_Moderate)."	1312992, 9860305, 9860305, 1312992, 14722928	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229404/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234250	617	C	T	NM_000277.1(PAH):c.1243G>A (p.Asp415Asn)	617	CA114364	NM_000277.1:c.1243G>A, NC_000012.12:g.102840472C>T, CM000674.2:g.102840472C>T, NC_000012.11:g.103234250C>T, CM000674.1:g.103234250C>T, NC_000012.10:g.101758380C>T, NG_008690.1:g.82131G>A, NG_008690.2:g.122939G>A, XM_011538422.1:c.1186G>A, NM_000277.2:c.1243G>A, NM_001354304.1:c.1243G>A, NM_000277.3:c.1243G>A, ENST00000307000.7:c.1228G>A, ENST00000551114.2:n.905G>A, ENST00000553106.5:c.1243G>A, ENST00000635477.1:n.347G>A, ENST00000635528.1:n.758G>A, NM_000277.1(PAH):c.1243G>A (p.Asp415Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [Unmet], PS3 [Unmet]	"The c.1243G>A (p.Asp415Asn) variant in PAH has been reported in 3 patients with Hyperphenylalaninemia (BH4 deficiency excluded). (PP4_Moderate; PMID: 1358789). This variant has an extremely low allele frequency (0.0001097 in gnomAD) (PM2; http://gnomad.broadinstitute.org). This variant was detected in trans with R408W, F39L, Y414C, IVS10-11G>A (Pathogenic in ClinVar) (PM3_Very-strong; PMID: 1358789; PMID: 12501224; PMID: 18299955). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong"	1358789, 1358789, 12501224, 18299955, 11161839	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	12/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114364/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103240726	618	T	C	NM_000277.1(PAH):c.916A>G (p.Ile306Val)	618	CA114365	NM_000277.1:c.916A>G, XM_011538422.1:c.913-2517A>G, NM_000277.2:c.916A>G, NM_001354304.1:c.916A>G, NM_000277.3:c.916A>G, ENST00000307000.7:c.901A>G, ENST00000549247.6:n.675A>G, ENST00000551114.2:n.578A>G, ENST00000553106.5:c.916A>G, ENST00000635477.1:n.74-2517A>G, ENST00000635528.1:n.431A>G, NC_000012.12:g.102846948T>C, CM000674.2:g.102846948T>C, NC_000012.11:g.103240726T>C, CM000674.1:g.103240726T>C, NC_000012.10:g.101764856T>C, NG_008690.1:g.75655A>G, NG_008690.2:g.116463A>G, NM_000277.1(PAH):c.916A>G (p.Ile306Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: MAF = 2.0e-5; PP3: Software agrees on a damaging effect.; PS3: Mutation ID#1, 18% residual enzyme activity (PMID:18590700); PM3: I306V / F55L (pathogenic in ClinVar) in a single patient with mild HPA (PMID:18299955); PP4_Moderate: BH4 defect excluded in all patients--single patient with mild hyperphe (Bercovich, 2008). (PMID:18299955). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4_Moderate)."	18299955, 18299955, 18590700	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114365/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237461	619	C	T	NM_000277.1(PAH):c.1162G>A (p.Val388Met)	619	CA251543	NM_000277.1:c.1162G>A, XM_011538422.1:c.1105G>A, NM_000277.2:c.1162G>A, NM_001354304.1:c.1162G>A, NM_000277.3:c.1162G>A, ENST00000307000.7:c.1147G>A, ENST00000549247.6:n.921G>A, ENST00000551114.2:n.824G>A, ENST00000553106.5:c.1162G>A, ENST00000635477.1:n.266G>A, ENST00000635528.1:n.677G>A, NC_000012.12:g.102843683C>T, CM000674.2:g.102843683C>T, NC_000012.11:g.103237461C>T, CM000674.1:g.103237461C>T, NC_000012.10:g.101761591C>T, NG_008690.1:g.78920G>A, NG_008690.2:g.119728G>A, NM_000277.1(PAH):c.1162G>A (p.Val388Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM3 [MET], PP3 [MET], PP4 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low in ExAC and 1000 genomes (PMID:9860305); PS3: PAH activity in COS cell expression system 15% (PMID:9860305); PM3: Compound het with severe mutation (PMID:9860305); PP3: ; PP4: Reported in patient with classic PKU (PMID:9860305). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PS3, PM3, PP3, PP4)."	9860305, 9860305, 9860305, 9860305	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251543/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103237454	625	T	C	NM_000277.1(PAH):c.1169A>G (p.Glu390Gly)	625	CA114367	NM_000277.1:c.1169A>G, NC_000012.12:g.102843676T>C, CM000674.2:g.102843676T>C, NC_000012.11:g.103237454T>C, CM000674.1:g.103237454T>C, NC_000012.10:g.101761584T>C, NG_008690.1:g.78927A>G, NG_008690.2:g.119735A>G, XM_011538422.1:c.1112A>G, NM_000277.2:c.1169A>G, NM_001354304.1:c.1169A>G, NM_000277.3:c.1169A>G, ENST00000307000.7:c.1154A>G, ENST00000549247.6:n.928A>G, ENST00000551114.2:n.831A>G, ENST00000553106.5:c.1169A>G, ENST00000635477.1:n.273A>G, ENST00000635528.1:n.684A>G, NM_000277.1(PAH):c.1169A>G (p.Glu390Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3-Very Strong [MET], PP3 [MET], PS3 [Unmet]	"The c.1169A>G (p.Glu390Gly) variant in PAH has been reported on at least 47 alleles, most often with Mild Hyperphenylalaninemia. (BH4 deficiency excluded). (PP4_Moderate; PMID: 8088845; PMID: 21147011). This variant has an extremely low allele frequency (MAF=0.00018 in gnomAD) (PM2; http://gnomAD.broadinstitute.org). This variant was detected in trans with IVS-12nt1, L333F (Pathogenic in ClinVar) + 8 homozygotes (PM3_Very-strong; PMID: 10479481; PMID: 21147011; PMID: 8088845). Computational prediction tools and conservation analysis suggest that the c.1169A>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong"	21147011, 8088845, 21147011, 8088845, 10479481, 21147011, 10479481	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	1/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114367/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103288572	627	A	G	NM_000277.2(PAH):c.293T>C (p.Leu98Ser)	627	CA114368	NM_000277.2:c.293T>C, NM_000277.1:c.293T>C, XM_011538422.1:c.293T>C, NM_001354304.1:c.293T>C, XM_017019370.2:c.293T>C, NM_000277.3:c.293T>C, ENST00000307000.7:c.278T>C, ENST00000546844.1:c.293T>C, ENST00000548928.1:n.215T>C, ENST00000549111.5:n.389T>C, ENST00000550978.6:n.277T>C, ENST00000551337.5:c.293T>C, ENST00000551988.5:n.382T>C, ENST00000553106.5:c.293T>C, NC_000012.12:g.102894794A>G, CM000674.2:g.102894794A>G, NC_000012.11:g.103288572A>G, CM000674.1:g.103288572A>G, NC_000012.10:g.101812702A>G, NG_008690.1:g.27809T>C, NG_008690.2:g.68617T>C, NM_000277.2(PAH):c.293T>C (p.Leu98Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PP3 [MET]	"The c.293T>C (p.Leu98Ser) variant in PAH has been reported in a Pakistani patient with non-PKU hyperphenylalaninemia (BH4 deficiency excluded) (PP4_Moderate; PMID: 8364546, 9634518) This variant is absent from 1000G and ESP, and has an extremely low frequency in ExAC and gnomAD (MAF=0.00016). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.846. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3."	8364546, 9634518	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114368/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237484	628	G	A	NM_000277.1(PAH):c.1139C>T (p.Thr380Met)	628	CA114369	NM_000277.1:c.1139C>T, XM_011538422.1:c.1082C>T, NM_000277.2:c.1139C>T, NM_001354304.1:c.1139C>T, NM_000277.3:c.1139C>T, ENST00000307000.7:c.1124C>T, ENST00000549247.6:n.898C>T, ENST00000551114.2:n.801C>T, ENST00000553106.5:c.1139C>T, ENST00000635477.1:n.243C>T, ENST00000635528.1:n.654C>T, NC_000012.12:g.102843706G>A, CM000674.2:g.102843706G>A, NC_000012.11:g.103237484G>A, CM000674.1:g.103237484G>A, NC_000012.10:g.101761614G>A, NG_008690.1:g.78897C>T, NG_008690.2:g.119705C>T, NM_000277.1(PAH):c.1139C>T (p.Thr380Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [MET], PS3 [MET]	"The c.1139C>T (p.Thr380Met) variant in PAH has been reported in 1 patient with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate; PMID: 8268925). This variant has 28% enzyme activity (PS3; PMID: 27620137). This variant was detected in trans with multiple known pathogenic variants: R408W, R261Q, I65T, F299C (PM3_Very-strong; PMID: 7981714). Computational prediction tools and conservation analysis suggest that the c.1139C>T variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Very-strong"	8268925, 7981714, 27620137	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	1/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114369/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246701	632	A	G	NM_000277.2(PAH):c.734T>C (p.Val245Ala)	632	CA114372	NM_000277.2:c.734T>C, NM_000277.1:c.734T>C, XM_011538422.1:c.734T>C, NM_001354304.1:c.734T>C, NM_000277.3:c.734T>C, ENST00000307000.7:c.719T>C, ENST00000549247.6:n.493T>C, ENST00000553106.5:c.734T>C, NC_000012.12:g.102852923A>G, CM000674.2:g.102852923A>G, NC_000012.11:g.103246701A>G, CM000674.1:g.103246701A>G, NC_000012.10:g.101770831A>G, NG_008690.1:g.69680T>C, NG_008690.2:g.110488T>C, NM_000277.2(PAH):c.734T>C (p.Val245Ala)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [MET], PM3-Very Strong [MET], PP3 [Unmet], PS3 [Unmet]	"PAH-specific ACMG/AMP criteria applied: PM5: V245L Pathogenic; PP4_Moderate: Seen in at least 7 MHP patients. Exclusion of a defect in tetrahydrobiopterin metabolism. Upgraded per ClinGen Metabolic Workgroup. (PMID:7981714; PMID:9298832; PMID:9634518); PM3_VeryStrong: V245A detected with IVS-12nt1, R252W, L194P (both P/LP), R408W (Path). Upgraded per ClinGen SVI Workgroup (PMID:7981714; PMID:9298832; PMID:8088845). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP4_Moderate, PM3_VeryStrong)."	9298832, 9634518, 7981714, 8088845, 9298832, 7981714, 11161839	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA114372/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103238111	633	T	C	NM_000277.2(PAH):c.1065+3A>G	633	CA212751	NM_000277.2:c.1065+3A>G, NM_000277.1:c.1065+3A>G, XM_011538422.1:c.1008+3A>G, NM_001354304.1:c.1065+3A>G, NM_000277.3:c.1065+3A>G, ENST00000307000.7:c.1050+3A>G, ENST00000549247.6:n.824+3A>G, ENST00000551114.2:n.727+3A>G, ENST00000553106.5:c.1065+3A>G, ENST00000635477.1:n.169+3A>G, ENST00000635528.1:n.580+3A>G, NC_000012.12:g.102844333T>C, CM000674.2:g.102844333T>C, NC_000012.11:g.103238111T>C, CM000674.1:g.103238111T>C, NC_000012.10:g.101762241T>C, NG_008690.1:g.78270A>G, NG_008690.2:g.119078A>G, NM_000277.2(PAH):c.1065+3A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM3 [MET], PP3 [MET], PP4 [MET], PP1 [MET]	"The c.1065+3A>G variant in PAH was detected in 2 siblings with an increased serum Phenylalanine level of 365 uM. BH4 deficiency was not assessed/reported. (PMID: 8088845) They were compound heterozygous for Y414C. The c.1065+3A>G variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted for this variant in HSF and MaxEnt (Alteration of the WT donor site; activation of an intronic cryptic donor site). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP1, PP3, PP4."	8088845, 8088845, 8088845	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA212751/MONDO:0009861/006	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288671	636	A	G	NM_000277.2(PAH):c.194T>C (p.Ile65Thr)	636	CA251544	NM_000277.2:c.194T>C, NC_000012.12:g.102894893A>G, CM000674.2:g.102894893A>G, NC_000012.11:g.103288671A>G, CM000674.1:g.103288671A>G, NC_000012.10:g.101812801A>G, NG_008690.1:g.27710T>C, NG_008690.2:g.68518T>C, NM_000277.1:c.194T>C, XM_011538422.1:c.194T>C, NM_001354304.1:c.194T>C, XM_017019370.2:c.194T>C, NM_000277.3:c.194T>C, ENST00000307000.7:c.179T>C, ENST00000546844.1:c.194T>C, ENST00000548677.2:n.281T>C, ENST00000548928.1:n.116T>C, ENST00000549111.5:n.290T>C, ENST00000550978.6:n.178T>C, ENST00000551337.5:c.194T>C, ENST00000551988.5:n.283T>C, ENST00000553106.5:c.194T>C, ENST00000635500.1:n.162T>C, NM_000277.2(PAH):c.194T>C (p.Ile65Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [MET], PP1 [Unmet], PS1 [Unmet], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM3_VeryStrong: Detected with Y414C (P), R408W (P), P281L (P), IVS10nt-11 (P), R252W (P/LP), and R243Q(P). (PMID:12501224; PMID:1301201; PMID:10767174); PP3: Predicted dleterious in SIZFT, Polyphen2, MutationTaster. REVEL=0.985; PP4_Moderate: Detected in a patient with mild PKU. BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:12501224); PS3: 25% mutant enzyme activity in COS cells as compared in wt (PMID:1301201). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM3_VeryStrong, PP3, PP4_Moderate, PS3)."	21871829, 12501224, 10767174, 1301201, 12501224, 1301201	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	21/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA251544/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	216363621	2353	CAG	C	NM_007123.5(USH2A):c.4338_4339delCT (p.Cys1447Glnfs)	2353	CA252228	NM_007123.5:c.4338_4339delCT, NC_000001.11:g.216190284_216190285del, CM000663.2:g.216190284_216190285del, NC_000001.10:g.216363626_216363627del, CM000663.1:g.216363626_216363627del, NC_000001.9:g.214430249_214430250del, NG_009497.1:g.238116_238117del, NM_007123.5:c.4338_4339del, NM_206933.2:c.4338_4339del, NM_206933.3:c.4338_4339del, ENST00000307340.7:c.4338_4339del, ENST00000366942.3:c.4338_4339del, NM_007123.5(USH2A):c.4338_4339delCT (p.Cys1447Glnfs)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PP1-Moderate [MET], PM2 [MET], PVS1 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP4 [MET], PM3-Very Strong [MET], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	"The allele frequency of the p.Cys1447GlnfsX29 variant in the USH2A gene is 0.0009% (1/111250) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). The p.Cys1447GlnfsX29 variant is predicted to cause a premature stop codon in biologically-relevant-exon 20 of 72 that leads to an absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected as compound heterozygous with p.Cys759Phe or p.Glu767SerfsX21 in six Usher syndrome probands, and as homozygous in eight Usher syndrome probands (PM3_VeryStrong; PMID: 9624053, 15325563, 18641288, 18665195, 20440071). The p.Cys1447GlnfsX29 variant in USH2A has been reported to segregate with hearing loss in at least 2 family members (PP1_Moderate; PMID: 20440071, 9624053). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 9624053, 15325563, 18641288, 18665195, 20440071). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2, PVS1, PM3_VeryStrong, PP1_Moderate, PP4."	20440071, 9624053, 20440071, 18641288, 15325563, 9624053, 18665195, 20440071, 15325563, 18641288, 9624053, 18665195, 20440071, 15325563, 18641288, 9624053, 18665195, 20613545, 10729113, 20440071, 9624053	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	25/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA252228/MONDO:0019501/005	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
7	107301201	4838	T	C	NM_000441.1(SLC26A4):c.-103T>C	4838	CA253314	NM_000441.1:c.-103T>C, NR_028137.1:n.198-550A>G, ENST00000265715.7:c.-103T>C, NC_000007.14:g.107660756T>C, CM000669.2:g.107660756T>C, NC_000007.13:g.107301201T>C, CM000669.1:g.107301201T>C, NC_000007.12:g.107088437T>C, NG_008489.1:g.5122T>C, NM_000441.1(SLC26A4):c.-103T>C	SLC26A4-AS1	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Uncertain Significance	PS3-Supporting [MET], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [MET], BS2 [Unmet], BS1-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], PM3 [MET], BP5 [Unmet], BP7 [Unmet], BS4 [Unmet]	"The filtering allele frequency of the c.-103T>C variant in the SLC26A4 gene is 0.28% for European (Non-Finnish) chromosomes by the Genome Aggregation Database (53/14998 with 95% CI), which is a higher frequency than would be expected for an  autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). This variant has been detected one patient with EVA in trans with p.Leu236Pro, pathogenic variant, as well as in two patients with EVA in which the variant in trans is benign (c.-66C>G) or the phase was not identified (p.Thr416Pro) (PM3; PMID:19204907, 30068397, 25991456). The variant has also been observed in 12 heterozygous cases in which a second variant was not identified (PMID: 17503324, 29196752, 25991456, 23208854). At least one patient with a variant in this gene displayed features of enlarged vestibular aqueduct (PP4; PMID: 19204907). Functional studies demonstrate that this variant may impact FOXI1-induced transcriptional activation of SLC26A4 (PS3_Supporting; PMID: 17503324, 25910213). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1_Supporting, PM3, PP4, PS3_Supporting."	25910213, 17503324, 19204907, 29196752, 30068397, 25991456, 23208854, 17503324, 23965030, 19204907, 29196752, 30068397, 25991456, 23208854, 17503324, 23965030	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA253314/MONDO:0010134/005	0.0507	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	73572579	4926	C	T	NM_022124.5(CDH23):c.9565C>T (p.Arg3189Trp)	4926	CA117145	NM_022124.5:c.9565C>T, NC_000010.11:g.71812822C>T, CM000672.2:g.71812822C>T, NC_000010.10:g.73572579C>T, CM000672.1:g.73572579C>T, NC_000010.9:g.73242585C>T, NG_008835.1:g.420876C>T, NM_001171933.1:c.2845C>T, NM_001171934.1:c.2845C>T, NM_001171935.1:c.256C>T, NM_001171936.1:c.256C>T, XM_006717940.2:c.9760C>T, XM_006717942.2:c.9694C>T, XM_011540039.1:c.9757C>T, XM_011540040.1:c.9754C>T, XM_011540041.1:c.9700C>T, XM_011540042.1:c.9670C>T, XM_011540043.1:c.9760C>T, XM_011540044.1:c.9625C>T, XM_011540045.1:c.9760C>T, XM_011540046.1:c.9220C>T, XM_011540047.1:c.8578C>T, XM_011540052.1:c.6088C>T, ENST00000224721.10:c.9580C>T, ENST00000398788.4:c.2845C>T, ENST00000475158.1:n.3101C>T, ENST00000619887.4:c.2845C>T, ENST00000622827.4:c.9565C>T, NM_022124.5(CDH23):c.9565C>T (p.Arg3189Trp)	CDH23	Usher syndrome type 1D	MONDO:0010984	Autosomal recessive inheritance	Uncertain Significance	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [MET], PP4 [Unmet], PP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4 [Unmet], PS3 [Unmet], PM5 [Unmet], PM1 [Unmet], PM3 [Unmet], PM4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.9565C>T (p.Arg3189Trp) variant in CDH23 has been identified in 2 heterozygous patients with Usher syndrome without another CDH23 variant in trans (Partners LMM internal data, SCV000062996.5; PMID 22381527, 18395802). This variant was identified in 4/10120 (0.00040) Ashkenazi Jewish alleles in gnomAD. This is above the BS1 autosomal recessive threshold of 0.02% of alleles. However the filtering allele frequency of the variant is 0.00003979. Which is less than the BS1_Supporting threshold (BS1/PM2 not met). The REVEL computational prediction analysis tool produced a score of 0.8, which is above the threshold necessary to apply PP3; however, this information is not predictive of pathogenicity on its own. A different missense variant (p.Arg3189Gln) has been previously identified at this codon of CDH23, however this variant does not have enough evidence to support pathogenicity (PM5 not met; ClinVar Variation ID 162956). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PP3."	18395802, 15660226, 22381527, 18395802, 15660226, 22381527	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA117145/MONDO:0010984/005	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	73490271	4927	A	G	NM_022124.5(CDH23):c.3625A>G (p.Thr1209Ala)	4927	CA137387	NM_022124.5:c.3625A>G, NC_000010.11:g.71730514A>G, CM000672.2:g.71730514A>G, NC_000010.10:g.73490271A>G, CM000672.1:g.73490271A>G, NC_000010.9:g.73160277A>G, NG_008835.1:g.338568A>G, NM_001168390.1:c.-6+7214T>C, NM_001171930.1:c.3625A>G, XM_006717940.2:c.3820A>G, XM_006717942.2:c.3754A>G, XM_011540039.1:c.3820A>G, XM_011540040.1:c.3814A>G, XM_011540041.1:c.3760A>G, XM_011540042.1:c.3820A>G, XM_011540043.1:c.3820A>G, XM_011540044.1:c.3685A>G, XM_011540045.1:c.3820A>G, XM_011540046.1:c.3280A>G, XM_011540047.1:c.2638A>G, XM_011540048.1:c.3820A>G, XM_011540049.1:c.3820A>G, XM_011540050.1:c.3820A>G, XM_011540051.1:c.3820A>G, XM_011540052.1:c.148A>G, XM_011540053.1:c.3820A>G, XR_945796.1:n.4063A>G, ENST00000224721.10:c.3640A>G, ENST00000398786.2:c.-6+7214T>C, ENST00000398792.3:n.317A>G, ENST00000398809.8:c.3622A>G, ENST00000616684.4:c.3625A>G, ENST00000622827.4:c.3625A>G, NM_022124.5(CDH23):c.3625A>G (p.Thr1209Ala)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP2 [Unmet], BP3 [Unmet], BP4 [MET], BA1 [MET], BS3-Supporting [MET], PS3 [Unmet], PS4 [Unmet], PS1 [Unmet], PS2 [Unmet], PM3 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet]	The filtering allele frequency (the lower threshold of the 95% CI of 3442/23972) of the c.3625A>G (p.Thr1209Ala) variant in the CDH23 gene is 13.15% for African chromosomes by gnomAD, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). A splicing assay did not show any impact to splicing but BS3 was not applied given no assessment of protein function  (PMID:18273900). Computational prediction analysis using the metapredictor tool REVEL did not predict an impact the protein (BP4). Of note, this variant was reported in 3 patients with Usher syndrome (PMID: 15537665, 15660226, 12075507) though without any convincing evidence for pathogenicity (PM3 not met). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BA1, BS3_Supporting, BP4.	15660226, 15537665, 19683999, 12075507, 18273900, 16963483, 21569298, 21738395, 15660226, 15537665, 19683999, 12075507	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA137387/MONDO:0019501/005	0.0028	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
1	41285565	6241	G	A	NM_004700.3(KCNQ4):c.853G>A (p.Gly285Ser)	6241	CA340532	NM_004700.3:c.853G>A, NM_172163.2:c.853G>A, XM_011542417.1:c.853G>A, XM_011542418.1:c.853G>A, XM_011542419.1:c.853G>A, XM_011542420.1:c.853G>A, XR_946798.1:n.859G>A, XR_946799.1:n.859G>A, XR_946800.1:n.859G>A, XM_017002792.1:c.-165G>A, NM_004700.4:c.853G>A, ENST00000347132.9:c.853G>A, ENST00000443478.3:n.539G>A, ENST00000506017.1:n.172G>A, ENST00000509682.6:n.853G>A, NC_000001.11:g.40819893G>A, CM000663.2:g.40819893G>A, NC_000001.10:g.41285565G>A, CM000663.1:g.41285565G>A, NC_000001.9:g.41058152G>A, NG_008139.1:g.40882G>A, NG_008139.2:g.40882G>A, NM_004700.3(KCNQ4):c.853G>A (p.Gly285Ser)	KCNQ4	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Pathogenic	PS3-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP4 [Unmet], BS2 [Unmet], PS4-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS2 [Unmet], PM5 [MET], PM1 [MET], PM4 [Unmet], PM3 [Unmet], PP1-Strong [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The p.Gly285Ser variant in the KCNQ4 gene was absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org) (PM2). The p.Gly285Ser variant has been reported to segregate with hearing loss in at least 16 family members (PP1_S; PMIDs: 10025409, 25116015). The variant meets PM2 and has been observed in at least 2 affected probands (PS4_P, PMID: 10025409, Partners LMM internal data SCV000198442.4). A different pathogenic missense variant (p.Gly285Cys) has been previously identified at this codon of KCNQ4 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar Variation ID 6244, PMID: 10369879). Furthermore, the variant is in a location that has been defined by the ClinGen Hearing Loss Expert Panel to be a mutational hotspot or domain of KCNQ4 (PM1; PMID: 23717403; https://www.uniprot.org/uniprot/P56696). A functional study demonstrates that this variant may impact protein function (PS3_P; PMID: 10025409, 18786918). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant nonsyndromic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: PM2, PP1_S, PS4_P, PM5, PM1, PS3_P."	18786918, 10025409, 10025409, 10369879, 8035838, 10369879, 8035838, 10025409, 25116015, 10025409, 25116015	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	11/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA340532/MONDO:0019497/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
14	31346846	6611	C	T	NM_004086.2(COCH):c.151C>T (p.Pro51Ser)	6611	CA253889	NM_004086.2:c.151C>T, NC_000014.9:g.30877640C>T, CM000676.2:g.30877640C>T, NC_000014.8:g.31346846C>T, CM000676.1:g.31346846C>T, NC_000014.7:g.30416597C>T, NG_008211.2:g.8106C>T, NM_001135058.1:c.151C>T, NR_038356.1:n.1618-1088G>A, XM_011536539.1:c.151C>T, NM_001347720.1:c.346C>T, XM_017021071.1:c.346C>T, XM_024449506.1:c.151C>T, NM_004086.3:c.151C>T, ENST00000216361.8:c.151C>T, ENST00000396618.7:c.151C>T, ENST00000460581.6:c.-186C>T, ENST00000475087.5:c.151C>T, ENST00000553772.5:c.151C>T, ENST00000553833.5:n.305C>T, ENST00000555881.5:c.82+2537C>T, ENST00000556908.5:c.103C>T, ENST00000557065.1:n.67C>T, NM_004086.2(COCH):c.151C>T (p.Pro51Ser)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [MET], PP4 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS4 [MET], PS3 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], PP1-Strong [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.151C>T (p.Pro51Ser) variant in COCH has been reported to segregate with late onset progressive hearing loss and vestibular dysfunction in > 25 family members (PP1_S; PMID: 9931344, 11332404). The variant meets PM2 and has been observed in at least 15 affected probands (PS4, PMID: 28733840, 16151338, 11332404). The allele frequency of the p.Pro51Ser variant is 0.001% (1/111716) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss (PM2). Computational prediction tools and conservation analysis suggest that the p.Pro51Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PP1_S, PS4, PM2, PP3."	11332404, 28733840, 16151338, 11332404, 25230692, 20228067, 16481359, 26256111, 12928864, 16151338, 24662630, 9931344, 16151338, 24662630, 9931344	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	19/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA253889/MONDO:0019497/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 1, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
14	31348132	6613	G	A	NM_004086.2(COCH):c.355G>A (p.Ala119Thr)	6613	CA253893	NM_004086.2:c.355G>A, NM_001135058.1:c.355G>A, NR_038356.1:n.1618-2374C>T, XM_011536539.1:c.355G>A, NM_001347720.1:c.550G>A, XM_017021071.1:c.550G>A, XM_024449506.1:c.355G>A, NM_004086.3:c.355G>A, ENST00000216361.8:c.355G>A, ENST00000396618.7:c.355G>A, ENST00000460581.6:c.19G>A, ENST00000475087.5:c.355G>A, ENST00000553772.5:c.239+1198G>A, ENST00000553833.5:n.509G>A, ENST00000555881.5:c.83-1526G>A, ENST00000556908.5:c.307G>A, ENST00000557065.1:n.156-497G>A, NC_000014.9:g.30878926G>A, CM000676.2:g.30878926G>A, NC_000014.8:g.31348132G>A, CM000676.1:g.31348132G>A, NC_000014.7:g.30417883G>A, NG_008211.2:g.9392G>A, NM_004086.2(COCH):c.355G>A (p.Ala119Thr)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.355G>A (p.Ala119Thr) variant in COCH has been reported in one Japanese individual with hearing loss, vestibular dysfunction, and a family history of hearing loss though no other affected family members were screened (PS4 not met; PMID: 14512963). The variant was absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org) (PM2). A functional study demonstrates that this variant may not impact protein function (BS3_P; PMID: 25230692). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2, BS3_P."	25230692, 14512963	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	17/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA253893/MONDO:0019497/005	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 1, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89692985	7814	G	T	NM_000314.6(PTEN):c.469G>T (p.Glu157Ter)	7814	CA000467	NM_000314.6:c.469G>T, NC_000010.11:g.87933228G>T, CM000672.2:g.87933228G>T, NC_000010.10:g.89692985G>T, CM000672.1:g.89692985G>T, NC_000010.9:g.89682965G>T, NG_007466.2:g.74790G>T, LRG_311:g.74790G>T, NM_000314.5:c.469G>T, NM_001304717.2:c.988G>T, NM_001304718.1:c.-282G>T, XM_006717926.2:c.424G>T, XM_011539981.1:c.469G>T, XM_011539982.1:c.373G>T, XR_945789.1:n.1181G>T, XR_945790.1:n.1181G>T, XR_945791.1:n.1181G>T, NM_000314.7:c.469G>T, NM_001304717.5:c.988G>T, NM_001304718.2:c.-282G>T, ENST00000371953.7:c.469G>T, ENST00000498703.1:n.295G>T, ENST00000610634.1:c.367G>T, NM_000314.6(PTEN):c.469G>T (p.Glu157Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PS4-Supporting [MET]	PTEN c.469G>T (p.E157X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 8071972)		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	30/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000467/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711892	7815	T	A	NM_000314.6(PTEN):c.510T>A (p.Ser170Arg)	7815	CA000492	NM_000314.6:c.510T>A, NC_000010.11:g.87952135T>A, CM000672.2:g.87952135T>A, NC_000010.10:g.89711892T>A, CM000672.1:g.89711892T>A, NC_000010.9:g.89701872T>A, NG_007466.2:g.93697T>A, LRG_311:g.93697T>A, NM_000314.5:c.510T>A, NM_001304717.2:c.1029T>A, NM_001304718.1:c.-82T>A, XM_006717926.2:c.465T>A, XM_011539981.1:c.510T>A, XM_011539982.1:c.414T>A, XR_945789.1:n.1381T>A, XR_945790.1:n.1498T>A, XR_945791.1:n.1205-5718T>A, NM_000314.7:c.510T>A, NM_001304717.5:c.1029T>A, NM_001304718.2:c.-82T>A, ENST00000371953.7:c.510T>A, NM_000314.6(PTEN):c.510T>A (p.Ser170Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PP1 [MET], PP2 [MET], PS4-Supporting [MET], PS3 [MET], BS3 [Unmet]	PTEN c.510T>A (p.S170R) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 17942903, PMID 10866302, PMID 9256433, PMID 21828076)PM2: Absent in large sequenced populations (PMID 27535533).PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 17526800, PMID 9241266)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 17526800)		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000492/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692884	7816	A	G	NM_000314.6(PTEN):c.368A>G (p.His123Arg)	7816	CA000418	NM_000314.6:c.368A>G, NC_000010.11:g.87933127A>G, CM000672.2:g.87933127A>G, NC_000010.10:g.89692884A>G, CM000672.1:g.89692884A>G, NC_000010.9:g.89682864A>G, NG_007466.2:g.74689A>G, LRG_311:g.74689A>G, NM_000314.5:c.368A>G, NM_001304717.2:c.887A>G, NM_001304718.1:c.-383A>G, XM_006717926.2:c.323A>G, XM_011539981.1:c.368A>G, XM_011539982.1:c.272A>G, XR_945789.1:n.1080A>G, XR_945790.1:n.1080A>G, XR_945791.1:n.1080A>G, NM_000314.7:c.368A>G, NM_001304717.5:c.887A>G, NM_001304718.2:c.-383A>G, ENST00000371953.7:c.368A>G, ENST00000498703.1:n.194A>G, ENST00000610634.1:c.266A>G, NM_000314.6(PTEN):c.368A>G (p.His123Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [MET], PP2 [MET], PM1 [MET]	PTEN c.368A>G (p.H123R)PTEN c.368A>G (p.H123R) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations. (PMID 27535533)PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10234502)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000418/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692886	7817	T	C	NM_000314.6(PTEN):c.370T>C (p.Cys124Arg)	7817	CA000422	NM_000314.6:c.370T>C, NM_000314.5:c.370T>C, NM_001304717.2:c.889T>C, NM_001304718.1:c.-381T>C, XM_006717926.2:c.325T>C, XM_011539981.1:c.370T>C, XM_011539982.1:c.274T>C, XR_945789.1:n.1082T>C, XR_945790.1:n.1082T>C, XR_945791.1:n.1082T>C, NM_000314.7:c.370T>C, NM_001304717.5:c.889T>C, NM_001304718.2:c.-381T>C, ENST00000371953.7:c.370T>C, ENST00000498703.1:n.196T>C, ENST00000610634.1:c.268T>C, NC_000010.11:g.87933129T>C, CM000672.2:g.87933129T>C, NC_000010.10:g.89692886T>C, CM000672.1:g.89692886T>C, NC_000010.9:g.89682866T>C, NG_007466.2:g.74691T>C, LRG_311:g.74691T>C, NM_000314.6(PTEN):c.370T>C (p.Cys124Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], PS4-Supporting [MET], PM6-Strong [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS2 [Unmet], PS3 [MET], PS1 [Unmet], PM1 [MET], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet]	PTEN c.370T>C (p.Cys124Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 10866302, PMID 29706350)PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (internal laboratory contributor SCV000568254.4)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor SCV000568254.4)	10234502, 9467011, 9259288, 29785012, 20194734, 15987703, 29706350, 10866302	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000422/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
10	89693010	7821	T	G	NM_000314.6(PTEN):c.492+2T>G	7821	CA000475	NM_000314.6:c.492+2T>G, NC_000010.11:g.87933253T>G, CM000672.2:g.87933253T>G, NC_000010.10:g.89693010T>G, CM000672.1:g.89693010T>G, NC_000010.9:g.89682990T>G, NG_007466.2:g.74815T>G, LRG_311:g.74815T>G, NM_000314.5:c.492+2T>G, NM_001304717.2:c.1011+2T>G, NM_001304718.1:c.-259+2T>G, XM_006717926.2:c.447+2T>G, XM_011539981.1:c.492+2T>G, XM_011539982.1:c.396+2T>G, XR_945789.1:n.1204+2T>G, XR_945790.1:n.1204+2T>G, XR_945791.1:n.1204+2T>G, NM_000314.7:c.492+2T>G, NM_001304717.5:c.1011+2T>G, NM_001304718.2:c.-259+2T>G, ENST00000371953.7:c.492+2T>G, ENST00000498703.1:n.320T>G, ENST00000610634.1:c.390+2T>G, NM_000314.6(PTEN):c.492+2T>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], BS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.492+2T>G (IVS5+2T>G) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).	12938083, 9425889, 11875759, 9662392	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000475/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89717670	7822	CA	C	NM_000314.6(PTEN):c.696delA (p.Arg233Aspfs)	7822	CA000548	NM_000314.6:c.696delA, NC_000010.11:g.87957914del, CM000672.2:g.87957914del, NC_000010.10:g.89717671del, CM000672.1:g.89717671del, NC_000010.9:g.89707651del, NG_007466.2:g.99476del, LRG_311:g.99476del, NM_000314.5:c.696del, NM_000314.6:c.696del, NM_001304717.2:c.1215del, NM_001304718.1:c.105del, XM_006717926.2:c.651del, XM_011539981.1:c.696del, XM_011539982.1:c.600del, XR_945791.1:n.1266del, NM_000314.7:c.696del, NM_001304717.5:c.1215del, NM_001304718.2:c.105del, ENST00000371953.7:c.696del, ENST00000472832.2:n.123del, NM_000314.6(PTEN):c.696delA (p.Arg233Aspfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM6 [Unmet], PM2 [MET], PVS1 [MET], BS2 [Unmet], PP1 [Unmet], PP4 [Unmet], PP3 [Unmet], PP2 [Unmet], BA1 [Unmet], BP2 [Unmet], BP4 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PS1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS4 [Unmet], BS3 [Unmet], BS1 [Unmet], BP5 [Unmet], BP7 [Unmet]	PTEN c.696delA (p.Arg233Aspfs)PTEN c.696delA (p.Arg233Aspfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).	9425889	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000548/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711967	7823	TC	T	NM_000314.6(PTEN):c.586delC (p.His196Thrfs)	7823	CA000526	NM_000314.6:c.586delC, NC_000010.11:g.87952211del, CM000672.2:g.87952211del, NC_000010.10:g.89711968del, CM000672.1:g.89711968del, NC_000010.9:g.89701948del, NG_007466.2:g.93773del, LRG_311:g.93773del, NM_000314.5:c.586del, NM_000314.6:c.586del, NM_001304717.2:c.1105del, NM_001304718.1:c.-6del, XM_006717926.2:c.541del, XM_011539981.1:c.586del, XM_011539982.1:c.490del, XR_945791.1:n.1205-5642del, NM_000314.7:c.586del, NM_001304717.5:c.1105del, NM_001304718.2:c.-6del, ENST00000371953.7:c.586del, ENST00000472832.2:n.13del, NM_000314.6(PTEN):c.586delC (p.His196Thrfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], PS4-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.586delC (p.H196Tfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032)	9832032	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000526/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711916	7824	TA	AT	NM_000314.6(PTEN):c.534_535delTAinsAT (p.Tyr178Ter)	7824	CA000509	NM_000314.6:c.534_535delTAinsAT, NC_000010.11:g.87952159_87952160delinsAT, CM000672.2:g.87952159_87952160delinsAT, NC_000010.10:g.89711916_89711917delinsAT, CM000672.1:g.89711916_89711917delinsAT, NC_000010.9:g.89701896_89701897delinsAT, NG_007466.2:g.93721_93722delinsAT, LRG_311:g.93721_93722delinsAT, NM_000314.5:c.534_535delinsAT, NM_000314.6:c.534_535delinsAT, NM_001304717.2:c.1053_1054delinsAT, NM_001304718.1:c.-58_-57delinsAT, XM_006717926.2:c.489_490delinsAT, XM_011539981.1:c.534_535delinsAT, XM_011539982.1:c.438_439delinsAT, XR_945789.1:n.1405_1406delinsAT, XR_945790.1:n.1522_1523delinsAT, XR_945791.1:n.1205-5694_1205-5693delinsAT, NM_000314.7:c.534_535delinsAT, NM_001304717.5:c.1053_1054delinsAT, NM_001304718.2:c.-58_-57delinsAT, ENST00000371953.7:c.534_535delinsAT, NM_000314.6(PTEN):c.534_535delTAinsAT (p.Tyr178Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PS4-Supporting [MET]	PTEN c.534_535delTAinsAT (p.Y178X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032, PMID 23335809)		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000509/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89653806	7825	T	G	NM_000314.6(PTEN):c.104T>G (p.Met35Arg)	7825	CA000268	NM_000314.6:c.104T>G, NM_000314.5:c.104T>G, NM_001304717.2:c.623T>G, NM_001304718.1:c.-602T>G, XM_006717926.2:c.104T>G, XM_011539981.1:c.104T>G, XM_011539982.1:c.68+13611T>G, XR_945789.1:n.816T>G, XR_945790.1:n.816T>G, XR_945791.1:n.816T>G, NM_000314.7:c.104T>G, NM_001304717.5:c.623T>G, NM_001304718.2:c.-602T>G, ENST00000371953.7:c.104T>G, ENST00000462694.1:n.106T>G, ENST00000610634.1:c.2T>G, NC_000010.11:g.87894049T>G, CM000672.2:g.87894049T>G, NC_000010.10:g.89653806T>G, CM000672.1:g.89653806T>G, NC_000010.9:g.89643786T>G, NG_007466.2:g.35611T>G, LRG_311:g.35611T>G, NM_000314.6(PTEN):c.104T>G (p.Met35Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [MET], PS2 [MET], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.104T>G (p.Met35Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (PMID 9425889)PS3: Phosphatase activity <50% of wild type. (PMID 21828076, 25875300)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	9425889, 21828076, 25875300, 9425889	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000268/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89685314	7826	T	C	NM_000314.6(PTEN):c.209T>C (p.Leu70Pro)	7826	CA000350	NM_000314.6:c.209T>C, NM_000314.5:c.209T>C, NM_001304717.2:c.728T>C, NM_001304718.1:c.-541-5489T>C, XM_006717926.2:c.165-5489T>C, XM_011539981.1:c.209T>C, XM_011539982.1:c.113T>C, XR_945789.1:n.921T>C, XR_945790.1:n.921T>C, XR_945791.1:n.921T>C, NM_000314.7:c.209T>C, NM_001304717.5:c.728T>C, NM_001304718.2:c.-541-5489T>C, ENST00000371953.7:c.209T>C, ENST00000498703.1:n.35T>C, ENST00000610634.1:c.107T>C, NC_000010.11:g.87925557T>C, CM000672.2:g.87925557T>C, NC_000010.10:g.89685314T>C, CM000672.1:g.89685314T>C, NC_000010.9:g.89675294T>C, NG_007466.2:g.67119T>C, LRG_311:g.67119T>C, NM_000314.6(PTEN):c.209T>C (p.Leu70Pro)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP4 [Unmet], PP1 [Unmet], PS4-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [MET], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.209T>C (p.Leu70Pro) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor(s) ClinVar Organization ID: 26957)	29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000350/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89717741	7828	G	T	NM_000314.6(PTEN):c.766G>T (p.Glu256Ter)	7828	CA000569	NM_000314.6:c.766G>T, NM_000314.5:c.766G>T, NM_001304717.2:c.1285G>T, NM_001304718.1:c.175G>T, XM_006717926.2:c.721G>T, XM_011539981.1:c.766G>T, XM_011539982.1:c.670G>T, XR_945791.1:n.1336G>T, NM_000314.7:c.766G>T, NM_001304717.5:c.1285G>T, NM_001304718.2:c.175G>T, ENST00000371953.7:c.766G>T, ENST00000472832.2:n.193G>T, NC_000010.11:g.87957984G>T, CM000672.2:g.87957984G>T, NC_000010.10:g.89717741G>T, CM000672.1:g.89717741G>T, NC_000010.9:g.89707721G>T, NG_007466.2:g.99546G>T, LRG_311:g.99546G>T, NM_000314.6(PTEN):c.766G>T (p.Glu256Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM6 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], PS4-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.766G>T (p.E256X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 9832032)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032)	9832032	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000569/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692905	7829	G	A	NM_000314.6(PTEN):c.389G>A (p.Arg130Gln)	7829	CA000437	NM_000314.6:c.389G>A, NC_000010.11:g.87933148G>A, CM000672.2:g.87933148G>A, NC_000010.10:g.89692905G>A, CM000672.1:g.89692905G>A, NC_000010.9:g.89682885G>A, NG_007466.2:g.74710G>A, LRG_311:g.74710G>A, NM_000314.5:c.389G>A, NM_001304717.2:c.908G>A, NM_001304718.1:c.-362G>A, XM_006717926.2:c.344G>A, XM_011539981.1:c.389G>A, XM_011539982.1:c.293G>A, XR_945789.1:n.1101G>A, XR_945790.1:n.1101G>A, XR_945791.1:n.1101G>A, NM_000314.7:c.389G>A, NM_001304717.5:c.908G>A, NM_001304718.2:c.-362G>A, ENST00000371953.7:c.389G>A, ENST00000498703.1:n.215G>A, ENST00000610634.1:c.287G>A, NM_000314.6(PTEN):c.389G>A (p.Arg130Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PP2 [MET], PM6-Strong [MET], PS3 [MET], PS4 [MET], PM1 [MET]	"PTEN c.389G>A (p.R130Q) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM6_VS: At least four assumed de novo observations in a patient with the disease and no family history. (PMID 22595938, PMID 22327138, internal laboratory contributor(s) SCV000222111.11)PS3: Phosphatase activity <50% of wild type (PMID 10866302)PS4: Probands with phenotype specificity score of 4-15.5 (PMID 26798346, PMID 17526801, PMID 23335809, PMID 22266152)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000437/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	5	Likely Pathogenic
10	89717734	7830	CAAAGT	C	NM_000314.6(PTEN):c.761_765delAAGTA (p.Lys254Argfs)	7830	CA000566	NM_000314.6:c.761_765delAAGTA, NM_000314.5:c.761_765del, NM_000314.6:c.761_765del, NM_001304717.2:c.1280_1284del, NM_001304718.1:c.170_174del, XM_006717926.2:c.716_720del, XM_011539981.1:c.761_765del, XM_011539982.1:c.665_669del, XR_945791.1:n.1331_1335del, NM_000314.7:c.761_765del, NM_001304717.5:c.1280_1284del, NM_001304718.2:c.170_174del, ENST00000371953.7:c.761_765del, ENST00000472832.2:n.188_192del, NC_000010.11:g.87957979_87957983del, CM000672.2:g.87957979_87957983del, NC_000010.10:g.89717736_89717740del, CM000672.1:g.89717736_89717740del, NC_000010.9:g.89707716_89707720del, NG_007466.2:g.99541_99545del, LRG_311:g.99541_99545del, NM_000314.6(PTEN):c.761_765delAAGTA (p.Lys254Argfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1 [MET], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.761_765delAAGTA (p.K254Rfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000566/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711946	7831	T	A	NM_000314.6(PTEN):c.564T>A (p.Tyr188Ter)	7831	CA000521	NM_000314.6:c.564T>A, NC_000010.11:g.87952189T>A, CM000672.2:g.87952189T>A, NC_000010.10:g.89711946T>A, CM000672.1:g.89711946T>A, NC_000010.9:g.89701926T>A, NG_007466.2:g.93751T>A, LRG_311:g.93751T>A, NM_000314.5:c.564T>A, NM_001304717.2:c.1083T>A, NM_001304718.1:c.-28T>A, XM_006717926.2:c.519T>A, XM_011539981.1:c.564T>A, XM_011539982.1:c.468T>A, XR_945791.1:n.1205-5664T>A, NM_000314.7:c.564T>A, NM_001304717.5:c.1083T>A, NM_001304718.2:c.-28T>A, ENST00000371953.7:c.564T>A, NM_000314.6(PTEN):c.564T>A (p.Tyr188Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet]	PTEN c.564T>A (p.Y188X) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000521/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89624262	7834	C	CA	NM_000314.6(PTEN):c.40dupA (p.Arg14Lysfs)	7834	CA254258	NM_000314.6:c.40dupA, NC_000010.11:g.87864509dup, CM000672.2:g.87864509dup, NC_000010.10:g.89624266dup, CM000672.1:g.89624266dup, NC_000010.9:g.89614246dup, NG_007466.2:g.6071dup, LRG_311:g.6071dup, NG_033079.1:g.3932dup, NM_000314.5:c.40dup, NM_000314.6:c.40dup, NM_001304717.2:c.559dup, NM_001304718.1:c.-666dup, XM_006717926.2:c.40dup, XM_011539981.1:c.40dup, XR_945789.1:n.752dup, XR_945790.1:n.752dup, XR_945791.1:n.752dup, NM_000314.7:c.40dup, NM_001304717.5:c.559dup, NM_001304718.2:c.-666dup, ENST00000371953.7:c.40dup, ENST00000462694.1:n.42dup, ENST00000487939.1:n.61dup, ENST00000610634.1:c.-63dup, ENST00000618586.1:n.9dup, NM_000314.6(PTEN):c.40dupA (p.Arg14Lysfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [MET], PVS1 [MET], PS4-Supporting [MET]	PTEN c.40dupA (p.R14Kfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10777358)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10777358)		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA254258/MONDO:0017623/003	0.9971	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89720649	7839	AG	A	NM_000314.6(PTEN):c.802delG (p.Asp268Thrfs)	7839	CA000595	NM_000314.6:c.802delG, NM_000314.5:c.802del, NM_000314.6:c.802del, NM_001304717.2:c.1321del, NM_001304718.1:c.211del, XM_006717926.2:c.757del, XM_011539981.1:c.802del, XM_011539982.1:c.706del, XR_945791.1:n.1372del, NM_000314.7:c.802del, NM_001304717.5:c.1321del, NM_001304718.2:c.211del, ENST00000371953.7:c.802del, ENST00000472832.2:n.229del, NC_000010.11:g.87960894del, CM000672.2:g.87960894del, NC_000010.10:g.89720651del, CM000672.1:g.89720651del, NC_000010.9:g.89710631del, NG_007466.2:g.102456del, LRG_311:g.102456del, NM_000314.6(PTEN):c.802delG (p.Asp268Thrfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.802delG (p.Asp268Thrfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).	11238682, 11238682, 11238682, 11238682, 11238682, 11238682	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	25/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000595/MONDO:0017623/003	0.9941	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89717676	7840	G	A	NM_000314.6(PTEN):c.701G>A (p.Arg234Gln)	7840	CA000551	NM_000314.6:c.701G>A, NC_000010.11:g.87957919G>A, CM000672.2:g.87957919G>A, NC_000010.10:g.89717676G>A, CM000672.1:g.89717676G>A, NC_000010.9:g.89707656G>A, NG_007466.2:g.99481G>A, LRG_311:g.99481G>A, NM_000314.5:c.701G>A, NM_001304717.2:c.1220G>A, NM_001304718.1:c.110G>A, XM_006717926.2:c.656G>A, XM_011539981.1:c.701G>A, XM_011539982.1:c.605G>A, XR_945791.1:n.1271G>A, NM_000314.7:c.701G>A, NM_001304717.5:c.1220G>A, NM_001304718.2:c.110G>A, ENST00000371953.7:c.701G>A, ENST00000472832.2:n.128G>A, NM_000314.6(PTEN):c.701G>A (p.Arg234Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP4 [Unmet], PP1 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	PTEN c.701G>A (p.Arg234Gln) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	12085208, 28755079, 12085208, 29785012, 29706350, 12085208, 29785012, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000551/MONDO:0017623/003	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89685286	7841	C	G	NM_000314.6(PTEN):c.181C>G (p.His61Asp)	7841	CA000330	NM_000314.6:c.181C>G, NC_000010.11:g.87925529C>G, CM000672.2:g.87925529C>G, NC_000010.10:g.89685286C>G, CM000672.1:g.89685286C>G, NC_000010.9:g.89675266C>G, NG_007466.2:g.67091C>G, LRG_311:g.67091C>G, NM_000314.5:c.181C>G, NM_001304717.2:c.700C>G, NM_001304718.1:c.-541-5517C>G, XM_006717926.2:c.165-5517C>G, XM_011539981.1:c.181C>G, XM_011539982.1:c.85C>G, XR_945789.1:n.893C>G, XR_945790.1:n.893C>G, XR_945791.1:n.893C>G, NM_000314.7:c.181C>G, NM_001304717.5:c.700C>G, NM_001304718.2:c.-541-5517C>G, ENST00000371953.7:c.181C>G, ENST00000498703.1:n.7C>G, ENST00000610634.1:c.79C>G, NM_000314.6(PTEN):c.181C>G (p.His61Asp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [MET], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [MET], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet]	PTEN c.181C>G (p.His61Asp) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 21828076, 17942903)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 11748304)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	11748304, 11748304, 17942903, 21828076, 11748304	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	25/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000330/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711886	7843	TC	T	NM_000314.6(PTEN):c.507delC (p.Ser170Valfs)	7843	CA000490	NM_000314.6:c.507delC, NC_000010.11:g.87952132del, CM000672.2:g.87952132del, NC_000010.10:g.89711889del, CM000672.1:g.89711889del, NC_000010.9:g.89701869del, NG_007466.2:g.93694del, LRG_311:g.93694del, NM_000314.5:c.507del, NM_000314.6:c.507del, NM_001304717.2:c.1026del, NM_001304718.1:c.-85del, XM_006717926.2:c.462del, XM_011539981.1:c.507del, XM_011539982.1:c.411del, XR_945789.1:n.1378del, XR_945790.1:n.1495del, XR_945791.1:n.1205-5721del, NM_000314.7:c.507del, NM_001304717.5:c.1026del, NM_001304718.2:c.-85del, ENST00000371953.7:c.507del, NM_000314.6(PTEN):c.507delC (p.Ser170Valfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM6 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [MET], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	PTEN c.507delC (p.Ser170Valfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 12471211)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 12471211)	12471211, 12938083, 12471211, 12471211, 12471211, 12938083	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000490/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89623462	7844	G	A	NM_000314.6(PTEN):c.-764G>A	7844	CA000567	NM_000314.6:c.-764G>A, NC_000010.11:g.87863705G>A, CM000672.2:g.87863705G>A, NC_000010.10:g.89623462G>A, CM000672.1:g.89623462G>A, NC_000010.9:g.89613442G>A, NG_007466.2:g.5268G>A, LRG_311:g.5268G>A, NG_033079.1:g.4733C>T, NM_000314.5:c.-764G>A, NM_001304717.2:c.-245G>A, NM_001304718.1:c.-1469G>A, NM_000314.7:c.-764G>A, NM_001304717.5:c.-245G>A, NM_001304718.2:c.-1469G>A, ENST00000371953.7:c.-765G>A, ENST00000610634.1:c.-867G>A, NM_000314.6(PTEN):c.-764G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET]	"PTEN c.-764G>A (NC_000010.10:g.89623462G>A) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533)."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000567/MONDO:0017623/003	0.1	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89623365	7845	G	T	NM_000314.6(PTEN):c.-861G>T	7845	CA000612	NM_000314.6:c.-861G>T, NM_000314.5:c.-861G>T, NM_001304717.2:c.-342G>T, NM_001304718.1:c.-1566G>T, ENST00000371953.7:c.-862G>T, ENST00000610634.1:c.-964G>T, NC_000010.11:g.87863608G>T, CM000672.2:g.87863608G>T, NC_000010.10:g.89623365G>T, CM000672.1:g.89623365G>T, NC_000010.9:g.89613345G>T, NG_007466.2:g.5171G>T, LRG_311:g.5171G>T, NG_033079.1:g.4830C>A, NM_000314.6(PTEN):c.-861G>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BP7 [Unmet], BP5 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.-861G>T (NC_000010.10:g.89623365G>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).No criteria currently apply to this variant.	17847000, 17847000	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000612/MONDO:0017623/003	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692794	7848	A	G	NM_000314.6(PTEN):c.278A>G (p.His93Arg)	7848	CA000381	NM_000314.6:c.278A>G, NC_000010.11:g.87933037A>G, CM000672.2:g.87933037A>G, NC_000010.10:g.89692794A>G, CM000672.1:g.89692794A>G, NC_000010.9:g.89682774A>G, NG_007466.2:g.74599A>G, LRG_311:g.74599A>G, NM_000314.5:c.278A>G, NM_001304717.2:c.797A>G, NM_001304718.1:c.-473A>G, XM_006717926.2:c.233A>G, XM_011539981.1:c.278A>G, XM_011539982.1:c.182A>G, XR_945789.1:n.990A>G, XR_945790.1:n.990A>G, XR_945791.1:n.990A>G, NM_000314.7:c.278A>G, NM_001304717.5:c.797A>G, NM_001304718.2:c.-473A>G, ENST00000371953.7:c.278A>G, ENST00000498703.1:n.104A>G, ENST00000610634.1:c.176A>G, NM_000314.6(PTEN):c.278A>G (p.His93Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [Unmet], PM2 [MET], PM6 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], PS4-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS2 [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [MET], PS3-Supporting [MET]	PTEN c.278A>G (p.His93Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor(s) ClinVar Organization ID: 26957)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 26579216, 25647146, 20718038, 21828076, 29373119, 29785012, 29706350)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 15805158, internal laboratory contributor(s) ClinVar Organization ID: 26957)	15805158, 21194675, 24345843, 15805158, 15805158, 15805158, 25647146, 21828076, 22505997, 29785012, 20718038, 29373119, 29706350, 26579216	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000381/MONDO:0017623/003	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	5	Likely Pathogenic
10	89717730	7849	A	G	NM_000314.6(PTEN):c.755A>G (p.Asp252Gly)	7849	CA000564	NM_000314.6:c.755A>G, NC_000010.11:g.87957973A>G, CM000672.2:g.87957973A>G, NC_000010.10:g.89717730A>G, CM000672.1:g.89717730A>G, NC_000010.9:g.89707710A>G, NG_007466.2:g.99535A>G, LRG_311:g.99535A>G, NM_000314.5:c.755A>G, NM_001304717.2:c.1274A>G, NM_001304718.1:c.164A>G, XM_006717926.2:c.710A>G, XM_011539981.1:c.755A>G, XM_011539982.1:c.659A>G, XR_945791.1:n.1325A>G, NM_000314.7:c.755A>G, NM_001304717.5:c.1274A>G, NM_001304718.2:c.164A>G, ENST00000371953.7:c.755A>G, ENST00000472832.2:n.182A>G, NM_000314.6(PTEN):c.755A>G (p.Asp252Gly)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1 [Unmet], PP4-Moderate [MET], PM2 [MET], PM6 [MET], PP3 [Unmet], PP2 [MET], PP1 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4-Moderate [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS3-Supporting [MET]	PTEN c.755A>G (p.D252G) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 23335809, personal communication with corresponding author)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 23335809, 15805158)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 21828076, 29706633, 25527629, 29706350)	21659347, 17286265, 21194675, 23335809, 15805158, 21828076, 29706633, 29373119, 25527629, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	25/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000564/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
10	89717697	7850	T	C	NM_000314.6(PTEN):c.722T>C (p.Phe241Ser)	7850	CA000555	NM_000314.6:c.722T>C, NC_000010.11:g.87957940T>C, CM000672.2:g.87957940T>C, NC_000010.10:g.89717697T>C, CM000672.1:g.89717697T>C, NC_000010.9:g.89707677T>C, NG_007466.2:g.99502T>C, LRG_311:g.99502T>C, NM_000314.5:c.722T>C, NM_001304717.2:c.1241T>C, NM_001304718.1:c.131T>C, XM_006717926.2:c.677T>C, XM_011539981.1:c.722T>C, XM_011539982.1:c.626T>C, XR_945791.1:n.1292T>C, NM_000314.7:c.722T>C, NM_001304717.5:c.1241T>C, NM_001304718.2:c.131T>C, ENST00000371953.7:c.722T>C, ENST00000472832.2:n.149T>C, NM_000314.6(PTEN):c.722T>C (p.Phe241Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM6 [Unmet], PM2 [MET], PVS1 [Unmet], BS2 [Unmet], PP1 [Unmet], PP3 [Unmet], PP2 [MET], PP4 [Unmet], PS4-Supporting [MET], BP2 [Unmet], BP4 [Unmet], BA1 [Unmet], PS2 [Unmet], PS3 [MET], PS1 [Unmet], BS4 [Unmet], BS3 [Unmet], BS1 [Unmet], BP5 [Unmet], BP7 [Unmet], PM1 [Unmet], PM4 [Unmet], PM5 [Unmet]	PTEN c.722T>C (p.Phe241Ser) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350, 29785012, 26579216, 25527629, 21828076)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 15805158)	15805158, 21194675, 15805158, 29785012, 26579216, 25527629, 29373119, 29706350, 25937288, 21828076	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000555/MONDO:0017623/003	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
19	4117550	8272	A	C	NM_030662.3(MAP2K2):c.170T>G (p.Phe57Cys)	8272	CA279958	NM_030662.3:c.170T>G, LRG_750t1:c.170T>G, XM_006722799.2:c.170T>G, XM_017026989.1:c.170T>G, XM_017026990.1:c.170T>G, XM_017026991.1:c.170T>G, ENST00000262948.9:c.170T>G, ENST00000394867.8:c.-122T>G, ENST00000599345.1:n.367T>G, NC_000019.10:g.4117552A>C, CM000681.2:g.4117552A>C, NC_000019.9:g.4117550A>C, CM000681.1:g.4117550A>C, NC_000019.8:g.4068550A>C, NG_007996.1:g.11577T>G, LRG_750:g.11577T>G, NM_030662.3(MAP2K2):c.170T>G (p.Phe57Cys)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PM5 [MET], PM1 [MET], PS3 [MET], PM6 [MET], PM2 [MET]	"The c.170T>G (p.Phe57Cys) variant in MAP2K2 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 16439621). In vitro functional studies provide some evidence that the p.Phe57Cys variant may impact protein function (PS3; PMID 16439621). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). A different pathogenic missense variant has been previously identified at this codon of MAP2K2 (p.Phe57Val for malignant melanoma) which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 8273). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common  (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe57Cys variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS3, PM2, PM5, PP2, PM1, PP3."	16439621	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA279958/MONDO:0015280/004	0.9749	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
19	4117551	8273	A	C	NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)	8273	CA279960	NM_030662.3:c.169T>G, NC_000019.10:g.4117553A>C, CM000681.2:g.4117553A>C, NC_000019.9:g.4117551A>C, CM000681.1:g.4117551A>C, NC_000019.8:g.4068551A>C, NG_007996.1:g.11576T>G, LRG_750:g.11576T>G, LRG_750t1:c.169T>G, XM_006722799.2:c.169T>G, XM_017026989.1:c.169T>G, XM_017026990.1:c.169T>G, XM_017026991.1:c.169T>G, ENST00000262948.9:c.169T>G, ENST00000394867.8:c.-123T>G, ENST00000599345.1:n.366T>G, NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PP2 [MET], PP3 [MET], PM1 [MET], PS2-Very Strong [MET], PM2 [MET]	"The c.169T>G (p.Phe57Val) variant in MAP2K2 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 18042262). The variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe57Val variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PM1, PM2, PP2, PP3."	18042262	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA279960/MONDO:0015280/004	0.9749	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
19	4110574	8275	G	T	NM_030662.3(MAP2K2):c.383C>A (p.Pro128Gln)	8275	CA279962	NM_030662.3:c.383C>A, LRG_750t1:c.383C>A, XM_006722799.2:c.383C>A, XM_017026989.1:c.383C>A, XM_017026990.1:c.383C>A, XM_017026991.1:c.383C>A, ENST00000262948.9:c.383C>A, ENST00000394867.8:c.92C>A, ENST00000599345.1:n.580C>A, NC_000019.10:g.4110576G>T, CM000681.2:g.4110576G>T, NC_000019.9:g.4110574G>T, CM000681.1:g.4110574G>T, NC_000019.8:g.4061574G>T, NG_007996.1:g.18553C>A, LRG_750:g.18553C>A, NM_030662.3(MAP2K2):c.383C>A (p.Pro128Gln)	MAP2K2	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PP1 [MET], PP3 [MET], PP2 [MET], PM1 [MET], PS3 [MET], PM2 [MET]	"The c.383C>A (p.Pro128Gln) variant in MAP2K2 has been reported in the literature to segregate with clinical features of a RASopathy in at least 7 family members (PP1_Strong; 20358587). In vitro functional studies provide some evidence that the p.Pro128Gln variant may impact protein function (PS3; PMID 20358587). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Pro128Gln variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K2 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP1_Strong, PS3, PM1, PM2, PP2, PP3."	20358587	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA279962/MONDO:0015280/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
11	76869378	11852	G	A	NM_000260.3(MYO7A):c.905G>A (p.Arg302His)	11852	CA132454	NM_000260.3:c.905G>A, NM_001127179.2:c.905G>A, NM_001127180.1:c.905G>A, XM_005274012.2:c.905G>A, XM_006718558.2:c.905G>A, XM_006718559.2:c.905G>A, XM_006718560.2:c.905G>A, XM_006718561.2:c.905G>A, XM_011545044.1:c.905G>A, XM_011545045.1:c.905G>A, XM_011545046.1:c.872G>A, XM_011545047.1:c.905G>A, XM_011545048.1:c.905G>A, XM_011545049.1:c.849+940G>A, XM_011545050.1:c.647G>A, XM_011545051.1:c.905G>A, XM_011545052.1:c.905G>A, XR_949938.1:n.1225G>A, XR_949941.1:n.1225G>A, XR_949942.1:n.1227G>A, XR_949943.1:n.1227G>A, XM_011545044.2:c.905G>A, XM_011545046.2:c.995G>A, XM_011545050.2:c.647G>A, XM_017017778.1:c.995G>A, XM_017017779.1:c.995G>A, XM_017017780.1:c.995G>A, XM_017017781.1:c.995G>A, XM_017017782.1:c.995G>A, XM_017017783.1:c.995G>A, XM_017017784.1:c.995G>A, XM_017017785.1:c.939+940G>A, XM_017017786.1:c.995G>A, XM_017017787.1:c.995G>A, XM_017017788.1:c.995G>A, XR_001747885.1:n.1010G>A, XR_001747886.1:n.1010G>A, XR_001747887.1:n.1010G>A, XR_001747888.1:n.1010G>A, XR_001747889.1:n.1010G>A, NM_000260.4:c.905G>A, ENST00000409619.6:c.872G>A, ENST00000409709.7:c.905G>A, ENST00000409893.5:c.905G>A, ENST00000458637.6:c.905G>A, ENST00000620575.4:c.905G>A, NC_000011.10:g.77158332G>A, CM000673.2:g.77158332G>A, NC_000011.9:g.76869378G>A, CM000673.1:g.76869378G>A, NC_000011.8:g.76547026G>A, NG_009086.1:g.35069G>A, NM_000260.3(MYO7A):c.905G>A (p.Arg302His)	MYO7A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Likely Benign	BS3-Supporting [MET], BP2 [MET], BP5 [Unmet], BS1 [MET]	"The filtering allele frequency of the c.905G>A (p.Arg302His) variant in the MYO7A gene is 0.4% for European chromosomes by gnomAD (587/126276 with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). While this variant has been reported in several individuals with Usher syndrome, in 2 individuals it was identified in cis with another pathogenic MYO7A variant (BP2; PMID 8900236). This variant has also been reported in at least 2 additional individuals with Usher syndrome who had alternate genetic etiologies identified (PMID: 25468891). In addition, in vitro functional evidence from one study suggests that the Arg302His variant had little effect on motor activity of MYO7A (BS3_Supporting PMID: 18700726). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BS1, BP2, BS3_Supporting."	18700726, 8900236, 25468891	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	22/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA132454/MONDO:0019501/005	0.3246	Likely Pathogenic	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	3	Uncertain Significance
16	68856041	12232	G	A	NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)	12232	CA121991	NM_004360.4:c.1849G>A, NM_004360.3:c.1849G>A, LRG_301t1:c.1849G>A, XM_011523488.1:c.1114G>A, XM_011523489.1:c.1114G>A, NM_001317184.1:c.1666G>A, NM_001317185.1:c.301G>A, NM_001317186.1:c.-117G>A, ENST00000261769.9:c.1849G>A, ENST00000422392.6:c.1666G>A, ENST00000562836.5:n.1920G>A, ENST00000566510.5:c.*515G>A, ENST00000566612.5:c.*89G>A, ENST00000611625.4:c.1912G>A, ENST00000612417.4:c.1830+19G>A, ENST00000621016.4:c.1849G>A, NC_000016.10:g.68822138G>A, CM000678.2:g.68822138G>A, NC_000016.9:g.68856041G>A, CM000678.1:g.68856041G>A, NC_000016.8:g.67413542G>A, NG_008021.1:g.89847G>A, LRG_301:g.89847G>A, NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BA1 [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	The c.1849G>A (p.Ala617Thr) variant has an allele frequency of 0.04479 (4.5%, 1076/24,022 alleles) in the African subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA121991/MONDO:0007648/007	0.0014	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
16	68867265	12233	A	G	NM_004360.4(CDH1):c.2512A>G (p.Ser838Gly)	12233	CA121994	NM_004360.4:c.2512A>G, NM_004360.3:c.2512A>G, LRG_301t1:c.2512A>G, XM_011523488.1:c.1777A>G, XM_011523489.1:c.1777A>G, NM_001317184.1:c.2329A>G, NM_001317185.1:c.964A>G, NM_001317186.1:c.547A>G, ENST00000261769.9:c.2512A>G, ENST00000422392.6:c.2329A>G, ENST00000562118.1:n.730A>G, ENST00000562836.5:n.2583A>G, ENST00000566510.5:c.*1178A>G, ENST00000566612.5:c.*752A>G, ENST00000611625.4:c.2575A>G, ENST00000612417.4:c.1854-829A>G, ENST00000621016.4:c.1866-841A>G, NC_000016.10:g.68833362A>G, CM000678.2:g.68833362A>G, NC_000016.9:g.68867265A>G, CM000678.1:g.68867265A>G, NC_000016.8:g.67424766A>G, NG_008021.1:g.101071A>G, LRG_301:g.101071A>G, NM_004360.4(CDH1):c.2512A>G (p.Ser838Gly)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [MET], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.2512A>G (p.Ser838Gly) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). There is no other supporting data that meet criteria for consideration. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA121994/MONDO:0007648/007	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
16	68855984	12241	C	T	NM_004360.4(CDH1):c.1792C>T (p.Arg598Ter)	12241	CA281000	NM_004360.4:c.1792C>T, NM_004360.3:c.1792C>T, LRG_301t1:c.1792C>T, XM_011523488.1:c.1057C>T, XM_011523489.1:c.1057C>T, NM_001317184.1:c.1609C>T, NM_001317185.1:c.244C>T, NM_001317186.1:c.-174C>T, ENST00000261769.9:c.1792C>T, ENST00000422392.6:c.1609C>T, ENST00000562836.5:n.1863C>T, ENST00000566510.5:c.*458C>T, ENST00000566612.5:c.*32C>T, ENST00000611625.4:c.1855C>T, ENST00000612417.4:c.1792C>T, ENST00000621016.4:c.1792C>T, NC_000016.10:g.68822081C>T, CM000678.2:g.68822081C>T, NC_000016.9:g.68855984C>T, CM000678.1:g.68855984C>T, NC_000016.8:g.67413485C>T, NG_008021.1:g.89790C>T, LRG_301:g.89790C>T, NM_004360.4(CDH1):c.1792C>T (p.Arg598Ter)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet], PP3 [Unmet], BS2 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS2 [MET], PS3 [Unmet], PS4 [MET], PS1 [Unmet], PP1-Strong [MET]	"The c.1792C>T (p.Arg598*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with >7 meioses observed across at least two families (PP1_Strong; PMID: 21696387, 16061854, 11419427 and SCV000275702.5). This variant has also been reported in at least four families meeting HDGC clinical criteria (PS4_Strong; PMID: 9751616, 21696387, 16061854, 11419427). There is one known de novo observation of this variant with parental confirmation in a patient with diffuse gastric cancer and/or lobular breast cancer (PS2; PMID: 21696387). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2, PP1_Strong, PS4, PS2."	21696387, 16061854, 21696387, 9751616, 16061854, 11419427, 21696387, 16061854	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA281000/MONDO:0007648/007	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68846047	12245	A	G	NM_004360.4(CDH1):c.1018A>G (p.Thr340Ala)	12245	CA288016	NM_004360.4:c.1018A>G, NM_004360.3:c.1018A>G, LRG_301t1:c.1018A>G, XM_011523488.1:c.283A>G, XM_011523489.1:c.283A>G, NM_001317184.1:c.1018A>G, NM_001317185.1:c.-598A>G, NM_001317186.1:c.-802A>G, ENST00000261769.9:c.1018A>G, ENST00000422392.6:c.1018A>G, ENST00000561751.1:n.640A>G, ENST00000562836.5:n.1089A>G, ENST00000565810.1:n.62A>G, ENST00000566510.5:c.862A>G, ENST00000566612.5:c.1018A>G, ENST00000611625.4:c.1018A>G, ENST00000612417.4:c.1018A>G, ENST00000621016.4:c.1018A>G, NC_000016.10:g.68812144A>G, CM000678.2:g.68812144A>G, NC_000016.9:g.68846047A>G, CM000678.1:g.68846047A>G, NC_000016.8:g.67403548A>G, NG_008021.1:g.79853A>G, LRG_301:g.79853A>G, NM_004360.4(CDH1):c.1018A>G (p.Thr340Ala)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BA1 [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	The c.1018A>G (p.Thr340Ala) variant has an allele frequency of 0.00360 (0.36%, 68/18,866 alleles) in the East Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA288016/MONDO:0007648/007	0.6752	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 0, 0] 	1	Uncertain Significance
12	25398304	12594	T	A	NM_004985.4(KRAS):c.15A>T (p.Lys5Asn)	12594	CA234191	NM_004985.4:c.15A>T, NM_033360.3:c.15A>T, XM_006719069.2:c.15A>T, XM_011520653.1:c.15A>T, XM_006719069.4:c.15A>T, XM_011520653.3:c.15A>T, ENST00000256078.8:c.15A>T, ENST00000311936.7:c.15A>T, ENST00000556131.1:c.15A>T, ENST00000557334.5:c.15A>T, NC_000012.12:g.25245370T>A, CM000674.2:g.25245370T>A, NC_000012.11:g.25398304T>A, CM000674.1:g.25398304T>A, NC_000012.10:g.25289571T>A, NG_007524.1:g.10551A>T, NM_004985.4(KRAS):c.15A>T (p.Lys5Asn)	KRAS	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PM6-Strong [MET], PS4-Moderate [MET], PM2 [MET]	"The c.15A>T (p.Lys5Asn) variant in KRAS has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; GeneDx, Institute of Human Genetics, Otto von Guericke University Magdeburg internal data GTR ID: 26957, 506381 PMID 17056636). The variant has been detected in This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The p.Lys5Asn variant has been identified in at least 4 independent occurrences in patients with a RASopathy (PS4_Moderate; EGL genetics internal data GTR ID: 500060; PMID: 17056636; ClinVar SCV000202928.6). Computational prediction tools and conservation analysis suggest that the p.Lys5Asn variant may impact the protein (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6_Strong, PM2, PS4_Moderate, PP3, PP2)"	17056636, 17056636	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA234191/MONDO:0018997/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
11	534289	12602	C	T	NM_005343.3(HRAS):c.34G>A (p.Gly12Ser)	12602	CA122549	NM_005343.3:c.34G>A, NC_000011.10:g.534289C>T, CM000673.2:g.534289C>T, NC_000011.9:g.534289C>T, CM000673.1:g.534289C>T, NC_000011.8:g.524289C>T, NG_007666.1:g.6262G>A, NM_001130442.1:c.34G>A, NM_005343.2:c.34G>A, NM_176795.3:c.34G>A, XM_011519875.1:c.-424-4309C>T, XM_011519877.1:c.-161-5291C>T, XR_242795.1:n.233G>A, NM_001130442.2:c.34G>A, NM_001318054.1:c.-286G>A, NM_176795.4:c.34G>A, XM_011519875.2:c.-424-4309C>T, XM_011519877.2:c.-161-5291C>T, XM_017017167.1:c.-499-4234C>T, XM_017017168.1:c.-499-4234C>T, NM_005343.4:c.34G>A, ENST00000311189.7:c.34G>A, ENST00000397594.5:c.34G>A, ENST00000397596.6:c.34G>A, ENST00000417302.5:c.34G>A, ENST00000451590.5:c.34G>A, ENST00000468682.2:n.522G>A, ENST00000482021.1:n.157G>A, ENST00000493230.5:c.34G>A, NM_005343.3(HRAS):c.34G>A (p.Gly12Ser)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PM1 [MET], PS4 [MET], PS3 [MET], PS2-Very Strong [MET], PM2 [MET]	"The c.34G>A (p.Gly12Ser) variant in HRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 16170316, 16835863, 16443854, 16835863, 16881968, 17054105, 19669404). The p.Gly12Ser variant has been identified in >5 independent occurrences in patients with clinical features of a RASopathy (PS4; PMID: 20660566, 16372351, 16329078, 16969868, 18039947, 19371735, 19206176, 16835863). In vitro functional studies provide some evidence that the p.Gly12Ser variant may impact protein function (PS3; PMID: 17412879). Computational prediction tools and conservation analysis suggest that the p.Gly12Ser variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PS3, PM1, PM2,  PP2, PP3."	29493581, 19206176, 19371735, 16329078, 16372351, 16969868, 16835863, 20660566, 18039947, 17412879, 17054105, 16443854, 19669404, 16170316, 16881968, 16835863	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA122549/MONDO:0009026/004	0.9941	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
11	533553	12605	T	C	NM_005343.3(HRAS):c.350A>G (p.Lys117Arg)	12605	CA256490	NM_005343.3:c.350A>G, NM_001130442.1:c.350A>G, NM_005343.2:c.350A>G, NM_176795.3:c.350A>G, XM_011519875.1:c.-424-5045T>C, XM_011519877.1:c.-162+5216T>C, XR_242795.1:n.549A>G, NM_001130442.2:c.350A>G, NM_001318054.1:c.31A>G, NM_176795.4:c.350A>G, XM_011519875.2:c.-424-5045T>C, XM_011519877.2:c.-162+5216T>C, XM_017017167.1:c.-499-4970T>C, XM_017017168.1:c.-499-4970T>C, NM_005343.4:c.350A>G, ENST00000311189.7:c.350A>G, ENST00000397594.5:c.350A>G, ENST00000397596.6:c.350A>G, ENST00000417302.5:c.350A>G, ENST00000451590.5:c.350A>G, ENST00000462734.1:n.43A>G, ENST00000478324.5:n.60A>G, ENST00000479482.1:n.271A>G, ENST00000493230.5:c.350A>G, NC_000011.10:g.533553T>C, CM000673.2:g.533553T>C, NC_000011.9:g.533553T>C, CM000673.1:g.533553T>C, NC_000011.8:g.523553T>C, NG_007666.1:g.6998A>G, NM_005343.3(HRAS):c.350A>G (p.Lys117Arg)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PM6-Strong [MET], PM1 [MET], PS3 [MET], PM2 [MET]	"The c.350A>G (p.Lys117Arg) variant in HRAS has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 16443854, 16155195). In vitro functional studies provide some evidence that the p.Lys117Arg variant may impact protein function (PS3; PMID 17979197, 21850009). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the p.Lys117Arg variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PS3, PM1, PM2, PP3."	16443854, 29493581, 21850009	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA256490/MONDO:0009026/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
11	534286	12606	C	A	NM_005343.3(HRAS):c.37G>T (p.Gly13Cys)	12606	CA295247	NM_005343.3:c.37G>T, NM_001130442.1:c.37G>T, NM_005343.2:c.37G>T, NM_176795.3:c.37G>T, XM_011519875.1:c.-424-4312C>A, XM_011519877.1:c.-161-5294C>A, XR_242795.1:n.236G>T, NM_001130442.2:c.37G>T, NM_001318054.1:c.-283G>T, NM_176795.4:c.37G>T, XM_011519875.2:c.-424-4312C>A, XM_011519877.2:c.-161-5294C>A, XM_017017167.1:c.-499-4237C>A, XM_017017168.1:c.-499-4237C>A, NM_005343.4:c.37G>T, ENST00000311189.7:c.37G>T, ENST00000397594.5:c.37G>T, ENST00000397596.6:c.37G>T, ENST00000417302.5:c.37G>T, ENST00000451590.5:c.37G>T, ENST00000468682.2:n.525G>T, ENST00000482021.1:n.160G>T, ENST00000493230.5:c.37G>T, NC_000011.10:g.534286C>A, CM000673.2:g.534286C>A, NC_000011.9:g.534286C>A, CM000673.1:g.534286C>A, NC_000011.8:g.524286C>A, NG_007666.1:g.6265G>T, NM_005343.3(HRAS):c.37G>T (p.Gly13Cys)	LRRC56	Noonan syndrome	MONDO:0018997	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PM1 [MET], PS4-Moderate [MET], PS2-Very Strong [MET], PM2 [MET]	"The c.37G>T (p.Gly13Cys) variant in HRAS has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 21438134, 16329078). The p.Gly13Cys variant has been identified in at least 3 other independent occurrence in patients with clinical features of a RASopathy (PS4_Moderate; PMID: 16372351). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gly13Cys variant may impact the protein (PP3). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581): PP2, PP3, PM1, PM2, PS4_Moderate, PS2_VeryStrong."	29493581, 16329078, 21438134	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA295247/MONDO:0018997/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
11	533883	12610	G	A	NM_176795.4(HRAS):c.173C>T (p.Thr58Ile)	12610	CA341206	NM_176795.4:c.173C>T, NM_001130442.1:c.173C>T, NM_005343.2:c.173C>T, NM_176795.3:c.173C>T, XM_011519875.1:c.-424-4715G>A, XM_011519877.1:c.-162+5546G>A, XR_242795.1:n.372C>T, NM_001130442.2:c.173C>T, NM_001318054.1:c.-147C>T, NM_005343.3:c.173C>T, XM_011519875.2:c.-424-4715G>A, XM_011519877.2:c.-162+5546G>A, XM_017017167.1:c.-499-4640G>A, XM_017017168.1:c.-499-4640G>A, NM_005343.4:c.173C>T, ENST00000311189.7:c.173C>T, ENST00000397594.5:c.173C>T, ENST00000397596.6:c.173C>T, ENST00000417302.5:c.173C>T, ENST00000451590.5:c.173C>T, ENST00000468682.2:n.661C>T, ENST00000479482.1:n.94C>T, ENST00000493230.5:c.173C>T, NC_000011.10:g.533883G>A, CM000673.2:g.533883G>A, NC_000011.9:g.533883G>A, CM000673.1:g.533883G>A, NC_000011.8:g.523883G>A, NG_007666.1:g.6668C>T, NM_176795.4(HRAS):c.173C>T (p.Thr58Ile)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PS4-Supporting [MET], PM1 [MET], PS1 [MET], PM6 [MET], PM2 [MET]	"The c.173C>T (p.Thr58Ile) variant in HRAS has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 20112233, 16474405). Also, at least 2 independent occurrences of this variant have been detected in patients with a RASopathy (PS4_Supporting; PMID: 22488832, 18247425, 23321623, 20949621, 16921267). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The p.Thr58Ile variant in HRAS is analogous to the same previously established amino acid change in the KRAS gene and the ClinGen RASopathy Expert Panel has defined that the pathogenicities of analogous variants in the HRAS and KRAS genes are correlated based on the assumption that a known functional residue in one gene is equivalent to other functions within that subgroup (PS1; 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581).  The variant is in HRAS, which has been defined by the ClinGen RASopathy Expert Panel as a gene with low rate of benign missense with missense variants commonly being pathogenic (PP2; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Thr58Ile variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS4_Supporting, PM2, PS1, PM1, PP2, PP3."	18247425, 16921267, 23321623, 22488832, 20949621, 20112233, 16474405	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA341206/MONDO:0009026/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
15	66727442	13350	T	C	NM_002755.3(MAP2K1):c.158T>C (p.Phe53Ser)	13350	CA279966	NM_002755.3:c.158T>C, LRG_725t1:c.158T>C, XM_011521783.1:c.92T>C, XM_011521783.3:c.92T>C, XM_017022411.2:c.158T>C, XM_017022412.1:c.92T>C, ENST00000307102.9:c.158T>C, ENST00000425818.2:n.669T>C, NC_000015.10:g.66435104T>C, CM000677.2:g.66435104T>C, NC_000015.9:g.66727442T>C, CM000677.1:g.66727442T>C, NC_000015.8:g.64514496T>C, NG_008305.1:g.53232T>C, LRG_725:g.53232T>C, NM_002755.3(MAP2K1):c.158T>C (p.Phe53Ser)	MAP2K1	cardiofaciocutaneous syndrome	MONDO:0015280	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PM1 [MET], PS3 [MET], PM6 [MET], PM2 [MET]	"The c.158T>C (p.Phe53Ser) variant in MAP2K1 has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; PMID 16439621). In vitro functional studies provide some evidence that the p.Phe53Ser variant may impact protein function (PS3; PMID 16439621). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the MAP2K1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of MAP2K1 (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe53Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID: 29493581):  PM6, PS3, PM2, PP2, PM1, PP3."	16439621, 16439621	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA279966/MONDO:0015280/004	0.9749	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 1, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36253011	14463	C	A	NM_001754.4(RUNX1):c.352-1G>T	14463	CA248609	NM_001754.4:c.352-1G>T, NM_001001890.2:c.271-1G>T, NM_001122607.1:c.271-1G>T, LRG_482t1:c.352-1G>T, XM_005261068.3:c.316-1G>T, XM_005261069.3:c.352-1G>T, XM_011529766.1:c.352-1G>T, XM_011529767.1:c.313-1G>T, XM_011529768.1:c.313-1G>T, XM_011529770.1:c.352-1G>T, XR_937576.1:n.531-1G>T, XM_005261069.4:c.352-1G>T, XM_011529766.2:c.352-1G>T, XM_011529767.2:c.313-1G>T, XM_011529768.2:c.313-1G>T, XM_011529770.2:c.352-1G>T, XM_017028487.1:c.199-1G>T, XR_937576.2:n.578-1G>T, ENST00000300305.7:c.352-1G>T, ENST00000344691.8:c.271-1G>T, ENST00000358356.9:c.271-1G>T, ENST00000399237.6:c.316-1G>T, ENST00000399240.5:c.271-1G>T, ENST00000437180.5:c.352-1G>T, ENST00000455571.5:c.313-1G>T, ENST00000482318.5:c.59-1G>T, NC_000021.9:g.34880714C>A, CM000683.2:g.34880714C>A, NC_000021.8:g.36253011C>A, CM000683.1:g.36253011C>A, NC_000021.7:g.35174881C>A, NG_011402.2:g.1108998G>T, LRG_482:g.1108998G>T, NM_001754.4(RUNX1):c.352-1G>T	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP1-Strong [MET], PP3 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [MET]	"The NM_001754.4:c.352-1G>T variant is a canonical splice site variant that is predicted to introduce a frameshift and a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1; PMID: 10508512). This variant was found to co-segregate with disease in multiple affected family members, with more than seven meioses (at least 25 affected individuals) observed in one family/across X families (PP1_Strong; 10508512). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PP1_Strong, PM2, PS4_Supporting."		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248609/MONDO:0011071/008	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36231782	14464	C	T	NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)	14464	CA248610	NM_001754.4:c.602G>A, NM_001001890.2:c.521G>A, NM_001122607.1:c.521G>A, LRG_482t1:c.602G>A, XM_005261068.3:c.566G>A, XM_005261069.3:c.602G>A, XM_011529766.1:c.602G>A, XM_011529767.1:c.563G>A, XM_011529768.1:c.563G>A, XM_011529770.1:c.602G>A, XR_937576.1:n.781G>A, XM_005261069.4:c.602G>A, XM_011529766.2:c.602G>A, XM_011529767.2:c.563G>A, XM_011529768.2:c.563G>A, XM_011529770.2:c.602G>A, XM_017028487.1:c.449G>A, XR_937576.2:n.828G>A, ENST00000300305.7:c.602G>A, ENST00000344691.8:c.521G>A, ENST00000358356.9:c.521G>A, ENST00000399237.6:c.566G>A, ENST00000399240.5:c.521G>A, ENST00000437180.5:c.602G>A, ENST00000467577.1:n.94G>A, ENST00000482318.5:c.*192G>A, NC_000021.9:g.34859485C>T, CM000683.2:g.34859485C>T, NC_000021.8:g.36231782C>T, CM000683.1:g.36231782C>T, NC_000021.7:g.35153652C>T, NG_011402.2:g.1130227G>A, LRG_482:g.1130227G>A, NM_001754.4(RUNX1):c.602G>A (p.Arg201Gln)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS1 [Unmet], PS4 [MET], PM4 [Unmet], PM1 [MET], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], PP3 [MET], PP1 [MET], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	"Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.602G>A (p.Arg201Gln) variant  and data from a secondary assays demonstrate altered DNA binding, CBFÎ² binding and sub-cellular localization (PS3; PMID: 17290219, 11830488, 23817177, 22318203, 25840971,  23848403). This variant has been reported in four probands meeting at least one of the RUNX1-phenotypic criteria (PS4; PMID: 27112265, 28748566, 10508512). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). The variant has a REVEL score >0.75 (0.94) (PP3). It was found to co-segregate with disease in multiple affected family members, with four meioses observed in across 3 families (PP1; PMID:  27112265, 28748566, 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PS4, PM1, PM2, PP1, PP3."	23817177, 22318203, 11830488, 23848403, 17290219, 25840971, 27112265, 10508512, 28748566, 27112265, 10508512, 28748566, 27112265, 10508512, 28748566	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248610/MONDO:0011071/008	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36259163	14465	T	C	NM_001754.4(RUNX1):c.328A>G (p.Lys110Glu)	14465	CA248613	NM_001754.4:c.328A>G, NC_000021.9:g.34886866T>C, CM000683.2:g.34886866T>C, NC_000021.8:g.36259163T>C, CM000683.1:g.36259163T>C, NC_000021.7:g.35181033T>C, NG_011402.2:g.1102846A>G, LRG_482:g.1102846A>G, NM_001001890.2:c.247A>G, NM_001122607.1:c.247A>G, LRG_482t1:c.328A>G, XM_005261068.3:c.292A>G, XM_005261069.3:c.328A>G, XM_011529766.1:c.328A>G, XM_011529767.1:c.289A>G, XM_011529768.1:c.289A>G, XM_011529770.1:c.328A>G, XR_937576.1:n.507A>G, XM_005261069.4:c.328A>G, XM_011529766.2:c.328A>G, XM_011529767.2:c.289A>G, XM_011529768.2:c.289A>G, XM_011529770.2:c.328A>G, XM_017028487.1:c.175A>G, XR_937576.2:n.554A>G, ENST00000300305.7:c.328A>G, ENST00000344691.8:c.247A>G, ENST00000358356.9:c.247A>G, ENST00000399237.6:c.292A>G, ENST00000399240.5:c.247A>G, ENST00000437180.5:c.328A>G, ENST00000455571.5:c.289A>G, ENST00000482318.5:c.59-6153A>G, NM_001754.4(RUNX1):c.328A>G (p.Lys110Glu)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [MET], PM5 [Unmet], PM4 [Unmet], PM1 [MET], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP1-Strong [MET], PP3 [MET], PS4-Supporting [MET], PVS1 [Unmet], PM2 [MET], PM6 [Unmet]	"Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.328A>G (p.Lys110Glu) variant and data from secondary assays demonstrate altered DNA binding, CBFÎ² binding and sub-cellular localization (PS3; PMID: 23848403; 17290219; 11830488). This variant was found to co-segregate with disease in multiple affected family members, with 7 meioses observed in one pedigree (PP1_Strong; PMID: 11830488). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.953) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PP1_Strong, PM1, PM2, PP3, PS4_Supporting."	11830488, 23848403, 17290219, 11830488, 11830488, 11830488	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248613/MONDO:0011071/008	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36252850	14466	GT	G	NM_001754.4(RUNX1):c.508+3delA	14466	CA248618	NM_001754.4:c.508+3delA, NM_001001890.2:c.427+3del, NM_001122607.1:c.427+3del, NM_001754.4:c.508+3del, LRG_482t1:c.508+3del, XM_005261068.3:c.472+3del, XM_005261069.3:c.508+3del, XM_011529766.1:c.508+3del, XM_011529767.1:c.469+3del, XM_011529768.1:c.469+3del, XM_011529770.1:c.508+3del, XR_937576.1:n.687+3del, XM_005261069.4:c.508+3del, XM_011529766.2:c.508+3del, XM_011529767.2:c.469+3del, XM_011529768.2:c.469+3del, XM_011529770.2:c.508+3del, XM_017028487.1:c.355+3del, XR_937576.2:n.734+3del, ENST00000300305.7:c.508+3del, ENST00000344691.8:c.427+3del, ENST00000358356.9:c.427+3del, ENST00000399237.6:c.472+3del, ENST00000399240.5:c.427+3del, ENST00000437180.5:c.508+3del, ENST00000482318.5:c.*98+3del, NC_000021.9:g.34880554del, CM000683.2:g.34880554del, NC_000021.8:g.36252851del, CM000683.1:g.36252851del, NC_000021.7:g.35174721del, NG_011402.2:g.1109158del, LRG_482:g.1109158del, NM_001754.4(RUNX1):c.508+3delA	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS3 [MET], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP1-Strong [MET], PP3 [MET], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	"There is RT-PCR assay evidence demonstrating that the NM_001754.4:c.508+3delA variant creates a cryptic splice donor site that is used and results in a frameshift and introduction of premature termination codon (PS3; PMID: 11830488). This variant was found to co-segregate with disease in multiple affected family members, with eight meioses observed in one family (PP1_Strong; PMID: 11830488). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This intronic variant (in intron 5) is located in reference to the exon at positions +3 for donor splice site and have a predicted decrease in the score of the canonical splice site by at least 75% (measured by both MES and SSF). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PP1_Strong, PM2, PP3, PS4_Supporting."	11830488, 11830488, 11830488, 11830488	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248618/MONDO:0011071/008	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36171704	14467	G	T	NM_001754.4(RUNX1):c.861C>A (p.Tyr287Ter)	14467	CA248619	NM_001754.4:c.861C>A, NM_001001890.2:c.780C>A, LRG_482t1:c.861C>A, XM_005261068.3:c.825C>A, XM_005261069.3:c.669C>A, XM_011529766.1:c.861C>A, XM_011529767.1:c.822C>A, XM_011529768.1:c.630C>A, XR_937576.1:n.1040C>A, XM_005261069.4:c.669C>A, XM_011529766.2:c.861C>A, XM_011529767.2:c.822C>A, XM_011529768.2:c.630C>A, XM_017028487.1:c.708C>A, XR_937576.2:n.1087C>A, ENST00000300305.7:c.861C>A, ENST00000344691.8:c.780C>A, ENST00000399240.5:c.588C>A, ENST00000437180.5:c.861C>A, ENST00000482318.5:c.*451C>A, NC_000021.9:g.34799407G>T, CM000683.2:g.34799407G>T, NC_000021.8:g.36171704G>T, CM000683.1:g.36171704G>T, NC_000021.7:g.35093574G>T, NG_011402.2:g.1190305C>A, LRG_482:g.1190305C>A, NM_001754.4(RUNX1):c.861C>A (p.Tyr287Ter)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS3 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP1-Strong [MET], PP3 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [MET]	"The NM_001754.4:c.861C>A (p.Tyr287Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed in one family (PP1_Strong; PMID: 11830488). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). The variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting;  PMID: 11830488). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PP1_Strong, PM2, PS4_Supporting."	11830488, 11830488, 11830488	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248619/MONDO:0011071/008	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36252962	14468	C	G	NM_001754.4(RUNX1):c.400G>C (p.Ala134Pro)	14468	CA248623	NM_001754.4:c.400G>C, NC_000021.9:g.34880665C>G, CM000683.2:g.34880665C>G, NC_000021.8:g.36252962C>G, CM000683.1:g.36252962C>G, NC_000021.7:g.35174832C>G, NG_011402.2:g.1109047G>C, LRG_482:g.1109047G>C, NM_001001890.2:c.319G>C, NM_001122607.1:c.319G>C, LRG_482t1:c.400G>C, XM_005261068.3:c.364G>C, XM_005261069.3:c.400G>C, XM_011529766.1:c.400G>C, XM_011529767.1:c.361G>C, XM_011529768.1:c.361G>C, XM_011529770.1:c.400G>C, XR_937576.1:n.579G>C, XM_005261069.4:c.400G>C, XM_011529766.2:c.400G>C, XM_011529767.2:c.361G>C, XM_011529768.2:c.361G>C, XM_011529770.2:c.400G>C, XM_017028487.1:c.247G>C, XR_937576.2:n.626G>C, ENST00000300305.7:c.400G>C, ENST00000344691.8:c.319G>C, ENST00000358356.9:c.319G>C, ENST00000399237.6:c.364G>C, ENST00000399240.5:c.319G>C, ENST00000437180.5:c.400G>C, ENST00000455571.5:c.361G>C, ENST00000482318.5:c.107G>C, NM_001754.4(RUNX1):c.400G>C (p.Ala134Pro)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [MET], PS1 [Unmet], PS3 [MET], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [MET], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	"Transactivation assays demonstrate altered transactivation (<20% of wt) for the missense variant, NM_001754.4:c.400G>C (p.Ala134Pro) and data from secondary assays demonstrate altered CBFÎ² binding and sub-cellular localization.(PS3; PMID: 23848403). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). It has a REVEL score >0.75 (0.945) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 12060124). It was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 12060124). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM1, PM2, PP1, PP3, PS4_Supporting."	23848403, 12060124, 12060124, 12060124	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248623/MONDO:0011071/008	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36259238	14469	G	T	NM_001754.4(RUNX1):c.253C>A (p.His85Asn)	14469	CA123975	NM_001754.4:c.253C>A, NM_001001890.2:c.172C>A, NM_001122607.1:c.172C>A, LRG_482t1:c.253C>A, XM_005261068.3:c.217C>A, XM_005261069.3:c.253C>A, XM_011529766.1:c.253C>A, XM_011529767.1:c.214C>A, XM_011529768.1:c.214C>A, XM_011529770.1:c.253C>A, XR_937576.1:n.432C>A, XM_005261069.4:c.253C>A, XM_011529766.2:c.253C>A, XM_011529767.2:c.214C>A, XM_011529768.2:c.214C>A, XM_011529770.2:c.253C>A, XM_017028487.1:c.100C>A, XR_937576.2:n.479C>A, ENST00000300305.7:c.253C>A, ENST00000344691.8:c.172C>A, ENST00000358356.9:c.172C>A, ENST00000399237.6:c.217C>A, ENST00000399240.5:c.172C>A, ENST00000437180.5:c.253C>A, ENST00000455571.5:c.214C>A, ENST00000482318.5:c.59-6228C>A, NC_000021.9:g.34886941G>T, CM000683.2:g.34886941G>T, NC_000021.8:g.36259238G>T, CM000683.1:g.36259238G>T, NC_000021.7:g.35181108G>T, NG_011402.2:g.1102771C>A, LRG_482:g.1102771C>A, NM_001754.4(RUNX1):c.253C>A (p.His85Asn)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [MET], BS4 [Unmet], BS1 [MET], PP3 [MET], PP1 [Unmet], PM6 [Unmet], PM2 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.253C>A (p.His85Asn) variant has a MAF of 0.00043 (0.043%, 8/18,768 alleles) in the East Asian subpopulation of the gnomAD cohort that is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). This missense variant has a REVEL score >0.75 (0.852) (PP3). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding, CBFÎ² binding and sub-cellular localization (BS3; PMID: 23817177, PMID: 10068652). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BS3, PP3."	10068652, 12200707, 10068652, 23817177	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA123975/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36252912	14470	GGCTGCGGT	G	NM_001754.4(RUNX1):c.442_449delACCGCAGC (p.Thr148Hisfs)	14470	CA248627	NM_001754.4:c.442_449delACCGCAGC, NM_001001890.2:c.361_368del, NM_001122607.1:c.361_368del, NM_001754.4:c.442_449del, LRG_482t1:c.442_449del, XM_005261068.3:c.406_413del, XM_005261069.3:c.442_449del, XM_011529766.1:c.442_449del, XM_011529767.1:c.403_410del, XM_011529768.1:c.403_410del, XM_011529770.1:c.442_449del, XR_937576.1:n.621_628del, XM_005261069.4:c.442_449del, XM_011529766.2:c.442_449del, XM_011529767.2:c.403_410del, XM_011529768.2:c.403_410del, XM_011529770.2:c.442_449del, XM_017028487.1:c.289_296del, XR_937576.2:n.668_675del, ENST00000300305.7:c.442_449del, ENST00000344691.8:c.361_368del, ENST00000358356.9:c.361_368del, ENST00000399237.6:c.406_413del, ENST00000399240.5:c.361_368del, ENST00000437180.5:c.442_449del, ENST00000455571.5:c.403_410del, ENST00000482318.5:c.*32_*39del, NC_000021.9:g.34880616_34880623del, CM000683.2:g.34880616_34880623del, NC_000021.8:g.36252913_36252920del, CM000683.1:g.36252913_36252920del, NC_000021.7:g.35174783_35174790del, NG_011402.2:g.1109089_1109096del, LRG_482:g.1109089_1109096del, NM_001754.4(RUNX1):c.442_449delACCGCAGC (p.Thr148Hisfs)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [MET]	"The NM_001754.4(RUNX1):c.442_449delACCGCAGC (p.Thr148Hisfs) variant is a frameshift variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting;  PMID: 27112265). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2, PS4_Supporting."	27112265, 27112265, 27112265	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248627/MONDO:0011071/008	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36252895	14471	G	T	NM_001754.4(RUNX1):c.467C>A (p.Ala156Glu)	14471	CA248628	NM_001754.4:c.467C>A, NM_001001890.2:c.386C>A, NM_001122607.1:c.386C>A, LRG_482t1:c.467C>A, XM_005261068.3:c.431C>A, XM_005261069.3:c.467C>A, XM_011529766.1:c.467C>A, XM_011529767.1:c.428C>A, XM_011529768.1:c.428C>A, XM_011529770.1:c.467C>A, XR_937576.1:n.646C>A, XM_005261069.4:c.467C>A, XM_011529766.2:c.467C>A, XM_011529767.2:c.428C>A, XM_011529768.2:c.428C>A, XM_011529770.2:c.467C>A, XM_017028487.1:c.314C>A, XR_937576.2:n.693C>A, ENST00000300305.7:c.467C>A, ENST00000344691.8:c.386C>A, ENST00000358356.9:c.386C>A, ENST00000399237.6:c.431C>A, ENST00000399240.5:c.386C>A, ENST00000437180.5:c.467C>A, ENST00000482318.5:c.*57C>A, NC_000021.9:g.34880598G>T, CM000683.2:g.34880598G>T, NC_000021.8:g.36252895G>T, CM000683.1:g.36252895G>T, NC_000021.7:g.35174765G>T, NG_011402.2:g.1109114C>A, LRG_482:g.1109114C>A, NM_001754.4(RUNX1):c.467C>A (p.Ala156Glu)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PM1-Supporting [MET], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP1-Strong [MET], PP3 [MET], PS4-Supporting [MET], PM6 [Unmet], PM2 [MET], PVS1 [Unmet]	"The NM_001754.4:c.467C>A (p.Ala156Glu) variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed in one family (PP1_Strong; PMID: 19357396, 27112265). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). It affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This missense variant has a REVEL score >0.75 (0.906) (PP3). It has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 19357396, 27112265). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP1_Strong, PM2, PP3, PM1_Supporting, PS4_Supporting."	27112265, 19357396, 27112265, 19357396, 27112265, 19357396	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248628/MONDO:0011071/008	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763620	17000	A	G	NM_004004.5(GJB2):c.101T>C (p.Met34Thr)	17000	CA172206	NM_004004.5:c.101T>C, NC_000013.11:g.20189481A>G, CM000675.2:g.20189481A>G, NC_000013.10:g.20763620A>G, CM000675.1:g.20763620A>G, NC_000013.9:g.19661620A>G, NG_008358.1:g.8495T>C, XM_011535049.1:c.101T>C, XM_011535049.2:c.101T>C, NM_004004.6:c.101T>C, ENST00000382844.1:c.101T>C, ENST00000382848.4:c.101T>C, NM_004004.5(GJB2):c.101T>C (p.Met34Thr)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP1 [MET], PP3 [MET], PP4 [Unmet], PM3-Very Strong [MET], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [Unmet], PS4 [MET], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PM5 [Unmet], PM1 [Unmet], PM4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS4 [Unmet], BS1 [Unmet]	"The filtering allele frequency (the lower threshold of the 95% CI of 510/25108) of the c.101T>C (p.Met34Thr) variant in the GJB2 gene is 1.46% for European (non-Finnish) genomes in gnomAD. This is a high enough frequency that, in the absence of conflicting data, might warrant a benign classification based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). However, based on the evidence outlined below, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs its high allele frequency in population databases. Therefore, the BA1 code will not contribute to the overall classification. The homozygous genotype and compound heterozygous genotype with another variant in GJB2 have shown to be statistically enriched in patients with nonsyndromic sensorineural hearing loss compared to individuals representative of the general population in gnomAD and/or those who underwent carrier screening at Counsyl. (PS4; PMID: 31160754). This study also reported the variant in 27 homozygous affected probands, 17 affected probands with the p.Val37Ile variant in trans, 138 affected probands with a variant asserted to be P/LP in ClinVar, and 78 affected probands with a premature GJB2 termination codon in trans (PM3; PMID 31160754). The REVEL computational prediction analysis tool produced a score of 0.702, which is above the threshold necessary to apply PP3. Most dye transfer and electrical coupling assays support that the variant impacts protein function (PMID: 16849369, 12189493, 10556284, 16300957, 15033936, 12189493); however, some assays showed partial function (PMID: 27884957), and therefore this evidence was not counted. At least 16 segregations of the p.Met34Thr variant in family members have been described (PP1_Strong, PMID: 31160754, 10903123). Of note, the severity of hearing loss is known to be mild on average and there have been multiple accounts of incomplete penetrance of the variant in families/individuals with p.Met34Thr in a biallelic genotype. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic genetic hearing lossbased on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PP1_Strong, PM3, PP3."	31160754, 31160754, 10903123, 31160754, 14694360, 31160754, 31160754, 31160754, 31160754, 15033936, 27884957, 16300957, 10556284, 12189493, 16849369, 10903123, 31160754, 14694360, 31160754	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA172206/MONDO:0019497/005	0.1	VUS	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
13	20763650	17002	C	T	NM_004004.5(GJB2):c.71G>A (p.Trp24Ter)	17002	CA172240	NM_004004.5:c.71G>A, XM_011535049.1:c.71G>A, XM_011535049.2:c.71G>A, NM_004004.6:c.71G>A, ENST00000382844.1:c.71G>A, ENST00000382848.4:c.71G>A, NC_000013.11:g.20189511C>T, CM000675.2:g.20189511C>T, NC_000013.10:g.20763650C>T, CM000675.1:g.20763650C>T, NC_000013.9:g.19661650C>T, NG_008358.1:g.8465G>A, NM_004004.5(GJB2):c.71G>A (p.Trp24Ter)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PM6 [Unmet], PVS1 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], PM3-Very Strong [MET], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [Unmet], PS3 [MET], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [MET], BS4 [Unmet]	"The filtering allele frequency of the p.Trp24X variant in the GJB2 gene is 0.38% (137/ 30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). However, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BS1 code will not contribute to the overall classification. The p.Trp24X variant in GJB2 is predicted to cause a premature stop codon in the only exon of GJB2 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 15070423, 24123366, 18941476, 9139825). A knock-in mouse model demonstrates that the p.Trp24X variant leads to the phenotype (PS3; PMID:18941476).  In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS3, BS1."	9139825, 18941476, 24123366, 15070423, 9139825, 18941476, 24123366, 15070423, 18941476	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	17/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA172240/MONDO:0019497/005	0.9986	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763685	17004	AC	A	NM_004004.5(GJB2):c.35delG (p.Gly12Valfs)	17004	CA127023	NM_004004.5:c.35del, NM_004004.5:c.35delG, NC_000013.11:g.20189552del, CM000675.2:g.20189552del, NC_000013.10:g.20763691del, CM000675.1:g.20763691del, NC_000013.9:g.19661691del, NG_008358.1:g.8429del, XM_011535049.1:c.35del, XM_011535049.2:c.35del, NM_004004.6:c.35del, ENST00000382844.1:c.35del, ENST00000382848.4:c.35del, NM_004004.5(GJB2):c.35delG (p.Gly12Valfs)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], PM3-Very Strong [MET], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [MET], PS4 [MET], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.35delG variant in GJB2 is predicted to cause a premature stop codon in biologically-relevant-exon 2/2 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 26445815). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMID: 26969326, 25999548). The filtering allele frequency of the c.35delG variant in the GJB2 gene is 0.9% for European (Non-Finnish) chromosomes in the Genome Aggregation Database (1207/124552 with 95% CI), which is  a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BA1 code will not contribute to the overall classification. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive non-syndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS4, BA1."	26969326, 25999548	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	20/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA127023/MONDO:0019497/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763485	17014	AG	A	NM_004004.5(GJB2):c.235delC (p.Leu79Cysfs)	17014	CA127025	NM_004004.5:c.235del, NM_004004.5:c.235delC, XM_011535049.1:c.235del, XM_011535049.2:c.235del, NM_004004.6:c.235del, ENST00000382844.1:c.235del, ENST00000382848.4:c.235del, NC_000013.11:g.20189349del, CM000675.2:g.20189349del, NC_000013.10:g.20763488del, CM000675.1:g.20763488del, NC_000013.9:g.19661488del, NG_008358.1:g.8629del, NM_004004.5(GJB2):c.235delC (p.Leu79Cysfs)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PVS1 [MET], PP3 [Unmet], PS3-Moderate [MET], PM3-Very Strong [MET], BA1 [Unmet], BS1 [MET]	"The filtering allele frequency of the p.Leu79CysfsX3 variant in the GJB2 gene is 0.55% (121/ 18870) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). The ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs the high allele frequency of the variant in population databases. Therefore, the BS1 code will not contribute to the overall classification. The p.Leu79CysfsX3 variant in GJB2 is predicted to cause a premature stop codon in the only exon of the gene, leading to absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 10983956, 10633133). A dye transfer assay, a functional study, has shown that the variant impacts protein function (PS3_M; PMID: 12352684). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_VS, PS3_M, BS1."	12352684, 10983956, 10633133	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	14/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA127025/MONDO:0019497/005	0.9492	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68845762	18453	G	T	NM_004360.4(CDH1):c.1008G>T (p.Glu336Asp)	18453	CA280990	NM_004360.4:c.1008G>T, NM_004360.3:c.1008G>T, LRG_301t1:c.1008G>T, XM_011523488.1:c.273G>T, XM_011523489.1:c.273G>T, NM_001317184.1:c.1008G>T, NM_001317185.1:c.-608G>T, NM_001317186.1:c.-812G>T, ENST00000261769.9:c.1008G>T, ENST00000422392.6:c.1008G>T, ENST00000561751.1:n.630G>T, ENST00000562836.5:n.1079G>T, ENST00000566510.5:c.852G>T, ENST00000566612.5:c.1008G>T, ENST00000611625.4:c.1008G>T, ENST00000612417.4:c.1008G>T, ENST00000621016.4:c.1008G>T, NC_000016.10:g.68811859G>T, CM000678.2:g.68811859G>T, NC_000016.9:g.68845762G>T, CM000678.1:g.68845762G>T, NC_000016.8:g.67403263G>T, NG_008021.1:g.79568G>T, LRG_301:g.79568G>T, NM_004360.4(CDH1):c.1008G>T (p.Glu336Asp)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS1 [Unmet], PS2 [Unmet], PVS1-Moderate [MET]	"The c.1008G>T (p.Glu336Asp) variant results in a G to non-G change at the last nucleotide of an exon (PVS1_Moderate). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). There is an RNA assay demonstrating an abnormal out-of-frame transcript for this variant (PS3; PMID: 9537325). Additionally, the variant has also been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 9537325). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Moderate, PM2, PS3, PS4_Supporting."	9537325	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA280990/MONDO:0007648/007	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763382	21385	A	C	NM_004004.5(GJB2):c.339T>G (p.Ser113Arg)	21385	CA342004	NM_004004.5:c.339T>G, XM_011535049.1:c.339T>G, XM_011535049.2:c.339T>G, NM_004004.6:c.339T>G, ENST00000382844.1:c.339T>G, ENST00000382848.4:c.339T>G, NC_000013.11:g.20189243A>C, CM000675.2:g.20189243A>C, NC_000013.10:g.20763382A>C, CM000675.1:g.20763382A>C, NC_000013.9:g.19661382A>C, NG_008358.1:g.8733T>G, NM_004004.5(GJB2):c.339T>G (p.Ser113Arg)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PP3 [Unmet], PS3-Moderate [MET], PM2-Supporting [MET], BP4 [Unmet], PM3 [MET]	"The allele frequency of the c.339T>G (p.Ser113Arg) variant in the GJB2 gene is 0.02% (3/10064) of Ashkenazi Jewish chromosomes by gnomAD, which is a low enough frequency to apply PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_Supporting). The REVEL computational prediction analysis tool produced a score of 0.55, which does not meet the threshold necessary to apply PP3 or BP4. An in vitro functional study performed in Xenopus oocytes showed that variant junctional conductance for p.Ser113Arg was similar to water (negative control), indicating a loss of function impact on protein function (PS3_Moderate; PMID:12505163). The p.Ser113Arg variant has been reported in at least 5 probands with hearing loss, and  2 individuals were compound heterozygous for a pathogenic variant without phase confirmation (PM3, PMID: 15365987, 11439000, 9529365, 16380907, 23826813).  In summary, although there is some evidence for pathogenicity the clinical significance of this variant is currently uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : PS3_Moderate, PM3, PM2_Supporting."	12505163, 9529365, 16380907, 11439000, 15365987, 24078562	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA342004/MONDO:0019497/005	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 0, 0] 	1	Uncertain Significance
10	89711882	39668	C	A	NM_000314.6(PTEN):c.500C>A (p.Thr167Asn)	39668	CA000487	NM_000314.6:c.500C>A, NM_000314.5:c.500C>A, NM_001304717.2:c.1019C>A, NM_001304718.1:c.-92C>A, XM_006717926.2:c.455C>A, XM_011539981.1:c.500C>A, XM_011539982.1:c.404C>A, XR_945789.1:n.1371C>A, XR_945790.1:n.1488C>A, XR_945791.1:n.1205-5728C>A, NM_000314.7:c.500C>A, NM_001304717.5:c.1019C>A, NM_001304718.2:c.-92C>A, ENST00000371953.7:c.500C>A, NC_000010.11:g.87952125C>A, CM000672.2:g.87952125C>A, NC_000010.10:g.89711882C>A, CM000672.1:g.89711882C>A, NC_000010.9:g.89701862C>A, NG_007466.2:g.93687C>A, LRG_311:g.93687C>A, NM_000314.6(PTEN):c.500C>A (p.Thr167Asn)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1 [Unmet], PM2 [MET], PM6 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [MET]	PTEN c.500C>A (p.Thr167Asn) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 23160955)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	28250423, 23160955, 28250423, 23160955, 23160955	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000487/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
10	89692908	39669	C	T	NM_000314.6(PTEN):c.392C>T (p.Thr131Ile)	39669	CA000442	NM_000314.6:c.392C>T, NM_000314.5:c.392C>T, NM_001304717.2:c.911C>T, NM_001304718.1:c.-359C>T, XM_006717926.2:c.347C>T, XM_011539981.1:c.392C>T, XM_011539982.1:c.296C>T, XR_945789.1:n.1104C>T, XR_945790.1:n.1104C>T, XR_945791.1:n.1104C>T, NM_000314.7:c.392C>T, NM_001304717.5:c.911C>T, NM_001304718.2:c.-359C>T, ENST00000371953.7:c.392C>T, ENST00000498703.1:n.218C>T, ENST00000610634.1:c.290C>T, NC_000010.11:g.87933151C>T, CM000672.2:g.87933151C>T, NC_000010.10:g.89692908C>T, CM000672.1:g.89692908C>T, NC_000010.9:g.89682888C>T, NG_007466.2:g.74713C>T, LRG_311:g.74713C>T, NM_000314.6(PTEN):c.392C>T (p.Thr131Ile)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP4 [Unmet], PP1 [Unmet], PM6-Strong [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS4-Moderate [MET], PS1 [Unmet], PS2 [Unmet], PS3 [MET], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.392C>T (p.Thr131Ile) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 21828076)PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (PMID 23160955, 23335809 author communication)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 23160955, 23335809)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	23335809, 23160955, 23335809, 28250423, 23160955, 23335809, 23160955, 23335809, 28250423, 29785012, 21828076, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000442/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
7	140624468	40333	C	T	NM_004333.4(BRAF):c.36G>A (p.Ala12=)	40333	CA281921	NM_004333.4:c.36G>A, LRG_299t1:c.36G>A, XM_005250045.1:c.36G>A, XM_005250046.1:c.36G>A, XM_011516529.1:c.36G>A, XM_011516530.1:c.36G>A, XR_242190.1:n.44G>A, XR_927520.1:n.44G>A, XR_927521.1:n.44G>A, XR_927522.1:n.44G>A, XR_927523.1:n.44G>A, NM_001354609.1:c.36G>A, NM_004333.5:c.36G>A, NR_148928.1:n.261G>A, XM_017012558.1:c.36G>A, XM_017012559.1:c.36G>A, XR_001744857.1:n.44G>A, XR_001744858.1:n.44G>A, ENST00000288602.10:c.36G>A, ENST00000469930.1:n.42G>A, NC_000007.14:g.140924668C>T, CM000669.2:g.140924668C>T, NC_000007.13:g.140624468C>T, CM000669.1:g.140624468C>T, NC_000007.12:g.140270937C>T, NG_007873.3:g.5097G>A, LRG_299:g.5097G>A, NM_004333.4(BRAF):c.36G>A (p.Ala12=)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.36G>A (p.Ala12=) variant in the BRAF gene is 0.116% (14/7290) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA281921/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
11	534242	40431	A	G	NM_005343.3(HRAS):c.81T>C (p.His27=)	40431	CA135996	NM_005343.3:c.81T>C, NC_000011.10:g.534242A>G, CM000673.2:g.534242A>G, NC_000011.9:g.534242A>G, CM000673.1:g.534242A>G, NC_000011.8:g.524242A>G, NG_007666.1:g.6309T>C, NM_001130442.1:c.81T>C, NM_005343.2:c.81T>C, NM_176795.3:c.81T>C, XM_011519875.1:c.-424-4356A>G, XM_011519877.1:c.-161-5338A>G, XR_242795.1:n.280T>C, NM_001130442.2:c.81T>C, NM_001318054.1:c.-239T>C, NM_176795.4:c.81T>C, XM_011519875.2:c.-424-4356A>G, XM_011519877.2:c.-161-5338A>G, XM_017017167.1:c.-499-4281A>G, XM_017017168.1:c.-499-4281A>G, NM_005343.4:c.81T>C, ENST00000311189.7:c.81T>C, ENST00000397594.5:c.81T>C, ENST00000397596.6:c.81T>C, ENST00000417302.5:c.81T>C, ENST00000451590.5:c.81T>C, ENST00000468682.2:n.569T>C, ENST00000493230.5:c.81T>C, NM_005343.3(HRAS):c.81T>C (p.His27=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.81T>C (p.His27=) variant in the HRAS gene is 36.7% for African chromosomes by the Exome Aggregation Consortium (3874/10274 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additional case-level data provided by: SCV000058315; SCV000062146; SCV000196686."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135996/MONDO:0021060/004	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
11	533881	40435	C	T	NM_005343.3(HRAS):c.175G>A (p.Ala59Thr)	40435	CA176353	NM_005343.3:c.175G>A, NC_000011.10:g.533881C>T, CM000673.2:g.533881C>T, NC_000011.9:g.533881C>T, CM000673.1:g.533881C>T, NC_000011.8:g.523881C>T, NG_007666.1:g.6670G>A, NM_001130442.1:c.175G>A, NM_005343.2:c.175G>A, NM_176795.3:c.175G>A, XM_011519875.1:c.-424-4717C>T, XM_011519877.1:c.-162+5544C>T, XR_242795.1:n.374G>A, NM_001130442.2:c.175G>A, NM_001318054.1:c.-145G>A, NM_176795.4:c.175G>A, XM_011519875.2:c.-424-4717C>T, XM_011519877.2:c.-162+5544C>T, XM_017017167.1:c.-499-4642C>T, XM_017017168.1:c.-499-4642C>T, NM_005343.4:c.175G>A, ENST00000311189.7:c.175G>A, ENST00000397594.5:c.175G>A, ENST00000397596.6:c.175G>A, ENST00000417302.5:c.175G>A, ENST00000451590.5:c.175G>A, ENST00000468682.2:n.663G>A, ENST00000479482.1:n.96G>A, ENST00000493230.5:c.175G>A, NM_005343.3(HRAS):c.175G>A (p.Ala59Thr)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Likely Pathogenic	PP1 [MET], PP3 [MET], PP2 [MET], PS4-Supporting [MET], PM1 [MET], PM2 [MET]	"The c.175G>A (p.Ala59Thr) variant has been identified in at least 2 independent occurrences in patients with a RASopathy (PS4_Supporting; GeneDx, Partners LMM internal data; GTR ID's: 26957, 21766; ClinVar SCV000198374; SCV000207851). The p.Ala59Thr variant in HRAS has been reported in the literature to segregate with clinical features of a RASopathy in at least 3 family members (PP1; SCV000198374). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of HRAS (PM1; PMID 29493581). Computational prediction tools and conservation analysis suggest that the p.Ala59Thr variant may impact the protein (PP3). The variant is located in the HRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP1, PP2, PP3, PS4_Supporting, PM1, PM2."	29493581	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA176353/MONDO:0009026/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
11	533799	40437	T	G	NM_005343.3(HRAS):c.257A>C (p.Asn86Thr)	40437	CA180888	NM_005343.3:c.257A>C, NM_001130442.1:c.257A>C, NM_005343.2:c.257A>C, NM_176795.3:c.257A>C, XM_011519875.1:c.-424-4799T>G, XM_011519877.1:c.-162+5462T>G, XR_242795.1:n.456A>C, NM_001130442.2:c.257A>C, NM_001318054.1:c.-63A>C, NM_176795.4:c.257A>C, XM_011519875.2:c.-424-4799T>G, XM_011519877.2:c.-162+5462T>G, XM_017017167.1:c.-499-4724T>G, XM_017017168.1:c.-499-4724T>G, NM_005343.4:c.257A>C, ENST00000311189.7:c.257A>C, ENST00000397594.5:c.257A>C, ENST00000397596.6:c.257A>C, ENST00000417302.5:c.257A>C, ENST00000451590.5:c.257A>C, ENST00000468682.2:n.745A>C, ENST00000479482.1:n.178A>C, ENST00000493230.5:c.257A>C, NC_000011.10:g.533799T>G, CM000673.2:g.533799T>G, NC_000011.9:g.533799T>G, CM000673.1:g.533799T>G, NC_000011.8:g.523799T>G, NG_007666.1:g.6752A>C, NM_005343.3(HRAS):c.257A>C (p.Asn86Thr)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5 [MET], BA1 [MET]	"The filtering allele frequency of the c.257A>C (p.Asn86Thr) variant in the HRAS gene is 0.07% for African chromosomes by the Exome Aggregation Consortium (12/10342 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).This variant has been identified in a patient with an alternate molecular basis for disease (BP5; Partners LMM, GeneDx internal data GTR ID: 21766, 26957 ClinVar SCV000204177.4; SCV000207861.7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied: BA1, BP5."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA180888/MONDO:0021060/004	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
11	533779	40439	T	C	NM_176795.4(HRAS):c.277A>G (p.Ile93Val)	40439	CA296061	NM_176795.4:c.277A>G, NM_001130442.1:c.277A>G, NM_005343.2:c.277A>G, NM_176795.3:c.277A>G, XM_011519875.1:c.-424-4819T>C, XM_011519877.1:c.-162+5442T>C, XR_242795.1:n.476A>G, NM_001130442.2:c.277A>G, NM_001318054.1:c.-43A>G, NM_005343.3:c.277A>G, XM_011519875.2:c.-424-4819T>C, XM_011519877.2:c.-162+5442T>C, XM_017017167.1:c.-499-4744T>C, XM_017017168.1:c.-499-4744T>C, NM_005343.4:c.277A>G, ENST00000311189.7:c.277A>G, ENST00000397594.5:c.277A>G, ENST00000397596.6:c.277A>G, ENST00000417302.5:c.277A>G, ENST00000451590.5:c.277A>G, ENST00000479482.1:n.198A>G, ENST00000493230.5:c.277A>G, NC_000011.10:g.533779T>C, CM000673.2:g.533779T>C, NC_000011.9:g.533779T>C, CM000673.1:g.533779T>C, NC_000011.8:g.523779T>C, NG_007666.1:g.6772A>G, NM_176795.4(HRAS):c.277A>G (p.Ile93Val)	LRRC56	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Uncertain Significance	PS4-Supporting [MET], PM2 [MET]	"The c.277A>G (p.Ile93Val) variant has been identified in at least 2 independent occurrences in patients with a RASopathy (PS4_Supporting; GeneDx, Blueprint genetics internal data; GTR ID's: 26957, 500188 ClinVar SCV000207855; SCV000188770). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In summary, the clinical significance of the p.Ile93Val variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM2."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA296061/MONDO:0009026/004	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
11	533594	40440	C	T	NM_005343.3(HRAS):c.309G>A (p.Val103=)	40440	CA5779334	NM_005343.3:c.309G>A, NC_000011.10:g.533594C>T, CM000673.2:g.533594C>T, NC_000011.9:g.533594C>T, CM000673.1:g.533594C>T, NC_000011.8:g.523594C>T, NG_007666.1:g.6957G>A, NM_001130442.1:c.309G>A, NM_005343.2:c.309G>A, NM_176795.3:c.309G>A, XM_011519875.1:c.-424-5004C>T, XM_011519877.1:c.-162+5257C>T, XR_242795.1:n.508G>A, NM_001130442.2:c.309G>A, NM_001318054.1:c.-11G>A, NM_176795.4:c.309G>A, XM_011519875.2:c.-424-5004C>T, XM_011519877.2:c.-162+5257C>T, XM_017017167.1:c.-499-4929C>T, XM_017017168.1:c.-499-4929C>T, NM_005343.4:c.309G>A, ENST00000311189.7:c.309G>A, ENST00000397594.5:c.309G>A, ENST00000397596.6:c.309G>A, ENST00000417302.5:c.309G>A, ENST00000451590.5:c.309G>A, ENST00000462734.1:n.2G>A, ENST00000478324.5:n.19G>A, ENST00000479482.1:n.230G>A, ENST00000493230.5:c.309G>A, NM_005343.3(HRAS):c.309G>A (p.Val103=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.309G>A (p.Val103=) variant in the HRAS gene is 0.063% (10/8640) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5779334/MONDO:0021060/004	0.025	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
11	533546	40441	G	A	NM_005343.3(HRAS):c.357C>T (p.Asp119=)	40441	CA135978	NM_005343.3:c.357C>T, NM_001130442.1:c.357C>T, NM_005343.2:c.357C>T, NM_176795.3:c.357C>T, XM_011519875.1:c.-424-5052G>A, XM_011519877.1:c.-162+5209G>A, XR_242795.1:n.556C>T, NM_001130442.2:c.357C>T, NM_001318054.1:c.38C>T, NM_176795.4:c.357C>T, XM_011519875.2:c.-424-5052G>A, XM_011519877.2:c.-162+5209G>A, XM_017017167.1:c.-499-4977G>A, XM_017017168.1:c.-499-4977G>A, NM_005343.4:c.357C>T, ENST00000311189.7:c.357C>T, ENST00000397594.5:c.357C>T, ENST00000397596.6:c.357C>T, ENST00000417302.5:c.357C>T, ENST00000451590.5:c.357C>T, ENST00000462734.1:n.50C>T, ENST00000478324.5:n.67C>T, ENST00000479482.1:n.278C>T, ENST00000493230.5:c.357C>T, NC_000011.10:g.533546G>A, CM000673.2:g.533546G>A, NC_000011.9:g.533546G>A, CM000673.1:g.533546G>A, NC_000011.8:g.523546G>A, NG_007666.1:g.7005C>T, NM_005343.3(HRAS):c.357C>T (p.Asp119=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.357C>T (p.Asp119=) variant in the HRAS gene is 0.129% (102/66416) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135978/MONDO:0021060/004	0.025	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
11	533525	40442	T	C	NM_005343.3(HRAS):c.378A>G (p.Glu126=)	40442	CA135984	NM_005343.3:c.378A>G, NM_001130442.1:c.378A>G, NM_005343.2:c.378A>G, NM_176795.3:c.378A>G, XM_011519875.1:c.-424-5073T>C, XM_011519877.1:c.-162+5188T>C, XR_242795.1:n.577A>G, NM_001130442.2:c.378A>G, NM_001318054.1:c.59A>G, NM_176795.4:c.378A>G, XM_011519875.2:c.-424-5073T>C, XM_011519877.2:c.-162+5188T>C, XM_017017167.1:c.-499-4998T>C, XM_017017168.1:c.-499-4998T>C, NM_005343.4:c.378A>G, ENST00000311189.7:c.378A>G, ENST00000397594.5:c.378A>G, ENST00000397596.6:c.378A>G, ENST00000417302.5:c.378A>G, ENST00000451590.5:c.378A>G, ENST00000462734.1:n.71A>G, ENST00000478324.5:n.88A>G, ENST00000479482.1:n.299A>G, ENST00000493230.5:c.378A>G, NC_000011.10:g.533525T>C, CM000673.2:g.533525T>C, NC_000011.9:g.533525T>C, CM000673.1:g.533525T>C, NC_000011.8:g.523525T>C, NG_007666.1:g.7026A>G, NM_005343.3(HRAS):c.378A>G (p.Glu126=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.378A>G (p.Glu126=) variant in the HRAS gene is 0.095% (23/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135984/MONDO:0021060/004	0.025	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
11	532729	40446	C	T	NM_005343.3(HRAS):c.477G>A (p.Leu159=)	40446	CA135990	NM_005343.3:c.477G>A, NC_000011.10:g.532729C>T, CM000673.2:g.532729C>T, NC_000011.9:g.532729C>T, CM000673.1:g.532729C>T, NC_000011.8:g.522729C>T, NG_007666.1:g.7822G>A, NM_001130442.1:c.477G>A, NM_005343.2:c.477G>A, NM_176795.3:c.*46G>A, XM_011519875.1:c.-425+4392C>T, XM_011519877.1:c.-162+4392C>T, XR_242795.1:n.758G>A, NM_001130442.2:c.477G>A, NM_001318054.1:c.240G>A, NM_176795.4:c.*46G>A, XM_011519875.2:c.-425+4392C>T, XM_011519877.2:c.-162+4392C>T, XM_017017167.1:c.-500+4392C>T, XM_017017168.1:c.-500+4392C>T, NM_005343.4:c.477G>A, ENST00000311189.7:c.477G>A, ENST00000397594.5:c.*46G>A, ENST00000397596.6:c.477G>A, ENST00000417302.5:c.*46G>A, ENST00000451590.5:c.477G>A, ENST00000462734.1:n.252G>A, ENST00000478324.5:n.243-99G>A, ENST00000479482.1:n.398G>A, ENST00000493230.5:c.*46G>A, NM_005343.3(HRAS):c.477G>A (p.Leu159=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.477G>A (p.Leu159=) variant in the HRAS gene is 0.185% (140/65296) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135990/MONDO:0021060/004	0.025	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
11	532698	40447	T	A	NM_005343.3(HRAS):c.508A>T (p.Lys170Ter)	40447	CA296052	NM_005343.3:c.508A>T, NC_000011.10:g.532698T>A, CM000673.2:g.532698T>A, NC_000011.9:g.532698T>A, CM000673.1:g.532698T>A, NC_000011.8:g.522698T>A, NG_007666.1:g.7853A>T, NM_001130442.1:c.508A>T, NM_005343.2:c.508A>T, NM_176795.3:c.*77A>T, XM_011519875.1:c.-425+4361T>A, XM_011519877.1:c.-162+4361T>A, XR_242795.1:n.789A>T, NM_001130442.2:c.508A>T, NM_001318054.1:c.271A>T, NM_176795.4:c.*77A>T, XM_011519875.2:c.-425+4361T>A, XM_011519877.2:c.-162+4361T>A, XM_017017167.1:c.-500+4361T>A, XM_017017168.1:c.-500+4361T>A, NM_005343.4:c.508A>T, ENST00000311189.7:c.508A>T, ENST00000397594.5:c.*77A>T, ENST00000397596.6:c.508A>T, ENST00000417302.5:c.*77A>T, ENST00000451590.5:c.508A>T, ENST00000462734.1:n.283A>T, ENST00000478324.5:n.243-68A>T, ENST00000479482.1:n.429A>T, ENST00000493230.5:c.*77A>T, NM_005343.3(HRAS):c.508A>T (p.Lys170Ter)	HRAS	Costello syndrome	MONDO:0009026	Autosomal dominant inheritance	Uncertain Significance	BS2 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4 [Unmet], PS3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [MET], BS3 [Unmet], PM2 [Unmet], PM6 [Unmet], BP1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet]	"The c.508A>T (p.Lys170Ter) variant in the HRAS gene has been identified in patients with cancer and individuals who underwent testing for RASopathies, however it was also identified in an unaffected parent (BS4; Invitae, GeneDx internal data, GTR Lab ID: 26957, 500031; "	SCV000207840.14, SCV000635092.3). The filtering allele frequency of the p.Lys170Ter variant is 0.0034% for European (non-Finnish) chromosomes by the gnomAD aggregation database (8/249358 with 95% CI), which is not a high enough frequency to meet thresholds defined by the ClinGen RASopahty Expert panel for autosomal dominant RASopathy variants (BA1/BS1 not met). Furthermore, LOF and/or haploinsufficiency has not been clearly identified as disease mechanisms for these genes relative to the RASopathy spectrum phenotype, therefore the PVS1 rule is not applicable. In summary, the clinical significance of the p.Lys170Ter variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS4.		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	0.9986	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
11	532686	40448	G	A	NM_005343.3(HRAS):c.520C>T (p.Pro174Ser)	40448	CA135994	NM_005343.3:c.520C>T, NM_001130442.1:c.520C>T, NM_005343.2:c.520C>T, NM_176795.3:c.*89C>T, XM_011519875.1:c.-425+4349G>A, XM_011519877.1:c.-162+4349G>A, XR_242795.1:n.801C>T, NM_001130442.2:c.520C>T, NM_001318054.1:c.283C>T, NM_176795.4:c.*89C>T, XM_011519875.2:c.-425+4349G>A, XM_011519877.2:c.-162+4349G>A, XM_017017167.1:c.-500+4349G>A, XM_017017168.1:c.-500+4349G>A, NM_005343.4:c.520C>T, ENST00000311189.7:c.520C>T, ENST00000397594.5:c.*89C>T, ENST00000397596.6:c.520C>T, ENST00000417302.5:c.*89C>T, ENST00000451590.5:c.520C>T, ENST00000462734.1:n.295C>T, ENST00000478324.5:n.243-56C>T, ENST00000479482.1:n.441C>T, ENST00000493230.5:c.*89C>T, NC_000011.10:g.532686G>A, CM000673.2:g.532686G>A, NC_000011.9:g.532686G>A, CM000673.1:g.532686G>A, NC_000011.8:g.522686G>A, NG_007666.1:g.7865C>T, NM_005343.3(HRAS):c.520C>T (p.Pro174Ser)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.520C>T (p.Pro174Ser) variant in the HRAS gene is 0.115% (20/11482) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135994/MONDO:0021060/004	0.025	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
12	112888228	40504	A	G	NM_002834.4(PTPN11):c.244A>G (p.Met82Val)	40504	CA243279	NM_002834.4:c.244A>G, NC_000012.12:g.112450424A>G, CM000674.2:g.112450424A>G, NC_000012.11:g.112888228A>G, CM000674.1:g.112888228A>G, NC_000012.10:g.111372611A>G, NG_007459.1:g.36693A>G, LRG_614:g.36693A>G, NM_002834.3:c.244A>G, LRG_614t1:c.244A>G, NM_080601.1:c.244A>G, XM_006719526.1:c.244A>G, XM_006719527.1:c.244A>G, XM_011538613.1:c.241A>G, NM_001330437.1:c.244A>G, NM_080601.2:c.244A>G, XM_011538613.2:c.241A>G, XM_017019722.1:c.241A>G, ENST00000351677.6:c.244A>G, ENST00000392597.5:c.244A>G, ENST00000635625.1:n.244A>G, NM_002834.4(PTPN11):c.244A>G (p.Met82Val)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP2 [MET], BP5 [MET]	"The c.244A>G p.Met82Val variant in PTPN11 has been identified in patients with clinical features of a RASopathy (PS4 not met; GeneDx, EGL genetics internal data; GTR ID's: 26957, 500060; SCV000057386.11; SCV000228999.4). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data; GTR ID's: 26957; SCV000057386.11). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581). In summary, the clinical significance of the p.Met82Val variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BP5, PP2."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA243279/MONDO:0021060/004	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	112915779	40541	G	A	NM_002834.4(PTPN11):c.1052G>A (p.Arg351Gln)	40541	CA282114	NM_002834.4:c.1052G>A, NC_000012.12:g.112477975G>A, CM000674.2:g.112477975G>A, NC_000012.11:g.112915779G>A, CM000674.1:g.112915779G>A, NC_000012.10:g.111400162G>A, NG_007459.1:g.64244G>A, LRG_614:g.64244G>A, NM_002834.3:c.1052G>A, LRG_614t1:c.1052G>A, NM_080601.1:c.1052G>A, XM_006719526.1:c.1052G>A, XM_006719527.1:c.938G>A, XM_011538613.1:c.1049G>A, NM_001330437.1:c.1052G>A, NM_080601.2:c.1052G>A, XM_011538613.2:c.1049G>A, XM_017019722.1:c.1049G>A, ENST00000351677.6:c.1052G>A, ENST00000392597.5:c.1052G>A, ENST00000635625.1:n.1052G>A, ENST00000635652.1:n.44G>A, NM_002834.4(PTPN11):c.1052G>A (p.Arg351Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1052G>A (p.Arg351Gln) variant in the PTPN11 gene is 0.263% (55/16488) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA282114/MONDO:0021060/004	0.0507	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	112926910	40567	G	C	NM_002834.4(PTPN11):c.1530G>C (p.Gln510His)	40567	CA220143	NM_002834.4:c.1530G>C, NC_000012.12:g.112489106G>C, CM000674.2:g.112489106G>C, NC_000012.11:g.112926910G>C, CM000674.1:g.112926910G>C, NC_000012.10:g.111411293G>C, NG_007459.1:g.75375G>C, LRG_614:g.75375G>C, NM_002834.3:c.1530G>C, LRG_614t1:c.1530G>C, XM_006719526.1:c.1542G>C, XM_006719527.1:c.1428G>C, XM_011538613.1:c.1539G>C, NM_001330437.1:c.1542G>C, XM_011538613.2:c.1539G>C, XM_017019722.1:c.1527G>C, ENST00000351677.6:c.1530G>C, ENST00000635625.1:n.1542G>C, ENST00000635652.1:n.543G>C, NM_002834.4(PTPN11):c.1530G>C (p.Gln510His)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP3 [MET], PP2 [MET], PM6-Strong [MET], PM5-Strong [MET], PM2 [MET]	"The c.1530G>C (p.Gln510His) variant in PTPN11 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; GeneDx, EGL, APHP-Robert DebrÃ© Hospital internal data; GTR ID's: 26957, 500060, 28338 ClinVar SCV000057460.11; SCV000331072.3). At least 2 other pathogenic missense variants have been previously identified at this codon of PTPN11 which may indicate that this residue is critical to the function of the protein (PM5_Strong; ClinVar 40566, 13345, 13344). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Gln510His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PM6_Strong, PM5_Strong, PM2, PP3, PP2."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220143/MONDO:0021060/004	0.9941	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
3	12660127	40584	T	C	NM_002880.3(RAF1):c.94A>G (p.Ile32Val)	40584	CA241481	NM_002880.3:c.94A>G, NC_000003.12:g.12618628T>C, CM000665.2:g.12618628T>C, NC_000003.11:g.12660127T>C, CM000665.1:g.12660127T>C, NC_000003.10:g.12635127T>C, NG_007467.1:g.50552A>G, LRG_413:g.50552A>G, LRG_413t1:c.94A>G, XM_005265355.1:c.94A>G, XM_005265357.1:c.94A>G, XM_005265358.3:c.-37A>G, XM_005265359.3:c.-37A>G, XM_005265360.1:c.94A>G, XM_011533974.1:c.94A>G, XM_011533975.1:c.-37A>G, NM_001354689.1:c.94A>G, NM_001354690.1:c.94A>G, NM_001354691.1:c.-37A>G, NM_001354692.1:c.-37A>G, NM_001354693.1:c.94A>G, NM_001354694.1:c.-37A>G, NM_001354695.1:c.-37A>G, NR_148940.1:n.509A>G, NR_148941.1:n.509A>G, NR_148942.1:n.509A>G, XM_011533974.3:c.94A>G, XM_017006966.1:c.94A>G, XR_001740227.1:n.425A>G, ENST00000251849.8:c.94A>G, ENST00000416093.1:c.94A>G, ENST00000423275.5:c.94A>G, ENST00000442415.6:c.94A>G, NM_002880.3(RAF1):c.94A>G (p.Ile32Val)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BS2 [MET], PP1 [Unmet], PP2 [MET], PP3 [Unmet], PM4 [Unmet], PM1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], BP7 [Unmet], BP5 [MET], BS1 [MET], BS4 [Unmet], BS3 [Unmet], PM2 [Unmet], PM6 [Unmet], BP1 [Unmet], BP4 [MET], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet]	"The c.94A>G (p.Ile32Val) variant in the RAF1 gene has been identified in patients who underwent testing for a RASopathy, however it has also been identified in multiple adults who did not have clinical features of a RASopathy (BS2, BP5; Invitae, EGL Diagnostics, GeneDx internal data; GTR Lab ID: 500031, 500060; SCV000287747.4, SCV000227277.5, SCV000209002.14). The filtering allele frequency of the p.Ile32Val variant is 0.017% for European (non-Finnish) genomes in the gnomAD database (8/31404 with 95% CI) which is a high enough frequency to be considered strong evidence that the variant is benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1). Computational prediction tools and conservation analysis suggest that the p.Ile32Val variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS2, BP5, BS1, BP4."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA241481/MONDO:0021060/004	0.1	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
3	12660102	40585	C	T	NM_002880.3(RAF1):c.119G>A (p.Arg40His)	40585	CA201617	NM_002880.3:c.119G>A, LRG_413t1:c.119G>A, XM_005265355.1:c.119G>A, XM_005265357.1:c.119G>A, XM_005265358.3:c.-12G>A, XM_005265359.3:c.-12G>A, XM_005265360.1:c.119G>A, XM_011533974.1:c.119G>A, XM_011533975.1:c.-12G>A, NM_001354689.1:c.119G>A, NM_001354690.1:c.119G>A, NM_001354691.1:c.-12G>A, NM_001354692.1:c.-12G>A, NM_001354693.1:c.119G>A, NM_001354694.1:c.-12G>A, NM_001354695.1:c.-12G>A, NR_148940.1:n.534G>A, NR_148941.1:n.534G>A, NR_148942.1:n.534G>A, XM_011533974.3:c.119G>A, XM_017006966.1:c.119G>A, XR_001740227.1:n.450G>A, ENST00000251849.8:c.119G>A, ENST00000416093.1:c.119G>A, ENST00000423275.5:c.119G>A, ENST00000442415.6:c.119G>A, NC_000003.12:g.12618603C>T, CM000665.2:g.12618603C>T, NC_000003.11:g.12660102C>T, CM000665.1:g.12660102C>T, NC_000003.10:g.12635102C>T, NG_007467.1:g.50577G>A, LRG_413:g.50577G>A, NM_002880.3(RAF1):c.119G>A (p.Arg40His)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BS4 [MET], BP5 [MET], BA1 [MET]	"The filtering allele frequency of the c.119G>A (p.Arg40His) variant in the RAF1 gene is 0.082% for Latino chromosomes by the Exome Aggregation Consortium (112/11578 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). Additionally, the variant did not segregate with disease in affected family members (BS4; GeneDx internal data; GTR ID: 26957; ClinVar SCV000171283.11; SCV000227278.4). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx internal data; GTR ID: 26957; SCV000171283.11). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BS4, BP5."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA201617/MONDO:0021060/004	0.0003	Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
3	12633207	40614	C	A	NM_002880.3(RAF1):c.1193G>T (p.Arg398Leu)	40614	CA235336	NM_002880.3:c.1193G>T, NC_000003.12:g.12591708C>A, CM000665.2:g.12591708C>A, NC_000003.11:g.12633207C>A, CM000665.1:g.12633207C>A, NC_000003.10:g.12608207C>A, NG_007467.1:g.77472G>T, LRG_413:g.77472G>T, LRG_413t1:c.1193G>T, XM_005265355.1:c.1193G>T, XM_005265357.1:c.1094G>T, XM_005265358.3:c.950G>T, XM_005265359.3:c.851G>T, XM_005265360.1:c.1193G>T, XM_011533974.1:c.1193G>T, XM_011533975.1:c.950G>T, NM_001354689.1:c.1253G>T, NM_001354690.1:c.1193G>T, NM_001354691.1:c.950G>T, NM_001354692.1:c.950G>T, NM_001354693.1:c.1094G>T, NM_001354694.1:c.1010G>T, NM_001354695.1:c.851G>T, NR_148940.1:n.1721G>T, NR_148941.1:n.1667G>T, NR_148942.1:n.1606G>T, XM_011533974.3:c.1193G>T, XM_017006966.1:c.1094G>T, XR_001740227.1:n.1484G>T, ENST00000251849.8:c.1193G>T, ENST00000423275.5:c.*870G>T, ENST00000432427.2:n.830G>T, ENST00000442415.6:c.1253G>T, ENST00000460610.1:n.150G>T, ENST00000465826.5:n.550G>T, ENST00000475353.1:n.361G>T, ENST00000494557.1:n.209G>T, NM_002880.3(RAF1):c.1193G>T (p.Arg398Leu)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP3 [MET], PP2 [MET], PM2 [MET]	"The c.1193G>T (p.Arg398Leu) variant has been identified in patients with clinical features of a RASopathy (PS4 not met; GeneDx, GGC internal data; GTR ID: 26957, 1019; ClinVar SCV000209025.5; SCV000207671.1). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg398Leu variant may impact the protein (PP3). In summary, the clinical significance of the p.Arg398Leu variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM2, PP2, PP3."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA235336/MONDO:0021060/004	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
3	12626702	40620	C	T	NM_002880.3(RAF1):c.1587G>A (p.Ser529=)	40620	CA2259466	NM_002880.3:c.1587G>A, LRG_413t1:c.1587G>A, XM_005265355.1:c.1587G>A, XM_005265357.1:c.1488G>A, XM_005265358.3:c.1344G>A, XM_005265359.3:c.1245G>A, XM_011533974.1:c.1587G>A, XM_011533975.1:c.1344G>A, NM_001354689.1:c.1647G>A, NM_001354690.1:c.1587G>A, NM_001354691.1:c.1344G>A, NM_001354692.1:c.1344G>A, NM_001354693.1:c.1488G>A, NM_001354694.1:c.1404G>A, NM_001354695.1:c.1245G>A, NR_148940.1:n.2115G>A, NR_148941.1:n.2061G>A, NR_148942.1:n.2000G>A, XM_011533974.3:c.1587G>A, XM_017006966.1:c.1488G>A, ENST00000251849.8:c.1587G>A, ENST00000423275.5:c.*1264G>A, ENST00000432427.2:n.1224G>A, ENST00000442415.6:c.1647G>A, ENST00000471449.1:n.276G>A, NC_000003.12:g.12585203C>T, CM000665.2:g.12585203C>T, NC_000003.11:g.12626702C>T, CM000665.1:g.12626702C>T, NC_000003.10:g.12601702C>T, NG_007467.1:g.83977G>A, LRG_413:g.83977G>A, NM_002880.3(RAF1):c.1587G>A (p.Ser529=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1587G>A (p.Ser529=) variant in the RAF1 gene is 0.052% (10/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA2259466/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
3	12626660	40621	C	G	NM_002880.3(RAF1):c.1629G>C (p.Thr543=)	40621	CA235376	NM_002880.3:c.1629G>C, LRG_413t1:c.1629G>C, XM_005265355.1:c.1629G>C, XM_005265357.1:c.1530G>C, XM_005265358.3:c.1386G>C, XM_005265359.3:c.1287G>C, XM_011533974.1:c.1629G>C, XM_011533975.1:c.1386G>C, NM_001354689.1:c.1689G>C, NM_001354690.1:c.1629G>C, NM_001354691.1:c.1386G>C, NM_001354692.1:c.1386G>C, NM_001354693.1:c.1530G>C, NM_001354694.1:c.1446G>C, NM_001354695.1:c.1287G>C, NR_148940.1:n.2157G>C, NR_148941.1:n.2103G>C, NR_148942.1:n.2042G>C, XM_011533974.3:c.1629G>C, XM_017006966.1:c.1530G>C, ENST00000251849.8:c.1629G>C, ENST00000423275.5:c.*1306G>C, ENST00000432427.2:n.1266G>C, ENST00000442415.6:c.1689G>C, ENST00000471449.1:n.318G>C, NC_000003.12:g.12585161C>G, CM000665.2:g.12585161C>G, NC_000003.11:g.12626660C>G, CM000665.1:g.12626660C>G, NC_000003.10:g.12601660C>G, NG_007467.1:g.84019G>C, LRG_413:g.84019G>C, NM_002880.3(RAF1):c.1629G>C (p.Thr543=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1629G>C (p.Thr543=) variant in the RAF1 gene is 0.054% (9/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA235376/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
2	39262409	40664	G	A	NM_005633.3(SOS1):c.1018C>T (p.Pro340Ser)	40664	CA1624660	NM_005633.3:c.1018C>T, LRG_754t1:c.1018C>T, XM_005264515.3:c.1018C>T, XM_011533060.1:c.1111C>T, XM_011533061.1:c.1111C>T, XM_011533062.1:c.997C>T, XM_011533063.1:c.994C>T, XM_011533064.1:c.847C>T, XM_011533065.1:c.1111C>T, XM_005264515.4:c.1018C>T, XM_011533062.2:c.997C>T, XM_011533064.2:c.847C>T, ENST00000395038.6:c.1018C>T, ENST00000402219.6:c.1018C>T, ENST00000426016.5:c.1018C>T, ENST00000461545.1:n.368C>T, NC_000002.12:g.39035268G>A, CM000664.2:g.39035268G>A, NC_000002.11:g.39262409G>A, CM000664.1:g.39262409G>A, NC_000002.10:g.39115913G>A, NG_007530.1:g.90196C>T, LRG_754:g.90196C>T, NM_005633.3(SOS1):c.1018C>T (p.Pro340Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	PP2 [MET], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4 [Unmet], PS3 [Unmet], BP5 [MET], BP7 [Unmet], BS1 [MET], BS4 [MET], BS3 [Unmet], PM2 [Unmet], PM6 [Unmet], BP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet]	"The c.1018C>T (p.Pro340Ser) variant in the SOS1 gene has been found not to segregate in a family member of a patient who underwent testing for RASopathies as well as another adult who was unaffected (BS4; GeneDx, Invitae internal data; GTR Lab ID: 26957, 500031; SCV000514724.5, SCV000659124.2). This variant has also been identified in a patient with an alternate molecular basis of disease (BP5; PMID 22585553). The filtering allele frequency of the p.Pro340Ser variant is 0.022% for East Asian exomes in the gnomAD database (20/251276 with 95% CI), which is high enough frequency to be considered strong evidence for the variant being benign by the ClinGen RASopathy Expert Panel (BS1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS4, BP5, BS1."	22585553	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624660/MONDO:0021060/004	0.6752	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
2	39249799	40687	C	T	NM_005633.3(SOS1):c.1770G>A (p.Glu590=)	40687	CA1624555	NM_005633.3:c.1770G>A, LRG_754t1:c.1770G>A, XM_005264515.3:c.1770G>A, XM_011533060.1:c.1863G>A, XM_011533061.1:c.1863G>A, XM_011533062.1:c.1749G>A, XM_011533063.1:c.1746G>A, XM_011533064.1:c.1599G>A, XM_011533065.1:c.1863G>A, XM_011533066.1:c.705G>A, XM_005264515.4:c.1770G>A, XM_011533062.2:c.1749G>A, XM_011533064.2:c.1599G>A, ENST00000395038.6:c.1770G>A, ENST00000402219.6:c.1770G>A, ENST00000426016.5:c.1770G>A, NC_000002.12:g.39022658C>T, CM000664.2:g.39022658C>T, NC_000002.11:g.39249799C>T, CM000664.1:g.39249799C>T, NC_000002.10:g.39103303C>T, NG_007530.1:g.102806G>A, LRG_754:g.102806G>A, NM_005633.3(SOS1):c.1770G>A (p.Glu590=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1770G>A (p.Glu590=) variant in the SOS1 gene is 0.29% (34/8634) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624555/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39240612	40698	C	G	NM_005633.3(SOS1):c.2156G>C (p.Gly719Ala)	40698	CA297202	NM_005633.3:c.2156G>C, NC_000002.12:g.39013471C>G, CM000664.2:g.39013471C>G, NC_000002.11:g.39240612C>G, CM000664.1:g.39240612C>G, NC_000002.10:g.39094116C>G, NG_007530.1:g.111993G>C, LRG_754:g.111993G>C, LRG_754t1:c.2156G>C, XM_005264515.3:c.2156G>C, XM_011533060.1:c.2249G>C, XM_011533061.1:c.2249G>C, XM_011533062.1:c.2135G>C, XM_011533063.1:c.2132G>C, XM_011533064.1:c.1985G>C, XM_011533065.1:c.2249G>C, XM_011533066.1:c.1091G>C, XM_005264515.4:c.2156G>C, XM_011533062.2:c.2135G>C, XM_011533064.2:c.1985G>C, ENST00000395038.6:c.2156G>C, ENST00000402219.6:c.2156G>C, ENST00000426016.5:c.2156G>C, NM_005633.3(SOS1):c.2156G>C (p.Gly719Ala)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.2156G>C (p.Gly719Ala) variant in the SOS1 gene is 0.0414% (37/66598) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA297202/MONDO:0021060/004	0.0059	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
2	39213367	40733	G	C	NM_005633.3(SOS1):c.3600C>G (p.Asp1200Glu)	40733	CA297240	NM_005633.3:c.3600C>G, LRG_754t1:c.3600C>G, XM_005264515.3:c.3555C>G, XM_011533060.1:c.3693C>G, XM_011533061.1:c.3648C>G, XM_011533062.1:c.3579C>G, XM_011533063.1:c.3576C>G, XM_011533064.1:c.3429C>G, XM_011533065.1:c.3604-863C>G, XM_011533066.1:c.2535C>G, XM_005264515.4:c.3555C>G, XM_011533062.2:c.3579C>G, XM_011533064.2:c.3429C>G, ENST00000395038.6:c.3555C>G, ENST00000402219.6:c.3600C>G, ENST00000426016.5:c.3600C>G, ENST00000469581.1:n.343C>G, NC_000002.12:g.38986226G>C, CM000664.2:g.38986226G>C, NC_000002.11:g.39213367G>C, CM000664.1:g.39213367G>C, NC_000002.10:g.39066871G>C, NG_007530.1:g.139238C>G, LRG_754:g.139238C>G, NM_005633.3(SOS1):c.3600C>G (p.Asp1200Glu)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PM1 [Unmet], PM4 [Unmet], PM5 [Unmet], PS4 [Unmet], PS3 [Unmet], PS2 [Unmet], PS1 [Unmet], BP5 [MET], BP7 [Unmet], BS1 [MET], BS4 [Unmet], BS3 [Unmet], PM2 [Unmet], PM6 [Unmet], BP1 [Unmet], BP4 [MET], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet]	"The c.3600C>G (p.Asp1200Glu) variant in the SOS1 gene has been identified in at least 6 individuals without detailed phenotypic information as well as one patient with an alternative molecular basis for disease in the BRAF gene (BP5; EGL, Invitae, GeneDx internal data, GTR Lab ID: 500060, 500031, 26957; SCV000854873.1, SCV000553268.3, SCV000209087.11). The filtering allele frequency of the c.3600C>G (p.Asp1200Glu) variant is 0.025% for European (non-Finnish) exomes by the gnomAD database (40/251300 with 95% CI) which is strong evidence to suggest that the variant may be benign based on thresholds defined by the ClinGen RASopathy Expert Panel for autosomal dominant RASopathy variants (BS1). Of note, the c.3600C>A change that also results in p.Asp1200Glu has been identified in one patient with a RASopathy but this variant has not met criteria to be classified as pathogenic and therefore PM5 is not met (Partners LMM internal data; GTR Lab ID: 21766; SCV000062231.5). Computational prediction tools and conservation analysis suggest that the p.Asp1200Glu variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS1, BP4, BP5."	27236105	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA297240/MONDO:0021060/004	0.1	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	1	Uncertain Significance
19	4117429	40787	G	T	NM_030662.3(MAP2K2):c.291C>A (p.Ile97=)	40787	CA9091060	NM_030662.3:c.291C>A, NC_000019.10:g.4117431G>T, CM000681.2:g.4117431G>T, NC_000019.9:g.4117429G>T, CM000681.1:g.4117429G>T, NC_000019.8:g.4068429G>T, NG_007996.1:g.11698C>A, LRG_750:g.11698C>A, LRG_750t1:c.291C>A, XM_006722799.2:c.291C>A, XM_017026989.1:c.291C>A, XM_017026990.1:c.291C>A, XM_017026991.1:c.291C>A, ENST00000262948.9:c.291C>A, ENST00000394867.8:c.-1C>A, ENST00000599345.1:n.488C>A, NM_030662.3(MAP2K2):c.291C>A (p.Ile97=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.291C>A (p.Ile97=) variant in the MAP2K2 gene is 0.182% (23/8614) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9091060/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
19	4101030	40818	C	A	NM_030662.3(MAP2K2):c.692G>T (p.Arg231Leu)	40818	CA296133	NM_030662.3:c.692G>T, NC_000019.10:g.4101032C>A, CM000681.2:g.4101032C>A, NC_000019.9:g.4101030C>A, CM000681.1:g.4101030C>A, NC_000019.8:g.4052030C>A, NG_007996.1:g.28097G>T, LRG_750:g.28097G>T, LRG_750t1:c.692G>T, XM_006722799.2:c.692G>T, XM_011528133.1:c.122G>T, XM_017026989.1:c.692G>T, XM_017026990.1:c.692G>T, XM_017026991.1:c.692G>T, ENST00000262948.9:c.692G>T, ENST00000394867.8:c.401G>T, ENST00000593364.5:n.639G>T, ENST00000597008.5:n.293G>T, ENST00000597263.5:n.156G>T, ENST00000599021.1:n.16G>T, ENST00000601786.5:n.993G>T, ENST00000602167.5:n.412G>T, NM_030662.3(MAP2K2):c.692G>T (p.Arg231Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	BS2 [Unmet], PP2 [MET], PP3 [MET], PP1 [Unmet], PS4-Supporting [MET], PM1 [Unmet], PM4 [Unmet], PM5 [Unmet], PS3 [Unmet], PS1 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP5 [Unmet], BP7 [Unmet], PM2 [MET], PM6 [Unmet], BA1 [Unmet], BP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet]	"The c.692G>T (p.Arg231Leu) variant has been identified in at least 2 independent occurrences in patients with clinical features of RASopathies  (PS4_Supporting GeneDx, Invitae internal data, GTR Lab IDs 26957, 500031; ClinVar SCV000207960.9, SCV000551455.2). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg231Leu variant may impact the protein (PP3).In summary, the clinical significance of the p.Arg231Leu variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PM2, PP2, PP3."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA296133/MONDO:0021060/004	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
19	4099300	40824	T	C	NM_030662.3(MAP2K2):c.818A>G (p.Lys273Arg)	40824	CA296139	NM_030662.3:c.818A>G, LRG_750t1:c.818A>G, XM_006722799.2:c.705+1717A>G, XM_011528133.1:c.248A>G, XM_017026989.1:c.818A>G, XM_017026990.1:c.705+1717A>G, ENST00000262948.9:c.818A>G, ENST00000394867.8:c.527A>G, ENST00000593364.5:n.765A>G, ENST00000595715.1:n.633A>G, ENST00000597263.5:n.169+1717A>G, ENST00000599021.1:n.29+1717A>G, ENST00000600584.5:n.1378A>G, ENST00000601786.5:n.1119A>G, NC_000019.10:g.4099302T>C, CM000681.2:g.4099302T>C, NC_000019.9:g.4099300T>C, CM000681.1:g.4099300T>C, NC_000019.8:g.4050300T>C, NG_007996.1:g.29827A>G, LRG_750:g.29827A>G, NM_030662.3(MAP2K2):c.818A>G (p.Lys273Arg)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.818A>G (p.Lys273Arg) variant in the MAP2K2 gene is 0.0368% (6/7088) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA296139/MONDO:0021060/004	0.0003	Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
19	4099195	40834	G	A	NM_030662.3(MAP2K2):c.919+4C>T	40834	CA9090795	NM_030662.3:c.919+4C>T, LRG_750t1:c.919+4C>T, XM_006722799.2:c.705+1822C>T, XM_011528133.1:c.349+4C>T, XM_017026989.1:c.919+4C>T, XM_017026990.1:c.705+1822C>T, ENST00000262948.9:c.919+4C>T, ENST00000394867.8:c.628+4C>T, ENST00000593364.5:n.870C>T, ENST00000595715.1:n.734+4C>T, ENST00000597263.5:n.169+1822C>T, ENST00000599021.1:n.29+1822C>T, ENST00000600584.5:n.1479+4C>T, ENST00000601786.5:n.1220+4C>T, NC_000019.10:g.4099197G>A, CM000681.2:g.4099197G>A, NC_000019.9:g.4099195G>A, CM000681.1:g.4099195G>A, NC_000019.8:g.4050195G>A, NG_007996.1:g.29932C>T, LRG_750:g.29932C>T, NM_030662.3(MAP2K2):c.919+4C>T	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS2 [Unmet], BS1 [Unmet], BP7 [MET], BP4 [MET]	The  variant c.919+4C>T is an intronic variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). Also, computational prediction tools and conservation analysis suggests that the variant does not impact the protein (BP4). In summary, the clinical significance of the c.919+4C>T variant is likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BP4, BP7.		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9090795/MONDO:0021060/004	0.0507	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
14	23894115	42913	CCTT	C	NM_000257.3(MYH7):c.2539_2541delAAG (p.Lys847del)	42913	CA012568	NM_000257.3:c.2539_2541delAAG, NC_000014.9:g.23424909_23424911del, CM000676.2:g.23424909_23424911del, NC_000014.8:g.23894118_23894120del, CM000676.1:g.23894118_23894120del, NC_000014.7:g.22963958_22963960del, NG_007884.1:g.15753_15755del, LRG_384:g.15753_15755del, NM_000257.3:c.2539_2541del, XR_245686.3:n.2645_2647del, XM_017021340.1:c.2539_2541del, NM_000257.4:c.2539_2541del, ENST00000355349.3:c.2539_2541del, NM_000257.3(MYH7):c.2539_2541delAAG (p.Lys847del)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PS4 [MET], PM2 [MET], PM4 [MET], PP1 [MET]	"The c.2539_2541del (p.Lys847del) variant in MYH7 has been reported in >15 individuals with hypertrophic cardiomyopathy (PS4; PMID:15358028; PMID:22429680; PMID:23233322; PMID:24093860; PMID:18258667; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000059453.5; Invitae ClinVar SCV000219043.3). This variant segregated with disease in 3 affected individuals (PP1; Partners LMM ClinVar SCV000059453.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant is a deletion of 1 amino acid at position 847 and is not predicted to alter the protein reading-frame (PM4). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM2; PM4; PP1"	18258667, 22429680, 15358028, 24093860, 23233322	Cardiovascular Cardiomyopathy VCEP	https://www.nature.com/articles/gim2017218#t1	15/12/16	16/11/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA012568/MONDO:0005045/002	0.9878	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
14	23893244	42934	TCTC	T	NM_000257.3(MYH7):c.2791_2793delGAG (p.Glu931del)	42934	CA013089	NM_000257.3:c.2791_2793delGAG, NM_000257.3:c.2791_2793del, XR_245686.3:n.2897_2899del, XM_017021340.1:c.2791_2793del, NM_000257.4:c.2791_2793del, ENST00000355349.3:c.2791_2793del, NC_000014.9:g.23424042_23424044del, CM000676.2:g.23424042_23424044del, NC_000014.8:g.23893251_23893253del, CM000676.1:g.23893251_23893253del, NC_000014.7:g.22963091_22963093del, NG_007884.1:g.16624_16626del, LRG_384:g.16624_16626del, NM_000257.3(MYH7):c.2791_2793delGAG (p.Glu931del)	MYH7	hypertrophic cardiomyopathy	MONDO:0005045	Autosomal dominant inheritance	Likely Pathogenic	PS4-Supporting [MET], PP1-Moderate [MET], PM2 [MET], PM4 [MET]	"The c.2791_2793del (p.Glu931del) variant in MYH7 has been reported in 4 individuals with hypertrophic cardiomyopathy (PS4_Supporting; PMID:9829907; PMID:12707239; PMID:27532257; Partners LMM ClinVar SCV000059478.5). This variant segregated with disease in 5 affected individuals (PP1_Moderate; PMID:9829907). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant is a deletion of 1 amino acid at position 931 and is not predicted to alter the protein reading-frame (PM4). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PM2; PM4; PP1_Moderate; PS4_ Supporting"	9829907, 12707239, 27532257, 9829907	Cardiovascular Cardiomyopathy VCEP	https://www.nature.com/articles/gim2017218#t1	15/12/16	16/11/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA013089/MONDO:0005045/002	0.9878	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
14	23889445	42956	T	TG	NM_000257.3(MYH7):c.3337-3dupC	42956	CA013590	NM_000257.3:c.3337-3dupC, NM_000257.3:c.3337-3_3337-2insC, NC_000014.9:g.23420238dup, CM000676.2:g.23420238dup, NC_000014.8:g.23889447dup, CM000676.1:g.23889447dup, NC_000014.7:g.22959287dup, NG_007884.1:g.20425dup, LRG_384:g.20425dup, NM_000257.3:c.3337-3dup, XR_245686.3:n.3445-3dup, XM_017021340.1:c.3337-3dup, NM_000257.4:c.3337-3dup, ENST00000355349.3:c.3337-3dup, NM_000257.3(MYH7):c.3337-3dupC	MYH7	cardiomyopathy	MONDO:0004994	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.3337-3dupC  variant in the MYH7 gene is 0.23% (146/54400) of European chromosomes by the Exome Aggregation Consortium (http://exac.broadinstitute.org), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Inherited Cardiomyopathy Expert Panel (BA1; PMID:29300372)."		Cardiovascular Cardiomyopathy VCEP	https://www.nature.com/articles/gim2017218#t1	15/12/16	16/11/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA013590/MONDO:0004994/002	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
14	23889119	42968	TCTC	T	NM_000257.3(MYH7):c.3658_3660delGAG (p.Glu1220del)	42968	CA013921	NM_000257.3:c.3658_3660delGAG, NC_000014.9:g.23419913_23419915del, CM000676.2:g.23419913_23419915del, NC_000014.8:g.23889122_23889124del, CM000676.1:g.23889122_23889124del, NC_000014.7:g.22958962_22958964del, NG_007884.1:g.20749_20751del, LRG_384:g.20749_20751del, NM_000257.3:c.3658_3660del, XM_017021340.1:c.3658_3660del, NM_000257.4:c.3658_3660del, ENST00000355349.3:c.3658_3660del, NM_000257.3(MYH7):c.3658_3660delGAG (p.Glu1220del)	MYH7	Ebstein anomaly	MONDO:0009144	Autosomal dominant inheritance	Likely Pathogenic	PS4-Supporting [MET], PM2 [MET], PM4 [MET], PP1 [MET]	"The c.3658_3660del (p.Glu1220del) variant in MYH7 has been reported in 2 individuals with Ebstein anomaly (PS4_Supporting; PMID:21127202; Partners LMM ClinVar SCV000059512.5). This variant segregated with disease in 3 affected individuals (PP1; Partners LMM ClinVar SCV000059512.5). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant is a deletion of 1 amino acid at position 1220 and is not predicted to alter the protein reading-frame (PM4). In summary, this variant meets criteria to be classified as likely pathogenic for Ebstein anomaly in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PM2; PM4; PP1; PS4_ Supporting"	21127202	Cardiovascular Cardiomyopathy VCEP	https://www.nature.com/articles/gim2017218#t1	15/12/16	16/11/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA013921/MONDO:0009144/002	0.9878	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
11	76870496	43134	G	A	NM_000260.3(MYO7A):c.1007G>A (p.Arg336His)	43134	CA132194	NM_000260.3:c.1007G>A, NC_000011.10:g.77159450G>A, CM000673.2:g.77159450G>A, NC_000011.9:g.76870496G>A, CM000673.1:g.76870496G>A, NC_000011.8:g.76548144G>A, NG_009086.1:g.36187G>A, NM_001127179.2:c.1007G>A, NM_001127180.1:c.1007G>A, XM_005274012.2:c.1007G>A, XM_006718558.2:c.1007G>A, XM_006718559.2:c.1007G>A, XM_006718560.2:c.1007G>A, XM_006718561.2:c.1007G>A, XM_011545044.1:c.1007G>A, XM_011545045.1:c.1007G>A, XM_011545046.1:c.974G>A, XM_011545047.1:c.1007G>A, XM_011545048.1:c.1007G>A, XM_011545049.1:c.850-713G>A, XM_011545050.1:c.749G>A, XM_011545051.1:c.1007G>A, XM_011545052.1:c.1007G>A, XR_949938.1:n.1327G>A, XR_949941.1:n.1327G>A, XR_949942.1:n.1329G>A, XR_949943.1:n.1329G>A, XM_011545044.2:c.1007G>A, XM_011545046.2:c.1097G>A, XM_011545050.2:c.749G>A, XM_017017778.1:c.1097G>A, XM_017017779.1:c.1097G>A, XM_017017780.1:c.1097G>A, XM_017017781.1:c.1097G>A, XM_017017782.1:c.1097G>A, XM_017017783.1:c.1097G>A, XM_017017784.1:c.1097G>A, XM_017017785.1:c.940-713G>A, XM_017017786.1:c.1097G>A, XM_017017787.1:c.1097G>A, XM_017017788.1:c.1097G>A, XR_001747885.1:n.1112G>A, XR_001747886.1:n.1112G>A, XR_001747887.1:n.1112G>A, XR_001747888.1:n.1112G>A, XR_001747889.1:n.1112G>A, NM_000260.4:c.1007G>A, ENST00000409619.6:c.974G>A, ENST00000409709.7:c.1007G>A, ENST00000409893.5:c.1007G>A, ENST00000458637.6:c.1007G>A, ENST00000620575.4:c.1007G>A, NM_000260.3(MYO7A):c.1007G>A (p.Arg336His)	MYO7A	nonsyndromic genetic deafness	MONDO:0019497		Uncertain Significance	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [MET], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], BS1-Supporting [MET], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], PM5 [Unmet], BP7 [Unmet], BP5 [Unmet], BS4 [Unmet]	"The filtering allele frequency of the p.Arg336His variant in the MYO7A gene is 0.20%  (275/126030) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a higher frequency than would be expected for an autosomal recessive pathogenic hearing loss variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). Computational prediction tools and conservation analysis suggest that the p.Arg336His variant may impact the protein (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMG criteria applied: PP3, BS1_Supporting."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	17/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA132194/MONDO:0019497/005	0.6752	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
11	76866991	43201	C	T	NM_000260.3(MYO7A):c.324C>T (p.Tyr108=)	43201	CA132282	NM_000260.3:c.324C>T, NC_000011.10:g.77155945C>T, CM000673.2:g.77155945C>T, NC_000011.9:g.76866991C>T, CM000673.1:g.76866991C>T, NC_000011.8:g.76544639C>T, NG_009086.1:g.32682C>T, NM_001127179.2:c.324C>T, NM_001127180.1:c.324C>T, XM_005274012.2:c.324C>T, XM_006718558.2:c.324C>T, XM_006718559.2:c.324C>T, XM_006718560.2:c.324C>T, XM_006718561.2:c.324C>T, XM_011545044.1:c.324C>T, XM_011545045.1:c.324C>T, XM_011545046.1:c.291C>T, XM_011545047.1:c.324C>T, XM_011545048.1:c.324C>T, XM_011545049.1:c.324C>T, XM_011545050.1:c.66C>T, XM_011545051.1:c.324C>T, XM_011545052.1:c.324C>T, XR_949938.1:n.644C>T, XR_949941.1:n.644C>T, XR_949942.1:n.646C>T, XR_949943.1:n.646C>T, XM_011545044.2:c.324C>T, XM_011545046.2:c.414C>T, XM_011545050.2:c.66C>T, XM_017017778.1:c.414C>T, XM_017017779.1:c.414C>T, XM_017017780.1:c.414C>T, XM_017017781.1:c.414C>T, XM_017017782.1:c.414C>T, XM_017017783.1:c.414C>T, XM_017017784.1:c.414C>T, XM_017017785.1:c.414C>T, XM_017017786.1:c.414C>T, XM_017017787.1:c.414C>T, XM_017017788.1:c.414C>T, XR_001747885.1:n.429C>T, XR_001747886.1:n.429C>T, XR_001747887.1:n.429C>T, XR_001747888.1:n.429C>T, XR_001747889.1:n.429C>T, NM_000260.4:c.324C>T, ENST00000409619.6:c.291C>T, ENST00000409709.7:c.324C>T, ENST00000409893.5:c.324C>T, ENST00000458637.6:c.324C>T, ENST00000620575.4:c.324C>T, NM_000260.3(MYO7A):c.324C>T (p.Tyr108=)	MYO7A	nonsyndromic genetic deafness	MONDO:0019497		Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The filtering allele frequency of the p.Tyr108= variant in the MYO7A gene is 1.45% (300/18658) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA132282/MONDO:0019497/005	0.0014	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
7	107329565	43491	G	A	NM_000441.1(SLC26A4):c.1069G>A (p.Ala357Thr)	43491	CA132654	NM_000441.1:c.1069G>A, XM_005250425.1:c.1069G>A, XM_006716025.2:c.1069G>A, XM_005250425.2:c.1069G>A, XM_006716025.3:c.1069G>A, XM_017012318.1:c.1069G>A, ENST00000265715.7:c.1069G>A, NC_000007.14:g.107689120G>A, CM000669.2:g.107689120G>A, NC_000007.13:g.107329565G>A, CM000669.1:g.107329565G>A, NC_000007.12:g.107116801G>A, NG_008489.1:g.33486G>A, NM_000441.1(SLC26A4):c.1069G>A (p.Ala357Thr)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Benign	PP3 [MET], BP4 [Unmet], BA1 [MET], PS1 [Unmet], PS4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP5 [Unmet]	"The filtering allele frequency of the p.Ala357Thr variant in the SLC26A4 gene is 0.47% for African chromosomes by gnomAD (136/24968 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Pendred syndrome variants (BA1). The REVEL computational prediction analysis tool produces a score of 0.849, which is above the threshold necessary to apply PP3; however, this information is not predictive of pathogenicity on its own and is not considered in conflict with evidence that supports a benign interpretation. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA132654/MONDO:0010134/005	0.3246	Likely Pathogenic	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[1, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
15	66782108	44586	CTATT	C	NM_002755.3(MAP2K1):c.1068+12_1068+15delTATT	44586	CA134591	NM_002755.3:c.1068+8_1068+11delTATT, NM_002755.3:c.1068+12_1068+15delTATT, NC_000015.10:g.66489775_66489778del, CM000677.2:g.66489775_66489778del, NC_000015.9:g.66782113_66782116del, CM000677.1:g.66782113_66782116del, NC_000015.8:g.64569167_64569170del, NG_008305.1:g.107903_107906del, LRG_725:g.107903_107906del, NG_051234.1:g.13042_13045del, NM_002755.3:c.1068+12_1068+15del, LRG_725t1:c.1068+12_1068+15del, XM_011521783.1:c.1002+12_1002+15del, NM_006049.3:c.*965_*968del, NR_138061.1:n.1484_1487del, XM_011521783.3:c.1002+12_1002+15del, XM_017022411.2:c.990+12_990+15del, XM_017022412.1:c.924+12_924+15del, XM_017022413.1:c.540+12_540+15del, ENST00000307102.9:c.1068+12_1068+15del, ENST00000566326.1:c.540+12_540+15del, NM_002755.3(MAP2K1):c.1068+12_1068+15delTATT	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1068+12_1068+15delTATT variant in the MAP2K1 gene is 0.285% (214/66740) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA134591/MONDO:0021060/004	0.0014	Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
13	20763687	44740	C	A	NM_004004.5(GJB2):c.34G>T (p.Gly12Cys)	44740	CA172224	NM_004004.5:c.34G>T, NC_000013.11:g.20189548C>A, CM000675.2:g.20189548C>A, NC_000013.10:g.20763687C>A, CM000675.1:g.20763687C>A, NC_000013.9:g.19661687C>A, NG_008358.1:g.8428G>T, XM_011535049.1:c.34G>T, XM_011535049.2:c.34G>T, NM_004004.6:c.34G>T, ENST00000382844.1:c.34G>T, ENST00000382848.4:c.34G>T, NM_004004.5(GJB2):c.34G>T (p.Gly12Cys)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Pathogenic	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [MET], PP4 [Unmet], PP1 [Unmet], PM3-Very Strong [MET], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4 [Unmet], PS3 [Unmet], PM5 [MET], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [MET], BS4 [Unmet]	"The filtering allele frequency of the p.Gly12Cys variant in the GJB2 gene is 0.32% (129/34098) of Latino chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/). This is a high enough frequency that, in absence of conflicting data, might warrant a likely benign classification based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). However, based on the evidence outline below, the ClinGen Hearing Loss Expert Panel believes that the evidence for the pathogenicity of this variant for nonsyndromic hearing loss outweighs its high allele frequency in population databases. Therefore, the BS1 code will not contribute to the overall classification. This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; Partners LMM internal data SCV000061501.5). The p.Gly12Cys variant has also been reported in the literature in 10 individuals with hearing loss; however, a variant affecting the remaining DFNB1 allele was not reported (PMID: 15365987, 17041943, 17666888, 25288386, 26969326). A different pathogenic missense variant (p.Gly12Val) has been previously identified at this codon of GJB2 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar Variation ID 21387). Computational prediction tools and conservation analysis suggest that the p.Gly12Cys variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: PM3_VS, PM5, PP3, BS1."	25288386, 26969326, 15365987, 17041943, 17666888	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	11/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA172224/MONDO:0019497/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763150	44760	A	G	NM_004004.5(GJB2):c.571T>C (p.Phe191Leu)	44760	CA134989	NM_004004.5:c.571T>C, XM_011535049.1:c.571T>C, XM_011535049.2:c.571T>C, NM_004004.6:c.571T>C, ENST00000382844.1:c.571T>C, ENST00000382848.4:c.571T>C, NC_000013.11:g.20189011A>G, CM000675.2:g.20189011A>G, NC_000013.10:g.20763150A>G, CM000675.1:g.20763150A>G, NC_000013.9:g.19661150A>G, NG_008358.1:g.8965T>C, NM_004004.5(GJB2):c.571T>C (p.Phe191Leu)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PS3-Supporting [MET], PP3 [MET], BS2 [MET], BS1-Supporting [MET], PS4 [Unmet], PM3-Supporting [MET]	"The c.571T>C (p.Phe191Leu) variant in GJB2 has been reported in over 19 Asian probands in the literature. However, a case control comparison using Chi-squared analysis did not show a statistical significance between cases and controls in the published studies, or between cases and East Asians in gnomAD (case chromosomes= 19/16415, control chromosomes = 6/8626, 36/18870 East Asian chromosomes in gnomAD; PMIDs 19366456, 15700112, 23826813, 27247933, 27792752, 12792423, 12560944, 19043807, 27627659, 20497192 and https://doi.org/10.1016/S1672-2930(07)50004-8). The filtering allele frequency of the p.Phe191Leu variant in the GJB2 gene is 0.14% for East Asian chromosomes in gnomAD (36/18870 with 95% CI), which is a higher frequency than would be expected for an autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). This variant has been detected in 1 individual with hearing loss who was homozygous for the variant, and in 4 compound heterozygous individuals who had a second pathogenic GJB2 variant identified (3 with p.Val37Ile and 1 with c.235delC) (Oguchi 2005 PMID: 15700112; ARUP SCV000603821; Partners Lab for Molecular Medicine SCV000061527). Phase was not confirmed for any of these individuals. It is possible that these homozygous and compound heterozygous observations are due to the relatively high allele frequencies of these variants in gnomAD and therefore PM3 was downgraded (PM3_Supporting). In addition, this variant was reported in the homozygous state in a normal hearing parent (BS2, Wattanasirichiagoon 2004, PMID 15479191). Computational prediction analysis using REVEL suggests that the variant may impact the protein (PP3). Two in vitro functional studies demonstrates that this variant resulted in abnormal protein trafficking and retention of the protein in the endoplasmic reticulum; however, further electrical coupling studies were not performed (PS3_Supporting; PMID: 23967136, 26749107). In summary, due to conflicting evidence, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1_Supporting, BS2, PM3_Supporting, PS3_Supporting, PP3."	25388846, 26749107, 23967136, 15479191, 16840571, 19043807, 26178431, 16840571, 12792423, 20497192, 19043807, 12560944, 23826813, 24256046, 27247933, 27792752, 15790391, 27627659, 15700112, 19366456, 15700112	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA134989/MONDO:0019497/005	0.8999	Likely Pathogenic	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	3	Uncertain Significance
12	25362762	45129	TTTC	T	NM_004985.4(KRAS):c.531_533delGAA (p.Lys180del)	45129	CA135584	NM_004985.4:c.531_533delGAA, NM_004985.4:c.531_533del, NM_033360.3:c.*85_*87del, XM_006719069.2:c.*85_*87del, XM_011520653.1:c.531_533del, XM_006719069.4:c.*85_*87del, XM_011520653.3:c.531_533del, ENST00000256078.8:c.*85_*87del, ENST00000311936.7:c.531_533del, ENST00000557334.5:c.192_194del, NC_000012.12:g.25209834_25209836del, CM000674.2:g.25209834_25209836del, NC_000012.11:g.25362768_25362770del, CM000674.1:g.25362768_25362770del, NC_000012.10:g.25254035_25254037del, NG_007524.1:g.46090_46092del, NM_004985.4(KRAS):c.531_533delGAA (p.Lys180del)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5 [MET], BA1 [MET]	"The filtering allele frequency of the c.531_533delGAA (p.Lys180del) variant in the KRAS gene is 0.51% for European (non-Finnish) chromosomes by the Exome Aggregation Consortium (55/64754 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM internal data; GTR ID's: 21766, 26957; ClinVar SCV000061947, SCV000207865). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581):  BA1, BP5."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135584/MONDO:0021060/004	0.1	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
6	76558195	45131	C	T	NM_004999.3(MYO6):c.1025C>T (p.Ala342Val)	45131	CA135587	NM_004999.3:c.1025C>T, NM_001300899.1:c.1025C>T, XM_005248719.2:c.1025C>T, XM_005248720.2:c.1025C>T, XM_005248721.2:c.1025C>T, XM_005248722.2:c.1025C>T, XM_005248724.2:c.1025C>T, XM_005248726.2:c.1025C>T, XM_005248719.4:c.1025C>T, XM_005248720.4:c.1025C>T, XM_005248721.4:c.1025C>T, XM_005248722.4:c.1025C>T, XM_005248724.4:c.1025C>T, XM_005248726.4:c.1025C>T, XM_017010899.2:c.1025C>T, XM_024446447.1:c.1025C>T, XM_024446448.1:c.1025C>T, NM_004999.4:c.1025C>T, ENST00000369975.5:c.1025C>T, ENST00000369977.7:c.1025C>T, ENST00000369981.7:c.1025C>T, ENST00000369985.8:c.1025C>T, ENST00000615563.4:c.1025C>T, ENST00000627432.2:c.1025C>T, NC_000006.12:g.75848478C>T, CM000668.2:g.75848478C>T, NC_000006.11:g.76558195C>T, CM000668.1:g.76558195C>T, NC_000006.10:g.76614915C>T, NG_009934.1:g.104287C>T, NG_009934.2:g.104286C>T, NM_004999.3(MYO6):c.1025C>T (p.Ala342Val)	MYO6	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	PM2 [Unmet], PVS1 [Unmet], PP3 [MET], PP4 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [MET], PS1 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet]	The filtering allele frequency of the p.Ala342Val variant in the MYO6 gene is 0.21% for European (non-Finnish) chromosomes by gnomAD (304/129090 with 95% CI), and one homozygous European (Finnish) individual, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1). The REVEL computational prediction analysis tool produced a score of 0.905, however, this information is not predictive of pathogenicity on its own and is not considered in conflict with evidence that supports a benign interpretation. In summary, the HL EP classified this variant as benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1.	27068579	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135587/MONDO:0019497/005	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
6	76542642	45163	G	A	NM_004999.3(MYO6):c.475G>A (p.Glu159Lys)	45163	CA135641	NM_004999.3:c.475G>A, NM_001300899.1:c.475G>A, XM_005248719.2:c.475G>A, XM_005248720.2:c.475G>A, XM_005248721.2:c.475G>A, XM_005248722.2:c.475G>A, XM_005248724.2:c.475G>A, XM_005248726.2:c.475G>A, XM_005248719.4:c.475G>A, XM_005248720.4:c.475G>A, XM_005248721.4:c.475G>A, XM_005248722.4:c.475G>A, XM_005248724.4:c.475G>A, XM_005248726.4:c.475G>A, XM_017010899.2:c.475G>A, XM_024446447.1:c.475G>A, XM_024446448.1:c.475G>A, NM_004999.4:c.475G>A, ENST00000369975.5:c.475G>A, ENST00000369977.7:c.475G>A, ENST00000369981.7:c.475G>A, ENST00000369985.8:c.475G>A, ENST00000615563.4:c.475G>A, ENST00000627432.2:c.475G>A, NC_000006.12:g.75832925G>A, CM000668.2:g.75832925G>A, NC_000006.11:g.76542642G>A, CM000668.1:g.76542642G>A, NC_000006.10:g.76599362G>A, NG_009934.1:g.88734G>A, NG_009934.2:g.88733G>A, NM_004999.3(MYO6):c.475G>A (p.Glu159Lys)	MYO6	nonsyndromic genetic deafness	MONDO:0019497		Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [MET], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	The filtering allele frequency of the p.Glu159Lys variant in the MYO6 gene is 0.7% for Ashkenazi Jewish chromosomes in the Genome Aggregation Database (91/10146 with 95%CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	20/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135641/MONDO:0019497/005	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
11	532696	45305	C	T	NM_005343.3(HRAS):c.510G>A (p.Lys170=)	45305	CA135992	NM_005343.3:c.510G>A, NM_001130442.1:c.510G>A, NM_005343.2:c.510G>A, NM_176795.3:c.*79G>A, XM_011519875.1:c.-425+4359C>T, XM_011519877.1:c.-162+4359C>T, XR_242795.1:n.791G>A, NM_001130442.2:c.510G>A, NM_001318054.1:c.273G>A, NM_176795.4:c.*79G>A, XM_011519875.2:c.-425+4359C>T, XM_011519877.2:c.-162+4359C>T, XM_017017167.1:c.-500+4359C>T, XM_017017168.1:c.-500+4359C>T, NM_005343.4:c.510G>A, ENST00000311189.7:c.510G>A, ENST00000397594.5:c.*79G>A, ENST00000397596.6:c.510G>A, ENST00000417302.5:c.*79G>A, ENST00000451590.5:c.510G>A, ENST00000462734.1:n.285G>A, ENST00000478324.5:n.243-66G>A, ENST00000479482.1:n.431G>A, ENST00000493230.5:c.*79G>A, NC_000011.10:g.532696C>T, CM000673.2:g.532696C>T, NC_000011.9:g.532696C>T, CM000673.1:g.532696C>T, NC_000011.8:g.522696C>T, NG_007666.1:g.7855G>A, NM_005343.3(HRAS):c.510G>A (p.Lys170=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BP5 [MET], BP7 [MET], BP4 [MET]	"The c.510G>A (p.Lys170=) variant is a synonymous (silent) variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). Computational prediction tools and conservation analysis suggest that the p.Lys170= variant does not impact the protein (BP4).This variant has been identified in a patient with an alternate molecular basis for disease (BP5; LMM and GeneDx internal data; GTR ID's: 21766, 26957; ClinVar SCV000062144; SCV000168832). In summary, this variant meets criteria to be classified as likely benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BP7, BP5, BP4."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA135992/MONDO:0021060/004	0.0122	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
11	120989335	45314	A	G	NM_005422.2(TECTA):c.1111A>G (p.Arg371Gly)	45314	CA136018	NM_005422.2:c.1111A>G, NM_005422.2:n.1111A>G, ENST00000264037.2:n.1111A>G, ENST00000392793.5:c.1111A>G, NC_000011.10:g.121118626A>G, CM000673.2:g.121118626A>G, NC_000011.9:g.120989335A>G, CM000673.1:g.120989335A>G, NC_000011.8:g.120494545A>G, NG_011633.1:g.20961A>G, NM_005422.2(TECTA):c.1111A>G (p.Arg371Gly)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Benign	PP3 [Unmet], BP4 [Unmet], BA1 [MET]	"The filtering allele frequency of the p.Arg317Gly variant in the TECTA gene is 67.5% (16434/24006) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant and autosomal recessive hearing loss variants (BA1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA136018/MONDO:0019497/005	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
11	120998747	45317	C	G	NM_005422.2(TECTA):c.2061C>G (p.Asn687Lys)	45317	CA136024	NM_005422.2:c.2061C>G, NM_005422.2:n.2061C>G, ENST00000264037.2:n.2061C>G, ENST00000392793.5:c.2061C>G, NC_000011.10:g.121128038C>G, CM000673.2:g.121128038C>G, NC_000011.9:g.120998747C>G, CM000673.1:g.120998747C>G, NC_000011.8:g.120503957C>G, NG_011633.1:g.30373C>G, NM_005422.2(TECTA):c.2061C>G (p.Asn687Lys)	TECTA	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Benign	BA1 [Unmet], BP4 [MET], PS4 [Unmet], PM3 [Unmet], BS1 [MET]	The p.Asn687Lys variant in TECTA has been identified in 1 patient with Asperger syndrome who was hypersensitive to sound (PMID: 30675382). However, the filtering allele frequency of the p.Asn687Lys variant is 0.3% for European chromosomes by gnomAD (399/126054, including one homozygous observation, with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss variants (BS1). Additionally, computational prediction analysis using the metapredictor tool REVEL suggests that the variant may not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BS1, BP4.	30675382	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA136024/MONDO:0019497/005	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
1	216498754	48347	T	G	NM_206933.2(USH2A):c.1036A>C (p.Asn346His)	48347	CA262054	NM_206933.2:c.1036A>C, NC_000001.11:g.216325412T>G, CM000663.2:g.216325412T>G, NC_000001.10:g.216498754T>G, CM000663.1:g.216498754T>G, NC_000001.9:g.214565377T>G, NG_009497.1:g.102985A>C, NM_007123.5:c.1036A>C, NM_206933.3:c.1036A>C, ENST00000307340.7:c.1036A>C, ENST00000366942.3:c.1036A>C, NM_206933.2(USH2A):c.1036A>C (p.Asn346His)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP4 [MET], PP3 [MET], PM3-Very Strong [MET], PM2-Supporting [MET], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], PS3 [Unmet], PM5 [Unmet], PM1 [Unmet], PM4 [Unmet], PP1-Strong [MET], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The allele frequency of the p.Asn346His variant in the USH2A gene is 0.016% (20/126318) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). The p.Asn346His variant in USH2A has been reported to segregate with hearing loss in at least 7 families including 13 family members (PP1_S; 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). This variant has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 15241801, 24160897, 22135276, 26969326). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 10729113, 15241801, 17405132, 25521520, 24160897, 22135276). Computational prediction tools and conservation analysis suggest that the p.Asn346His variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP1_S, PM3_VS, PP4, PP3."	25521520, 24160897, 10729113, 17405132, 15241801, 22135276, 24160897, 26969326, 15241801, 22135276, 24160897, 26969326, 15241801, 22135276, 25521520, 24160897, 10729113, 15241801, 17405132, 22135276, 25521520, 24160897, 10729113, 15241801, 17405132, 22135276	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	14/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA262054/MONDO:0019501/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	215807798	48459	T	C	NM_206933.2(USH2A):c.15297+3A>G	48459	CA143392	NM_206933.2:c.15297+3A>G, NM_206933.3:c.15297+3A>G, ENST00000307340.7:c.15297+3A>G, NC_000001.11:g.215634456T>C, CM000663.2:g.215634456T>C, NC_000001.10:g.215807798T>C, CM000663.1:g.215807798T>C, NC_000001.9:g.213874421T>C, NG_009497.1:g.793941A>G, NM_206933.2(USH2A):c.15297+3A>G	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [MET], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The filtering allele frequency of the c.15297+3A>G variant in the USH2A gene is 0.99% (265/24032) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	14/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA143392/MONDO:0019501/005	0.025	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
1	215802242	48464	C	T	NM_206933.2(USH2A):c.15433G>A (p.Val5145Ile)	48464	CA143401	NM_206933.2:c.15433G>A, NM_206933.3:c.15433G>A, ENST00000307340.7:c.15433G>A, NC_000001.11:g.215628900C>T, CM000663.2:g.215628900C>T, NC_000001.10:g.215802242C>T, CM000663.1:g.215802242C>T, NC_000001.9:g.213868865C>T, NG_009497.1:g.799497G>A, NM_206933.2(USH2A):c.15433G>A (p.Val5145Ile)	USH2A	Usher syndrome type 2	MONDO:0016484	Autosomal recessive inheritance	Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [MET], BP4 [MET], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The p.Val5145Ile variant in USH2A has been identified in at least 5 individuals with Usher syndrome; however, in 3 individuals no variant on the second allele was identified and in two individuals, no information about the other allele was provided (PMIDs 28041643, 25999674, 20829743, 27353947, 23591405). Additionally, the p.Val5145Ile variant was identified in 2 alleles of 56 retinitis pigmentosa patients, however it is unclear in which one or two patients these alleles were found (PMID 20591486). The filtering allele frequency of the p.Val5145Ile variant in the USH2A gene is 0.7% for European (Finnish) chromosomes by gnomAD (201/25124 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1). Additionally, computational prediction analysis using the metapredictor tool REVEL suggests that the variant may not impact the protein (BP4) .In summary, this variant meets criteria to be classified as benign based primarily on population frequency data and the absence of cases with biallelic variants. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BA1, BP4."	20507924, 27353947, 25999674, 20829743, 20591486, 28041643, 23591405	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA143401/MONDO:0016484/005	0.0507	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
1	215799170	48468	T	C	NM_206933.2(USH2A):c.15562A>G (p.Ser5188Gly)	48468	CA143409	NM_206933.2:c.15562A>G, NM_206933.3:c.15562A>G, ENST00000307340.7:c.15562A>G, NC_000001.11:g.215625828T>C, CM000663.2:g.215625828T>C, NC_000001.10:g.215799170T>C, CM000663.1:g.215799170T>C, NC_000001.9:g.213865793T>C, NG_009497.1:g.802569A>G, NM_206933.2(USH2A):c.15562A>G (p.Ser5188Gly)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the p.Ser5188Gly variant in the USH2A gene is 6.8% (2200/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	17/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA143409/MONDO:0019501/005	0.025	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	3	Uncertain Significance
1	216373231	48503	AAT	A	NM_007123.5(USH2A):c.3547_3548delAT (p.Ile1183Phefs)	48503	CA262101	NM_007123.5:c.3547_3548delAT, NM_007123.5:c.3547_3548del, NM_206933.2:c.3547_3548del, XR_922595.1:n.354+3969_354+3970del, XR_922596.1:n.354+3969_354+3970del, XR_922597.1:n.354+3969_354+3970del, XR_922598.1:n.484+3969_484+3970del, XR_922595.3:n.1076+3969_1076+3970del, XR_922596.3:n.1076+3969_1076+3970del, NM_206933.3:c.3547_3548del, ENST00000307340.7:c.3547_3548del, ENST00000366942.3:c.3547_3548del, NC_000001.11:g.216199894_216199895del, CM000663.2:g.216199894_216199895del, NC_000001.10:g.216373236_216373237del, CM000663.1:g.216373236_216373237del, NC_000001.9:g.214439859_214439860del, NG_009497.1:g.228506_228507del, NM_007123.5(USH2A):c.3547_3548delAT (p.Ile1183Phefs)	USH2A	Usher syndrome type 2A	MONDO:0010169	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], PP4 [Unmet], PP1 [Unmet], PP3 [Unmet], BS2 [Unmet], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PS1 [Unmet], PM3 [Unmet], PM1 [Unmet], PM5 [Unmet], PM4 [Unmet], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The p.Ile1183fs variant introduces a premature stop codon in biologically-relevant-exon 17/72 (NM_206933.2) that is predicted to lead to a truncated or absent protein in a gene wherein which loss-of-function is an established mechanism (PVS1; PMIDs: 9624053, 25211151, 20497194). The allele frequency of the p.Ile1183fs variant in USH2A is 0.0009% (1/111274) of non-Finnish European alleles in gnomAD , which is a low enough frequency to apply PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive Usher syndrome type 2A based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel (PVS1, PM2)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA262101/MONDO:0010169/005	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	216246634	48535	C	T	NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)	48535	CA262105	NM_206933.2:c.5581G>A, NR_125992.1:n.136+692C>T, NR_125993.1:n.136+692C>T, NM_206933.3:c.5581G>A, ENST00000307340.7:c.5581G>A, NC_000001.11:g.216073292C>T, CM000663.2:g.216073292C>T, NC_000001.10:g.216246634C>T, CM000663.1:g.216246634C>T, NC_000001.9:g.214313257C>T, NG_009497.1:g.355105G>A, NM_206933.2(USH2A):c.5581G>A (p.Gly1861Ser)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PM6 [Unmet], PVS1 [Unmet], PP3 [MET], PP1 [MET], PP4 [MET], BS2 [Unmet], PM2-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [MET], PS2 [Unmet], PM3-Strong [MET], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The allele frequency of the p.Gly1861Ser variant in USH2A is 0.017% (3/17184) of East Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). This variant was found to have a statistically higher prevalence in affected individuals over controls (PS4; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). This variant has been detected in 4 patients with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3_S; PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). The variant has been reported to segregate with hearing loss in one affected family member (PP1, PMID: 26310143). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: PMIDs: 26310143, 26338283, 23737954, Partners LMM internal data SCV000065557.5). Computational prediction tools and conservation analysis suggest that the p.Gly1861Ser variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PS4, PM2_P, PP3, PM3_S, PP1, PP4."	26310143, 25356976, 23737954, 26310143, 26338283, 25356976, 23737954, 26310143, 26338283, 26310143	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	14/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA262105/MONDO:0019501/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
7	140501331	55793	A	C	NM_004333.4(BRAF):c.741T>G (p.Phe247Leu)	55793	CA284654	NM_004333.4:c.741T>G, LRG_299t1:c.741T>G, XM_005250045.1:c.741T>G, XM_005250046.1:c.741T>G, XM_011516529.1:c.741T>G, XM_011516530.1:c.741T>G, XR_242190.1:n.749T>G, XR_927520.1:n.749T>G, XR_927521.1:n.749T>G, XR_927522.1:n.749T>G, XR_927523.1:n.749T>G, NM_001354609.1:c.741T>G, NM_004333.5:c.741T>G, NR_148928.1:n.1046T>G, XM_017012558.1:c.741T>G, XM_017012559.1:c.741T>G, XR_001744857.1:n.749T>G, XR_001744858.1:n.749T>G, ENST00000288602.10:c.741T>G, ENST00000497784.1:n.776T>G, NC_000007.14:g.140801531A>C, CM000669.2:g.140801531A>C, NC_000007.13:g.140501331A>C, CM000669.1:g.140501331A>C, NC_000007.12:g.140147800A>C, NG_007873.3:g.128234T>G, LRG_299:g.128234T>G, NM_004333.4(BRAF):c.741T>G (p.Phe247Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	PP2 [MET], PP3 [MET], PP1 [Unmet], BS2 [Unmet], PS4-Supporting [MET], PM1 [MET], PM4 [Unmet], PM5 [Unmet], PS2 [MET], PS3 [MET], PS1 [Unmet], BP5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PM6 [MET], PM2 [MET], BP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet]	"The c.741T>G (p.Phe247Leu) variant in BRAF has been reported in the literature as a confirmed and unconfirmed de novo occurrence in 2 patients with clinical features of a RASopathy (PM6, PS2, PS4_Supporting; GeneDx internal data; GTR Lab ID 26957; SCV000077236.10). In vitro functional studies provide some evidence that the p.Phe247Leu variant may impact protein function (PS3; PMID: 28512244). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PS2, PS3, PM1, PM2, PP2, PP3, PS4_Supporting."	28512244	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA284654/MONDO:0021060/004	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237555	92729	G	T	NM_000277.2(PAH):c.1068C>A (p.Tyr356Ter)	92729	CA273107	NM_000277.2:c.1068C>A, NC_000012.12:g.102843777G>T, CM000674.2:g.102843777G>T, NC_000012.11:g.103237555G>T, CM000674.1:g.103237555G>T, NC_000012.10:g.101761685G>T, NG_008690.1:g.78826C>A, NG_008690.2:g.119634C>A, NM_000277.1:c.1068C>A, XM_011538422.1:c.1011C>A, NM_001354304.1:c.1068C>A, NM_000277.3:c.1068C>A, ENST00000307000.7:c.1053C>A, ENST00000549247.6:n.827C>A, ENST00000551114.2:n.730C>A, ENST00000553106.5:c.1068C>A, ENST00000635477.1:n.172C>A, ENST00000635528.1:n.583C>A, NM_000277.2(PAH):c.1068C>A (p.Tyr356Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PP4-Moderate [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: gnomAD MAF 0.00017; PP4_Moderate: Detected in PKU patients (PMID:25894915); PM3_Strong: in trans with p.W326X (Pathogenic), and IVS4-1G>A (Pathogenic). (PMID:25894915). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong)."	25894915, 25894915	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273107/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234285	92731	G	A	NM_000277.1(PAH):c.1208C>T (p.Ala403Val)	92731	CA273106	NM_000277.1:c.1208C>T, NC_000012.12:g.102840507G>A, CM000674.2:g.102840507G>A, NC_000012.11:g.103234285G>A, CM000674.1:g.103234285G>A, NC_000012.10:g.101758415G>A, NG_008690.1:g.82096C>T, NG_008690.2:g.122904C>T, XM_011538422.1:c.1151C>T, NM_000277.2:c.1208C>T, NM_001354304.1:c.1208C>T, NM_000277.3:c.1208C>T, ENST00000307000.7:c.1193C>T, ENST00000551114.2:n.870C>T, ENST00000553106.5:c.1208C>T, ENST00000635477.1:n.312C>T, ENST00000635528.1:n.723C>T, NM_000277.1(PAH):c.1208C>T (p.Ala403Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [Unmet], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP4_Moderate: Seen on 3 PKU alleles, BH4 deficiency was ruled out. Upgraded per ClinGen Metabolic WG. (PMID:8268925); PM3_VeryStrong: A403V found with 4 pathogenic variants . Upgraded per ClinGen SVI workgroup. (PMID:9429153); PS3: In vitro A403V mutant protein activity was ~43% wt. (PMID:21820508). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong, PS3)."	8268925, 9429153, 21820508	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273106/MONDO:0009861/006	0.3246	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234215	92732	A	G	NM_000277.2(PAH):c.1278T>C (p.Asn426=)	92732	CA145978	NM_000277.2:c.1278T>C, NM_000277.1:c.1278T>C, XM_011538422.1:c.1221T>C, NM_001354304.1:c.1278T>C, NM_000277.3:c.1278T>C, ENST00000307000.7:c.1263T>C, ENST00000551114.2:n.940T>C, ENST00000553106.5:c.1278T>C, ENST00000635477.1:n.382T>C, ENST00000635528.1:n.793T>C, NC_000012.12:g.102840437A>G, CM000674.2:g.102840437A>G, NC_000012.11:g.103234215A>G, CM000674.1:g.103234215A>G, NC_000012.10:g.101758345A>G, NG_008690.1:g.82166T>C, NG_008690.2:g.122974T>C, NM_000277.2(PAH):c.1278T>C (p.Asn426=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BA1 [MET], BP4 [MET]	"PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.16641; BP4: no impact on gene in SIFT, Polyphen2, MutationTaster. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1, BP4)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA145978/MONDO:0009861/006	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
12	103306550	92736	A	G	NM_000277.2(PAH):c.168+19T>C	92736	CA145980	NM_000277.2:c.168+19T>C, NC_000012.12:g.102912772A>G, CM000674.2:g.102912772A>G, NC_000012.11:g.103306550A>G, CM000674.1:g.103306550A>G, NC_000012.10:g.101830680A>G, NG_008690.1:g.9831T>C, NG_008690.2:g.50639T>C, NM_000277.1:c.168+19T>C, XM_011538422.1:c.168+19T>C, NM_001354304.1:c.168+19T>C, XM_017019370.2:c.168+19T>C, NM_000277.3:c.168+19T>C, ENST00000307000.7:c.153+19T>C, ENST00000546844.1:c.168+19T>C, ENST00000548677.2:n.255+19T>C, ENST00000548928.1:n.90+19T>C, ENST00000549111.5:n.264+19T>C, ENST00000550978.6:n.152+19T>C, ENST00000551337.5:c.168+19T>C, ENST00000551988.5:n.257+19T>C, ENST00000553106.5:c.168+19T>C, ENST00000635500.1:n.136+19T>C, NM_000277.2(PAH):c.168+19T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	PP4 [Unmet], BA1 [MET], BP4 [Unmet]	PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.44942 in ExAC. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1).	23690520	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA145980/MONDO:0009861/006	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
12	103288696	92737	C	T	NM_000277.2(PAH):c.169G>A (p.Glu57Lys)	92737	CA220578	NM_000277.2:c.169G>A, NC_000012.12:g.102894918C>T, CM000674.2:g.102894918C>T, NC_000012.11:g.103288696C>T, CM000674.1:g.103288696C>T, NC_000012.10:g.101812826C>T, NG_008690.1:g.27685G>A, NG_008690.2:g.68493G>A, NM_000277.1:c.169G>A, XM_011538422.1:c.169G>A, NM_001354304.1:c.169G>A, XM_017019370.2:c.169G>A, NM_000277.3:c.169G>A, ENST00000307000.7:c.154G>A, ENST00000546844.1:c.169G>A, ENST00000548677.2:n.256G>A, ENST00000548928.1:n.91G>A, ENST00000549111.5:n.265G>A, ENST00000550978.6:n.153G>A, ENST00000551337.5:c.169G>A, ENST00000551988.5:n.258G>A, ENST00000553106.5:c.169G>A, ENST00000635500.1:n.137G>A, NM_000277.2(PAH):c.169G>A (p.Glu57Lys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PP3 [Unmet], PM3-Supporting [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ESP MAF=0.00012.; PP4_Moderate: Detected in a patient with mild HPA. Assessment of the PAH, PTS, and QDPR genes was performed. (PMID:21147011); PM3-supporting: Detected with V388M, pathogenic in ClinVar, but parental testing not performed. (PMID:21147011). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_supporting)."	21147011, 21147011	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220578/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103288546	92740	GGACAGTGGC	G	NM_000277.2(PAH):c.310_318delGCCACTGTC (p.Ala104_Val106del)	92740	CA220580	NM_000277.2:c.310_318delGCCACTGTC, NM_000277.1:c.310_318del, XM_011538422.1:c.310_318del, NM_000277.2:c.310_318del, NM_001354304.1:c.310_318del, XM_017019370.2:c.310_318del, NM_000277.3:c.310_318del, ENST00000307000.7:c.295_303del, ENST00000546844.1:c.310_318del, ENST00000548928.1:n.232_240del, ENST00000549111.5:n.406_414del, ENST00000550978.6:n.294_302del, ENST00000551337.5:c.310_318del, ENST00000551988.5:n.399_407del, ENST00000553106.5:c.310_318del, NC_000012.12:g.102894769_102894777del, CM000674.2:g.102894769_102894777del, NC_000012.11:g.103288547_103288555del, CM000674.1:g.103288547_103288555del, NC_000012.10:g.101812677_101812685del, NG_008690.1:g.27826_27834del, NG_008690.2:g.68634_68642del, NM_000277.2(PAH):c.310_318delGCCACTGTC (p.Ala104_Val106del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM4 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Identified a single time in gnomAD (4.06e-06) and absent in ExAC; PM4: p.Ala104_Val106del; PP4: Single patient picked up on NBS with no confirmation studies, no clinical info, no Phe levels, etc. (PMID:27308838). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4, PP4)."	27308838	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220580/MONDO:0009861/006	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103271326	92741	G	A	NM_000277.2(PAH):c.355C>T (p.Pro119Ser)	92741	CA220582	NM_000277.2:c.355C>T, NM_000277.1:c.355C>T, XM_011538422.1:c.355C>T, NM_001354304.1:c.355C>T, XM_017019370.2:c.355C>T, NM_000277.3:c.355C>T, ENST00000307000.7:c.340C>T, ENST00000549111.5:n.451C>T, ENST00000550978.6:n.339C>T, ENST00000551337.5:c.355C>T, ENST00000551988.5:n.444C>T, ENST00000553106.5:c.355C>T, NC_000012.12:g.102877548G>A, CM000674.2:g.102877548G>A, NC_000012.11:g.103271326G>A, CM000674.1:g.103271326G>A, NC_000012.10:g.101795456G>A, NG_008690.1:g.45055C>T, NG_008690.2:g.85863C>T, NM_000277.2(PAH):c.355C>T (p.Pro119Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PP3: in silico analysis supportive of damaging effect; PM3_Strong: In trans with R261Q (PMID 21147011), and in trans with IVS2+1G>A (PMID 12655554) (PMID:21147011; PMID:12655554); PP4_Moderate: BH4 deficiency excluded (PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PM3_Strong, PP4_Moderate)."	21147011, 21147011, 12655554	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	29/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220582/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103271235	92742	C	A	NM_000277.1(PAH):c.441+5G>T	92742	CA273112	NM_000277.1:c.441+5G>T, NC_000012.12:g.102877457C>A, CM000674.2:g.102877457C>A, NC_000012.11:g.103271235C>A, CM000674.1:g.103271235C>A, NC_000012.10:g.101795365C>A, NG_008690.1:g.45146G>T, NG_008690.2:g.85954G>T, XM_011538422.1:c.441+5G>T, NM_000277.2:c.441+5G>T, NM_001354304.1:c.441+5G>T, XM_017019370.2:c.441+5G>T, NM_000277.3:c.441+5G>T, ENST00000307000.7:c.426+5G>T, ENST00000549111.5:n.537+5G>T, ENST00000550978.6:n.430G>T, ENST00000551988.5:n.530+5G>T, ENST00000553106.5:c.441+5G>T, NM_000277.1(PAH):c.441+5G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PS3 [MET], PM3-Strong [MET]	"The c.441+5G>T variant in PAH has been reported on >17 PKU alleles (BH4 deficiency excluded). (PP4_Moderate; PMID: 17935162; PMID: 23514811). This variant has an extremely low allele frequency (0.00002886) in gnomAD (PM2; http://gnomad.broadinstitute.org). This variant has 0% enzyme activity (PS3; http://www.biopku.org). This variant was detected in trans with IVS10-11g>a and p.V388M (Pathogenic in ClinVar) (PM3_Strong; PMID: 23514811). Computational prediction tools and conservation analysis suggest that the c.441+5G>T variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Strong"	17935162, 23514811, 23514811	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	24/5/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273112/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260383	92743	T	A	NM_000277.2(PAH):c.500A>T (p.Asn167Ile)	92743	CA220584	NM_000277.2:c.500A>T, NC_000012.12:g.102866605T>A, CM000674.2:g.102866605T>A, NC_000012.11:g.103260383T>A, CM000674.1:g.103260383T>A, NC_000012.10:g.101784513T>A, NG_008690.1:g.55998A>T, NG_008690.2:g.96806A>T, NM_000277.1:c.500A>T, XM_011538422.1:c.500A>T, NM_001354304.1:c.500A>T, XM_017019370.2:c.500A>T, NM_000277.3:c.500A>T, ENST00000307000.7:c.485A>T, ENST00000549111.5:n.596A>T, ENST00000551988.5:n.530+10857A>T, ENST00000553106.5:c.500A>T, NM_000277.2(PAH):c.500A>T (p.Asn167Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [Unmet], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC (MAF=0.00003). Absent from gnomAD, 1000G, ESP; PP4_Moderate: Found in a French patient with HPA and 2 unrelated UK patients. BH4 deficiencies not assessed/reported. Seen in 1 German patient, Cofactor deficiency was excluded by the BH4 test. 1 Spanish patient, a defect in the synthesis or regeneration pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels and measuring dihydropteridine reductase activity. (PMID:26666653; PMID:9012412; PMID:10679941); PM3_Strong: Patient 664 with genotype N167I/Rl58Q (Pathogenic in ClinVar). Detected with G272X and R408W, known pathogenic variants. (PMID:24368688; PMID:26666653). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong)."	10679941, 9012412, 26666653, 26666653, 24368688	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	28/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220584/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260375	92744	G	C	NM_000277.1(PAH):c.508C>G (p.His170Asp)	92744	CA273111	NM_000277.1:c.508C>G, XM_011538422.1:c.508C>G, NM_000277.2:c.508C>G, NM_001354304.1:c.508C>G, XM_017019370.2:c.508C>G, NM_000277.3:c.508C>G, ENST00000307000.7:c.493C>G, ENST00000549111.5:n.604C>G, ENST00000551988.5:n.530+10865C>G, ENST00000553106.5:c.508C>G, NC_000012.12:g.102866597G>C, CM000674.2:g.102866597G>C, NC_000012.11:g.103260375G>C, CM000674.1:g.103260375G>C, NC_000012.10:g.101784505G>C, NG_008690.1:g.56006C>G, NG_008690.2:g.96814C>G, NM_000277.1(PAH):c.508C>G (p.His170Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP3 [MET], PP4 [MET], PM3-Strong [MET], PS3 [MET]	"The c.508C>G (p.His170Asp) variant in PAH has been reported in 1 patient with hyperphenylalaninemia, and 1 patient with benign persistent hyperphenylalaninemia. (PP4; PMID: 11385716). This variant has an extremely low allele frequency (0.00018) in gnomAD (PM2; http://gnomad.broadinstitute.org). This variant has 43% enzyme activity (PS3; PMID: 17935162). This variant was detected in trans with R261X, c.60+5G>T, c.1315+1G>A  (Pathogenic in ClinVar) (PM3_Strong; PMID: 11385716; PMID: 24941924). Computational prediction tools and conservation analysis suggest that the c.829T>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PM3_Strong"	11385716, 24941924, 11385716, 17935162	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	28/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273111/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103249087	92746	T	C	NM_000277.2(PAH):c.533A>G (p.Glu178Gly)	92746	CA273110	NM_000277.2:c.533A>G, NC_000012.12:g.102855309T>C, CM000674.2:g.102855309T>C, NC_000012.11:g.103249087T>C, CM000674.1:g.103249087T>C, NC_000012.10:g.101773217T>C, NG_008690.1:g.67294A>G, NG_008690.2:g.108102A>G, NM_000277.1:c.533A>G, XM_011538422.1:c.533A>G, NM_001354304.1:c.533A>G, XM_017019370.2:c.533A>G, NM_000277.3:c.533A>G, ENST00000307000.7:c.518A>G, ENST00000549111.5:n.629A>G, ENST00000551988.5:n.554A>G, ENST00000553106.5:c.533A>G, NM_000277.2(PAH):c.533A>G (p.Glu178Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. ExAC MAF=0.00017; PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.841; PS3: 39% residual phenylalanine hydroxylase activity (PMID:17935162); PP4_Moderate: Detected in 6 PKU patients. BH4 deficiency excluded. Upgraded per ClinGen PAHEP. (PMID:18294361; PMID:9634518); PM3_Strong: In trans with 3 pathogenic variants (PMID:18294361). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4_Moderate, PM3_Strong)."	9634518, 18294361, 18294361, 17935162	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273110/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103248982	92747	A	G	NM_000277.1(PAH):c.638T>C (p.Leu213Pro)	92747	CA273109	NM_000277.1:c.638T>C, XM_011538422.1:c.638T>C, NM_000277.2:c.638T>C, NM_001354304.1:c.638T>C, XM_017019370.2:c.638T>C, NM_000277.3:c.638T>C, ENST00000307000.7:c.623T>C, ENST00000549111.5:n.734T>C, ENST00000553106.5:c.638T>C, NC_000012.12:g.102855204A>G, CM000674.2:g.102855204A>G, NC_000012.11:g.103248982A>G, CM000674.1:g.103248982A>G, NC_000012.10:g.101773112A>G, NG_008690.1:g.67399T>C, NG_008690.2:g.108207T>C, NM_000277.1(PAH):c.638T>C (p.Leu213Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3-Very Strong [MET], PP3 [MET]	"The c.638T>C (p.Leu213Pro) variant in PAH has been reported in in 4 patients with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate; PMID: 8659548; PMID: 19292873; PMID: 21147011). This variant is absent from large population studies (PM2; http://exac.broadinstitute.org). This variant was detected in trans with c.1066-11G>A, E390G, D415N, R261X.(Pathogenic in ClinVar) (PM3_Very-strong; PMID: 19292873; PMID: 21147011; PMID: 8632937). Computational prediction tools and conservation analysis suggest that the c.638T>C variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong"	21147011, 8659548, 19292873, 21147011, 8632937, 19292873	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	1/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273109/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246700	92748	C	T	NM_000277.2(PAH):c.735G>A (p.Val245=)	92748	CA145982	NM_000277.2:c.735G>A, NM_000277.1:c.735G>A, XM_011538422.1:c.735G>A, NM_001354304.1:c.735G>A, NM_000277.3:c.735G>A, ENST00000307000.7:c.720G>A, ENST00000549247.6:n.494G>A, ENST00000553106.5:c.735G>A, NC_000012.12:g.102852922C>T, CM000674.2:g.102852922C>T, NC_000012.11:g.103246700C>T, CM000674.1:g.103246700C>T, NC_000012.10:g.101770830C>T, NG_008690.1:g.69681G>A, NG_008690.2:g.110489G>A, NM_000277.2(PAH):c.735G>A (p.Val245=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BS2 [MET], BA1 [MET], BP4 [MET]	"The c.735G>A (p.Val245=) variant in PAH has a MAF of 0.29058 in ExAC (BA1; http://exac.broadinstitute.org) with 6,524 homozygotes (BS2). This is a synonymous variant, predicted tolerated and benign in SIFT, Polyphen. MutationTaster predicted polymorphism with no abrogation of splice sites (BP4). In summary, this variant meets criteria to be classified as benign."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	24/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA145982/MONDO:0009861/006	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
12	103246594	92749	G	A	NM_000277.1(PAH):c.841C>T (p.Pro281Ser)	92749	CA220587	NM_000277.1:c.841C>T, XM_011538422.1:c.841C>T, NM_000277.2:c.841C>T, NM_001354304.1:c.841C>T, NM_000277.3:c.841C>T, ENST00000307000.7:c.826C>T, ENST00000549247.6:n.600C>T, ENST00000553106.5:c.841C>T, ENST00000635477.1:n.2C>T, NC_000012.12:g.102852816G>A, CM000674.2:g.102852816G>A, NC_000012.11:g.103246594G>A, CM000674.1:g.103246594G>A, NC_000012.10:g.101770724G>A, NG_008690.1:g.69787C>T, NG_008690.2:g.110595C>T, NM_000277.1(PAH):c.841C>T (p.Pro281Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: 1 allele in ExAC ; PP3: tools predict damaging ; PP4_Moderate: P281S Identified in at least one patient with classic PKU. BH4 deficiency excluded. (PMID:15589814); PM3_Strong: Detected with c.1315+1G>A & p.Arg243Ter, pathogenic in ClinVar (PMID:26666653; PMID:27121329). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong)."	15589814, 27121329, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220587/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245487	92750	C	T	NM_000277.2(PAH):c.890G>A (p.Arg297His)	92750	CA220590	NM_000277.2:c.890G>A, NM_000277.1:c.890G>A, XM_011538422.1:c.890G>A, NM_001354304.1:c.890G>A, NM_000277.3:c.890G>A, ENST00000307000.7:c.875G>A, ENST00000549247.6:n.649G>A, ENST00000551114.2:n.552G>A, ENST00000553106.5:c.890G>A, ENST00000635477.1:n.51G>A, NC_000012.12:g.102851709C>T, CM000674.2:g.102851709C>T, NC_000012.11:g.103245487C>T, CM000674.1:g.103245487C>T, NC_000012.10:g.101769617C>T, NG_008690.1:g.70894G>A, NG_008690.2:g.111702G>A, NM_000277.2(PAH):c.890G>A (p.Arg297His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PS3 [MET], PM3-Strong [MET]	The c.890G>A (p.Arg297His) variant in PAH has been reported in 6 patients with PKU, in trans with established pathogenic variants (PMID: 9298832,24401910)  with BH4 deficiency excluded in one (PMIDs 24401910 & 9298832). This variant has an extremely low allele frequency in gnomAD (2/245792). The arginine at position 297 is in the C-terminal aromatic amino acid hydroxylase domain, and computational prediction tools and conservation analysis suggest that the c.890G>A variant may impact the protein function. Mutant enzyme activity is 20% as compared to wild type (PMID:24401910). Overall, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PP4_moderate, PM2, PM3_strong, PS3.	24401910, 9298832, 24401910, 24401910, 9298832	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220590/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
12	103245479	92751	C	A	NM_000277.1(PAH):c.898G>T (p.Ala300Ser)	92751	CA273108	NM_000277.1:c.898G>T, NC_000012.12:g.102851701C>A, CM000674.2:g.102851701C>A, NC_000012.11:g.103245479C>A, CM000674.1:g.103245479C>A, NC_000012.10:g.101769609C>A, NG_008690.1:g.70902G>T, NG_008690.2:g.111710G>T, XM_011538422.1:c.898G>T, NM_000277.2:c.898G>T, NM_001354304.1:c.898G>T, NM_000277.3:c.898G>T, ENST00000307000.7:c.883G>T, ENST00000549247.6:n.657G>T, ENST00000551114.2:n.560G>T, ENST00000553106.5:c.898G>T, ENST00000635477.1:n.59G>T, NM_000277.1(PAH):c.898G>T (p.Ala300Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP3: Deleterious in SIFT, Polyphen2, MutationTaster; PP4_Moderate: A300S found on 56/588 hyperphenylalaninemic patients, BH4 deficiency excluded. Upgraded per ClinGen Metabolic WG. (PMID:21147011); PM3_VeryStrong: Detected with c.1066-11G>A (P), R261Q(P/LP), L48S (P), R176X (P) in 20 patients. (PMID:21147011); PS3: A300S in vitro PAH activity of 31% (PMID:17935162). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PP4_Moderate, PM3_VeryStrong, PS3)."	21147011, 21147011, 17935162	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273108/MONDO:0009861/006	0.3246	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245464	92752	C	T	NM_000277.2(PAH):c.912+1G>A	92752	CA220591	NM_000277.2:c.912+1G>A, NM_000277.1:c.912+1G>A, XM_011538422.1:c.912+1G>A, NM_001354304.1:c.912+1G>A, NM_000277.3:c.912+1G>A, ENST00000307000.7:c.897+1G>A, ENST00000549247.6:n.671+1G>A, ENST00000551114.2:n.574+1G>A, ENST00000553106.5:c.912+1G>A, ENST00000635477.1:n.73+1G>A, NC_000012.12:g.102851686C>T, CM000674.2:g.102851686C>T, NC_000012.11:g.103245464C>T, CM000674.1:g.103245464C>T, NC_000012.10:g.101769594C>T, NG_008690.1:g.70917G>A, NG_008690.2:g.111725G>A, NM_000277.2(PAH):c.912+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ExAC MAF=0.00006.; PVS1: Canonical +1 splice site; PP4: Detected in 5 patients with classical PKU. (PMID:8659548). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4)."	8659548	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220591/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103240716	92753	G	A	NM_000277.1(PAH):c.926C>T (p.Ala309Val)	92753	CA220592	NM_000277.1:c.926C>T, XM_011538422.1:c.913-2507C>T, NM_000277.2:c.926C>T, NM_001354304.1:c.926C>T, NM_000277.3:c.926C>T, ENST00000307000.7:c.911C>T, ENST00000549247.6:n.685C>T, ENST00000551114.2:n.588C>T, ENST00000553106.5:c.926C>T, ENST00000635477.1:n.74-2507C>T, ENST00000635528.1:n.441C>T, NC_000012.12:g.102846938G>A, CM000674.2:g.102846938G>A, NC_000012.11:g.103240716G>A, CM000674.1:g.103240716G>A, NC_000012.10:g.101764846G>A, NG_008690.1:g.75665C>T, NG_008690.2:g.116473C>T, NM_000277.1(PAH):c.926C>T (p.Ala309Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM3 [MET], PP3 [MET], PP4 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Low frequency. 1.0e-5; PP3: All databases agree on damaging effect. REVEL=0.921; PS3: Enzyme activity = 30% (Ho, 2008) (PMID:18590700); PM3: Single patient with classic PKU, c.842C>T (pathogenic in ClinVar) / c.926C>T (PMID:26666653); PP4: Single patient with classic PKU (>1200umol/L), BH4 defect not excluded (PMID:26666653). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4)."	26666653, 26666653, 18590700	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220592/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103240630	92755	C	A	NM_000277.2(PAH):c.969+43G>T	92755	CA145984	NM_000277.2:c.969+43G>T, NM_000277.1:c.969+43G>T, XM_011538422.1:c.913-2421G>T, NM_001354304.1:c.969+43G>T, NM_000277.3:c.969+43G>T, ENST00000307000.7:c.954+43G>T, ENST00000549247.6:n.728+43G>T, ENST00000551114.2:n.631+43G>T, ENST00000553106.5:c.969+43G>T, ENST00000635477.1:n.74-2421G>T, ENST00000635528.1:n.484+43G>T, NC_000012.12:g.102846852C>A, CM000674.2:g.102846852C>A, NC_000012.11:g.103240630C>A, CM000674.1:g.103240630C>A, NC_000012.10:g.101764760C>A, NG_008690.1:g.75751G>T, NG_008690.2:g.116559G>T, NM_000277.2(PAH):c.969+43G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BP4 [Unmet], BA1 [MET]	PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.49022 in ExAC. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1).		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA145984/MONDO:0009861/006	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89624218	92808	C	G	NM_000314.6(PTEN):c.-9C>G	92808	CA000663	NM_000314.6:c.-9C>G, NC_000010.11:g.87864461C>G, CM000672.2:g.87864461C>G, NC_000010.10:g.89624218C>G, CM000672.1:g.89624218C>G, NC_000010.9:g.89614198C>G, NG_007466.2:g.6023C>G, LRG_311:g.6023C>G, NG_033079.1:g.3977G>C, NM_000314.5:c.-9C>G, NM_001304717.2:c.511C>G, NM_001304718.1:c.-714C>G, XM_006717926.2:c.-9C>G, XM_011539981.1:c.-9C>G, XR_945789.1:n.704C>G, XR_945790.1:n.704C>G, XR_945791.1:n.704C>G, NM_000314.7:c.-9C>G, NM_001304717.5:c.511C>G, NM_001304718.2:c.-714C>G, ENST00000371953.7:c.-9C>G, ENST00000487939.1:n.13C>G, ENST00000610634.1:c.-111C>G, NM_000314.6(PTEN):c.-9C>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1 [MET]	"PTEN c.-9C>G (NC_000010.10:g.89624218C>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.048 (4.8%, 903/18,870 alleles) in the East Asian subpopulation of the gnomAD cohort. (PMID 27535533)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	9/11/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000663/MONDO:0017623/003	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
10	89720907	92810	T	G	NM_000314.6(PTEN):c.1026+32T>G	92810	CA000255	NM_000314.6:c.1026+32T>G, NC_000010.11:g.87961150T>G, CM000672.2:g.87961150T>G, NC_000010.10:g.89720907T>G, CM000672.1:g.89720907T>G, NC_000010.9:g.89710887T>G, NG_007466.2:g.102712T>G, LRG_311:g.102712T>G, NM_000314.5:c.1026+32T>G, NM_001304717.2:c.1545+32T>G, NM_001304718.1:c.435+32T>G, XM_006717926.2:c.981+32T>G, XM_011539981.1:c.1026+32T>G, XM_011539982.1:c.930+32T>G, XR_945791.1:n.1596+32T>G, NM_000314.7:c.1026+32T>G, NM_001304717.5:c.1545+32T>G, NM_001304718.2:c.435+32T>G, ENST00000371953.7:c.1026+32T>G, ENST00000472832.2:n.485T>G, NM_000314.6(PTEN):c.1026+32T>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1 [MET]	"PTEN c.1026+32T>G (IVS8+32T>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.374 (37.4%, 102,771/274,696 alleles) in the gnomAD cohort. (PMID 27535533)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/9/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000255/MONDO:0017623/003	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89653834	92813	C	T	NM_000314.6(PTEN):c.132C>T (p.Gly44=)	92813	CA000318	NM_000314.6:c.132C>T, NM_000314.5:c.132C>T, NM_001304717.2:c.651C>T, NM_001304718.1:c.-574C>T, XM_006717926.2:c.132C>T, XM_011539981.1:c.132C>T, XM_011539982.1:c.68+13639C>T, XR_945789.1:n.844C>T, XR_945790.1:n.844C>T, XR_945791.1:n.844C>T, NM_000314.7:c.132C>T, NM_001304717.5:c.651C>T, NM_001304718.2:c.-574C>T, ENST00000371953.7:c.132C>T, ENST00000462694.1:n.134C>T, ENST00000610634.1:c.30C>T, NC_000010.11:g.87894077C>T, CM000672.2:g.87894077C>T, NC_000010.10:g.89653834C>T, CM000672.1:g.89653834C>T, NC_000010.9:g.89643814C>T, NG_007466.2:g.35639C>T, LRG_311:g.35639C>T, NM_000314.6(PTEN):c.132C>T (p.Gly44=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP5 [MET], BP7 [MET], BS1 [MET], BS2-Supporting [MET]	"PTEN c.132C>T (p.G44=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.167 (1.67%, 463/276,792 alleles) in the gnomAD cohort. (PMID 27535533)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000212700.3)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000212700.3)BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	9/11/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000318/MONDO:0017623/003	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89685314	92816	TGTAA	T	NM_000314.6(PTEN):c.209+4_209+7delAGTA	92816	CA220637	NM_000314.6:c.209+4_209+7delAGTA, NC_000010.11:g.87925561_87925564del, CM000672.2:g.87925561_87925564del, NC_000010.10:g.89685318_89685321del, CM000672.1:g.89685318_89685321del, NC_000010.9:g.89675298_89675301del, NG_007466.2:g.67123_67126del, LRG_311:g.67123_67126del, NM_000314.5:c.209+4_209+7del, NM_000314.6:c.209+4_209+7del, NM_001304717.2:c.728+4_728+7del, NM_001304718.1:c.-541-5485_-541-5482del, XM_006717926.2:c.165-5485_165-5482del, XM_011539981.1:c.209+4_209+7del, XM_011539982.1:c.113+4_113+7del, XR_945789.1:n.921+4_921+7del, XR_945790.1:n.921+4_921+7del, XR_945791.1:n.921+4_921+7del, NM_000314.7:c.209+4_209+7del, NM_001304717.5:c.728+4_728+7del, NM_001304718.2:c.-541-5485_-541-5482del, ENST00000371953.7:c.209+4_209+7del, ENST00000498703.1:n.35+4_35+7del, ENST00000610634.1:c.107+4_107+7del, NM_000314.6(PTEN):c.209+4_209+7delAGTA	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PS4-Supporting [MET], PM6-Strong [MET], PS3 [MET], PP1-Moderate [MET]	"PTEN c.209+4_209+7delAGTA (IVS3+4_IVS3+7delAGTA) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: RNA, mini-gene, or other assay shows impact on splicing. (PMID 28677221)PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (Internal laboratory contributor(s))PM2: Absent in large sequenced populations (PMID 27535533).PP1_M: Co-segregation with disease in multiple affected family members, with 5 or 6 meioses observed. (Internal laboratory contributor(s))PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 28677221, internal laboratory contributor(s) SCV000273868.4)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/12/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA220637/MONDO:0017623/003	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692731	92818	G	T	NM_000314.6(PTEN):c.254-39G>T	92818	CA000368	NM_000314.6:c.254-39G>T, NC_000010.11:g.87932974G>T, CM000672.2:g.87932974G>T, NC_000010.10:g.89692731G>T, CM000672.1:g.89692731G>T, NC_000010.9:g.89682711G>T, NG_007466.2:g.74536G>T, LRG_311:g.74536G>T, NM_000314.5:c.254-39G>T, NM_001304717.2:c.773-39G>T, NM_001304718.1:c.-497-39G>T, XM_006717926.2:c.209-39G>T, XM_011539981.1:c.254-39G>T, XM_011539982.1:c.158-39G>T, XR_945789.1:n.966-39G>T, XR_945790.1:n.966-39G>T, XR_945791.1:n.966-39G>T, NM_000314.7:c.254-39G>T, NM_001304717.5:c.773-39G>T, NM_001304718.2:c.-497-39G>T, ENST00000371953.7:c.254-39G>T, ENST00000498703.1:n.80-39G>T, ENST00000610634.1:c.152-39G>T, NM_000314.6(PTEN):c.254-39G>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP4 [MET], BP7 [MET], BS1 [MET]	"PTEN c.254-39G>T (IVS4-39G>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0064 (0.64%, 112/17,490 alleles) in the South Asian subpopulation of the gnomAD cohort. (PMID 27535533)BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is intronic and at or beyond +7/-21, nucleotide is not conserved, and no splicing impact is predicted."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/12/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000368/MONDO:0017623/003	0.0028	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89692847	92820	T	C	NM_000314.6(PTEN):c.331T>C (p.Trp111Arg)	92820	CA000401	NM_000314.6:c.331T>C, NM_000314.5:c.331T>C, NM_001304717.2:c.850T>C, NM_001304718.1:c.-420T>C, XM_006717926.2:c.286T>C, XM_011539981.1:c.331T>C, XM_011539982.1:c.235T>C, XR_945789.1:n.1043T>C, XR_945790.1:n.1043T>C, XR_945791.1:n.1043T>C, NM_000314.7:c.331T>C, NM_001304717.5:c.850T>C, NM_001304718.2:c.-420T>C, ENST00000371953.7:c.331T>C, ENST00000498703.1:n.157T>C, ENST00000610634.1:c.229T>C, NC_000010.11:g.87933090T>C, CM000672.2:g.87933090T>C, NC_000010.10:g.89692847T>C, CM000672.1:g.89692847T>C, NC_000010.9:g.89682827T>C, NG_007466.2:g.74652T>C, LRG_311:g.74652T>C, NM_000314.6(PTEN):c.331T>C (p.Trp111Arg)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS3 [MET], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet]	PTEN c.331T>C (p.W111R) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29785012, 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	11476841, 29785012, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000401/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
10	89692911	92822	G	A	NM_000314.6(PTEN):c.395G>A (p.Gly132Asp)	92822	CA000444	NM_000314.6:c.395G>A, NC_000010.11:g.87933154G>A, CM000672.2:g.87933154G>A, NC_000010.10:g.89692911G>A, CM000672.1:g.89692911G>A, NC_000010.9:g.89682891G>A, NG_007466.2:g.74716G>A, LRG_311:g.74716G>A, NM_000314.5:c.395G>A, NM_001304717.2:c.914G>A, NM_001304718.1:c.-356G>A, XM_006717926.2:c.350G>A, XM_011539981.1:c.395G>A, XM_011539982.1:c.299G>A, XR_945789.1:n.1107G>A, XR_945790.1:n.1107G>A, XR_945791.1:n.1107G>A, NM_000314.7:c.395G>A, NM_001304717.5:c.914G>A, NM_001304718.2:c.-356G>A, ENST00000371953.7:c.395G>A, ENST00000498703.1:n.221G>A, ENST00000610634.1:c.293G>A, NM_000314.6(PTEN):c.395G>A (p.Gly132Asp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [MET], PP2 [MET], PS4-Moderate [MET]	PTEN c.395G>A (p.G132D) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000279163.8)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 25288137, PMID 23335809, PMID 23470840, internal laboratory contributor(s))PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	23335809, 23470840, 25288137	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000444/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	5	Likely Pathogenic
10	89624340	92827	C	T	NM_000314.6(PTEN):c.79+35C>T	92827	CA000576	NM_000314.6:c.79+35C>T, NC_000010.11:g.87864583C>T, CM000672.2:g.87864583C>T, NC_000010.10:g.89624340C>T, CM000672.1:g.89624340C>T, NC_000010.9:g.89614320C>T, NG_007466.2:g.6145C>T, LRG_311:g.6145C>T, NG_033079.1:g.3855G>A, NM_000314.5:c.79+35C>T, NM_001304717.2:c.598+35C>T, NM_001304718.1:c.-627+35C>T, XM_006717926.2:c.79+35C>T, XM_011539981.1:c.79+35C>T, XR_945789.1:n.791+35C>T, XR_945790.1:n.791+35C>T, XR_945791.1:n.791+35C>T, NM_000314.7:c.79+35C>T, NM_001304717.5:c.598+35C>T, NM_001304718.2:c.-627+35C>T, ENST00000371953.7:c.79+35C>T, ENST00000462694.1:n.81+35C>T, ENST00000487939.1:n.100+35C>T, ENST00000610634.1:c.-24+35C>T, ENST00000618586.1:n.83C>T, NM_000314.6(PTEN):c.79+35C>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BS1 [MET], BS3 [MET]	"PTEN c.79+35C>T (IVS1+35C>T) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.00178 (1.78%, 492/277,200 alleles) in the gnomAD cohort. (PMID 27535533) BS3: Intronic variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID 17636424)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/9/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000576/MONDO:0017623/003	0.0507	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89717799	92829	G	A	NM_000314.6(PTEN):c.801+23G>A	92829	CA000585	NM_000314.6:c.801+23G>A, NM_000314.5:c.801+23G>A, NM_001304717.2:c.1320+23G>A, NM_001304718.1:c.210+23G>A, XM_006717926.2:c.756+23G>A, XM_011539981.1:c.801+23G>A, XM_011539982.1:c.705+23G>A, XR_945791.1:n.1371+23G>A, NM_000314.7:c.801+23G>A, NM_001304717.5:c.1320+23G>A, NM_001304718.2:c.210+23G>A, ENST00000371953.7:c.801+23G>A, ENST00000472832.2:n.228+23G>A, NC_000010.11:g.87958042G>A, CM000672.2:g.87958042G>A, NC_000010.10:g.89717799G>A, CM000672.1:g.89717799G>A, NC_000010.9:g.89707779G>A, NG_007466.2:g.99604G>A, LRG_311:g.99604G>A, NM_000314.6(PTEN):c.801+23G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP4 [MET], BS1 [MET]	"PTEN c.801+23G>A (IVS7+23G>A) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0024 (0.24%, 58/24,016 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	26/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000585/MONDO:0017623/003	0.0507	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
15	66777315	94082	G	GTC	NM_002755.3(MAP2K1):c.694-8_694-7dupTC	94082	CA147595	NM_002755.3:c.694-7_694-6insTC, NM_002755.3:c.694-8_694-7dupTC, NM_002755.3:c.694-8_694-7dup, LRG_725t1:c.694-8_694-7dup, XM_011521783.1:c.628-8_628-7dup, XM_011521783.3:c.628-8_628-7dup, XM_017022411.2:c.616-8_616-7dup, XM_017022412.1:c.550-8_550-7dup, XM_017022413.1:c.166-8_166-7dup, ENST00000307102.9:c.694-8_694-7dup, ENST00000566326.1:c.166-8_166-7dup, NC_000015.10:g.66484982_66484983dup, CM000677.2:g.66484982_66484983dup, NC_000015.9:g.66777320_66777321dup, CM000677.1:g.66777320_66777321dup, NC_000015.8:g.64564374_64564375dup, NG_008305.1:g.103110_103111dup, LRG_725:g.103110_103111dup, NM_002755.3(MAP2K1):c.694-8_694-7dupTC	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP5 [MET], BA1 [MET]	"The filtering allele frequency of the c.694-8_694-7dupTC variant in the MAP2K1 gene is 4.97% for African chromosomes by the Exome Aggregation Consortium (515/10368 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). This variant has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM, EGL genetics internal data 26957, 21766, 500060; ClinVar SCV000111925.5; SCV000204171.4; SCV000207934.6). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA147595/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
12	103238154	102475	GC	G	NM_000277.2(PAH):c.1024delG (p.Ala342Hisfs)	102475	CA229279	NM_000277.2:c.1024delG, NC_000012.12:g.102844378del, CM000674.2:g.102844378del, NC_000012.11:g.103238156del, CM000674.1:g.103238156del, NC_000012.10:g.101762286del, NG_008690.1:g.78226del, NG_008690.2:g.119034del, NM_000277.1:c.1024del, XM_011538422.1:c.967del, NM_000277.2:c.1024del, NM_001354304.1:c.1024del, NM_000277.3:c.1024del, ENST00000307000.7:c.1009del, ENST00000549247.6:n.783del, ENST00000551114.2:n.686del, ENST00000553106.5:c.1024del, ENST00000635477.1:n.128del, ENST00000635528.1:n.539del, NM_000277.2(PAH):c.1024delG (p.Ala342Hisfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4-Moderate [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PVS1: Frameshift variant; PP4_Moderate: Reported in patients with PAH deficiency. Bh4 defects excluded. (PMID:9634518). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4_Moderate)."	9634518	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229279/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103238146	102483	C	T	NM_000277.2(PAH):c.1033G>A (p.Ala345Thr)	102483	CA229291	NM_000277.2:c.1033G>A, NM_000277.1:c.1033G>A, XM_011538422.1:c.976G>A, NM_001354304.1:c.1033G>A, NM_000277.3:c.1033G>A, ENST00000307000.7:c.1018G>A, ENST00000549247.6:n.792G>A, ENST00000551114.2:n.695G>A, ENST00000553106.5:c.1033G>A, ENST00000635477.1:n.137G>A, ENST00000635528.1:n.548G>A, NC_000012.12:g.102844368C>T, CM000674.2:g.102844368C>T, NC_000012.11:g.103238146C>T, CM000674.1:g.103238146C>T, NC_000012.10:g.101762276C>T, NG_008690.1:g.78235G>A, NG_008690.2:g.119043G>A, NM_000277.2(PAH):c.1033G>A (p.Ala345Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [MET], PM3 [MET], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from controls in ExaC, 100 Genomes, ESP, and gnomAD; PP3: Deleterious effected predicted by SIFT, Polyphen2, and MutationTaster; PM5: A345S (Variant ID 102484) predicted pathogenic in ClinVar; PP4_Moderate: Found in two individuals with Classic PKU on exon 10.Urinary pterin analysis and dihydropteridine reductase (DHPR) assay were performed t (PMID:15503242); PM3: Found in trans with R243Q (pathogenic in ClinVar). (PMID:15503242). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM5, PP4_Moderate, PM3)."	15503242, 15503242	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229291/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103238123	102498	AC	A	NM_000277.2(PAH):c.1055delG (p.Gly352Valfs)	102498	CA229311	NM_000277.2:c.1055delG, NM_000277.1:c.1055del, XM_011538422.1:c.998del, NM_000277.2:c.1055del, NM_001354304.1:c.1055del, NM_000277.3:c.1055del, ENST00000307000.7:c.1040del, ENST00000549247.6:n.814del, ENST00000551114.2:n.717del, ENST00000553106.5:c.1055del, ENST00000635477.1:n.159del, ENST00000635528.1:n.570del, NC_000012.12:g.102844347del, CM000674.2:g.102844347del, NC_000012.11:g.103238125del, CM000674.1:g.103238125del, NC_000012.10:g.101762255del, NG_008690.1:g.78257del, NG_008690.2:g.119065del, NM_000277.2(PAH):c.1055delG (p.Gly352Valfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency in ExAC, MAF=0.00002.; PP4: Identified in a pair of siblings with PKU. (PMID:7913581). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4)."	7913581	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229311/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237533	102518	GC	G	NM_000277.2(PAH):c.1089delG (p.Lys363Asnfs)	102518	CA229336	NM_000277.2:c.1089delG, NC_000012.12:g.102843756del, CM000674.2:g.102843756del, NC_000012.11:g.103237534del, CM000674.1:g.103237534del, NC_000012.10:g.101761664del, NG_008690.1:g.78847del, NG_008690.2:g.119655del, NM_000277.1:c.1089del, XM_011538422.1:c.1032del, NM_000277.2:c.1089del, NM_001354304.1:c.1089del, NM_000277.3:c.1089del, ENST00000307000.7:c.1074del, ENST00000549247.6:n.848del, ENST00000551114.2:n.751del, ENST00000553106.5:c.1089del, ENST00000635477.1:n.193del, ENST00000635528.1:n.604del, NM_000277.2(PAH):c.1089delG (p.Lys363Asnfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP4: Detected in a patient with Classical PKU. (PMID:8659548). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4)."	8659548	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229336/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237523	102525	A	G	NM_000277.2(PAH):c.1100T>C (p.Leu367Pro)	102525	CA229344	NM_000277.2:c.1100T>C, NM_000277.1:c.1100T>C, XM_011538422.1:c.1043T>C, NM_001354304.1:c.1100T>C, NM_000277.3:c.1100T>C, ENST00000307000.7:c.1085T>C, ENST00000549247.6:n.859T>C, ENST00000551114.2:n.762T>C, ENST00000553106.5:c.1100T>C, ENST00000635477.1:n.204T>C, ENST00000635528.1:n.615T>C, NC_000012.12:g.102843745A>G, CM000674.2:g.102843745A>G, NC_000012.11:g.103237523A>G, CM000674.1:g.103237523A>G, NC_000012.10:g.101761653A>G, NG_008690.1:g.78858T>C, NG_008690.2:g.119666T>C, NM_000277.2(PAH):c.1100T>C (p.Leu367Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PP3 [MET]	The c.1100T>C (p.Leu367Pro) variant in PAH is reported in a Japanese patient with PKU, BH4 deficiency was excluded. (PMID: 21307867) This variant is absent in population databases. It is predicted deleterious by SIFT, Polyphen-2 and MutationTaster. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3.	21307867	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	8/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229344/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237522	102526	C	T	NM_000277.2(PAH):c.1101G>A (p.Leu367=)	102526	CA229346	NM_000277.2:c.1101G>A, NM_000277.1:c.1101G>A, XM_011538422.1:c.1044G>A, NM_001354304.1:c.1101G>A, NM_000277.3:c.1101G>A, ENST00000307000.7:c.1086G>A, ENST00000549247.6:n.860G>A, ENST00000551114.2:n.763G>A, ENST00000553106.5:c.1101G>A, ENST00000635477.1:n.205G>A, ENST00000635528.1:n.616G>A, NC_000012.12:g.102843744C>T, CM000674.2:g.102843744C>T, NC_000012.11:g.103237522C>T, CM000674.1:g.103237522C>T, NC_000012.10:g.101761652C>T, NG_008690.1:g.78859G>A, NG_008690.2:g.119667G>A, NM_000277.2(PAH):c.1101G>A (p.Leu367=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM3 [MET], PP3 [MET], PP4 [MET]	"The c.1101G>A (p.Leu367=) variant in PAH is reported in an individual with Classic PKU, in trans with p.R243Q. (PMID: 16256386) This variant is absent in population databases. Two splicing algorthms predict a deleterious effect (Human splicing finder: potential alteration of splicing; MaxEnt scan: +571.94% Variation). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3."	16256386, 16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	8/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229346/MONDO:0009861/006	0.3246	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
12	103306625	102531	T	TC	NM_000277.1(PAH):c.111_112insG (p.Ile38Aspfs)	102531	CA229354	NM_000277.1:c.111_112insG, NM_000277.1:c.111dup, XM_011538422.1:c.111dup, NM_000277.2:c.111dup, NM_001354304.1:c.111dup, XM_017019370.2:c.111dup, NM_000277.3:c.111dup, ENST00000307000.7:c.96dup, ENST00000546844.1:c.111dup, ENST00000548677.2:n.198dup, ENST00000548928.1:n.33dup, ENST00000549111.5:n.207dup, ENST00000550978.6:n.95dup, ENST00000551337.5:c.111dup, ENST00000551988.5:n.200dup, ENST00000553106.5:c.111dup, ENST00000635500.1:n.79dup, NC_000012.12:g.102912848dup, CM000674.2:g.102912848dup, NC_000012.11:g.103306626dup, CM000674.1:g.103306626dup, NC_000012.10:g.101830756dup, NG_008690.1:g.9755dup, NG_008690.2:g.50563dup, NM_000277.1(PAH):c.111_112insG (p.Ile38Aspfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"The c.112dupG variant in PAH has been previously reported as a single variant (no second mutation detected) in 1 Chinese patient with classic PKU (PMID: 16256386); BH4 deficiency was not excluded (PP4). The variant is a frameshift variant occurring in exon 2 of 13 in the in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (see PMID: 30192042) (PVS1). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PP4, PM2."	16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229354/MONDO:0009861/006	0.9941	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237423	102557	C	G	NM_000277.2(PAH):c.1199+1G>C	102557	CA274088	NM_000277.2:c.1199+1G>C, NC_000012.12:g.102843645C>G, CM000674.2:g.102843645C>G, NC_000012.11:g.103237423C>G, CM000674.1:g.103237423C>G, NC_000012.10:g.101761553C>G, NG_008690.1:g.78958G>C, NG_008690.2:g.119766G>C, NM_000277.1:c.1199+1G>C, XM_011538422.1:c.1142+1G>C, NM_001354304.1:c.1199+1G>C, NM_000277.3:c.1199+1G>C, ENST00000307000.7:c.1184+1G>C, ENST00000549247.6:n.958+1G>C, ENST00000551114.2:n.861+1G>C, ENST00000553106.5:c.1199+1G>C, ENST00000635477.1:n.303+1G>C, ENST00000635528.1:n.714+1G>C, NM_000277.2(PAH):c.1199+1G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4-Moderate [MET], PM3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: 8.1e-6 allele frequency in GnomAD, not found in any other databases; PM3: [c.898G>T];[c.1199+1G>C] in a patient with mild hyperphe (180umol/L); PP4_Moderate: Single patient in Sterl 2013, BH4 defect excluded. Also identified in multiple other patients (7 publications linked through ClinVar) (PMID:22526846); PVS1: +1 canonical splice site. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM3, PP4_Moderate, PVS1)."	22526846	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	27/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA274088/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234276	102567	A	G	NM_000277.2(PAH):c.1217T>C (p.Ile406Thr)	102567	CA229398	NM_000277.2:c.1217T>C, NM_000277.1:c.1217T>C, XM_011538422.1:c.1160T>C, NM_001354304.1:c.1217T>C, NM_000277.3:c.1217T>C, ENST00000307000.7:c.1202T>C, ENST00000551114.2:n.879T>C, ENST00000553106.5:c.1217T>C, ENST00000635477.1:n.321T>C, ENST00000635528.1:n.732T>C, NC_000012.12:g.102840498A>G, CM000674.2:g.102840498A>G, NC_000012.11:g.103234276A>G, CM000674.1:g.103234276A>G, NC_000012.10:g.101758406A>G, NG_008690.1:g.82105T>C, NG_008690.2:g.122913T>C, NM_000277.2(PAH):c.1217T>C (p.Ile406Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	"The c.1217T>C (p.Ile406Thr) variant in PAH is reported in 2 unrelated patients with PKU; BH4 cofactor deficiency was ruled out. (PMID: 10234516, 27121329, 28754886) This variant was reported in trans with known pathogenic variants p.I65T (PMID: 10234516) and IVS4-1G>A (PMID: 28754886). It is absent in population databases, and multiple lines of computational evidence support a deleterious effect. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PP3."	27121329, 10234516, 28754886, 10234516	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229398/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234251	102577	G	A	NM_000277.2(PAH):c.1242C>T (p.Tyr414=)	102577	CA200893	NM_000277.2:c.1242C>T, NM_000277.1:c.1242C>T, XM_011538422.1:c.1185C>T, NM_001354304.1:c.1242C>T, NM_000277.3:c.1242C>T, ENST00000307000.7:c.1227C>T, ENST00000551114.2:n.904C>T, ENST00000553106.5:c.1242C>T, ENST00000635477.1:n.346C>T, ENST00000635528.1:n.757C>T, NC_000012.12:g.102840473G>A, CM000674.2:g.102840473G>A, NC_000012.11:g.103234251G>A, CM000674.1:g.103234251G>A, NC_000012.10:g.101758381G>A, NG_008690.1:g.82130C>T, NG_008690.2:g.122938C>T, NM_000277.2(PAH):c.1242C>T (p.Tyr414=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BS1 [MET], BS2 [MET], BP4 [Unmet]	"PAH-specific ACMG/AMP criteria applied: BS1: MAF=0.01361 in ENF from gnomAD; BS2: 19 homozygotes in gnomAD. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BS2)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA200893/MONDO:0009861/006	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
12	103306612	102581	T	A	NM_000277.2(PAH):c.125A>T (p.Lys42Ile)	102581	CA229419	NM_000277.2:c.125A>T, NM_000277.1:c.125A>T, XM_011538422.1:c.125A>T, NM_001354304.1:c.125A>T, XM_017019370.2:c.125A>T, NM_000277.3:c.125A>T, ENST00000307000.7:c.110A>T, ENST00000546844.1:c.125A>T, ENST00000548677.2:n.212A>T, ENST00000548928.1:n.47A>T, ENST00000549111.5:n.221A>T, ENST00000550978.6:n.109A>T, ENST00000551337.5:c.125A>T, ENST00000551988.5:n.214A>T, ENST00000553106.5:c.125A>T, ENST00000635500.1:n.93A>T, NC_000012.12:g.102912834T>A, CM000674.2:g.102912834T>A, NC_000012.11:g.103306612T>A, CM000674.1:g.103306612T>A, NC_000012.10:g.101830742T>A, NG_008690.1:g.9769A>T, NG_008690.2:g.50577A>T, NM_000277.2(PAH):c.125A>T (p.Lys42Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM3 [MET], PP3 [Unmet], PP4 [MET], PS3 [MET]	"The c.125A>T (p.Lys42Ile) variant in PAH has been reported in 1 individual with classic PKU (BH4 deficiency not assessed/reported). (PP4; PMID: 9380432; 9781015). This variant is absent in population databases (PM2). This variant was detected with p.E280K (Pathogenic in ClinVar) (PM3). This variant has 12% enzyme activity in vitro (PS3; PMID: 21953985). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PP4, PM2, PM3."	9380432, 9380432, 9781015, 21953985, 11461190	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229419/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234222	102584	A	G	NM_000277.2(PAH):c.1271T>C (p.Leu424Ser)	102584	CA229424	NM_000277.2:c.1271T>C, NM_000277.1:c.1271T>C, XM_011538422.1:c.1214T>C, NM_001354304.1:c.1271T>C, NM_000277.3:c.1271T>C, ENST00000307000.7:c.1256T>C, ENST00000551114.2:n.933T>C, ENST00000553106.5:c.1271T>C, ENST00000635477.1:n.375T>C, ENST00000635528.1:n.786T>C, NC_000012.12:g.102840444A>G, CM000674.2:g.102840444A>G, NC_000012.11:g.103234222A>G, CM000674.1:g.103234222A>G, NC_000012.10:g.101758352A>G, NG_008690.1:g.82159T>C, NG_008690.2:g.122967T>C, NM_000277.2(PAH):c.1271T>C (p.Leu424Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], BS1 [Unmet], PM5 [Unmet], PP3 [MET], BS2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet]	The NM_000277.2:c.1271T>C (p.Leu424Ser) variant in PAH has not been reported in the medical literature. This variant is absent from 1000G, ESP, ExAC, and gnomAD. A deleterious effect is predicted in SIFT, Polyphen-2, and REVEL=0.966. Overall, there is not enough evidence to classify the p.Leu424Ser variant with certainty. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229424/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234176	102588	A	G	NM_000277.2(PAH):c.1315+2T>C	102588	CA229429	NM_000277.2:c.1315+2T>C, NM_000277.1:c.1315+2T>C, XM_011538422.1:c.1258+2T>C, NM_001354304.1:c.1315+2T>C, NM_000277.3:c.1315+2T>C, ENST00000307000.7:c.1300+2T>C, ENST00000551114.2:n.977+2T>C, ENST00000553106.5:c.1315+2T>C, ENST00000635477.1:n.419+2T>C, ENST00000635528.1:n.830+2T>C, NC_000012.12:g.102840398A>G, CM000674.2:g.102840398A>G, NC_000012.11:g.103234176A>G, CM000674.1:g.103234176A>G, NC_000012.10:g.101758306A>G, NG_008690.1:g.82205T>C, NG_008690.2:g.123013T>C, NM_000277.2(PAH):c.1315+2T>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [Unmet], PM3-Strong [MET]	"The c.1315+2T>C variant is at the 3' canonical splice site in the penultimate exon of PAH.  It is absent form population databases and has been identified in trans with pathogenic variants in three independent patients (F39del, Y414C, and R261X; PMID: 9452062; 9521426).  A defect of BH4 metabolism was excluded as a cause of elevated phenylalanine in all patients. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong."	9521426, 9521426, 9452062	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229429/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306599	102597	AC	A	NM_000277.2(PAH):c.137delG (p.Gly46Valfs)	102597	CA229440	NC_000012.12:g.102912823del, CM000674.2:g.102912823del, NC_000012.11:g.103306601del, CM000674.1:g.103306601del, NC_000012.10:g.101830731del, NG_008690.1:g.9781del, NG_008690.2:g.50589del, NM_000277.1:c.137del, XM_011538422.1:c.137del, NM_000277.2:c.137del, NM_001354304.1:c.137del, XM_017019370.2:c.137del, NM_000277.3:c.137del, ENST00000307000.7:c.122del, ENST00000546844.1:c.137del, ENST00000548677.2:n.224del, ENST00000548928.1:n.59del, ENST00000549111.5:n.233del, ENST00000550978.6:n.121del, ENST00000551337.5:c.137del, ENST00000551988.5:n.226del, ENST00000553106.5:c.137del, ENST00000635500.1:n.105del, NM_000277.2(PAH):c.137delG (p.Gly46Valfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"The c.137delG (p.Gly46Vfs*15) is a frameshift in exon 2 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in 1 individual with PKU (BH4 deficiency not excluded), who carried a second splicing variant (PP4; PMID: 10196714 ). This variant is absent from population databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4."	10196714	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229440/MONDO:0009861/006	0.9941	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306579	102601	C	T	NM_000277.2(PAH):c.158G>A (p.Arg53His)	102601	CA229447	NM_000277.2:c.158G>A, NC_000012.12:g.102912801C>T, CM000674.2:g.102912801C>T, NC_000012.11:g.103306579C>T, CM000674.1:g.103306579C>T, NC_000012.10:g.101830709C>T, NG_008690.1:g.9802G>A, NG_008690.2:g.50610G>A, NM_000277.1:c.158G>A, XM_011538422.1:c.158G>A, NM_001354304.1:c.158G>A, XM_017019370.2:c.158G>A, NM_000277.3:c.158G>A, ENST00000307000.7:c.143G>A, ENST00000546844.1:c.158G>A, ENST00000548677.2:n.245G>A, ENST00000548928.1:n.80G>A, ENST00000549111.5:n.254G>A, ENST00000550978.6:n.142G>A, ENST00000551337.5:c.158G>A, ENST00000551988.5:n.247G>A, ENST00000553106.5:c.158G>A, ENST00000635500.1:n.126G>A, NM_000277.2(PAH):c.158G>A (p.Arg53His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	BS1 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [Unmet]	"PAH-specific ACMG/AMP criteria applied: BS1: MAF=0.01596 in ExAC (138/8648) and 0.0104 in gnomAD (265/18868 with 3 homozygotes); PP4_moderate: Detected in multiple patients with hyperphenylalaninemia, BH4 deficiency excluded (PMID:24401910, 26322415); PM3: Detected in trans with pathogenic variant p.R243Q. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, PP4_moderate, PM3)."	24401910, 26322415, 24401910, 26322415	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229447/MONDO:0009861/006	0.3246	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306568	102604	C	T	NM_000277.2(PAH):c.168+1G>A	102604	CA229452	NM_000277.2:c.168+1G>A, NM_000277.1:c.168+1G>A, XM_011538422.1:c.168+1G>A, NM_001354304.1:c.168+1G>A, XM_017019370.2:c.168+1G>A, NM_000277.3:c.168+1G>A, ENST00000307000.7:c.153+1G>A, ENST00000546844.1:c.168+1G>A, ENST00000548677.2:n.255+1G>A, ENST00000548928.1:n.90+1G>A, ENST00000549111.5:n.264+1G>A, ENST00000550978.6:n.152+1G>A, ENST00000551337.5:c.168+1G>A, ENST00000551988.5:n.257+1G>A, ENST00000553106.5:c.168+1G>A, ENST00000635500.1:n.136+1G>A, NC_000012.12:g.102912790C>T, CM000674.2:g.102912790C>T, NC_000012.11:g.103306568C>T, CM000674.1:g.103306568C>T, NC_000012.10:g.101830698C>T, NG_008690.1:g.9813G>A, NG_008690.2:g.50621G>A, NM_000277.2(PAH):c.168+1G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PVS1 [MET], PM3 [MET]	The c.168+1G>A variant in PAH is at a canonical splice site at intron 3, and is absent in all population databases.  It has been identified in trans with a pathogenic variant (Ho, 2014), and as a homozygous variant (PMID: 18294361) in patients with phenylketonuria.  Defects in BH4 metabolism were excluded as a cause of elevated phenylalanine in two patients (PMID: 24368688, 8807331). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4_Moderate.	24368688, 8807331, 24368688, 18294361	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229452/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306564	102605	C	T	NM_000277.2(PAH):c.168+5G>A	102605	CA229453	NM_000277.2:c.168+5G>A, NM_000277.1:c.168+5G>A, XM_011538422.1:c.168+5G>A, NM_001354304.1:c.168+5G>A, XM_017019370.2:c.168+5G>A, NM_000277.3:c.168+5G>A, ENST00000307000.7:c.153+5G>A, ENST00000546844.1:c.168+5G>A, ENST00000548677.2:n.255+5G>A, ENST00000548928.1:n.90+5G>A, ENST00000549111.5:n.264+5G>A, ENST00000550978.6:n.152+5G>A, ENST00000551337.5:c.168+5G>A, ENST00000551988.5:n.257+5G>A, ENST00000553106.5:c.168+5G>A, ENST00000635500.1:n.136+5G>A, NC_000012.12:g.102912786C>T, CM000674.2:g.102912786C>T, NC_000012.11:g.103306564C>T, CM000674.1:g.103306564C>T, NC_000012.10:g.101830694C>T, NG_008690.1:g.9817G>A, NG_008690.2:g.50625G>A, NM_000277.2(PAH):c.168+5G>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	The c.168+5G>A variant has been identified in at least 4 probands with phenotypes ranging from mild HPA to classic PKU, with at least 2 probands excluding BH4 deficiency (PMIDs: 9429153, 26413448, 27121329). It has been detected in the homozygous form (PMID: 26413448) as well as in trans with pathogenic variants R297H (PMID: 9429153), I65T, and S349P (PMID: 27121329). This variant is absent from 1000G, ESP, and gnomAD databases. Computational analysis predicts an alteration of the WT donor site, most probably affecting splicing. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Strong, PM2, PP4_Moderate, PP3.	27121329, 26413448, 9429153, 27121329, 26413448, 9429153	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229453/MONDO:0009861/006	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306564	102607	C	A	NM_000277.2(PAH):c.168+5G>T	102607	CA229455	NM_000277.2:c.168+5G>T, NC_000012.12:g.102912786C>A, CM000674.2:g.102912786C>A, NC_000012.11:g.103306564C>A, CM000674.1:g.103306564C>A, NC_000012.10:g.101830694C>A, NG_008690.1:g.9817G>T, NG_008690.2:g.50625G>T, NM_000277.1:c.168+5G>T, XM_011538422.1:c.168+5G>T, NM_001354304.1:c.168+5G>T, XM_017019370.2:c.168+5G>T, NM_000277.3:c.168+5G>T, ENST00000307000.7:c.153+5G>T, ENST00000546844.1:c.168+5G>T, ENST00000548677.2:n.255+5G>T, ENST00000548928.1:n.90+5G>T, ENST00000549111.5:n.264+5G>T, ENST00000550978.6:n.152+5G>T, ENST00000551337.5:c.168+5G>T, ENST00000551988.5:n.257+5G>T, ENST00000553106.5:c.168+5G>T, ENST00000635500.1:n.136+5G>T, NM_000277.2(PAH):c.168+5G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM3 [Unmet], PP3 [MET]	The c.168+5G>T variant has been identified in at least 2 probands, with at least 1 classic PKU proband excluding BH4 deficiency (PMIDs: 30747360). This variant is absent from 1000G, ESP, and gnomAD databases. Computational analysis predicts an alteration of the WT donor site, most probably affecting splicing. In summary, this variant meets criteria to be classified as unknown significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PP3.	30747360	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229455/MONDO:0009861/006	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288689	102616	T	C	NM_000277.2(PAH):c.176A>G (p.Asp59Gly)	102616	CA229468	NM_000277.2:c.176A>G, NC_000012.12:g.102894911T>C, CM000674.2:g.102894911T>C, NC_000012.11:g.103288689T>C, CM000674.1:g.103288689T>C, NC_000012.10:g.101812819T>C, NG_008690.1:g.27692A>G, NG_008690.2:g.68500A>G, NM_000277.1:c.176A>G, XM_011538422.1:c.176A>G, NM_001354304.1:c.176A>G, XM_017019370.2:c.176A>G, NM_000277.3:c.176A>G, ENST00000307000.7:c.161A>G, ENST00000546844.1:c.176A>G, ENST00000548677.2:n.263A>G, ENST00000548928.1:n.98A>G, ENST00000549111.5:n.272A>G, ENST00000550978.6:n.160A>G, ENST00000551337.5:c.176A>G, ENST00000551988.5:n.265A>G, ENST00000553106.5:c.176A>G, ENST00000635500.1:n.144A>G, NM_000277.2(PAH):c.176A>G (p.Asp59Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [Unmet]	"The c.176A>G (p.Asp59Gly) variant in PAH has not been reported in the literature to our knowledge. A reference from BioPKU/PAHdb is not located (Carducci C, 1999). It is absent from ExAC, gnomAD, 1000G, and ESP.  There are conflicting predictions of pathogenicity: SIFT/Polyphen2: benign; MutationTaster: Damaging; REVEL=0.565. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229468/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103288678	102619	T	G	NM_000277.2(PAH):c.187A>C (p.Thr63Pro)	102619	CA229473	NM_000277.2:c.187A>C, NM_000277.1:c.187A>C, XM_011538422.1:c.187A>C, NM_001354304.1:c.187A>C, XM_017019370.2:c.187A>C, NM_000277.3:c.187A>C, ENST00000307000.7:c.172A>C, ENST00000546844.1:c.187A>C, ENST00000548677.2:n.274A>C, ENST00000548928.1:n.109A>C, ENST00000549111.5:n.283A>C, ENST00000550978.6:n.171A>C, ENST00000551337.5:c.187A>C, ENST00000551988.5:n.276A>C, ENST00000553106.5:c.187A>C, ENST00000635500.1:n.155A>C, NC_000012.12:g.102894900T>G, CM000674.2:g.102894900T>G, NC_000012.11:g.103288678T>G, CM000674.1:g.103288678T>G, NC_000012.10:g.101812808T>G, NG_008690.1:g.27703A>C, NG_008690.2:g.68511A>C, NM_000277.2(PAH):c.187A>C (p.Thr63Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [Unmet]	"The c.187A>C (p.Thr63Pro) variant in PAH was detected in 1 Danish PKU patient (Phenylalanine > 600 umol/L). Other causes of hyperphenylalaninemia had been ruled out. (PMID: 8406445). It was in cis with a p.H64N variant (No assertion provided, ClinVar). The c.187A>C variant is absent from ExAC, gnomAD, 1000G, and ESP. There are conflicting predictions of pathogenicity: SIFT:T,D; Polyphen2:D,P; MutationTaster:Disease causing; REVEL:0.768. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate."	8406445	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229473/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288675	102620	G	T	NM_000277.2(PAH):c.190C>A (p.His64Asn)	102620	CA229475	NM_000277.2:c.190C>A, NM_000277.1:c.190C>A, XM_011538422.1:c.190C>A, NM_001354304.1:c.190C>A, XM_017019370.2:c.190C>A, NM_000277.3:c.190C>A, ENST00000307000.7:c.175C>A, ENST00000546844.1:c.190C>A, ENST00000548677.2:n.277C>A, ENST00000548928.1:n.112C>A, ENST00000549111.5:n.286C>A, ENST00000550978.6:n.174C>A, ENST00000551337.5:c.190C>A, ENST00000551988.5:n.279C>A, ENST00000553106.5:c.190C>A, ENST00000635500.1:n.158C>A, NC_000012.12:g.102894897G>T, CM000674.2:g.102894897G>T, NC_000012.11:g.103288675G>T, CM000674.1:g.103288675G>T, NC_000012.10:g.101812805G>T, NG_008690.1:g.27706C>A, NG_008690.2:g.68514C>A, NM_000277.2(PAH):c.190C>A (p.His64Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET]	The c.190C>A (p.His64Asn) variant in PAH has been reported in a Danish mild PKU patient. Serum Phe levels exceeded 600 umol/L and other causes of hyperphenylalaninemia had been ruled out. It was In cis with p.T63P. PMID: 8406445. The c.190C>A variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, and MutationTaster. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PP3.	8406445	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229475/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288671	102623	A	T	NM_000277.2(PAH):c.194T>A (p.Ile65Asn)	102623	CA229479	NM_000277.2:c.194T>A, NM_000277.1:c.194T>A, XM_011538422.1:c.194T>A, NM_001354304.1:c.194T>A, XM_017019370.2:c.194T>A, NM_000277.3:c.194T>A, ENST00000307000.7:c.179T>A, ENST00000546844.1:c.194T>A, ENST00000548677.2:n.281T>A, ENST00000548928.1:n.116T>A, ENST00000549111.5:n.290T>A, ENST00000550978.6:n.178T>A, ENST00000551337.5:c.194T>A, ENST00000551988.5:n.283T>A, ENST00000553106.5:c.194T>A, ENST00000635500.1:n.162T>A, NC_000012.12:g.102894893A>T, CM000674.2:g.102894893A>T, NC_000012.11:g.103288671A>T, CM000674.1:g.103288671A>T, NC_000012.10:g.101812801A>T, NG_008690.1:g.27710T>A, NG_008690.2:g.68518T>A, NM_000277.2(PAH):c.194T>A (p.Ile65Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"The c.194T>A (p.Ile65Asn) variant was identified in a patient with classic PKU. BH4 deficiency was ruled out. (PMID: 9521426). It was detected in trans with known pathogenic mutation c.143T>C (p.L48S). It has an extremely low frequency in PAGE (0.00026); and is absent from ExAC, 1000 Genomes, gnomAD. Multiple lines of computational evidence support a deleterious effect (SIFT, Polyphen-2, MutationTaster; REVEL=0.957). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate, PP3."	9521426, 9521426	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229479/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310908	102626	T	A	NM_000277.2(PAH):c.1A>T (p.Met1Leu)	102626	CA229482	NM_000277.2:c.1A>T, NM_000277.1:c.1A>T, XM_011538422.1:c.1A>T, NM_001354304.1:c.1A>T, XM_017019370.2:c.1A>T, NM_000277.3:c.1A>T, ENST00000307000.7:c.-147A>T, ENST00000546844.1:c.1A>T, ENST00000547319.1:n.312A>T, ENST00000549111.5:n.97A>T, ENST00000551337.5:c.1A>T, ENST00000551988.5:n.90A>T, ENST00000553106.5:c.1A>T, ENST00000635500.1:n.29-4232A>T, NC_000012.12:g.102917130T>A, CM000674.2:g.102917130T>A, NC_000012.11:g.103310908T>A, CM000674.1:g.103310908T>A, NC_000012.10:g.101835038T>A, NG_008690.1:g.5473A>T, NG_008690.2:g.46281A>T, NM_000277.2(PAH):c.1A>T (p.Met1Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PM5 [Unmet], PP4 [MET]	"The PAH:p.M1L variant is a predicted start-lost variant in the canonical transcript of PAH (ENST00000553106); There are no other PAH RefSeq transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. This variant was reported in trans with the pathogenic variant p.Arg241His (PM3) in 1 Mexican proband with mild PKU (PMID: 24941924; PP4). It is absent from control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM3, PVS1."	24941924, 24941924	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229482/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103288654	102632	GAGA	G	NM_000277.1(PAH):c.208_210delTCT (p.Ser70del)	102632	CA229490	NM_000277.1:c.208_210delTCT, NM_000277.1:c.207_209delTTC, NM_000277.1:c.206_208delCTT, NM_000277.1:c.208_210del, XM_011538422.1:c.208_210del, NM_000277.2:c.208_210del, NM_001354304.1:c.208_210del, XM_017019370.2:c.208_210del, NM_000277.3:c.208_210del, ENST00000307000.7:c.193_195del, ENST00000546844.1:c.208_210del, ENST00000548677.2:n.295_297del, ENST00000548928.1:n.130_132del, ENST00000549111.5:n.304_306del, ENST00000550978.6:n.192_194del, ENST00000551337.5:c.208_210del, ENST00000551988.5:n.297_299del, ENST00000553106.5:c.208_210del, ENST00000635500.1:n.176_178del, NC_000012.12:g.102894879_102894881del, CM000674.2:g.102894879_102894881del, NC_000012.11:g.103288657_103288659del, CM000674.1:g.103288657_103288659del, NC_000012.10:g.101812787_101812789del, NG_008690.1:g.27724_27726del, NG_008690.2:g.68532_68534del, NM_000277.1(PAH):c.208_210delTCT (p.Ser70del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM3 [MET], PM4 [MET], PP4 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP4: Phe>120 umol/L with PKU (PMID:25456745); PM3: In trans with: c.842+2T>A (P, ClinGen) (PMID:25456745); PS3: 0% in BioPKU; PM2: Extremely low frequency. ExAC MAF=0.00012; PM4: In frame deletion. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4, PM3, PS3, PM2, PM4)."	25456745, 25456745	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	5/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229490/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310907	102647	A	C	NM_000277.2(PAH):c.2T>G (p.Met1Arg)	102647	CA229509	NM_000277.2:c.2T>G, NC_000012.12:g.102917129A>C, CM000674.2:g.102917129A>C, NC_000012.11:g.103310907A>C, CM000674.1:g.103310907A>C, NC_000012.10:g.101835037A>C, NG_008690.1:g.5474T>G, NG_008690.2:g.46282T>G, NM_000277.1:c.2T>G, XM_011538422.1:c.2T>G, NM_001354304.1:c.2T>G, XM_017019370.2:c.2T>G, NM_000277.3:c.2T>G, ENST00000307000.7:c.-146T>G, ENST00000546844.1:c.2T>G, ENST00000547319.1:n.313T>G, ENST00000549111.5:n.98T>G, ENST00000551337.5:c.2T>G, ENST00000551988.5:n.91T>G, ENST00000553106.5:c.2T>G, ENST00000635500.1:n.29-4231T>G, NM_000277.2(PAH):c.2T>G (p.Met1Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4-Moderate [MET], PM3 [MET], PM5 [Unmet], PP3 [Unmet]	"The PAH:p.M1R variant is a predicted start-lost variant in the canonical transcript of PAH (ENST00000553106). There are no known alternative start codons in other transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. The variant has been previously reported in 2 unrelated probands with classic PKU, in trans with the pathogenic variant p.R408W (PMID: 10679941; PM3); BH4 deficiency was excluded (PP4_Moderate). The variant is sufficiently rare in control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3, PM2, PP4_moderate, PVS1."	10679941, 10679941	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229509/MONDO:0009861/006	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288554	102650	G	T	NM_000277.2(PAH):c.311C>A (p.Ala104Asp)	102650	CA229515	NM_000277.2:c.311C>A, NM_000277.1:c.311C>A, XM_011538422.1:c.311C>A, NM_001354304.1:c.311C>A, XM_017019370.2:c.311C>A, NM_000277.3:c.311C>A, ENST00000307000.7:c.296C>A, ENST00000546844.1:c.311C>A, ENST00000548928.1:n.233C>A, ENST00000549111.5:n.407C>A, ENST00000550978.6:n.295C>A, ENST00000551337.5:c.311C>A, ENST00000551988.5:n.400C>A, ENST00000553106.5:c.311C>A, NC_000012.12:g.102894776G>T, CM000674.2:g.102894776G>T, NC_000012.11:g.103288554G>T, CM000674.1:g.103288554G>T, NC_000012.10:g.101812684G>T, NG_008690.1:g.27827C>A, NG_008690.2:g.68635C>A, NM_000277.2(PAH):c.311C>A (p.Ala104Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP3 [Unmet], PM3-Strong [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency: 0.00009 in gnomAD; PS3: 26% PAH enzyme activity; PM3_Strong: Detected with Y414C, pathogenic in ClinVar and V245L (P/LP) (PMID:9429153; PMID:24368688). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PS3, PM3_Strong)."	9429153, 24368688	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	7/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229515/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103271313	102658	C	A	NM_000277.2(PAH):c.368G>T (p.Arg123Ile)	102658	CA286501	NM_000277.2:c.368G>T, NM_000277.1:c.368G>T, XM_011538422.1:c.368G>T, NM_001354304.1:c.368G>T, XM_017019370.2:c.368G>T, NM_000277.3:c.368G>T, ENST00000307000.7:c.353G>T, ENST00000549111.5:n.464G>T, ENST00000550978.6:n.352G>T, ENST00000551337.5:c.368G>T, ENST00000551988.5:n.457G>T, ENST00000553106.5:c.368G>T, NC_000012.12:g.102877535C>A, CM000674.2:g.102877535C>A, NC_000012.11:g.103271313C>A, CM000674.1:g.103271313C>A, NC_000012.10:g.101795443C>A, NG_008690.1:g.45068G>T, NG_008690.2:g.85876G>T, NM_000277.2(PAH):c.368G>T (p.Arg123Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [MET]	The c.368G>T (p.Arg123Ile) variant in PAH has not been reported in the literature to our knowledge. A reference listed in BioPKU/PAHdb cannot be located (Carducci, C 2009). This variant is absent from ExAC, gnomAD, 1000G, and ESP. Deleterious effect is predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.864. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA286501/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103271296	102660	C	A	NM_000277.2(PAH):c.385G>T (p.Asp129Tyr)	102660	CA286503	NM_000277.2:c.385G>T, NC_000012.12:g.102877518C>A, CM000674.2:g.102877518C>A, NC_000012.11:g.103271296C>A, CM000674.1:g.103271296C>A, NC_000012.10:g.101795426C>A, NG_008690.1:g.45085G>T, NG_008690.2:g.85893G>T, NM_000277.1:c.385G>T, XM_011538422.1:c.385G>T, NM_001354304.1:c.385G>T, XM_017019370.2:c.385G>T, NM_000277.3:c.385G>T, ENST00000307000.7:c.370G>T, ENST00000549111.5:n.481G>T, ENST00000550978.6:n.369G>T, ENST00000551337.5:c.385G>T, ENST00000551988.5:n.474G>T, ENST00000553106.5:c.385G>T, NM_000277.2(PAH):c.385G>T (p.Asp129Tyr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [MET], PP3 [MET]	"The c.385G>T (p.Asp129Tyr) variant in PAH has not been reported in the literature to our knowledge. This variant is absent from 1000G, ESP, ExAC and gnomAD (PM2). Multiple lines of computational evidence support a deleterious effect (PP3). There are 2 other missense variants at this residue in ClinVar; p.Asp129Gly is Likely Pathogenic by 1 submitter and PAH EP (PM5). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP3."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA286503/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103271295	102661	T	C	NM_000277.2(PAH):c.386A>G (p.Asp129Gly)	102661	CA229527	NM_000277.2:c.386A>G, NM_000277.1:c.386A>G, XM_011538422.1:c.386A>G, NM_001354304.1:c.386A>G, XM_017019370.2:c.386A>G, NM_000277.3:c.386A>G, ENST00000307000.7:c.371A>G, ENST00000549111.5:n.482A>G, ENST00000550978.6:n.370A>G, ENST00000551337.5:c.386A>G, ENST00000551988.5:n.475A>G, ENST00000553106.5:c.386A>G, NC_000012.12:g.102877517T>C, CM000674.2:g.102877517T>C, NC_000012.11:g.103271295T>C, CM000674.1:g.103271295T>C, NC_000012.10:g.101795425T>C, NG_008690.1:g.45086A>G, NG_008690.2:g.85894A>G, NM_000277.2(PAH):c.386A>G (p.Asp129Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"The c.386A>G (p.Asp129Gly) variant in PAH has been reported in multiple individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 8981952). This variant has extremely low frequency in gnomAD (MAF: 0.00001; PM2). This variant was detected in trans with known pathogenic variant c.1066-11G>A (PM3; PMID: 27121329). Computational evidence supports a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3."	8981952, 26666653, 23357515, 23062575, 27121329	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229527/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103271247	102667	T	A	NM_000277.2(PAH):c.434A>T (p.Asp145Val)	102667	CA229539	NM_000277.2:c.434A>T, NC_000012.12:g.102877469T>A, CM000674.2:g.102877469T>A, NC_000012.11:g.103271247T>A, CM000674.1:g.103271247T>A, NC_000012.10:g.101795377T>A, NG_008690.1:g.45134A>T, NG_008690.2:g.85942A>T, NM_000277.1:c.434A>T, XM_011538422.1:c.434A>T, NM_001354304.1:c.434A>T, XM_017019370.2:c.434A>T, NM_000277.3:c.434A>T, ENST00000307000.7:c.419A>T, ENST00000549111.5:n.530A>T, ENST00000550978.6:n.418A>T, ENST00000551988.5:n.523A>T, ENST00000553106.5:c.434A>T, NM_000277.2(PAH):c.434A>T (p.Asp145Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PM3-Strong [MET]	"The c.434A>T (p.Asp145Val) PAH variant has been identified in patients with PAH deficiency from the US, Germany, Italy and Spain. BH4 deficiency was excluded. (PMID: 8659548; 11385716; 12655553; 17096675; 23514811) It was detected with known pathogenic variants: V388M (PMID: 8659548), I65T (PMID: 24368688), and R408W (PMID: 26666653). It is found at extremely low frequency (MAF 0.00012 in gnomAD). A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.987. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PP3"	11385716, 12655553, 23514811, 8659548, 17096675, 8659548, 26666653, 24368688	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229539/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103271241	102670	G	A	NM_000277.2(PAH):c.440C>T (p.Pro147Leu)	102670	CA229543	NM_000277.2:c.440C>T, NC_000012.12:g.102877463G>A, CM000674.2:g.102877463G>A, NC_000012.11:g.103271241G>A, CM000674.1:g.103271241G>A, NC_000012.10:g.101795371G>A, NG_008690.1:g.45140C>T, NG_008690.2:g.85948C>T, NM_000277.1:c.440C>T, XM_011538422.1:c.440C>T, NM_001354304.1:c.440C>T, XM_017019370.2:c.440C>T, NM_000277.3:c.440C>T, ENST00000307000.7:c.425C>T, ENST00000549111.5:n.536C>T, ENST00000550978.6:n.424C>T, ENST00000551988.5:n.529C>T, ENST00000553106.5:c.440C>T, NM_000277.2(PAH):c.440C>T (p.Pro147Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	"The c.440C>T (p.Pro147Leu) variant in PAH has been reported in multiple individuals with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 27121329, 26322415, 16527067, 30050108, 28982351). This variant is absent in population databases (PM2). This variant was detected in trans with known pathogenic variants p.R261Ter (PMID: 27121329); c.611A>G (PMID: 30050108); p.S70del (PMID: 28982351) (PM3_strong). Computational evidence supports a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong, PP3."	26503515, 26322415, 28982351, 27121329, 26322415, 30050108	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229543/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260419	102686	C	T	NM_000277.2(PAH):c.464G>A (p.Arg155His)	102686	CA229559	NM_000277.2:c.464G>A, NC_000012.12:g.102866641C>T, CM000674.2:g.102866641C>T, NC_000012.11:g.103260419C>T, CM000674.1:g.103260419C>T, NC_000012.10:g.101784549C>T, NG_008690.1:g.55962G>A, NG_008690.2:g.96770G>A, NM_000277.1:c.464G>A, XM_011538422.1:c.464G>A, NM_001354304.1:c.464G>A, XM_017019370.2:c.464G>A, NM_000277.3:c.464G>A, ENST00000307000.7:c.449G>A, ENST00000549111.5:n.560G>A, ENST00000551988.5:n.530+10821G>A, ENST00000553106.5:c.464G>A, NM_000277.2(PAH):c.464G>A (p.Arg155His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PP1 [MET], PS3 [Unmet], PM3-Strong [MET]	"The c.464G>A (p.Arg155His) has been reported in multiple individuals with mild hyperphenylalaninaemia, with BH4 deficiency excluded including 3 siblings (PP4_moderate, PMID: 9634518; PP1, PMID:18937047). This variant has low frequency in ExAC/gnomad (MAF=0.00012) in EA population (PM2). Multiple lines of computational evidence support a deleterious effect (PP3). This variant has been detected with 3 pathogenic variants: R243Q (PMID: 23932990), R111X (PMID: 24401910), IVS4+5G>T c.441+5G>T (PMID: 26210745) (PM3-strong). Experimental study showed the R155H mutant retained 55% activity, but this is higher than the cutoff set by PAH VCEP for PS3. (PMID: 18937047). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_strong, PM2, PP3, PP1."	9634518, 18937047, 18937047, 23932990, 26210745, 24401910, 18937047	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229559/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260419	102687	C	G	NM_000277.2(PAH):c.464G>C (p.Arg155Pro)	102687	CA229561	NM_000277.2:c.464G>C, NC_000012.12:g.102866641C>G, CM000674.2:g.102866641C>G, NC_000012.11:g.103260419C>G, CM000674.1:g.103260419C>G, NC_000012.10:g.101784549C>G, NG_008690.1:g.55962G>C, NG_008690.2:g.96770G>C, NM_000277.1:c.464G>C, XM_011538422.1:c.464G>C, NM_001354304.1:c.464G>C, XM_017019370.2:c.464G>C, NM_000277.3:c.464G>C, ENST00000307000.7:c.449G>C, ENST00000549111.5:n.560G>C, ENST00000551988.5:n.530+10821G>C, ENST00000553106.5:c.464G>C, NM_000277.2(PAH):c.464G>C (p.Arg155Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: absent from ExAC, gnomAD, 1000G, ESP. PAGE MAF=0.00066; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.967; PP4_Moderate: Detected in a patient with classic PKU. Cofactor deficiency excluded. (PMID:10679941); PM3: Detected in trans with R408W (P) (PMID:10679941). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3)."	10679941, 10679941	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229561/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310863	102689	A	G	NM_000277.2(PAH):c.46T>C (p.Ser16Pro)	102689	CA229564	NM_000277.2:c.46T>C, NM_000277.1:c.46T>C, XM_011538422.1:c.46T>C, NM_001354304.1:c.46T>C, XM_017019370.2:c.46T>C, NM_000277.3:c.46T>C, ENST00000307000.7:c.-102T>C, ENST00000546844.1:c.46T>C, ENST00000547319.1:n.357T>C, ENST00000549111.5:n.142T>C, ENST00000550978.6:n.30T>C, ENST00000551337.5:c.46T>C, ENST00000551988.5:n.135T>C, ENST00000553106.5:c.46T>C, ENST00000635500.1:n.29-4187T>C, NC_000012.12:g.102917085A>G, CM000674.2:g.102917085A>G, NC_000012.11:g.103310863A>G, CM000674.1:g.103310863A>G, NC_000012.10:g.101834993A>G, NG_008690.1:g.5518T>C, NG_008690.2:g.46326T>C, NM_000277.2(PAH):c.46T>C (p.Ser16Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], BP4 [MET]	VUS: The c.46T>C (p.S16P) variant in PAH has not been reported in the medical literature. It is tolerated by computation predictors: SIFT, Polyphen, MutationTaster, and REVEL=0.567 (BP4). It is however absent from population databases, including gnomAD, 1000 Genomes, and ESP (PM2). In summary this variant meets the criteria to be classified as uncertain significance. PAH-specific ACMG/AMP criteria applied: BP4, PM2.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229564/MONDO:0009861/006	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260411	102693	G	A	NM_000277.2(PAH):c.472C>T (p.Arg158Trp)	102693	CA229570	NM_000277.2:c.472C>T, NC_000012.12:g.102866633G>A, CM000674.2:g.102866633G>A, NC_000012.11:g.103260411G>A, CM000674.1:g.103260411G>A, NC_000012.10:g.101784541G>A, NG_008690.1:g.55970C>T, NG_008690.2:g.96778C>T, NM_000277.1:c.472C>T, XM_011538422.1:c.472C>T, NM_001354304.1:c.472C>T, XM_017019370.2:c.472C>T, NM_000277.3:c.472C>T, ENST00000307000.7:c.457C>T, ENST00000549111.5:n.568C>T, ENST00000551988.5:n.530+10829C>T, ENST00000553106.5:c.472C>T, NM_000277.2(PAH):c.472C>T (p.Arg158Trp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ExAC MAF=0.00019.; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.939; PS3: 2% mutant enzyme activity in BioPKU; PP4_Moderate: Detected in at least 3 patients with PAH deficiency. BH4 deficiency ruled out in 1 patient. (PMID:1307609; PMID:10429004; PMID:9634518); PM3_Strong: Detected with 3 pathogenic/likely pathogenic variants (PMID:14681498; PMID:23430918). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4_Moderate, PM3_Strong)."	9634518, 10429004, 1307609, 23430918, 14681498	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229570/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260410	102694	C	G	NM_000277.2(PAH):c.473G>C (p.Arg158Pro)	102694	CA229571	NM_000277.2:c.473G>C, NM_000277.1:c.473G>C, XM_011538422.1:c.473G>C, NM_001354304.1:c.473G>C, XM_017019370.2:c.473G>C, NM_000277.3:c.473G>C, ENST00000307000.7:c.458G>C, ENST00000549111.5:n.569G>C, ENST00000551988.5:n.530+10830G>C, ENST00000553106.5:c.473G>C, NC_000012.12:g.102866632C>G, CM000674.2:g.102866632C>G, NC_000012.11:g.103260410C>G, CM000674.1:g.103260410C>G, NC_000012.10:g.101784540C>G, NG_008690.1:g.55971G>C, NG_008690.2:g.96779G>C, NM_000277.2(PAH):c.473G>C (p.Arg158Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [MET], PM3 [MET], PP3 [MET], PP4 [MET]	The c.473G>C (p.Arg158Pro) variant in PAH was reported in a patient with Mild Hyperphenylalaninemia (Phenylalanine level 380 umol/l) PMID: 8659548. It was detected with V388M (known pathogenic variant). It has an extremely low frequency in ExAC and gnomAD (MAF 0.00002). It is predicted deleterious in SIFT, Polyphen2, MutationTaster and REVEL=0.98. Two different pathogenic missense changes at this amino acid have been seen before (R158W, R158Q). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PM5, PP3, PP4.	8659548, 8659548	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229571/MONDO:0009861/006	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310860	102696	CAG	C	NM_000277.2(PAH):c.47_48delCT (p.Ser16Terfs)	102696	CA229574	NM_000277.2:c.47_48delCT, NC_000012.12:g.102917087_102917088del, CM000674.2:g.102917087_102917088del, NC_000012.11:g.103310865_103310866del, CM000674.1:g.103310865_103310866del, NC_000012.10:g.101834995_101834996del, NG_008690.1:g.5519_5520del, NG_008690.2:g.46327_46328del, NM_000277.1:c.47_48del, XM_011538422.1:c.47_48del, NM_000277.2:c.47_48del, NM_001354304.1:c.47_48del, XM_017019370.2:c.47_48del, NM_000277.3:c.47_48del, ENST00000307000.7:c.-101_-100del, ENST00000546844.1:c.47_48del, ENST00000547319.1:n.358_359del, ENST00000549111.5:n.143_144del, ENST00000550978.6:n.31_32del, ENST00000551337.5:c.47_48del, ENST00000551988.5:n.136_137del, ENST00000553106.5:c.47_48del, ENST00000635500.1:n.29-4186_29-4185del, NM_000277.2(PAH):c.47_48delCT (p.Ser16Terfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP3 [Unmet], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: ExAC:8.238e-06; gnomAD:0.000004062; 1000G + ESP: absent; PVS1: Null variant- frameshift. Subject to nonsense mediated decay.; PM3: found in trans with L48S (VarID608, Pathogenic) (PMID:8535445); PP4: 47delCT found in 1 patient with moderate PKU. BH4 deficiency not ruled out. (PMID:8535445). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PM3, PP4)."	8535445, 8535445	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229574/MONDO:0009861/006	0.9971	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260393	102698	T	C	NM_000277.2(PAH):c.490A>G (p.Ile164Val)	102698	CA229576	NM_000277.2:c.490A>G, NM_000277.1:c.490A>G, XM_011538422.1:c.490A>G, NM_001354304.1:c.490A>G, XM_017019370.2:c.490A>G, NM_000277.3:c.490A>G, ENST00000307000.7:c.475A>G, ENST00000549111.5:n.586A>G, ENST00000551988.5:n.530+10847A>G, ENST00000553106.5:c.490A>G, NC_000012.12:g.102866615T>C, CM000674.2:g.102866615T>C, NC_000012.11:g.103260393T>C, CM000674.1:g.103260393T>C, NC_000012.10:g.101784523T>C, NG_008690.1:g.55988A>G, NG_008690.2:g.96796A>G, NM_000277.2(PAH):c.490A>G (p.Ile164Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [Unmet], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: ExAC MAF: 0.00012; PP4_Moderate: Detected in patients with PKU/HPA. BH4 deficiency excluded. (PMID:11244681; PMID:23942198); PM3_Strong: Detected with D145V, A403V (Pathogenic) (PMID:11244681; PMID:23942198). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong)."	11244681, 23942198, 11244681, 23942198	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229576/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103260390	102700	C	T	NM_000277.2(PAH):c.493G>A (p.Ala165Thr)	102700	CA229579	NM_000277.2:c.493G>A, NM_000277.1:c.493G>A, XM_011538422.1:c.493G>A, NM_001354304.1:c.493G>A, XM_017019370.2:c.493G>A, NM_000277.3:c.493G>A, ENST00000307000.7:c.478G>A, ENST00000549111.5:n.589G>A, ENST00000551988.5:n.530+10850G>A, ENST00000553106.5:c.493G>A, NC_000012.12:g.102866612C>T, CM000674.2:g.102866612C>T, NC_000012.11:g.103260390C>T, CM000674.1:g.103260390C>T, NC_000012.10:g.101784520C>T, NG_008690.1:g.55991G>A, NG_008690.2:g.96799G>A, NM_000277.2(PAH):c.493G>A (p.Ala165Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PP1 [MET]	"The c.493G>A (p.Ala165Thr) variant in PAH has been reported in multiple individuals with PKU, including siblings (BH4 deficiency excluded). (PP4_Moderate, PMID: 8981952; PP1, PMID: 26666653). This variant has extremely low frequency in gnomAD (MAF=0.00001) (PM2). This variant was detected with c.1066-11G>A (PM3; PMID: 10598814). Multiple lines of computational evidence support a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP1, PP3."	8981952, 19786003, 10598814, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229579/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260390	102701	C	G	NM_000277.2(PAH):c.493G>C (p.Ala165Pro)	102701	CA229581	NM_000277.2:c.493G>C, NC_000012.12:g.102866612C>G, CM000674.2:g.102866612C>G, NC_000012.11:g.103260390C>G, CM000674.1:g.103260390C>G, NC_000012.10:g.101784520C>G, NG_008690.1:g.55991G>C, NG_008690.2:g.96799G>C, NM_000277.1:c.493G>C, XM_011538422.1:c.493G>C, NM_001354304.1:c.493G>C, XM_017019370.2:c.493G>C, NM_000277.3:c.493G>C, ENST00000307000.7:c.478G>C, ENST00000549111.5:n.589G>C, ENST00000551988.5:n.530+10850G>C, ENST00000553106.5:c.493G>C, NM_000277.2(PAH):c.493G>C (p.Ala165Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM3 [Unmet], PP3 [MET], PP4 [MET]	"The c.493G>C (p.Ala165Pro) variant in PAH has been reported in a French patient with mild PKU with p.Glu390Gly, but parents were not tested (PP4; PMID: 26666653) This variant is absent from 1000G and ESP, and has extremely low frequency in ExAC/gnomAD: MAF 0.00001 (PM2). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.956 (PP3). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3."	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229581/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103260385	102702	G	T	NM_000277.2(PAH):c.498C>A (p.Tyr166Ter)	102702	CA229583	NM_000277.2:c.498C>A, NM_000277.1:c.498C>A, XM_011538422.1:c.498C>A, NM_001354304.1:c.498C>A, XM_017019370.2:c.498C>A, NM_000277.3:c.498C>A, ENST00000307000.7:c.483C>A, ENST00000549111.5:n.594C>A, ENST00000551988.5:n.530+10855C>A, ENST00000553106.5:c.498C>A, NC_000012.12:g.102866607G>T, CM000674.2:g.102866607G>T, NC_000012.11:g.103260385G>T, CM000674.1:g.103260385G>T, NC_000012.10:g.101784515G>T, NG_008690.1:g.55996C>A, NG_008690.2:g.96804C>A, NM_000277.2(PAH):c.498C>A (p.Tyr166Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP4 [MET]	"The c.498C>A (p.Tyr166Ter) variant in PAH is a nonsense variant in exon 5 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in individuals with Classic PKU in German and Chinese cohorts. (PP4, PMID:16256386; 10394930). This variant is absent from ExAC/gnomAD, 1000 Genomes, and ESP (PM2). This variant was detected with multiple known pathogenic variants (PM3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4."	16256386, 16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229583/MONDO:0009861/006	0.9941	Likely Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260383	102703	T	C	NM_000277.2(PAH):c.500A>G (p.Asn167Ser)	102703	CA229585	NM_000277.2:c.500A>G, NC_000012.12:g.102866605T>C, CM000674.2:g.102866605T>C, NC_000012.11:g.103260383T>C, CM000674.1:g.103260383T>C, NC_000012.10:g.101784513T>C, NG_008690.1:g.55998A>G, NG_008690.2:g.96806A>G, NM_000277.1:c.500A>G, XM_011538422.1:c.500A>G, NM_001354304.1:c.500A>G, XM_017019370.2:c.500A>G, NM_000277.3:c.500A>G, ENST00000307000.7:c.485A>G, ENST00000549111.5:n.596A>G, ENST00000551988.5:n.530+10857A>G, ENST00000553106.5:c.500A>G, NM_000277.2(PAH):c.500A>G (p.Asn167Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	BS1 [MET], PP4 [MET], PP3 [Unmet]	"PAH-specific ACMG/AMP criteria applied: PP4: N167S was observed in 1 case (genotype N167S/-) with benign persistent hyperphenylalaninemia (200-600 uM). (PMID:11385716); BS1: gnomAD MAF: 0.01461. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4, BS1)."	11385716	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229585/MONDO:0009861/006	0.1	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103260379	102705	GT	G	NM_000277.2(PAH):c.503delA (p.Tyr168Serfs)	102705	CA229588	NM_000277.2:c.503delA, NC_000012.12:g.102866602del, CM000674.2:g.102866602del, NC_000012.11:g.103260380del, CM000674.1:g.103260380del, NC_000012.10:g.101784510del, NG_008690.1:g.56001del, NG_008690.2:g.96809del, NM_000277.1:c.503del, XM_011538422.1:c.503del, NM_000277.2:c.503del, NM_001354304.1:c.503del, XM_017019370.2:c.503del, NM_000277.3:c.503del, ENST00000307000.7:c.488del, ENST00000549111.5:n.599del, ENST00000551988.5:n.530+10860del, ENST00000553106.5:c.503del, NM_000277.2(PAH):c.503delA (p.Tyr168Serfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency. ExAC MAF: 0.00001.; PP4: Detected in PKU patient in international phase II clinical trial for sapropterin. (PMID:23430918). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4)."	23430918	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229588/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260377	102706	C	T	NM_000277.2(PAH):c.506G>A (p.Arg169His)	102706	CA286505	NM_000277.2:c.506G>A, NC_000012.12:g.102866599C>T, CM000674.2:g.102866599C>T, NC_000012.11:g.103260377C>T, CM000674.1:g.103260377C>T, NC_000012.10:g.101784507C>T, NG_008690.1:g.56004G>A, NG_008690.2:g.96812G>A, NM_000277.1:c.506G>A, XM_011538422.1:c.506G>A, NM_001354304.1:c.506G>A, XM_017019370.2:c.506G>A, NM_000277.3:c.506G>A, ENST00000307000.7:c.491G>A, ENST00000549111.5:n.602G>A, ENST00000551988.5:n.530+10863G>A, ENST00000553106.5:c.506G>A, NM_000277.2(PAH):c.506G>A (p.Arg169His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PP3 [Unmet], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PP4_Moderate: This variant has been reported in multiple mild hyperphenylalaninaemia (MHP) patients, with BH4 defects excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:10234516); PM3_Strong: Detected with P281L and A403V, both pathogenic variants (PMID:10234516). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_Strong)."	10234516, 10234516	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA286505/MONDO:0009861/006	0.3246	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249109	102716	C	T	NM_000277.2(PAH):c.511G>A (p.Gly171Arg)	102716	CA229598	NM_000277.2:c.511G>A, NC_000012.12:g.102855331C>T, CM000674.2:g.102855331C>T, NC_000012.11:g.103249109C>T, CM000674.1:g.103249109C>T, NC_000012.10:g.101773239C>T, NG_008690.1:g.67272G>A, NG_008690.2:g.108080G>A, NM_000277.1:c.511G>A, XM_011538422.1:c.511G>A, NM_001354304.1:c.511G>A, XM_017019370.2:c.511G>A, NM_000277.3:c.511G>A, ENST00000307000.7:c.496G>A, ENST00000549111.5:n.607G>A, ENST00000551988.5:n.532G>A, ENST00000553106.5:c.511G>A, NM_000277.2(PAH):c.511G>A (p.Gly171Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.966; PP4_Moderate: Detected in PKU patients. BH4 deficiency assessed. Upgraded per ClinGen PAH EP. (PMID:26600521; PMID:23430918); PM3_Strong: Detected with c.611A>G (P/LP) and R408W (P). Upgraded per ClinGen SVI workgroup. (PMID:23430918; PMID:26600521). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong)."	23430918, 26600521, 23430918, 26600521	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229598/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249100	102720	T	C	NM_000277.1(PAH):c.520A>G (p.Ile174Val)	102720	CA229603	NM_000277.1:c.520A>G, XM_011538422.1:c.520A>G, NM_000277.2:c.520A>G, NM_001354304.1:c.520A>G, XM_017019370.2:c.520A>G, NM_000277.3:c.520A>G, ENST00000307000.7:c.505A>G, ENST00000549111.5:n.616A>G, ENST00000551988.5:n.541A>G, ENST00000553106.5:c.520A>G, NC_000012.12:g.102855322T>C, CM000674.2:g.102855322T>C, NC_000012.11:g.103249100T>C, CM000674.1:g.103249100T>C, NC_000012.10:g.101773230T>C, NG_008690.1:g.67281A>G, NG_008690.2:g.108089A>G, NM_000277.1(PAH):c.520A>G (p.Ile174Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Not found in any population databases; PP3: All predictors agree--damaging; PM3: Single patient IVS4+5G>T (null) / I174V (Bercovich 2008 PMID 18299955) (PMID:18299955); PP4: Two independent patients (one in Zschocke (PMID 10394930) and one in Bercovich (PMID 18299955) with ""PKU"". While no specific levels are mentioned, they are followed in clinic and were diagnosed with Phe >120umol/L. BH4 defect WAS NOT excluded in either paper.. In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM3, PP4)."	18299955	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229603/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103249099	102721	A	G	NM_000277.2(PAH):c.521T>C (p.Ile174Thr)	102721	CA229604	NM_000277.2:c.521T>C, NM_000277.1:c.521T>C, XM_011538422.1:c.521T>C, NM_001354304.1:c.521T>C, XM_017019370.2:c.521T>C, NM_000277.3:c.521T>C, ENST00000307000.7:c.506T>C, ENST00000549111.5:n.617T>C, ENST00000551988.5:n.542T>C, ENST00000553106.5:c.521T>C, NC_000012.12:g.102855321A>G, CM000674.2:g.102855321A>G, NC_000012.11:g.103249099A>G, CM000674.1:g.103249099A>G, NC_000012.10:g.101773229A>G, NG_008690.1:g.67282T>C, NG_008690.2:g.108090T>C, NM_000277.2(PAH):c.521T>C (p.Ile174Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PS3 [MET]	"The c.521T>C (p.Ile174Thr) variant in PAH has been reported in 2 individuals with PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 9634518). This variant is absent from ExAC/gnomAD, 1000 Genomes, ESP (PM2). This variant has 1-15% enzyme activity (PS3; PMID: 11161839). This variant was detected in with p.F299C (P/LP, 6 submitters) (PM3; PMID: 23842451). Computational prediction tools and conservation analysis suggest that the variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM3, PP3"	9634518, 23842451, 11161839	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229604/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249094	102723	G	A	NM_000277.2(PAH):c.526C>T (p.Arg176Ter)	102723	CA275338	NM_000277.2:c.526C>T, NC_000012.12:g.102855316G>A, CM000674.2:g.102855316G>A, NC_000012.11:g.103249094G>A, CM000674.1:g.103249094G>A, NC_000012.10:g.101773224G>A, NG_008690.1:g.67287C>T, NG_008690.2:g.108095C>T, NM_000277.1:c.526C>T, XM_011538422.1:c.526C>T, NM_001354304.1:c.526C>T, XM_017019370.2:c.526C>T, NM_000277.3:c.526C>T, ENST00000307000.7:c.511C>T, ENST00000549111.5:n.622C>T, ENST00000551988.5:n.547C>T, ENST00000553106.5:c.526C>T, NM_000277.2(PAH):c.526C>T (p.Arg176Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PP4-Moderate [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: ExAC MAF: 0.00010; PP4_Moderate: BH4 defect excluded in all patients in Liu 2015. Identified in 6 patients in this study (PMID:10394930; PMID:26600521); PM3_Strong: Identified in 6 patients, in trans with R243Q and R241C (both pathogenic) (PMID:26600521). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong)."	26600521, 10394930, 26600521	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA275338/MONDO:0009861/006	0.9941	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249091	102726	C	T	NM_000277.2(PAH):c.529G>A (p.Val177Met)	102726	CA229609	NM_000277.2:c.529G>A, NC_000012.12:g.102855313C>T, CM000674.2:g.102855313C>T, NC_000012.11:g.103249091C>T, CM000674.1:g.103249091C>T, NC_000012.10:g.101773221C>T, NG_008690.1:g.67290G>A, NG_008690.2:g.108098G>A, NM_000277.1:c.529G>A, XM_011538422.1:c.529G>A, NM_001354304.1:c.529G>A, XM_017019370.2:c.529G>A, NM_000277.3:c.529G>A, ENST00000307000.7:c.514G>A, ENST00000549111.5:n.625G>A, ENST00000551988.5:n.550G>A, ENST00000553106.5:c.529G>A, NM_000277.2(PAH):c.529G>A (p.Val177Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [MET], PP3 [MET], PM3-Strong [MET]	"The c.529G>A (p.Val177Met) variant in PAH was detected in a patient with Mild hyperphenylalaninemia (BH4 deficiency ruled out). PMID: 12501224 It has been detected with known pathogenic variants R408W (PMID: 12501224), and IVS12+1G>A (PMID: 23764561). It is absent from 1000G, ESP, and gnomAD; and at extremely low frequency in ExAC (MAF=0.00003). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.89. A different pathogenic missense change has been seen at this amino acid (V177L). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PM5, PP4_Moderate, PP3."	12501224, 23764561, 12501224	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229609/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103249085	102729	A	T	NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)	102729	CA229613	NM_000277.2:c.535T>A, NC_000012.12:g.102855307A>T, CM000674.2:g.102855307A>T, NC_000012.11:g.103249085A>T, CM000674.1:g.103249085A>T, NC_000012.10:g.101773215A>T, NG_008690.1:g.67296T>A, NG_008690.2:g.108104T>A, NM_000277.1:c.535T>A, XM_011538422.1:c.535T>A, NM_001354304.1:c.535T>A, XM_017019370.2:c.535T>A, NM_000277.3:c.535T>A, ENST00000307000.7:c.520T>A, ENST00000549111.5:n.631T>A, ENST00000551988.5:n.556T>A, ENST00000553106.5:c.535T>A, NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.929; PP4_Moderate: Detected in 1 PKU patient, primary BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:23430918); PM3: Detected with c.1066-11G>A (P) (PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3)."	23430918, 23430918	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229613/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249061	102735	A	G	NM_000277.2(PAH):c.559T>C (p.Trp187Arg)	102735	CA229622	NM_000277.2:c.559T>C, NM_000277.1:c.559T>C, XM_011538422.1:c.559T>C, NM_001354304.1:c.559T>C, XM_017019370.2:c.559T>C, NM_000277.3:c.559T>C, ENST00000307000.7:c.544T>C, ENST00000549111.5:n.655T>C, ENST00000551988.5:n.580T>C, ENST00000553106.5:c.559T>C, NC_000012.12:g.102855283A>G, CM000674.2:g.102855283A>G, NC_000012.11:g.103249061A>G, CM000674.1:g.103249061A>G, NC_000012.10:g.101773191A>G, NG_008690.1:g.67320T>C, NG_008690.2:g.108128T>C, NM_000277.2(PAH):c.559T>C (p.Trp187Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], BS1 [Unmet], PP3 [MET], BP4 [Unmet], BA1 [Unmet], PM3-Strong [MET]	The PAH: c.559T>C (p.Trp187Arg) variant was found in two cases in trans with other P/LP alleles: one case with classic PKU (assessed via plasma Phe measurement in trans with the p.R158Q allele (PMID: 18956252) and one case whose PKU sub-phenotype was not mentioned in trans with the p.R261Q allele (PMID: 23074961) (PM3_Strong). It has also been found in trans with the p.Gln419Arg allele, classified as Likely Pathogenic in ClinVar, in 1 case with mild hyperphenylalanemia (BH4 deficiency excluded. PP4_moderate. PMID: 28982351). The variant is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). It is predicted damaging by multiple lines of computational evidence: SIFT, Polyphen2, Mutation Taster, REVEL = 0.918 (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong, PP3.	18956252, 28982351, 18956252, 28982351, 23074961	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229622/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249059	102736	C	T	NM_000277.2(PAH):c.561G>A (p.Trp187Ter)	102736	CA229624	NM_000277.2:c.561G>A, NC_000012.12:g.102855281C>T, CM000674.2:g.102855281C>T, NC_000012.11:g.103249059C>T, CM000674.1:g.103249059C>T, NC_000012.10:g.101773189C>T, NG_008690.1:g.67322G>A, NG_008690.2:g.108130G>A, NM_000277.1:c.561G>A, XM_011538422.1:c.561G>A, NM_001354304.1:c.561G>A, XM_017019370.2:c.561G>A, NM_000277.3:c.561G>A, ENST00000307000.7:c.546G>A, ENST00000549111.5:n.657G>A, ENST00000551988.5:n.582G>A, ENST00000553106.5:c.561G>A, NM_000277.2(PAH):c.561G>A (p.Trp187Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PP4-Moderate [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: Extremely low frequency in gnomAD. MAF=0.00002.; PP4_Moderate: Detected in 3 chromosomes of patients with PAH deficiency. BH4 deficiency ruled out. (PMID:8268925). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate)."	8268925	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229624/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249039	102742	A	G	NM_000277.2(PAH):c.581T>C (p.Leu194Pro)	102742	CA229633	NM_000277.2:c.581T>C, NM_000277.1:c.581T>C, XM_011538422.1:c.581T>C, NM_001354304.1:c.581T>C, XM_017019370.2:c.581T>C, NM_000277.3:c.581T>C, ENST00000307000.7:c.566T>C, ENST00000549111.5:n.677T>C, ENST00000553106.5:c.581T>C, NC_000012.12:g.102855261A>G, CM000674.2:g.102855261A>G, NC_000012.11:g.103249039A>G, CM000674.1:g.103249039A>G, NC_000012.10:g.101773169A>G, NG_008690.1:g.67342T>C, NG_008690.2:g.108150T>C, NM_000277.2(PAH):c.581T>C (p.Leu194Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. gnomAD MAF:0.00004.; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.899; PM3_Strong: Detected in trans with V245A and R261X, both pathogenic (PMID:7981714; PMID:16601866); PP4_Moderate: Detected in 3 patients (1 HPA, 1 PKU). BH4 deficiency excluded in 2 patients. (PMID:8533759; PMID:7981714; PMID:9012412; PMID:16601866). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM3_Strong, PP4_Moderate)."	16601866, 9012412, 8533759, 7981714, 16601866, 7981714	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229633/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310851	102744	G	A	NM_000277.2(PAH):c.58C>T (p.Gln20Ter)	102744	CA229635	NM_000277.2:c.58C>T, NM_000277.1:c.58C>T, XM_011538422.1:c.58C>T, NM_001354304.1:c.58C>T, XM_017019370.2:c.58C>T, NM_000277.3:c.58C>T, ENST00000307000.7:c.-90C>T, ENST00000546844.1:c.58C>T, ENST00000547319.1:n.369C>T, ENST00000549111.5:n.154C>T, ENST00000550978.6:n.42C>T, ENST00000551337.5:c.58C>T, ENST00000551988.5:n.147C>T, ENST00000553106.5:c.58C>T, ENST00000635500.1:n.29-4175C>T, NC_000012.12:g.102917073G>A, CM000674.2:g.102917073G>A, NC_000012.11:g.103310851G>A, CM000674.1:g.103310851G>A, NC_000012.10:g.101834981G>A, NG_008690.1:g.5530C>T, NG_008690.2:g.46338C>T, NM_000277.2(PAH):c.58C>T (p.Gln20Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	Pathogenic: The c.58C>T (p.Gln20Ter) is a null variant reported in one patient with classic PKU phenotype (PVS1, PP4, PMID: 9391881). This variant is absent from population databases, including gnomAD, 1000 Genomes, and ESP (PM2). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4.	9391881	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229635/MONDO:0009861/006	0.9971	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310850	102749	T	A	NM_000277.2(PAH):c.59A>T (p.Gln20Leu)	102749	CA229641	NM_000277.2:c.59A>T, NC_000012.12:g.102917072T>A, CM000674.2:g.102917072T>A, NC_000012.11:g.103310850T>A, CM000674.1:g.103310850T>A, NC_000012.10:g.101834980T>A, NG_008690.1:g.5531A>T, NG_008690.2:g.46339A>T, NM_000277.1:c.59A>T, XM_011538422.1:c.59A>T, NM_001354304.1:c.59A>T, XM_017019370.2:c.59A>T, NM_000277.3:c.59A>T, ENST00000307000.7:c.-89A>T, ENST00000546844.1:c.59A>T, ENST00000547319.1:n.370A>T, ENST00000549111.5:n.155A>T, ENST00000550978.6:n.43A>T, ENST00000551337.5:c.59A>T, ENST00000551988.5:n.148A>T, ENST00000553106.5:c.59A>T, ENST00000635500.1:n.29-4174A>T, NM_000277.2(PAH):c.59A>T (p.Gln20Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP3 [Unmet], PP4 [MET], PM3-Supporting [MET]	"VUS:The c.59A>T (p.Q20L) variant was detected in trans with a known pathogenic variant (c.1315+1G>A) in a patient with hyperphenylalaninemia (parental testing not reported) (PP4, PM3-supporting; PMID: 10679941). This variant is absent from population databases including, gnomAD, ESP, and 1000 Genomes (PM2). Computation predictors on protein structure and function indicate conflicting results (SIFT: tolerated, Polyphen: Benign, MutationTaster: Disease causing, REVEL=0.582). In summary this variant meets the criteria  to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3-supporting, PP4."	10679941, 10679941	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229641/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310849	102757	C	G	NM_000277.2(PAH):c.60G>C (p.Gln20His)	102757	CA229651	NM_000277.2:c.60G>C, NM_000277.1:c.60G>C, XM_011538422.1:c.60G>C, NM_001354304.1:c.60G>C, XM_017019370.2:c.60G>C, NM_000277.3:c.60G>C, ENST00000307000.7:c.-88G>C, ENST00000546844.1:c.60G>C, ENST00000547319.1:n.371G>C, ENST00000549111.5:n.156G>C, ENST00000550978.6:n.44G>C, ENST00000551337.5:c.60G>C, ENST00000551988.5:n.149G>C, ENST00000553106.5:c.60G>C, ENST00000635500.1:n.29-4173G>C, NC_000012.12:g.102917071C>G, CM000674.2:g.102917071C>G, NC_000012.11:g.103310849C>G, CM000674.1:g.103310849C>G, NC_000012.10:g.101834979C>G, NG_008690.1:g.5532G>C, NG_008690.2:g.46340G>C, NM_000277.2(PAH):c.60G>C (p.Gln20His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM3 [Unmet], PP3 [MET], PP4 [MET]	The c.60G>C (p.Q20H) variant has been reported in 1 patient with PKU (not excluding BH4 deficiency), who carried 2 pathogenic variants (p.R158Q, p.R408W) in PAH (PMID: 18321666, PMID: 23430918). This variant is absent from population databases, including 1000 Genomes, ESP, and gnomAD. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.571. In summary, this variant meets our criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PP4.	23430918, 18321666, 18321666	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229651/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103248987	102767	TG	T	NM_000277.2(PAH):c.632delC (p.Pro211Hisfs)	102767	CA229667	NM_000277.2:c.632delC, NC_000012.12:g.102855211del, CM000674.2:g.102855211del, NC_000012.11:g.103248989del, CM000674.1:g.103248989del, NC_000012.10:g.101773119del, NG_008690.1:g.67393del, NG_008690.2:g.108201del, NM_000277.1:c.632del, XM_011538422.1:c.632del, NM_000277.2:c.632del, NM_001354304.1:c.632del, XM_017019370.2:c.632del, NM_000277.3:c.632del, ENST00000307000.7:c.617del, ENST00000549111.5:n.728del, ENST00000553106.5:c.632del, NM_000277.2(PAH):c.632delC (p.Pro211Hisfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP4 [MET]	"The c.632delC (p.Pro211Hisfs) variant in PAH leads to a frameshift at amino acid 211/432. It is identified with low frequency in population databases (1.648e-5).  It has been identified in two individuals with Phenylketonuria as a homozygous variant and in trans with c.1066-11G>A (PMID: 26413448; 26666653).  It has been described in multiple patients with PKU, although a defect in BH4 metabolism has not been excluded as a cause of elevated phenylalanine in any case. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4."	26413448, 26666653, 26413448, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229667/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103248970	102772	C	T	NM_000277.2(PAH):c.650G>A (p.Cys217Tyr)	102772	CA229674	NM_000277.2:c.650G>A, NC_000012.12:g.102855192C>T, CM000674.2:g.102855192C>T, NC_000012.11:g.103248970C>T, CM000674.1:g.103248970C>T, NC_000012.10:g.101773100C>T, NG_008690.1:g.67411G>A, NG_008690.2:g.108219G>A, NM_000277.1:c.650G>A, XM_011538422.1:c.650G>A, NM_001354304.1:c.650G>A, XM_017019370.2:c.650G>A, NM_000277.3:c.650G>A, ENST00000307000.7:c.635G>A, ENST00000549111.5:n.746G>A, ENST00000553106.5:c.650G>A, NM_000277.2(PAH):c.650G>A (p.Cys217Tyr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET]	The c.650G>A (p.Cys217Tyr) variant in PAH was reported in 1 Japanese PKU patient. DHPR activity, biopterin and/or pteridine analysis was performed to rule out other causes of hyperphenylalaninemia. (PMID: 21307867). This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.982. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PP3.	21307867	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229674/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103248932	102784	C	T	NM_000277.1(PAH):c.688G>A (p.Val230Ile)	102784	CA286506	NM_000277.1:c.688G>A, NC_000012.12:g.102855154C>T, CM000674.2:g.102855154C>T, NC_000012.11:g.103248932C>T, CM000674.1:g.103248932C>T, NC_000012.10:g.101773062C>T, NG_008690.1:g.67449G>A, NG_008690.2:g.108257G>A, XM_011538422.1:c.688G>A, NM_000277.2:c.688G>A, NM_001354304.1:c.688G>A, XM_017019370.2:c.688G>A, NM_000277.3:c.688G>A, ENST00000307000.7:c.673G>A, ENST00000549111.5:n.784G>A, ENST00000553106.5:c.688G>A, NM_000277.1(PAH):c.688G>A (p.Val230Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [Unmet], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [Unmet], PS3 [Unmet]	"PAH-specific ACMG/AMP criteria applied: PP4_Moderate: V2301 seen in 1 patient with PAH deficiency. BH4 deficiency ruled out. Upgraded per ClinGen Metabolism WG. (PMID:8268925); PM3_VeryStrong: Detected in trans with IVS 10-11G>A, L48S, R408W, E390G). Upgraded per ClinGen SVI Workgroup. (PMID:15943553; PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong)."	8268925, 21147011, 15943553, 11161839, 17924342	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	12/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA286506/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103248897	102792	C	A	NM_000277.2(PAH):c.706+17G>T	102792	CA229702	NM_000277.2:c.706+17G>T, NC_000012.12:g.102855119C>A, CM000674.2:g.102855119C>A, NC_000012.11:g.103248897C>A, CM000674.1:g.103248897C>A, NC_000012.10:g.101773027C>A, NG_008690.1:g.67484G>T, NG_008690.2:g.108292G>T, NM_000277.1:c.706+17G>T, XM_011538422.1:c.706+17G>T, NM_001354304.1:c.706+17G>T, XM_017019370.2:c.706+17G>T, NM_000277.3:c.706+17G>T, ENST00000307000.7:c.691+17G>T, ENST00000549111.5:n.819G>T, ENST00000553106.5:c.706+17G>T, NM_000277.2(PAH):c.706+17G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Benign	BS1 [MET], PP4 [Unmet], BP4 [MET]	The c.706+17G>T variant in PAH has been reported in the mother of a patient with PKU (not found in the patient). PMID: 11139255. The MAF for this variant is 0.00269, greater than expected. Multiple splicing predictors suggest no impact (HSF: No significant splicing motif alteration detected. This mutation has probably no impact on splicing. MaxEnt: +15.3 % variation). In summary, this variant meets criteria to be classified as likely benign: BS1, BP4.	11139255	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229702/MONDO:0009861/006	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246735	102795	T	A	NM_000277.2(PAH):c.707-7A>T	102795	CA180267	NM_000277.2:c.707-7A>T, NM_000277.1:c.707-7A>T, XM_011538422.1:c.707-7A>T, NM_001354304.1:c.707-7A>T, NM_000277.3:c.707-7A>T, ENST00000307000.7:c.692-7A>T, ENST00000549247.6:n.459A>T, ENST00000553106.5:c.707-7A>T, NC_000012.12:g.102852957T>A, CM000674.2:g.102852957T>A, NC_000012.11:g.103246735T>A, CM000674.1:g.103246735T>A, NC_000012.10:g.101770865T>A, NG_008690.1:g.69646A>T, NG_008690.2:g.110454A>T, NM_000277.2(PAH):c.707-7A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BP4 [MET], BA1 [MET]	"PAH-specific ACMG/AMP criteria applied: BA1: Highest MAF=0.10514 in 1000G. 35 homozygotes in ExAC; BP4: HSF: No significant splicing motif alteration detected. This mutation has probably no impact on splicing. CADD=1.163344. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1, BP4)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA180267/MONDO:0009861/006	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
12	103246714	102803	G	A	NM_000277.1(PAH):c.721C>T (p.Arg241Cys)	102803	CA273357	NM_000277.1:c.721C>T, NC_000012.12:g.102852936G>A, CM000674.2:g.102852936G>A, NC_000012.11:g.103246714G>A, CM000674.1:g.103246714G>A, NC_000012.10:g.101770844G>A, NG_008690.1:g.69667C>T, NG_008690.2:g.110475C>T, XM_011538422.1:c.721C>T, NM_000277.2:c.721C>T, NM_001354304.1:c.721C>T, NM_000277.3:c.721C>T, ENST00000307000.7:c.706C>T, ENST00000549247.6:n.480C>T, ENST00000553106.5:c.721C>T, NM_000277.1(PAH):c.721C>T (p.Arg241Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PS3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC (0.00014) and gnomAD (0.0001301); PP3: Deleterious effect predicted in SIFT, PolyPhen2, MutationTaster; PP4_Moderate: Seen in multiple PKU patients. BH4 deficiency excluded in 2 patients. Upgraded per ClinGen Metabolic Workgroup. (PMID:8222245; PMID:11142755); PM3_Strong: R241C seen once in trans with R413P, and once with R243Q, both pathogenic. Upgraded per ClinGen SVI Workgroup. (PMID:11142755); PS3: In vitro PAH R241C mutant was found to have 25% PAH activity of normal. In vivo phenylalanine breath test measured a decreased level in R241C homozygote. (PMID:15319459; PMID:7915167). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong, PS3)."	11142755, 8222245, 7915167, 15319459, 11142755	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273357/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246713	102804	C	T	NM_000277.1(PAH):c.722G>A (p.Arg241His)	102804	CA286507	NM_000277.1:c.722G>A, NC_000012.12:g.102852935C>T, CM000674.2:g.102852935C>T, NC_000012.11:g.103246713C>T, CM000674.1:g.103246713C>T, NC_000012.10:g.101770843C>T, NG_008690.1:g.69668G>A, NG_008690.2:g.110476G>A, XM_011538422.1:c.722G>A, NM_000277.2:c.722G>A, NM_001354304.1:c.722G>A, NM_000277.3:c.722G>A, ENST00000307000.7:c.707G>A, ENST00000549247.6:n.481G>A, ENST00000553106.5:c.722G>A, NM_000277.1(PAH):c.722G>A (p.Arg241His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [MET], PP3 [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC, gnomAD, 1000G, ESP (0.000077- 0.0001518); PP3: Predicted deleterious in SIFT, PolyPhen2, MutationTaster; PM5: R241C (VarID 102803) is Pathogenic in ClinVar based on 3 submitters; PP4_Moderate: R241H seen in 1 PKU patient. BH4 deficiency ruled out. Upgraded per ClinGen Metabolism WG. (PMID:8268925); PM3_Strong: R241H detected in trans with pathogenic variants (IVS10, R408W, R252W). Upgraded per ClinGen SVI Workgroup. (PMID:9429153). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM5, PP4_Moderate, PM3_Strong)."	8268925, 9429153	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA286507/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103246696	102815	C	T	NM_000277.2(PAH):c.739G>A (p.Gly247Ser)	102815	CA229730	NM_000277.2:c.739G>A, NM_000277.1:c.739G>A, XM_011538422.1:c.739G>A, NM_001354304.1:c.739G>A, NM_000277.3:c.739G>A, ENST00000307000.7:c.724G>A, ENST00000549247.6:n.498G>A, ENST00000553106.5:c.739G>A, NC_000012.12:g.102852918C>T, CM000674.2:g.102852918C>T, NC_000012.11:g.103246696C>T, CM000674.1:g.103246696C>T, NC_000012.10:g.101770826C>T, NG_008690.1:g.69685G>A, NG_008690.2:g.110493G>A, NM_000277.2(PAH):c.739G>A (p.Gly247Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PP3 [MET]	The c.739G>A (p.Gly247Ser) variant in PAH was reported in 1 patient with classical PKU, BH4 deficiency excluded. (PMID: 16256386, 25456745) It was detected with T200Nfs, (pathogenic per PAH VCEP). This variant is absent from ExAC, 1000G, gnomAD, and ESP. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.981. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3, PP3.	25456745, 16256386, 25456745	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229730/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246696	102816	C	G	NM_000277.2(PAH):c.739G>C (p.Gly247Arg)	102816	CA229732	NM_000277.2:c.739G>C, NC_000012.12:g.102852918C>G, CM000674.2:g.102852918C>G, NC_000012.11:g.103246696C>G, CM000674.1:g.103246696C>G, NC_000012.10:g.101770826C>G, NG_008690.1:g.69685G>C, NG_008690.2:g.110493G>C, NM_000277.1:c.739G>C, XM_011538422.1:c.739G>C, NM_001354304.1:c.739G>C, NM_000277.3:c.739G>C, ENST00000307000.7:c.724G>C, ENST00000549247.6:n.498G>C, ENST00000553106.5:c.739G>C, NM_000277.2(PAH):c.739G>C (p.Gly247Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET], PM3-Strong [MET]	The c.739G>C (p.Gly247Arg) variant in PAH has been reported in 3 patients with PAH deficiency, with BH4 deficiency assessed in 2 patients. PMID: 21307867, 18985011, 16256386. It was detected with known pathogenic variants R413P (PMID: 16256386) and V388M (PMID: 18985011). It was absent from ExAC, gnomAD, 1000G, and ESP. This variant is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.981. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PP3.	21307867, 18985011, 16256386, 18985011, 16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229732/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246695	102817	C	T	NM_000277.2(PAH):c.740G>A (p.Gly247Asp)	102817	CA229734	NM_000277.2:c.740G>A, NM_000277.1:c.740G>A, XM_011538422.1:c.740G>A, NM_001354304.1:c.740G>A, NM_000277.3:c.740G>A, ENST00000307000.7:c.725G>A, ENST00000549247.6:n.499G>A, ENST00000553106.5:c.740G>A, NC_000012.12:g.102852917C>T, CM000674.2:g.102852917C>T, NC_000012.11:g.103246695C>T, CM000674.1:g.103246695C>T, NC_000012.10:g.101770825C>T, NG_008690.1:g.69686G>A, NG_008690.2:g.110494G>A, NM_000277.2(PAH):c.740G>A (p.Gly247Asp)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [MET], PP4 [MET]	The c.740G>A (p.Gly247Asp) variant in PAH was reported in 2 patients with classic PKU. PMID: 20920871. This varant is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.975. It has an extremely low frequency in ExAC/gnomAD (MAF 0.00003). In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4, PP3.	20920871	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229734/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103246690	102821	G	A	NM_000277.2(PAH):c.745C>T (p.Leu249Phe)	102821	CA273356	NM_000277.2:c.745C>T, NC_000012.12:g.102852912G>A, CM000674.2:g.102852912G>A, NC_000012.11:g.103246690G>A, CM000674.1:g.103246690G>A, NC_000012.10:g.101770820G>A, NG_008690.1:g.69691C>T, NG_008690.2:g.110499C>T, NM_000277.1:c.745C>T, XM_011538422.1:c.745C>T, NM_001354304.1:c.745C>T, NM_000277.3:c.745C>T, ENST00000307000.7:c.730C>T, ENST00000549247.6:n.504C>T, ENST00000553106.5:c.745C>T, NM_000277.2(PAH):c.745C>T (p.Leu249Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3-Very Strong [MET], PP3 [MET], PS3 [Unmet]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extremely low frequency in ExAC and gnomAD (0.00004065); PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.981; PP4_Moderate: L249F was seen 3 times in HPA patients associated with 2 different haplotypes. DHPR defeciency was excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:8533759); PM3_VeryStrong: Seen with R261X, A309V, V388M, R261Q. All Pathogenic/Likely Pathogenic in ClinVar. Upgraded per ClinGen SVI Workgroup (PMID:21871829; PMID:24765287). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_VeryStrong)."	8533759, 24765287, 21871829	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	12/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273356/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246681	102823	G	C	NM_000277.1(PAH):c.754C>G (p.Arg252Gly)	102823	CA229742	NM_000277.1:c.754C>G, XM_011538422.1:c.754C>G, NM_000277.2:c.754C>G, NM_001354304.1:c.754C>G, NM_000277.3:c.754C>G, ENST00000307000.7:c.739C>G, ENST00000549247.6:n.513C>G, ENST00000553106.5:c.754C>G, NC_000012.12:g.102852903G>C, CM000674.2:g.102852903G>C, NC_000012.11:g.103246681G>C, CM000674.1:g.103246681G>C, NC_000012.10:g.101770811G>C, NG_008690.1:g.69700C>G, NG_008690.2:g.110508C>G, NM_000277.1(PAH):c.754C>G (p.Arg252Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [MET], PP3 [MET], PS3 [MET]	"The c.754C>G (p.Arg252Gly) variant in PAH has been reported in multiple individuals with Classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 1363786, 9634518). This variant is absent in population databases (PM2). This variant has 3% enzyme activity (PS3; PMID: 9799096). Computational prediction tools and conservation analysis suggest this variant may impact the protein (PP3). This missense change is at an amino acid residue where different pathogenic missense changes have been seen before (p.Arg252Gln/Trp). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM5, PP3."	1363786, 9634518, 9799096	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	8/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229742/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246680	102824	C	T	NM_000277.1(PAH):c.755G>A (p.Arg252Gln)	102824	CA229743	NM_000277.1:c.755G>A, NC_000012.12:g.102852902C>T, CM000674.2:g.102852902C>T, NC_000012.11:g.103246680C>T, CM000674.1:g.103246680C>T, NC_000012.10:g.101770810C>T, NG_008690.1:g.69701G>A, NG_008690.2:g.110509G>A, XM_011538422.1:c.755G>A, NM_000277.2:c.755G>A, NM_001354304.1:c.755G>A, NM_000277.3:c.755G>A, ENST00000307000.7:c.740G>A, ENST00000549247.6:n.514G>A, ENST00000553106.5:c.755G>A, NM_000277.1(PAH):c.755G>A (p.Arg252Gln)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PS3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: ; PP3: tools predict damaging; PS3: BioPKU 3% enzyme activity; 3.8% residual activity (PMID:24401910); PM3: Detected in trans with p.Pro407fs (PMID:7833954); PP4_Moderate: Detected in 2 patients with classic PKU (Phe>1.5mM). BH4 deficiency excluded (PMID:7833954; PMID:9634518). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4_Moderate)."	9634518, 7833954, 7833954, 24401910	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229743/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246653	102832	C	G	NM_000277.1(PAH):c.782G>C (p.Arg261Pro)	102832	CA229759	NM_000277.1:c.782G>C, NC_000012.12:g.102852875C>G, CM000674.2:g.102852875C>G, NC_000012.11:g.103246653C>G, CM000674.1:g.103246653C>G, NC_000012.10:g.101770783C>G, NG_008690.1:g.69728G>C, NG_008690.2:g.110536G>C, XM_011538422.1:c.782G>C, NM_000277.2:c.782G>C, NM_001354304.1:c.782G>C, NM_000277.3:c.782G>C, ENST00000307000.7:c.767G>C, ENST00000549247.6:n.541G>C, ENST00000553106.5:c.782G>C, NM_000277.1(PAH):c.782G>C (p.Arg261Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM5 [MET], PP4 [MET], PP3 [MET], PM3-Strong [MET]	The PAH c.782G>C (p.Arg261Pro) variant has been reported in multiple affected individuals (PMID: 26666653, Bh4 deficiency not ruled out, PP4). It has been detected with 5 known pathogenic variants (PM3_S). It is absent from ExAC/gnomAD. Computational evidence supports a deleterious effect. Also, p.R261Q is interpreted as pathogenic. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_S, PM2, PM5, PP4, PP3.	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229759/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246646	102833	G	C	NM_000277.2(PAH):c.789C>G (p.Phe263Leu)	102833	CA229760	NM_000277.2:c.789C>G, NM_000277.1:c.789C>G, XM_011538422.1:c.789C>G, NM_001354304.1:c.789C>G, NM_000277.3:c.789C>G, ENST00000307000.7:c.774C>G, ENST00000549247.6:n.548C>G, ENST00000553106.5:c.789C>G, NC_000012.12:g.102852868G>C, CM000674.2:g.102852868G>C, NC_000012.11:g.103246646G>C, CM000674.1:g.103246646G>C, NC_000012.10:g.101770776G>C, NG_008690.1:g.69735C>G, NG_008690.2:g.110543C>G, NM_000277.2(PAH):c.789C>G (p.Phe263Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [Unmet], PP3 [MET]	The c.789C>G (p.Phe263Leu) variant in PAH is reported in 1 patient with classical PKU, and 1 Chinese PKU patient. (BH4 deficiency excluded. PMID: 8222245, 26600521) This variant is absent from 1000G and ESP with extremely low frequency in ExAC/gnomAD (MAF=0.00003). It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.929. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PP3.	26600521, 8222245, 26600521	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229760/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103246636	102839	G	C	NM_000277.2(PAH):c.799C>G (p.Gln267Glu)	102839	CA229769	NM_000277.2:c.799C>G, NC_000012.12:g.102852858G>C, CM000674.2:g.102852858G>C, NC_000012.11:g.103246636G>C, CM000674.1:g.103246636G>C, NC_000012.10:g.101770766G>C, NG_008690.1:g.69745C>G, NG_008690.2:g.110553C>G, NM_000277.1:c.799C>G, XM_011538422.1:c.799C>G, NM_001354304.1:c.799C>G, NM_000277.3:c.799C>G, ENST00000307000.7:c.784C>G, ENST00000549247.6:n.558C>G, ENST00000553106.5:c.799C>G, NM_000277.2(PAH):c.799C>G (p.Gln267Glu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PP4 [MET], PS3 [MET]	The c.799C>G (p.Gln267Glu) variant in PAH was reported in 2 Chinese PKU patients. BH4 deficiencies not completely ruled out. (PMID: 26600521) This variant was detected with known pathogenic variants p.R111X (PMID: 16256386), and D101N (not in ClinVar, PMID: 26600521). It is absent from ExAC, gnomAD, 1000G, and ESP. This variant is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.935. This variant was expressed in e. coli using a rat Q267E mutant. It has 11% activity of wt. based on duplicate determinations of a single clone. (PMID: 7914195). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PS3, PP3, PP4.	26600521, 16256386, 26600521, 16256386, 9450897, 7914195	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229769/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246634	102840	C	G	NM_000277.2(PAH):c.801G>C (p.Gln267His)	102840	CA229771	NM_000277.2:c.801G>C, NM_000277.1:c.801G>C, XM_011538422.1:c.801G>C, NM_001354304.1:c.801G>C, NM_000277.3:c.801G>C, ENST00000307000.7:c.786G>C, ENST00000549247.6:n.560G>C, ENST00000553106.5:c.801G>C, NC_000012.12:g.102852856C>G, CM000674.2:g.102852856C>G, NC_000012.11:g.103246634C>G, CM000674.1:g.103246634C>G, NC_000012.10:g.101770764C>G, NG_008690.1:g.69747G>C, NG_008690.2:g.110555G>C, NM_000277.2(PAH):c.801G>C (p.Gln267His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PP4 [MET]	The c.801G>C (p.Gln267His) variant in PAH has been reported in 1 Chinese patient with classical PKU. BH4 deficiencies were not assessed. PMID: 16256386, 19915519. It was detected with a known pathogenic variant p.R252Q. PMID: 16256386. It is absent from population databases. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.952. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP3, PP4.	16256386, 19915519, 16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229771/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246633	102841	A	G	NM_000277.2(PAH):c.802T>C (p.Tyr268His)	102841	CA229773	NM_000277.2:c.802T>C, NC_000012.12:g.102852855A>G, CM000674.2:g.102852855A>G, NC_000012.11:g.103246633A>G, CM000674.1:g.103246633A>G, NC_000012.10:g.101770763A>G, NG_008690.1:g.69748T>C, NG_008690.2:g.110556T>C, NM_000277.1:c.802T>C, XM_011538422.1:c.802T>C, NM_001354304.1:c.802T>C, NM_000277.3:c.802T>C, ENST00000307000.7:c.787T>C, ENST00000549247.6:n.561T>C, ENST00000553106.5:c.802T>C, NM_000277.2(PAH):c.802T>C (p.Tyr268His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [MET]	The c.802T>C (p.Tyr268His) variant in PAH has not been reported in the literature to our knowledge. The reference in BioPKU/PAHdb (Eisensmith, 1996) does not include this variant. It is absent from ExAC, 1000G, and ESP, with Extremely low frequency in gnomAD (0.000004063). A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.977. . In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229773/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246630	102842	T	G	NM_000277.1(PAH):c.805A>C (p.Ile269Leu)	102842	CA229775	NM_000277.1:c.805A>C, NC_000012.12:g.102852852T>G, CM000674.2:g.102852852T>G, NC_000012.11:g.103246630T>G, CM000674.1:g.103246630T>G, NC_000012.10:g.101770760T>G, NG_008690.1:g.69751A>C, NG_008690.2:g.110559A>C, XM_011538422.1:c.805A>C, NM_000277.2:c.805A>C, NM_001354304.1:c.805A>C, NM_000277.3:c.805A>C, ENST00000307000.7:c.790A>C, ENST00000549247.6:n.564A>C, ENST00000553106.5:c.805A>C, NM_000277.1(PAH):c.805A>C (p.Ile269Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3-Very Strong [MET], PP3 [MET]	"The c.805A>C (p.Ile269Leu) variant in PAH has been reported in multiple individuals with PAH deficiency, including non-PKU HPA (BH4 deficiency excluded). (PP4_Moderate; PMID10767174, PMID 2350059). This variant has an extremely low allele frequency in ExAC and gnomAD (PM2; ENF=0.00013). This variant was detected in trans with multiple known pathogenic variants: PMID 9521426: c.842+3G>C; PMID 10767174: R261X; PMID 14726806: E280K; PMID 21871829: IVS10-11G>A (PM3_Very-strong). Computational prediction tools and conservation analysis suggest this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Very-strong, PP4_Moderate, PM2, PP3."	10767174, 9521426, 14726806, 10767174, 9521426, 21871829	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229775/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246628	102844	GA	G	NM_000277.2(PAH):c.806delT (p.Ile269Thrfs)	102844	CA229778	NM_000277.2:c.806delT, NM_000277.1:c.806del, XM_011538422.1:c.806del, NM_000277.2:c.806del, NM_001354304.1:c.806del, NM_000277.3:c.806del, ENST00000307000.7:c.791del, ENST00000549247.6:n.565del, ENST00000553106.5:c.806del, NC_000012.12:g.102852851del, CM000674.2:g.102852851del, NC_000012.11:g.103246629del, CM000674.1:g.103246629del, NC_000012.10:g.101770759del, NG_008690.1:g.69752del, NG_008690.2:g.110560del, NM_000277.2(PAH):c.806delT (p.Ile269Thrfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency. gnomAD MAF=0.00007.; PP4: Detected in a PKU patient. BH4 deficiency not assessed. (PMID:9012412). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4)."	9012412	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229778/MONDO:0009861/006	0.9971	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246624	102849	G	A	NM_000277.2(PAH):c.811C>T (p.His271Tyr)	102849	CA229784	NM_000277.2:c.811C>T, NC_000012.12:g.102852846G>A, CM000674.2:g.102852846G>A, NC_000012.11:g.103246624G>A, CM000674.1:g.103246624G>A, NC_000012.10:g.101770754G>A, NG_008690.1:g.69757C>T, NG_008690.2:g.110565C>T, NM_000277.1:c.811C>T, XM_011538422.1:c.811C>T, NM_001354304.1:c.811C>T, NM_000277.3:c.811C>T, ENST00000307000.7:c.796C>T, ENST00000549247.6:n.570C>T, ENST00000553106.5:c.811C>T, NM_000277.2(PAH):c.811C>T (p.His271Tyr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [MET], PP4 [MET]	The c.811C>T (p.His271Tyr) variant in PAH has been reported in 2 unrelated PKU patients. BH4 deficiencies not assessed. (PMID: 9012412) A deleterious effect is predicted in SIFT, Polyphen2, MutationTaster, and REVEL=0.978. This variant has an extremely low frequency in ExAC, 1000G, ESP, and gnomAD (MAF=0.00001). . In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3, PP4.	9012412	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229784/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103246623	102850	T	C	NM_000277.2(PAH):c.812A>G (p.His271Arg)	102850	CA286508	NM_000277.2:c.812A>G, NM_000277.1:c.812A>G, XM_011538422.1:c.812A>G, NM_001354304.1:c.812A>G, NM_000277.3:c.812A>G, ENST00000307000.7:c.797A>G, ENST00000549247.6:n.571A>G, ENST00000553106.5:c.812A>G, NC_000012.12:g.102852845T>C, CM000674.2:g.102852845T>C, NC_000012.11:g.103246623T>C, CM000674.1:g.103246623T>C, NC_000012.10:g.101770753T>C, NG_008690.1:g.69758A>G, NG_008690.2:g.110566A>G, NM_000277.2(PAH):c.812A>G (p.His271Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PP3 [MET]	The c.812A>G (p.His271Arg) variant in the PAH gene has been reported in PKU patients in Henan, and France. Dihydropteridine reductase activity, urinary biopterin and neopterin ratio, and tetrahydrobiopterin loading were collected for the Chinese patient. (PMID: 21462123, 26666653, 26503515). This variant was detected with R408W (PMID: 26666653). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.969. It has an extremely low frequency in ExAC and gnomAD (MAF=0.00006). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate, PP3.	26503515, 26666653, 21462123, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA286508/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246615	102851	T	C	NM_000277.2(PAH):c.820A>G (p.Lys274Glu)	102851	CA229786	NM_000277.2:c.820A>G, NM_000277.1:c.820A>G, XM_011538422.1:c.820A>G, NM_001354304.1:c.820A>G, NM_000277.3:c.820A>G, ENST00000307000.7:c.805A>G, ENST00000549247.6:n.579A>G, ENST00000553106.5:c.820A>G, NC_000012.12:g.102852837T>C, CM000674.2:g.102852837T>C, NC_000012.11:g.103246615T>C, CM000674.1:g.103246615T>C, NC_000012.10:g.101770745T>C, NG_008690.1:g.69766A>G, NG_008690.2:g.110574A>G, NM_000277.2(PAH):c.820A>G (p.Lys274Glu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Benign	BS1 [MET], PM5 [Unmet], PP3 [Unmet], BS3-Supporting [MET]	"PAH-specific ACMG/AMP criteria applied: BS1: MAF= 0.01815 in 1000G. 2 homozygotes in ExAC, 1 homozygote in 1000G.; BS3_Supporting: Enzyme activity of K274E is indistinguishable from that of the wild-type protein. Detailed kinetic analyses of PAH expressed in E. coli showed that the K274E mutant protein has kinetic properties similar to that of the wild-type protein. (PMID:11461196). In summary this variant meets criteria to be classified as likely benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BS3_Supporting)."	11461196	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229786/MONDO:0009861/006	0.1	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
12	103246612	102853	G	A	NM_000277.2(PAH):c.823C>T (p.Pro275Ser)	102853	CA229789	NM_000277.2:c.823C>T, NC_000012.12:g.102852834G>A, CM000674.2:g.102852834G>A, NC_000012.11:g.103246612G>A, CM000674.1:g.103246612G>A, NC_000012.10:g.101770742G>A, NG_008690.1:g.69769C>T, NG_008690.2:g.110577C>T, NM_000277.1:c.823C>T, XM_011538422.1:c.823C>T, NM_001354304.1:c.823C>T, NM_000277.3:c.823C>T, ENST00000307000.7:c.808C>T, ENST00000549247.6:n.582C>T, ENST00000553106.5:c.823C>T, NM_000277.2(PAH):c.823C>T (p.Pro275Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [MET], PP3 [MET], PM3-Strong [MET]	"The c.823C>T (p.Pro275Ser) variant in PAH is absent from all population databases, and is in the same codon as two other likely pathogenic variants.  In silico algorithms agree on a damaging effect.  It has been identified in trans with two independent pathogenic variants (R408W and c.669delC; PMID: 20123475, 24705691), and a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine in multiple patients. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PP4_Moderate, PM5, PP3."	20123475, 24705691, 20123475, 24705691	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229789/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246611	102854	G	C	NM_000277.2(PAH):c.824C>G (p.Pro275Arg)	102854	CA229791	NM_000277.2:c.824C>G, NM_000277.1:c.824C>G, XM_011538422.1:c.824C>G, NM_001354304.1:c.824C>G, NM_000277.3:c.824C>G, ENST00000307000.7:c.809C>G, ENST00000549247.6:n.583C>G, ENST00000553106.5:c.824C>G, NC_000012.12:g.102852833G>C, CM000674.2:g.102852833G>C, NC_000012.11:g.103246611G>C, CM000674.1:g.103246611G>C, NC_000012.10:g.101770741G>C, NG_008690.1:g.69770C>G, NG_008690.2:g.110578C>G, NM_000277.2(PAH):c.824C>G (p.Pro275Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PM5 [MET], PP3 [MET]	The c.824C>G (p.Pro275Arg) variant in PAH is absent from population databases and predicted deleterious by multiple in silico algorithms.  It is in the same codon as two previously reported likely pathogenic variants (p.Pro275Ser and p.Pro275Leu).  It has been identified in trans with a pathogenic variant (PMID: 23514811), and a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine in that patient. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PM5, PP3.	23514811, 23514811	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229791/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246609	102856	T	C	NM_000277.2(PAH):c.826A>G (p.Met276Val)	102856	CA229794	NM_000277.2:c.826A>G, NM_000277.1:c.826A>G, XM_011538422.1:c.826A>G, NM_001354304.1:c.826A>G, NM_000277.3:c.826A>G, ENST00000307000.7:c.811A>G, ENST00000549247.6:n.585A>G, ENST00000553106.5:c.826A>G, NC_000012.12:g.102852831T>C, CM000674.2:g.102852831T>C, NC_000012.11:g.103246609T>C, CM000674.1:g.103246609T>C, NC_000012.10:g.101770739T>C, NG_008690.1:g.69772A>G, NG_008690.2:g.110580A>G, NM_000277.2(PAH):c.826A>G (p.Met276Val)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [Unmet], PM3-Strong [MET]	"The c.826A>G (p.Met276Val) variant in PAH is absent from population databases.  It has been identified in trans with pathogenic variants in two patients (A300S and R261Q; PMID: 16198137), and identified in an additional patient in which a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine (PMID: 9634518). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3_strong."	9634518, 16198137	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229794/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246608	102857	A	T	NM_000277.2(PAH):c.827T>A (p.Met276Lys)	102857	CA229795	NM_000277.2:c.827T>A, NC_000012.12:g.102852830A>T, CM000674.2:g.102852830A>T, NC_000012.11:g.103246608A>T, CM000674.1:g.103246608A>T, NC_000012.10:g.101770738A>T, NG_008690.1:g.69773T>A, NG_008690.2:g.110581T>A, NM_000277.1:c.827T>A, XM_011538422.1:c.827T>A, NM_001354304.1:c.827T>A, NM_000277.3:c.827T>A, ENST00000307000.7:c.812T>A, ENST00000549247.6:n.586T>A, ENST00000553106.5:c.827T>A, NM_000277.2(PAH):c.827T>A (p.Met276Lys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PM5 [MET], PP3 [Unmet]	The c.827T>A (p.Met276Lys) variant in PAH is absent from population databases, and found in the same codon as a previously reported pathogenic variant (p.Met276Val).  It has been identified in trans with a known pathogenic variant (I95del), in which a defect of BH4 metabolism was excluded as a cause of elevated phenylalanine (PMID: 25894915).	25894915, 25894915	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229795/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246608	102858	A	C	NM_000277.2(PAH):c.827T>G (p.Met276Arg)	102858	CA229797	NM_000277.2:c.827T>G, NM_000277.1:c.827T>G, XM_011538422.1:c.827T>G, NM_001354304.1:c.827T>G, NM_000277.3:c.827T>G, ENST00000307000.7:c.812T>G, ENST00000549247.6:n.586T>G, ENST00000553106.5:c.827T>G, NC_000012.12:g.102852830A>C, CM000674.2:g.102852830A>C, NC_000012.11:g.103246608A>C, CM000674.1:g.103246608A>C, NC_000012.10:g.101770738A>C, NG_008690.1:g.69773T>G, NG_008690.2:g.110581T>G, NM_000277.2(PAH):c.827T>G (p.Met276Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [MET], PP3 [MET], PP4 [MET]	The c.827T>G (p.Met276Arg) variant in PAH is absent from population databases and predicted damaging by in silico models.  It is a novel missense change at an amino acid residue where different pathogenic missense changes have been reported (p.Met276Val is LP in ClinVar, p.Met276Lys is LP via PAH EP). It has been reported in individuals with phenylkeonuria in the literature, although a defect in the metabolism of BH4 has not been excluded as a cause for elevated phenylalanine in any of these patients (PMID: 23932990, 15300621). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM5, PP3.	15300621, 23932990	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229797/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103246592	102869	C	A	NM_000277.2(PAH):c.842+1G>T	102869	CA229812	NM_000277.2:c.842+1G>T, NC_000012.12:g.102852814C>A, CM000674.2:g.102852814C>A, NC_000012.11:g.103246592C>A, CM000674.1:g.103246592C>A, NC_000012.10:g.101770722C>A, NG_008690.1:g.69789G>T, NG_008690.2:g.110597G>T, NM_000277.1:c.842+1G>T, XM_011538422.1:c.842+1G>T, NM_001354304.1:c.842+1G>T, NM_000277.3:c.842+1G>T, ENST00000307000.7:c.827+1G>T, ENST00000549247.6:n.601+1G>T, ENST00000553106.5:c.842+1G>T, ENST00000635477.1:n.3+1G>T, NM_000277.2(PAH):c.842+1G>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	The PAH c.842+1G>T variant has been reported at least once in the literature in a 15 month old patient with moderate PKU in the homozygote state (PP4, PMID: 23220018). This variant is absent from 1000G, ESP, and gnomAD databases. This variant disrupts the canonical splice donor site of intron 7 where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 7 is present in biologically-relevant transcript. In summary, this variant meets criteria to be pathogenic. PAH-specific ACMG/AMP criteria applied: PM2, PP4, PVS1.	23220018	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229812/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246590	102871	C	G	NM_000277.2(PAH):c.842+3G>C	102871	CA229814	NM_000277.2:c.842+3G>C, NM_000277.1:c.842+3G>C, XM_011538422.1:c.842+3G>C, NM_001354304.1:c.842+3G>C, NM_000277.3:c.842+3G>C, ENST00000307000.7:c.827+3G>C, ENST00000549247.6:n.601+3G>C, ENST00000553106.5:c.842+3G>C, ENST00000635477.1:n.3+3G>C, NC_000012.12:g.102852812C>G, CM000674.2:g.102852812C>G, NC_000012.11:g.103246590C>G, CM000674.1:g.103246590C>G, NC_000012.10:g.101770720C>G, NG_008690.1:g.69791G>C, NG_008690.2:g.110599G>C, NM_000277.2(PAH):c.842+3G>C	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3-Strong [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in gnomAD+ExAC (MAF=0.00006). Absent from 1000G, ESP.; PP4_Moderate: Detected in Costa Rican and 1 Spanish PKU patients, exclusion of defects in tetrahydrobiopterine metabolism. (PMID:8860005; PMID:8981952); PM3_Strong: Detected in trans with I269L and R408W, known pathogenic variants. (PMID:9521426; PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong)."	8860005, 8981952, 23430918, 9521426	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	11/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229814/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245536	102873	T	A	NM_000277.2(PAH):c.843-2A>T	102873	CA229816	NM_000277.2:c.843-2A>T, NM_000277.1:c.843-2A>T, XM_011538422.1:c.843-2A>T, NM_001354304.1:c.843-2A>T, NM_000277.3:c.843-2A>T, ENST00000307000.7:c.828-2A>T, ENST00000549247.6:n.602-2A>T, ENST00000551114.2:n.503A>T, ENST00000553106.5:c.843-2A>T, ENST00000635477.1:n.4-2A>T, NC_000012.12:g.102851758T>A, CM000674.2:g.102851758T>A, NC_000012.11:g.103245536T>A, CM000674.1:g.103245536T>A, NC_000012.10:g.101769666T>A, NG_008690.1:g.70845A>T, NG_008690.2:g.111653A>T, NM_000277.2(PAH):c.843-2A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [Unmet], PP4 [MET]	The c.843-2A>T variant in PAH has been reported in 1 homozygote individual with classic PKU (PMID: 9452062). This variant disrupts the canonical splice acceptor site of intron 8 where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 8 is present in biologically-relevant transcript. This variant is absent from population databases, including: 1000 Genomes, ESP, and gnomAD. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229816/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245529	102877	A	T	NM_000277.2(PAH):c.848T>A (p.Ile283Asn)	102877	CA229821	NM_000277.2:c.848T>A, NC_000012.12:g.102851751A>T, CM000674.2:g.102851751A>T, NC_000012.11:g.103245529A>T, CM000674.1:g.103245529A>T, NC_000012.10:g.101769659A>T, NG_008690.1:g.70852T>A, NG_008690.2:g.111660T>A, NM_000277.1:c.848T>A, XM_011538422.1:c.848T>A, NM_001354304.1:c.848T>A, NM_000277.3:c.848T>A, ENST00000307000.7:c.833T>A, ENST00000549247.6:n.607T>A, ENST00000551114.2:n.510T>A, ENST00000553106.5:c.848T>A, ENST00000635477.1:n.9T>A, NM_000277.2(PAH):c.848T>A (p.Ile283Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [MET], PP3 [MET], PM3-Strong [MET]	The c.848T>A (p.Ile283Asn) variant in PAH is absent from population databases and predicted damaging with in silico predictors.  It is a novel missense change in a residue where a different pathogenic variant has been identified (c.847A>T (p.Ile283Phe).  It has been identified in multiple affected individuals in trans with known pathogenic variants (PMID: 9521426, 26413448), and was identified in a patient in which a defect in BH4 metabolism had been excluded. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_strong, PM2, PM5, PP4_Moderate, PP3.	26413448, 9521426	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229821/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245521	102880	C	T	NM_000277.2(PAH):c.856G>A (p.Glu286Lys)	102880	CA229826	NM_000277.2:c.856G>A, NC_000012.12:g.102851743C>T, CM000674.2:g.102851743C>T, NC_000012.11:g.103245521C>T, CM000674.1:g.103245521C>T, NC_000012.10:g.101769651C>T, NG_008690.1:g.70860G>A, NG_008690.2:g.111668G>A, NM_000277.1:c.856G>A, XM_011538422.1:c.856G>A, NM_001354304.1:c.856G>A, NM_000277.3:c.856G>A, ENST00000307000.7:c.841G>A, ENST00000549247.6:n.615G>A, ENST00000551114.2:n.518G>A, ENST00000553106.5:c.856G>A, ENST00000635477.1:n.17G>A, NM_000277.2(PAH):c.856G>A (p.Glu286Lys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PS3 [MET]	The c.856G>A (p.Glu286Lys) variant in PAH is present with low frequency in population databases (1.2e-4), and is predicted to be deleterious using in silico algorithms.  It has been identified in trans with pathogenic variants in two independent patients (R243Q, R241C), and has been identified in a patients with Phenylketonuria in which a defect in BH4 metabolism has been excluded (PMID: 14722928, 24401910).  Enzyme activity has been measured as 1% of wild type controls (BioPKU). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4_Moderate, PS3, PP3.	24401910, 14722928, 14722928	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229826/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245513	102881	C	G	NM_000277.2(PAH):c.864G>C (p.Leu288Phe)	102881	CA229828	NM_000277.2:c.864G>C, NM_000277.1:c.864G>C, XM_011538422.1:c.864G>C, NM_001354304.1:c.864G>C, NM_000277.3:c.864G>C, ENST00000307000.7:c.849G>C, ENST00000549247.6:n.623G>C, ENST00000551114.2:n.526G>C, ENST00000553106.5:c.864G>C, ENST00000635477.1:n.25G>C, NC_000012.12:g.102851735C>G, CM000674.2:g.102851735C>G, NC_000012.11:g.103245513C>G, CM000674.1:g.103245513C>G, NC_000012.10:g.101769643C>G, NG_008690.1:g.70868G>C, NG_008690.2:g.111676G>C, NM_000277.2(PAH):c.864G>C (p.Leu288Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP3 [MET], PP4 [MET]	The c.864G>C (p.Leu288Phe) variant in PAH is absent from population databases, and in silico predictors suggest a damaging effect on protein function.  It is listed in hPAHdb 2009 McGill, but there is no clinical information on any patient.  To our current knowledge (December, 2018), this variant has not been previously reported in the literature. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PP3.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229828/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245512	102882	C	G	NM_000277.2(PAH):c.865G>C (p.Gly289Arg)	102882	CA229830	NM_000277.2:c.865G>C, NC_000012.12:g.102851734C>G, CM000674.2:g.102851734C>G, NC_000012.11:g.103245512C>G, CM000674.1:g.103245512C>G, NC_000012.10:g.101769642C>G, NG_008690.1:g.70869G>C, NG_008690.2:g.111677G>C, NM_000277.1:c.865G>C, XM_011538422.1:c.865G>C, NM_001354304.1:c.865G>C, NM_000277.3:c.865G>C, ENST00000307000.7:c.850G>C, ENST00000549247.6:n.624G>C, ENST00000551114.2:n.527G>C, ENST00000553106.5:c.865G>C, ENST00000635477.1:n.26G>C, NM_000277.2(PAH):c.865G>C (p.Gly289Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET], PS1 [MET]	"The c.865G>C (p.Gly289Arg) variant in PAH is absent from population databases and predicted deleterious with in silico prediction software.  This is the same amnio acid change as a previously established pathogenic variant (c.865G>A; p.Gly289Arg).  It has been identified in trans with a pathogenic variant (R155C, curated by the PAH EP), and a defect in BH4 metabolism was excluded (PMID: 22921945). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS1, PM2, PM3, PP3."	22921945, 23514811	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229830/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245493	102884	G	C	NM_000277.2(PAH):c.884C>G (p.Ser295Ter)	102884	CA229834	NM_000277.2:c.884C>G, NC_000012.12:g.102851715G>C, CM000674.2:g.102851715G>C, NC_000012.11:g.103245493G>C, CM000674.1:g.103245493G>C, NC_000012.10:g.101769623G>C, NG_008690.1:g.70888C>G, NG_008690.2:g.111696C>G, NM_000277.1:c.884C>G, XM_011538422.1:c.884C>G, NM_001354304.1:c.884C>G, NM_000277.3:c.884C>G, ENST00000307000.7:c.869C>G, ENST00000549247.6:n.643C>G, ENST00000551114.2:n.546C>G, ENST00000553106.5:c.884C>G, ENST00000635477.1:n.45C>G, NM_000277.2(PAH):c.884C>G (p.Ser295Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [Unmet], PP4 [MET]	The c.884C>G (p.S295*) variant in PAH has been reported in 1 individual with PKU, however without indication of complete genotype (PMID:10394930). This variant is absent in  population databases, including 1000 Genomes, Exome Sequencing Project (ESP) and the Genome Aggregation database (gnomAD). This is a nonsense variant in exon 8 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. Overall this variant meets criteria to be classified as pathogenic for PAH. ACMG/AMP criteria applied: PM2, PVS1, PP4.	10394930, 10394930	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229834/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245488	102885	G	A	NM_000277.2(PAH):c.889C>T (p.Arg297Cys)	102885	CA229836	NM_000277.2:c.889C>T, NC_000012.12:g.102851710G>A, CM000674.2:g.102851710G>A, NC_000012.11:g.103245488G>A, CM000674.1:g.103245488G>A, NC_000012.10:g.101769618G>A, NG_008690.1:g.70893C>T, NG_008690.2:g.111701C>T, NM_000277.1:c.889C>T, XM_011538422.1:c.889C>T, NM_001354304.1:c.889C>T, NM_000277.3:c.889C>T, ENST00000307000.7:c.874C>T, ENST00000549247.6:n.648C>T, ENST00000551114.2:n.551C>T, ENST00000553106.5:c.889C>T, ENST00000635477.1:n.50C>T, NM_000277.2(PAH):c.889C>T (p.Arg297Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PM5 [MET], PP3 [MET]	"The c.889C>T (p.R297C) variant in PAH has been reported in multiple individuals with PAH deficiency (BH4 deficiency excluded: PMID: 8807331, 21307867). It was detected in trans with the pathogenic variant IVS12nt1 (VarID576; PMID 8807331). This variant has an extremely low allele frequency in gnomAD (7/245782). Two other missense variants at the same codon are pathogenic. (92750). Computational prediction tools and conservation analysis suggest that the c.889C>T variant may impact the protein. Overall, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP3, PM2, PM3, PM5, PP4_moderate."	8807331, 21307867, 8807331, 27121329	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229836/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245479	102886	CAAA	C	NM_000277.2(PAH):c.895_897delTTT (p.Phe299del)	102886	CA229837	NM_000277.2:c.895_897del, NM_000277.1:c.895_897del, XM_011538422.1:c.895_897del, NM_001354304.1:c.895_897del, NM_000277.3:c.895_897del, ENST00000307000.7:c.880_882del, ENST00000549247.6:n.654_656del, ENST00000551114.2:n.557_559del, ENST00000553106.5:c.895_897del, ENST00000635477.1:n.56_58del, NC_000012.12:g.102851702_102851704del, CM000674.2:g.102851702_102851704del, NC_000012.11:g.103245480_103245482del, CM000674.1:g.103245480_103245482del, NC_000012.10:g.101769610_101769612del, NG_008690.1:g.70899_70901del, NG_008690.2:g.111707_111709del, NM_000277.2(PAH):c.895_897delTTT (p.Phe299del)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM4 [MET], PP4 [MET]	The c.895_897del (p.Phe299del) variant in PAH has been reported in 1 individual with PKU without genotype information (BH4 deficiency not ruled out) (PMID: 10541324) . This variant is absent in gnomAD and the ESP population databases. The c.895_897del variant results in an in-frame deletion of phenylalanine 299 in a hydrophobic pocket of the hydroxylase domain of PAH.  In summary, this variant meets the criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM4.	10541324	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229837/MONDO:0009861/006	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245469	102888	GA	G	NM_000277.2(PAH):c.904delT (p.Ser303Profs)	102888	CA229840	NC_000012.12:g.102851695del, CM000674.2:g.102851695del, NC_000012.11:g.103245473del, CM000674.1:g.103245473del, NC_000012.10:g.101769603del, NG_008690.1:g.70911del, NG_008690.2:g.111719del, NM_000277.1:c.907del, XM_011538422.1:c.907del, NM_000277.2:c.907del, NM_001354304.1:c.907del, NM_000277.3:c.907del, ENST00000307000.7:c.892del, ENST00000549247.6:n.666del, ENST00000551114.2:n.569del, ENST00000553106.5:c.907del, ENST00000635477.1:n.68del, NM_000277.2(PAH):c.904delT (p.Ser303Profs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP4 [MET]	The c.904delT (p.Ser303Profs*38) variant in PAH has been observed in at least one patient with classic PKU (plasma phenylalanine greater than 1200 micromolar) with a known pathogenic variant p.Ser70del (PMID:16256386). This variant is absent in population databases including: 1000 Genomes, ESP, and extremely low in gnomAD. This is a single base pair deletion that creates a frameshift in exon 9 and is predicted to undergo nonsense mediated decay with the truncated region critical to protein function. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4.	16256386, 16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229840/MONDO:0009861/006	0.9941	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245470	102889	A	G	NM_000277.2(PAH):c.907T>C (p.Ser303Pro)	102889	CA229841	NM_000277.2:c.907T>C, NM_000277.1:c.907T>C, XM_011538422.1:c.907T>C, NM_001354304.1:c.907T>C, NM_000277.3:c.907T>C, ENST00000307000.7:c.892T>C, ENST00000549247.6:n.666T>C, ENST00000551114.2:n.569T>C, ENST00000553106.5:c.907T>C, ENST00000635477.1:n.68T>C, NC_000012.12:g.102851692A>G, CM000674.2:g.102851692A>G, NC_000012.11:g.103245470A>G, CM000674.1:g.103245470A>G, NC_000012.10:g.101769600A>G, NG_008690.1:g.70911T>C, NG_008690.2:g.111719T>C, NM_000277.2(PAH):c.907T>C (p.Ser303Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"The c.907T>C (p.Ser303Pro) variant in PAH has been reported in 1 affected individual (BH4 deficiency excluded). (PP4_Moderate; PMID: 9634518). This variant is absent in population databases (PM2). This variant was detected with p.D282G (LP via PAH workgroup) (PM3; PMID: 16256386). Computational evidence supports a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3."	9634518, 16256386	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229841/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245465	102892	C	T	NM_000277.2(PAH):c.912G>A (p.Gln304=)	102892	CA229845	NM_000277.2:c.912G>A, NM_000277.1:c.912G>A, XM_011538422.1:c.912G>A, NM_001354304.1:c.912G>A, NM_000277.3:c.912G>A, ENST00000307000.7:c.897G>A, ENST00000549247.6:n.671G>A, ENST00000551114.2:n.574G>A, ENST00000553106.5:c.912G>A, ENST00000635477.1:n.73G>A, NC_000012.12:g.102851687C>T, CM000674.2:g.102851687C>T, NC_000012.11:g.103245465C>T, CM000674.1:g.103245465C>T, NC_000012.10:g.101769595C>T, NG_008690.1:g.70916G>A, NG_008690.2:g.111724G>A, NM_000277.2(PAH):c.912G>A (p.Gln304=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	"The c.912G>A (p.Gln304Gln) variant in PAH has been reported in multiple PKU patients  (BH4 deficiency excluded in some) (PMID: 23514811). This variant is absent from 1000G and ESP, and has an extremely low frequency in gnomAD (MAF=0.000004).  This is a synonymous variant that occurs at the junction of exon8/intron8, and computational analyses (Alamut v.2.11) predict that this variant may impact splicing by reducing (~20%) the canonical donor site.  p.Gln304= has been detected with multiple pathogenic variants without confirmation of parental testing to determine phase: R241H (VarID102804, PMID: 27413125); K363fsdelG (c.1089delG, VarID102518, PMID: 8659548); I65T (VarID636) and A300S (VarID92751, PMID: 2351481); p.R176L (VarID631, PMID: 23500595). In summary, this variant meets criteria to be classified as likely pathogenic for PAH.  PAH-specific ACMG/AMP criteria applied: PP3, PM2, PM3_strong, PP4_moderate."	7766951, 23514811, 24941924, 23500595, 8659548, 26413448, 23514811, 27413125	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229845/MONDO:0009861/006	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103240702	102905	G	A	NM_000277.2(PAH):c.940C>T (p.Pro314Ser)	102905	CA229865	NM_000277.2:c.940C>T, NC_000012.12:g.102846924G>A, CM000674.2:g.102846924G>A, NC_000012.11:g.103240702G>A, CM000674.1:g.103240702G>A, NC_000012.10:g.101764832G>A, NG_008690.1:g.75679C>T, NG_008690.2:g.116487C>T, NM_000277.1:c.940C>T, XM_011538422.1:c.913-2493C>T, NM_001354304.1:c.940C>T, NM_000277.3:c.940C>T, ENST00000307000.7:c.925C>T, ENST00000549247.6:n.699C>T, ENST00000551114.2:n.602C>T, ENST00000553106.5:c.940C>T, ENST00000635477.1:n.74-2493C>T, ENST00000635528.1:n.455C>T, NM_000277.2(PAH):c.940C>T (p.Pro314Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PM5 [MET], PP3 [Unmet], PS3 [MET]	The c.940C>T (p.Pro314Ser) variant in PAH is absent in population databases, and is in the same codon as two previously described Pathogenic/Likely pathogenic variants (p.Pro314His and p.Pro314Thr).  It has been found in trans with a pathogenic variant (p.R408W) in a patient with PAH deficiency (BH4 defects excluded, PMID: 12501224). Functional studies showed it has 26% enzyme activity compared to wild type controls. PMID: 18590700. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM3, PM5.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229865/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103240679	102911	G	A	NM_000277.2(PAH):c.963C>T (p.Leu321=)	102911	CA229873	NM_000277.2:c.963C>T, NM_000277.1:c.963C>T, XM_011538422.1:c.913-2470C>T, NM_001354304.1:c.963C>T, NM_000277.3:c.963C>T, ENST00000307000.7:c.948C>T, ENST00000549247.6:n.722C>T, ENST00000551114.2:n.625C>T, ENST00000553106.5:c.963C>T, ENST00000635477.1:n.74-2470C>T, ENST00000635528.1:n.478C>T, NC_000012.12:g.102846901G>A, CM000674.2:g.102846901G>A, NC_000012.11:g.103240679G>A, CM000674.1:g.103240679G>A, NC_000012.10:g.101764809G>A, NG_008690.1:g.75702C>T, NG_008690.2:g.116510C>T, NM_000277.2(PAH):c.963C>T (p.Leu321=)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Benign	BP7 [MET], BS1 [MET], BS2 [MET], BS3-Supporting [MET]	"PAH-specific ACMG/AMP criteria applied: BS1: >0.02% as set by the PAH specific specifications; BP7: ; BS3_Supporting: cDNA method demonstrates 98% and intinic system demonstrates 81% residual enzyme activity; BS2: 38 homozygotes in gnomAD. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BP7, BS3_Supporting, BS2)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	29/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA229873/MONDO:0009861/006	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
12	103237559	120258	T	A	NM_000277.2(PAH):c.1066-2A>T	120258	CA267625	NM_000277.2:c.1066-2A>T, NM_000277.1:c.1066-2A>T, XM_011538422.1:c.1009-2A>T, NM_001354304.1:c.1066-2A>T, NM_000277.3:c.1066-2A>T, ENST00000307000.7:c.1051-2A>T, ENST00000549247.6:n.825-2A>T, ENST00000551114.2:n.728-2A>T, ENST00000553106.5:c.1066-2A>T, ENST00000635477.1:n.170-2A>T, ENST00000635528.1:n.581-2A>T, NC_000012.12:g.102843781T>A, CM000674.2:g.102843781T>A, NC_000012.11:g.103237559T>A, CM000674.1:g.103237559T>A, NC_000012.10:g.101761689T>A, NG_008690.1:g.78822A>T, NG_008690.2:g.119630A>T, NM_000277.2(PAH):c.1066-2A>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PVS1 [MET]	The c.1066-2A>T variant in PAH is absent from all population databases, and has been identified in a patient in which a defect in BH4 metabolism was excluded as a cause of elevated phenylalanine. PMID: 21307867. It is a null variant  where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 11 is present in biologically-relevant transcripts. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PVS1, PM2.	21307867	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267625/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103237460	120260	A	G	NM_000277.2(PAH):c.1163T>C (p.Val388Ala)	120260	CA267628	NM_000277.2:c.1163T>C, NC_000012.12:g.102843682A>G, CM000674.2:g.102843682A>G, NC_000012.11:g.103237460A>G, CM000674.1:g.103237460A>G, NC_000012.10:g.101761590A>G, NG_008690.1:g.78921T>C, NG_008690.2:g.119729T>C, NM_000277.1:c.1163T>C, XM_011538422.1:c.1106T>C, NM_001354304.1:c.1163T>C, NM_000277.3:c.1163T>C, ENST00000307000.7:c.1148T>C, ENST00000549247.6:n.922T>C, ENST00000551114.2:n.825T>C, ENST00000553106.5:c.1163T>C, ENST00000635477.1:n.267T>C, ENST00000635528.1:n.678T>C, NM_000277.2(PAH):c.1163T>C (p.Val388Ala)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [MET], PM3 [Unmet], PP3 [MET], PP4 [MET]	"The c.1163T>C (p.Val388Ala) variant in PAH has been previously reported Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 120260); the collection method is stated as â€œliterature onlyâ€ and no further information is provided. With respect to the published literature, it has been previously reported in a French proband classified as having mild PKU (defined by the authors as plasma phenylalanine levels between 600-1200uL/L) (PMID: 26666653); formal testing to exclude BH4 deficiency was not noted (PP4). The proband was said to be heterozygous for the variant and also harbor the known pathogenic (per ClinGen PAH working group classification, see ClinVar ID 92731) c.1208C>T (Ala403Val); however, the manuscript did not specify whether the phase of the variants was confirmed via parental testing. Thus, at this point, PM3 cannot be applied with full confidence. The variant results in the substitution of a moderately conserved Valine residue with Alanine, a physiochemically similar amino acid. However, the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., Predicted deleterious in SIFT, Polyphen2, Mutation Taster. REVEL= 0.919) (PP3). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). Other missense changes at this Valine residue (Val388) have been previously reported Pathogenic or Likely Pathogenic in ClinVar, e.g., p.Val388Met (Pathogenic per internal PAH ClinGen Working Group classification, ClinVar ID 619), as well as p.Val388Leu (PM5). The c.181A>G (p.Asn61Asp) variant in PAH has been reported in 1 individual with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 12501224). This variant is absent in population databases (PM2). This variant was detected with p.R261Q (Pathogenic/likely pathogenic in ClinVar) (PM3; PMID: 12501224). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM5, PP3."	26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267628/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103234253	120265	A	G	NM_000277.2(PAH):c.1240T>C (p.Tyr414His)	120265	CA267637	NM_000277.2:c.1240T>C, NM_000277.1:c.1240T>C, XM_011538422.1:c.1183T>C, NM_001354304.1:c.1240T>C, NM_000277.3:c.1240T>C, ENST00000307000.7:c.1225T>C, ENST00000551114.2:n.902T>C, ENST00000553106.5:c.1240T>C, ENST00000635477.1:n.344T>C, ENST00000635528.1:n.755T>C, NC_000012.12:g.102840475A>G, CM000674.2:g.102840475A>G, NC_000012.11:g.103234253A>G, CM000674.1:g.103234253A>G, NC_000012.10:g.101758383A>G, NG_008690.1:g.82128T>C, NG_008690.2:g.122936T>C, NM_000277.2(PAH):c.1240T>C (p.Tyr414His)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [MET], PP3 [MET]	"The c.1240T>C (p.Tyr414His) variant in PAH has been previously reported Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 125859); the collection method is stated as â€œliterature onlyâ€ and no further information is provided. To our knowledge, as of 4/29/19, it has not been reported in the published literature. The variant results in the substitution of a highly conserved Tyrosine residue with Histidine, a physiochemically distinct amino acid (nonpolar versus basic side chains), and the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., Predicted deleterious in SIFT, Polyphen2, Mutation Taster. REVEL= 0.969) (PP3). It is present at extremely low frequency in control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP: the highest MAF reported is 0.00001, in the gnomAD/ExAC Non-Finnish European subpopulation, which falls below the 0.0002 allele frequency cutoff for PAH variants (PM2). Another missense variant at this site, p.Tyr414Cys, has been previously reported Pathogenic, including by the ClinGen PAH working group (see ClinVar variant ID 593) (PM5)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267637/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103306573	120266	A	G	NM_000277.2(PAH):c.164T>C (p.Phe55Ser)	120266	CA267639	NM_000277.2:c.164T>C, NM_000277.1:c.164T>C, XM_011538422.1:c.164T>C, NM_001354304.1:c.164T>C, XM_017019370.2:c.164T>C, NM_000277.3:c.164T>C, ENST00000307000.7:c.149T>C, ENST00000546844.1:c.164T>C, ENST00000548677.2:n.251T>C, ENST00000548928.1:n.86T>C, ENST00000549111.5:n.260T>C, ENST00000550978.6:n.148T>C, ENST00000551337.5:c.164T>C, ENST00000551988.5:n.253T>C, ENST00000553106.5:c.164T>C, ENST00000635500.1:n.132T>C, NC_000012.12:g.102912795A>G, CM000674.2:g.102912795A>G, NC_000012.11:g.103306573A>G, CM000674.1:g.103306573A>G, NC_000012.10:g.101830703A>G, NG_008690.1:g.9808T>C, NG_008690.2:g.50616T>C, NM_000277.2(PAH):c.164T>C (p.Phe55Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PP4 [MET]	The c.164T>C (p.Phe55Ser) variant in PAH is reported in 1 French patient with classic PKU. BH4 deficiency was not assessed. It was detected with a known pathogenic variant c.1066-11G>A (PMID: 26666653). This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.96. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3.	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267639/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288669	120270	C	A	NM_000277.2(PAH):c.196G>T (p.Glu66Ter)	120270	CA267645	NM_000277.2:c.196G>T, NM_000277.1:c.196G>T, XM_011538422.1:c.196G>T, NM_001354304.1:c.196G>T, XM_017019370.2:c.196G>T, NM_000277.3:c.196G>T, ENST00000307000.7:c.181G>T, ENST00000546844.1:c.196G>T, ENST00000548677.2:n.283G>T, ENST00000548928.1:n.118G>T, ENST00000549111.5:n.292G>T, ENST00000550978.6:n.180G>T, ENST00000551337.5:c.196G>T, ENST00000551988.5:n.285G>T, ENST00000553106.5:c.196G>T, ENST00000635500.1:n.164G>T, NC_000012.12:g.102894891C>A, CM000674.2:g.102894891C>A, NC_000012.11:g.103288669C>A, CM000674.1:g.103288669C>A, NC_000012.10:g.101812799C>A, NG_008690.1:g.27712G>T, NG_008690.2:g.68520G>T, NM_000277.2(PAH):c.196G>T (p.Glu66Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET], PM3-Supporting [MET]	"The c.196G>T (p.Glu66Ter) variant in PAH has been previously reported in one proband with classic PKU (PMID: 26666653) (PP4). The proband was heterozygous for the variant and also harbor the pathogenic allele (per ClinGen VCEP) c. 1315+1G>A; however, the phase of the variants was not confirmed via parental testing. (PM3_supporting). The sequence change results in a nonsense variant which occurs in exon 3 of 13 in the in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (see PMID: 30192042) (PVS1). It is absent from control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4, PM3_supporting."	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267645/MONDO:0009861/006	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288653	120271	C	CGAGAAG	NM_000277.2(PAH):c.205_210dup (p.Ser70_Arg71insProSer)	120271	CA267647	NM_000277.2:c.205_210dup, NC_000012.12:g.102894877_102894882dup, CM000674.2:g.102894877_102894882dup, NC_000012.11:g.103288655_103288660dup, CM000674.1:g.103288655_103288660dup, NC_000012.10:g.101812785_101812790dup, NG_008690.1:g.27722_27727dup, NG_008690.2:g.68530_68535dup, NM_000277.1:c.206_211dup, XM_011538422.1:c.206_211dup, NM_000277.2:c.206_211dup, NM_001354304.1:c.206_211dup, XM_017019370.2:c.206_211dup, NM_000277.3:c.206_211dup, ENST00000307000.7:c.191_196dup, ENST00000546844.1:c.206_211dup, ENST00000548677.2:n.293_298dup, ENST00000548928.1:n.128_133dup, ENST00000549111.5:n.302_307dup, ENST00000550978.6:n.190_195dup, ENST00000551337.5:c.206_211dup, ENST00000551988.5:n.295_300dup, ENST00000553106.5:c.206_211dup, ENST00000635500.1:n.174_179dup, NM_000277.2(PAH):c.205_210dup (p.Ser70_Arg71insProSer)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM4 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: chr12-103288654--GAGAAG; Absent from population databases; PM4: in-frame insertion. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267647/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288515	120273	G	A	NM_000277.2(PAH):c.350C>T (p.Thr117Ile)	120273	CA267651	NM_000277.2:c.350C>T, NC_000012.12:g.102894737G>A, CM000674.2:g.102894737G>A, NC_000012.11:g.103288515G>A, CM000674.1:g.103288515G>A, NC_000012.10:g.101812645G>A, NG_008690.1:g.27866C>T, NG_008690.2:g.68674C>T, NM_000277.1:c.350C>T, XM_011538422.1:c.350C>T, NM_001354304.1:c.350C>T, XM_017019370.2:c.350C>T, NM_000277.3:c.350C>T, ENST00000307000.7:c.335C>T, ENST00000546844.1:c.350C>T, ENST00000548928.1:n.272C>T, ENST00000549111.5:n.446C>T, ENST00000550978.6:n.334C>T, ENST00000551337.5:c.350C>T, ENST00000551988.5:n.439C>T, ENST00000553106.5:c.350C>T, NM_000277.2(PAH):c.350C>T (p.Thr117Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [Unmet]	PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC& gnomAD (MAF 0.00018). Absent from 1000G, ESP. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2).		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267651/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103288514	120274	TG	T	NM_000277.2(PAH):c.350delC (p.Thr117Lysfs)	120274	CA267653	NM_000277.2:c.350delC, NM_000277.1:c.350del, XM_011538422.1:c.350del, NM_000277.2:c.350del, NM_001354304.1:c.350del, XM_017019370.2:c.350del, NM_000277.3:c.350del, ENST00000307000.7:c.335del, ENST00000546844.1:c.350del, ENST00000548928.1:n.272del, ENST00000549111.5:n.446del, ENST00000550978.6:n.334del, ENST00000551337.5:c.350del, ENST00000551988.5:n.439del, ENST00000553106.5:c.350del, NC_000012.12:g.102894737del, CM000674.2:g.102894737del, NC_000012.11:g.103288515del, CM000674.1:g.103288515del, NC_000012.10:g.101812645del, NG_008690.1:g.27866del, NG_008690.2:g.68674del, NM_000277.2(PAH):c.350delC (p.Thr117Lysfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	BS1 [Unmet], PM2 [MET], PVS1 [MET], PP4 [MET], BS2 [Unmet], BA1 [Unmet], PS3 [Unmet]	"The c.350delC variant in PAH has been previously reported in at least 2 Arab-Israeli probands with classic PKU (PMID: 18299955; PMID: 18294361); BH4 deficiency was not excluded (PP4). The variant is a frameshift variant occurring in exon 3 of 13 in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (PVS1; see PVS1: Recommendations for Interpreting the Loss of Function PVS1 ACMG/AMP Variant Criteria). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and the Greater Middle East Variome (PM2)."	18294361, 18299955	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267653/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103271234	120275	A	T	NM_000277.2(PAH):c.441+6T>A	120275	CA267654	NM_000277.2:c.441+6T>A, NM_000277.1:c.441+6T>A, XM_011538422.1:c.441+6T>A, NM_001354304.1:c.441+6T>A, XM_017019370.2:c.441+6T>A, NM_000277.3:c.441+6T>A, ENST00000307000.7:c.426+6T>A, ENST00000549111.5:n.537+6T>A, ENST00000550978.6:n.431T>A, ENST00000551988.5:n.530+6T>A, ENST00000553106.5:c.441+6T>A, NC_000012.12:g.102877456A>T, CM000674.2:g.102877456A>T, NC_000012.11:g.103271234A>T, CM000674.1:g.103271234A>T, NC_000012.10:g.101795364A>T, NG_008690.1:g.45147T>A, NG_008690.2:g.85955T>A, NM_000277.2(PAH):c.441+6T>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [MET], PM3-Strong [MET]	The c.441+6T>A variant in PAH has been reported in at least 2 patients with PKU (BH4 deficiency ruled out), who carried pathogenic variants (ClinVar IDs: 589 & 576)  (PMID: 22526846). This variant is absent from 1000G and ESP, and has an extremely low frequency in gnomAD (MAF= 0.000004). This intronic variant changes a moderately conserved nucleotide, and computational analyses (Alamut) predict that this variant may weaken (~60%) the splice donor site of intron 4. Based on the available information, this variant is considered to be likely pathogenic. PAH-specific ACMG/AMP criteria applied: PP3, PP4_M, PM2, PM3_S.	22526846, 22526846	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267654/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260379	120277	G	T	NM_000277.2(PAH):c.504C>A (p.Tyr168Ter)	120277	CA267656	NM_000277.2:c.504C>A, NM_000277.1:c.504C>A, XM_011538422.1:c.504C>A, NM_001354304.1:c.504C>A, XM_017019370.2:c.504C>A, NM_000277.3:c.504C>A, ENST00000307000.7:c.489C>A, ENST00000549111.5:n.600C>A, ENST00000551988.5:n.530+10861C>A, ENST00000553106.5:c.504C>A, NC_000012.12:g.102866601G>T, CM000674.2:g.102866601G>T, NC_000012.11:g.103260379G>T, CM000674.1:g.103260379G>T, NC_000012.10:g.101784509G>T, NG_008690.1:g.56002C>A, NG_008690.2:g.96810C>A, NM_000277.2(PAH):c.504C>A (p.Tyr168Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET], PM3-Supporting [MET]	"The c.504C>A (p.Tyr168Ter) variant in PAH has been previously reported in one proband with mild hyperphenylalanemia (PMID: 26666653; PP4). The proband was said to be heterozygous for the variant and also harbor the known pathogenic allele (per ClinGen PAH VCEP, see ClinVar ID 92751) c.898G>T (p.Ala300Ser); however, the phase of the variants was not confirmed via parental testing (PM3_supporting).The sequence change results in a nonsense variant which occurs in exon 5 of 13 in the in the canonical transcript of PAH, a gene fulfilling the most recent criteria for LOF being a known disease mechanism (see PMID: 30192042) (PVS1). It is absent from control databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4, PM3_supporting."	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267656/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249072	120278	TC	AA	NM_000277.2(PAH):c.547_548delGAinsTT (p.Glu183Leu)	120278	CA267658	NM_000277.2:c.547_548delGAinsTT, NC_000012.12:g.102855294_102855295delinsAA, CM000674.2:g.102855294_102855295delinsAA, NC_000012.11:g.103249072_103249073delinsAA, CM000674.1:g.103249072_103249073delinsAA, NC_000012.10:g.101773202_101773203delinsAA, NG_008690.1:g.67308_67309delinsTT, NG_008690.2:g.108116_108117delinsTT, NM_000277.1:c.547_548delinsTT, XM_011538422.1:c.547_548delinsTT, NM_000277.2:c.547_548delinsTT, NM_001354304.1:c.547_548delinsTT, XM_017019370.2:c.547_548delinsTT, NM_000277.3:c.547_548delinsTT, ENST00000307000.7:c.532_533delinsTT, ENST00000549111.5:n.643_644delinsTT, ENST00000551988.5:n.568_569delinsTT, ENST00000553106.5:c.547_548delinsTT, NM_000277.2(PAH):c.547_548delGAinsTT (p.Glu183Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM3 [MET], PP4 [MET], PP3 [MET]	"The c.547_548delGAinsTT PAH variant has been identified in at least one patient with classic PKU (PMID: 26666653). It was detected in trans with the pathogenic variant c.143T>C; p.Leu48Ser (ClinVar 608). This variant is absent from 1000G, ESP, and gnomAD databases. It is predicted deleterious in multiple in silico models. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM3, PP3."	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267658/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249052	120279	C	T	NM_000277.2(PAH):c.568G>A (p.Val190Met)	120279	CA267660	NM_000277.2:c.568G>A, NM_000277.1:c.568G>A, XM_011538422.1:c.568G>A, NM_001354304.1:c.568G>A, XM_017019370.2:c.568G>A, NM_000277.3:c.568G>A, ENST00000307000.7:c.553G>A, ENST00000549111.5:n.664G>A, ENST00000553106.5:c.568G>A, NC_000012.12:g.102855274C>T, CM000674.2:g.102855274C>T, NC_000012.11:g.103249052C>T, CM000674.1:g.103249052C>T, NC_000012.10:g.101773182C>T, NG_008690.1:g.67329G>A, NG_008690.2:g.108137G>A, NM_000277.2(PAH):c.568G>A (p.Val190Met)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [MET], PP3 [MET]	The c.568G>A (p.Val190Met) variant in PAH has not been reported in the literature to our knowledge. The reference from BioPKU (Namour B, Jeannesson E, Chery C, Gueant JL, Feillet F, 2013) cannot be located. This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen2, MutationTaster, and REVEL=0.836. Another variant at this amino acid (p.V190G) is interpreted as pathogenic by the PAH VCEP. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM5, PP3.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267660/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103249029	120280	C	G	NM_000277.2(PAH):c.591G>C (p.Leu197Phe)	120280	CA267662	NM_000277.2:c.591G>C, NC_000012.12:g.102855251C>G, CM000674.2:g.102855251C>G, NC_000012.11:g.103249029C>G, CM000674.1:g.103249029C>G, NC_000012.10:g.101773159C>G, NG_008690.1:g.67352G>C, NG_008690.2:g.108160G>C, NM_000277.1:c.591G>C, XM_011538422.1:c.591G>C, NM_001354304.1:c.591G>C, XM_017019370.2:c.591G>C, NM_000277.3:c.591G>C, ENST00000307000.7:c.576G>C, ENST00000549111.5:n.687G>C, ENST00000553106.5:c.591G>C, NM_000277.2(PAH):c.591G>C (p.Leu197Phe)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"The c.591G>C (p.Leu197Phe) variant in PAH has been reported in 3 individuals with classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 18299955). This variant is absent in population databases (PM2). This variant was detected with a pathogenic variant (c.168+1G>A) and twice in the homozygous state (PM3). Multiple lines of computational evidence support a deleterious effect (SIFT, PolyPhen2, MutationTaster, REVEL=0.82). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3."	18299955, 18299955	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267662/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246650	120285	A	C	NM_000277.2(PAH):c.785T>G (p.Val262Gly)	120285	CA267671	NM_000277.2:c.785T>G, NM_000277.1:c.785T>G, XM_011538422.1:c.785T>G, NM_001354304.1:c.785T>G, NM_000277.3:c.785T>G, ENST00000307000.7:c.770T>G, ENST00000549247.6:n.544T>G, ENST00000553106.5:c.785T>G, NC_000012.12:g.102852872A>C, CM000674.2:g.102852872A>C, NC_000012.11:g.103246650A>C, CM000674.1:g.103246650A>C, NC_000012.10:g.101770780A>C, NG_008690.1:g.69731T>G, NG_008690.2:g.110539T>G, NM_000277.2(PAH):c.785T>G (p.Val262Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PP4 [MET]	The c.785T>G (p.Val262Gly) variant in PAH is observed in 1 patient with classic PKU. BH4 deficiencies were not assessed. It was detected with a known pathogenic variant p.F39L. PMID: 26666653. This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen-2, MutationTaster, and REVEL=0.954. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3.	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267671/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246639	120286	T	G	NM_000277.2(PAH):c.796A>C (p.Thr266Pro)	120286	CA267673	NM_000277.2:c.796A>C, NM_000277.1:c.796A>C, XM_011538422.1:c.796A>C, NM_001354304.1:c.796A>C, NM_000277.3:c.796A>C, ENST00000307000.7:c.781A>C, ENST00000549247.6:n.555A>C, ENST00000553106.5:c.796A>C, NC_000012.12:g.102852861T>G, CM000674.2:g.102852861T>G, NC_000012.11:g.103246639T>G, CM000674.1:g.103246639T>G, NC_000012.10:g.101770769T>G, NG_008690.1:g.69742A>C, NG_008690.2:g.110550A>C, NM_000277.2(PAH):c.796A>C (p.Thr266Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PP3 [MET]	The c.796A>C (p.Thr266Pro) variant in PAH is reported in 1 classic PKU patient with BH4 deficiency excluded. (PMID: 26666653, 23430918) It was detected with p.V190A, which is interpreted as pathogenic by our PAH VCEP. (PMID: 23430918) This variant is absent from ExAC, gnomAD, 1000G, and ESP. It is predicted deleterious in SIFT, Polyphen-2, MutationTaster, and REVEL=0.98. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3, PP3.	26666653, 23430918, 23430918	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267673/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246623	120287	T	A	NM_000277.2(PAH):c.812A>T (p.His271Leu)	120287	CA267675	NM_000277.2:c.812A>T, NM_000277.1:c.812A>T, XM_011538422.1:c.812A>T, NM_001354304.1:c.812A>T, NM_000277.3:c.812A>T, ENST00000307000.7:c.797A>T, ENST00000549247.6:n.571A>T, ENST00000553106.5:c.812A>T, NC_000012.12:g.102852845T>A, CM000674.2:g.102852845T>A, NC_000012.11:g.103246623T>A, CM000674.1:g.103246623T>A, NC_000012.10:g.101770753T>A, NG_008690.1:g.69758A>T, NG_008690.2:g.110566A>T, NM_000277.2(PAH):c.812A>T (p.His271Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Predicted deleterious in SIFT, Polyphen2, MutationTaster. REVEL=0.957; PP4_Moderate: H271L seen in a Chinese PKU patient. BH4 deficiencies excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:26503515). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate)."	26503515	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267675/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246597	120288	CG	C	NM_000277.2(PAH):c.837delC (p.Glu280Asnfs)	120288	CA267677	NM_000277.2:c.837del, NM_000277.1:c.837del, XM_011538422.1:c.837del, NM_001354304.1:c.837del, NM_000277.3:c.837del, ENST00000307000.7:c.822del, ENST00000549247.6:n.596del, ENST00000553106.5:c.837del, NC_000012.12:g.102852824del, CM000674.2:g.102852824del, NC_000012.11:g.103246602del, CM000674.1:g.103246602del, NC_000012.10:g.101770732del, NG_008690.1:g.69783del, NG_008690.2:g.110591del, NM_000277.2(PAH):c.837delC (p.Glu280Asnfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP4 [MET]	The c.837del frameshift variant has been identified in at least 2 probands with classic PKU, BH4 deficiency not excluded (PMIDs: 10598814, 26666653). It has been detected in trans with pathogenic variants V388M (PMID: 10598814) and c.1315+1G>A (PMID: 26666653). This variant is absent from 1000G, Exac, and gnomAD databases. C.837delC generates a frameshift predicted to result in a premature stop codon 61 residues downstream in exon 10 and undergo NMD. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM3, PM2, PP4.	26666653, 10598814, 26666653, 10598814	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267677/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245490	120291	T	C	NM_000277.2(PAH):c.887A>G (p.Asp296Gly)	120291	CA267682	NM_000277.2:c.887A>G, NM_000277.1:c.887A>G, XM_011538422.1:c.887A>G, NM_001354304.1:c.887A>G, NM_000277.3:c.887A>G, ENST00000307000.7:c.872A>G, ENST00000549247.6:n.646A>G, ENST00000551114.2:n.549A>G, ENST00000553106.5:c.887A>G, ENST00000635477.1:n.48A>G, NC_000012.12:g.102851712T>C, CM000674.2:g.102851712T>C, NC_000012.11:g.103245490T>C, CM000674.1:g.103245490T>C, NC_000012.10:g.101769620T>C, NG_008690.1:g.70891A>G, NG_008690.2:g.111699A>G, NM_000277.2(PAH):c.887A>G (p.Asp296Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP4 [MET], PP3 [MET], PM3-Supporting [MET]	"The c.887A>G (p.Asp296Gly) variant in PAH has been reported in a proband with classic PKU (PMID: 26666653; PP4). The proband was heterozygous for variant; it was found with the known pathogenic (per ClinGen PAH Working Group â€“ see ClinVar variant ID 577) c.1222C > T (p.Arg408Trp) allele; however, the although paper did say that parental samples were collected in the study, it did not explicitly state whether the phase of the variants was confirmed via parental testing. Thus, PM3 is downgraded to supporting. The variant is predicted damaging by multiple lines of computational evidence (PP3). It is absent from ethnically diverse control databases (PM2). Another missense at the site, p.Asp296His, has been previously reported (BioPKU PAH0955) heterozygous in a Chinese proband with PKU; no further information appears to be provided in the manuscript or supplementary information regarding phenotype or second variant (PMID: 26503515). . In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM3_supporting, PP3."	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267682/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103240709	120297	CAG	C	NM_000277.2(PAH):c.931_932delCT (p.Leu311Glyfs)	120297	CA267689	NM_000277.2:c.931_932del, NC_000012.12:g.102846936_102846937del, CM000674.2:g.102846936_102846937del, NC_000012.11:g.103240714_103240715del, CM000674.1:g.103240714_103240715del, NC_000012.10:g.101764844_101764845del, NG_008690.1:g.75670_75671del, NG_008690.2:g.116478_116479del, NM_000277.1:c.931_932del, XM_011538422.1:c.913-2502_913-2501del, NM_001354304.1:c.931_932del, NM_000277.3:c.931_932del, ENST00000307000.7:c.916_917del, ENST00000549247.6:n.690_691del, ENST00000551114.2:n.593_594del, ENST00000553106.5:c.931_932del, ENST00000635477.1:n.74-2502_74-2501del, ENST00000635528.1:n.446_447del, NM_000277.2(PAH):c.931_932delCT (p.Leu311Glyfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET], PM3-Supporting [MET]	The c.931_932del frameshift variant has been identified in at least 1 proband with mild PKU, BH4 deficiency not excluded (PMID: 26666653). It has been detected in trans with the pathogenic variant R241C (PMID: 26666653). This variant is absent from 1000G, Exac, and gnomAD databases. c.931_932delCT generates a frameshift predicted to result in a premature stop codon 4 residues downstream in exon 9 and undergo NMD. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM3_Supporting, PM2, PP4.	26666653, 26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267689/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306581	120310	CA	C	NM_000277.2(PAH):c.155delT (p.Leu52Cysfs)	120310	CA267691	NC_000012.12:g.102912805del, CM000674.2:g.102912805del, NC_000012.11:g.103306583del, CM000674.1:g.103306583del, NC_000012.10:g.101830713del, NG_008690.1:g.9799del, NG_008690.2:g.50607del, NM_000277.1:c.155del, XM_011538422.1:c.155del, NM_000277.2:c.155del, NM_001354304.1:c.155del, XM_017019370.2:c.155del, NM_000277.3:c.155del, ENST00000307000.7:c.140del, ENST00000546844.1:c.155del, ENST00000548677.2:n.242del, ENST00000548928.1:n.77del, ENST00000549111.5:n.251del, ENST00000550978.6:n.139del, ENST00000551337.5:c.155del, ENST00000551988.5:n.244del, ENST00000553106.5:c.155del, ENST00000635500.1:n.123del, NM_000277.2(PAH):c.155delT (p.Leu52Cysfs)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"The c.155delT (p.Leu52Cysfs) is a frameshift variant in exon 2 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in 1 individual with PKU (BH4 deficiency not excluded), who carried a second nonsense variant in PAH (PP4; PMID: 26666653 ). This variant is absent from population databases (PM2). In summary, this variant meets our criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4."	26666653	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267691/MONDO:0009861/006	0.9941	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103260378	125436	G	A	NM_000277.2(PAH):c.505C>T (p.Arg169Cys)	125436	CA267693	NM_000277.2:c.505C>T, NC_000012.12:g.102866600G>A, CM000674.2:g.102866600G>A, NC_000012.11:g.103260378G>A, CM000674.1:g.103260378G>A, NC_000012.10:g.101784508G>A, NG_008690.1:g.56003C>T, NG_008690.2:g.96811C>T, NM_000277.1:c.505C>T, XM_011538422.1:c.505C>T, NM_001354304.1:c.505C>T, XM_017019370.2:c.505C>T, NM_000277.3:c.505C>T, ENST00000307000.7:c.490C>T, ENST00000549111.5:n.601C>T, ENST00000551988.5:n.530+10862C>T, ENST00000553106.5:c.505C>T, NM_000277.2(PAH):c.505C>T (p.Arg169Cys)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PP3 [Unmet], PM3-Strong [MET]	The c.505C>T (p.Arg169Cys) PAH variant has been identified in at least 3 compound heterozygous probands with mild HPA to classic PKU, with at least 1 proband excluding BH4 deficiency (PMIDs: 28771436, 30050108, 30747360). It has been detected in trans with pathogenic variants Arg243Gln (ClinVar 591), Arg408Gln (ClinVar 577), and c.208_210del (ClinVar 102632). This variant occurs and a very low frequency of 0.00001194 in gnomAD. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Strong, PM2, PP4_Moderate.	30747360, 30050108, 28771436, 30050108	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA267693/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89622915	127667	T	C	NM_000314.6(PTEN):c.-1311T>C	127667	CA287476	NM_000314.6:c.-1311T>C, NC_000010.11:g.87863158T>C, CM000672.2:g.87863158T>C, NC_000010.10:g.89622915T>C, CM000672.1:g.89622915T>C, NC_000010.9:g.89612895T>C, NG_007466.2:g.4721T>C, LRG_311:g.4721T>C, NG_033079.1:g.5280A>G, NM_001126049.1:c.-671A>G, ENST00000371953.7:c.-1312T>C, ENST00000445946.3:c.-671A>G, NM_000314.6(PTEN):c.-1311T>C	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1 [MET]	"PTEN c.-1311T>C (NC_000010.10:g.89622915T>C) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.0142 (1.42%, 23/1618 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	2/6/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA287476/MONDO:0017623/003	0.0122	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89623492	127672	G	A	NM_000314.6(PTEN):c.-734G>A	127672	CA10602385	NM_000314.6:c.-734G>A, NC_000010.11:g.87863735G>A, CM000672.2:g.87863735G>A, NC_000010.10:g.89623492G>A, CM000672.1:g.89623492G>A, NC_000010.9:g.89613472G>A, NG_007466.2:g.5298G>A, LRG_311:g.5298G>A, NG_033079.1:g.4703C>T, NM_000314.5:c.-734G>A, NM_001304717.2:c.-215G>A, NM_001304718.1:c.-1439G>A, NM_000314.7:c.-734G>A, NM_001304717.5:c.-215G>A, NM_001304718.2:c.-1439G>A, ENST00000371953.7:c.-735G>A, ENST00000610634.1:c.-837G>A, NM_000314.6(PTEN):c.-734G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP2 [Unmet], PP3 [Unmet], PP4 [Unmet], PP1 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP5 [Unmet], BP7 [Unmet]	PTEN c.-734G>A (NC_000010.10:g.89623492G>A) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).No criteria currently apply to this variant.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10602385/MONDO:0017623/003	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89623428	127674	G	C	NM_000314.6(PTEN):c.-798G>C	127674	CA000581	NM_000314.6:c.-798G>C, NM_000314.5:c.-798G>C, NM_001304717.2:c.-279G>C, NM_001304718.1:c.-1503G>C, NM_000314.7:c.-798G>C, NM_001304717.5:c.-279G>C, NM_001304718.2:c.-1503G>C, ENST00000371953.7:c.-799G>C, ENST00000610634.1:c.-901G>C, NC_000010.11:g.87863671G>C, CM000672.2:g.87863671G>C, NC_000010.10:g.89623428G>C, CM000672.1:g.89623428G>C, NC_000010.9:g.89613408G>C, NG_007466.2:g.5234G>C, LRG_311:g.5234G>C, NG_033079.1:g.4767C>G, NM_000314.6(PTEN):c.-798G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [Unmet]	PTEN c.-798G>C (NC_000010.10:g.89623428G>C) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).No criteria currently apply to this variant.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000581/MONDO:0017623/003	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89623251	127685	G	C	NM_000314.6(PTEN):c.-975G>C	127685	CA000654	NM_000314.6:c.-975G>C, NM_000314.5:c.-975G>C, NM_001304717.2:c.-456G>C, NM_001304718.1:c.-1680G>C, ENST00000371953.7:c.-976G>C, ENST00000610634.1:c.-1078G>C, NC_000010.11:g.87863494G>C, CM000672.2:g.87863494G>C, NC_000010.10:g.89623251G>C, CM000672.1:g.89623251G>C, NC_000010.9:g.89613231G>C, NG_007466.2:g.5057G>C, LRG_311:g.5057G>C, NG_033079.1:g.4944C>G, NM_000314.6(PTEN):c.-975G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BP5 [MET], BS1 [MET], BS3 [Unmet], BS4 [Unmet]	PTEN c.-975G>C (g.89623251G>C) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.006 (0.6%, 21/3466 alleles) in the European (Finnish) subpopulation and 0.002 (0.2%, 30/14,976) in the European (Non-Finnish) subpopulation of the gnomAD cohort. (PMID 27535533)BP5: Variant found in multiple cases with alternate molecular basis for disease. (internal laboratory contributors SCV000187238.1, SCV000149489.5)	22171747, 22171747	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000654/MONDO:0017623/003	0.0122	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89725066	127687	CAGT	C	NM_000314.6(PTEN):c.1052_1054delTAG (p.Val351del)	127687	CA000271	NM_000314.6:c.1052_1054delTAG, NC_000010.11:g.87965312_87965314del, CM000672.2:g.87965312_87965314del, NC_000010.10:g.89725069_89725071del, CM000672.1:g.89725069_89725071del, NC_000010.9:g.89715049_89715051del, NG_007466.2:g.106874_106876del, LRG_311:g.106874_106876del, NM_000314.5:c.1052_1054del, NM_000314.6:c.1052_1054del, NM_001304717.2:c.1571_1573del, NM_001304718.1:c.461_463del, XM_006717926.2:c.1007_1009del, XM_011539982.1:c.956_958del, XR_945791.1:n.1622_1624del, NM_000314.7:c.1052_1054del, NM_001304717.5:c.1571_1573del, NM_001304718.2:c.461_463del, ENST00000371953.7:c.1052_1054del, NM_000314.6(PTEN):c.1052_1054delTAG (p.Val351del)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET]	"PTEN c.1052_1054delTAG (p.V351del) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533)."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	8/11/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000271/MONDO:0017623/003	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89624312	127692	A	G	NM_000314.6(PTEN):c.79+7A>G	127692	CA000580	NM_000314.6:c.79+7A>G, NM_000314.5:c.79+7A>G, NM_001304717.2:c.598+7A>G, NM_001304718.1:c.-627+7A>G, XM_006717926.2:c.79+7A>G, XM_011539981.1:c.79+7A>G, XR_945789.1:n.791+7A>G, XR_945790.1:n.791+7A>G, XR_945791.1:n.791+7A>G, NM_000314.7:c.79+7A>G, NM_001304717.5:c.598+7A>G, NM_001304718.2:c.-627+7A>G, ENST00000371953.7:c.79+7A>G, ENST00000462694.1:n.81+7A>G, ENST00000487939.1:n.100+7A>G, ENST00000610634.1:c.-24+7A>G, ENST00000618586.1:n.55A>G, NC_000010.11:g.87864555A>G, CM000672.2:g.87864555A>G, NC_000010.10:g.89624312A>G, CM000672.1:g.89624312A>G, NC_000010.9:g.89614292A>G, NG_007466.2:g.6117A>G, LRG_311:g.6117A>G, NG_033079.1:g.3883T>C, NM_000314.6(PTEN):c.79+7A>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP4 [Unmet], PP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [MET], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.79+7A>G (IVS1+7A>G) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS3: Intronic variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID 28677221)	25669429, 21659347, 28677221, 28677221	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	25/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000580/MONDO:0017623/003	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89720763	127696	G	A	NM_000314.6(PTEN):c.914G>A (p.Ser305Asn)	127696	CA000632	NM_000314.6:c.914G>A, NM_000314.5:c.914G>A, NM_001304717.2:c.1433G>A, NM_001304718.1:c.323G>A, XM_006717926.2:c.869G>A, XM_011539981.1:c.914G>A, XM_011539982.1:c.818G>A, XR_945791.1:n.1484G>A, NM_000314.7:c.914G>A, NM_001304717.5:c.1433G>A, NM_001304718.2:c.323G>A, ENST00000371953.7:c.914G>A, ENST00000472832.2:n.341G>A, NC_000010.11:g.87961006G>A, CM000672.2:g.87961006G>A, NC_000010.10:g.89720763G>A, CM000672.1:g.89720763G>A, NC_000010.9:g.89710743G>A, NG_007466.2:g.102568G>A, LRG_311:g.102568G>A, NM_000314.6(PTEN):c.914G>A (p.Ser305Asn)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.914G>A (p.S305N) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000632/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
16	68847240	127906	G	A	NM_004360.4(CDH1):c.1162G>A (p.Glu388Lys)	127906	CA157986	NM_004360.4:c.1162G>A, NM_004360.3:c.1162G>A, LRG_301t1:c.1162G>A, XM_011523488.1:c.427G>A, XM_011523489.1:c.427G>A, NM_001317184.1:c.1137+1074G>A, NM_001317185.1:c.-454G>A, NM_001317186.1:c.-658G>A, ENST00000261769.9:c.1162G>A, ENST00000422392.6:c.1137+1074G>A, ENST00000562836.5:n.1233G>A, ENST00000565810.1:n.206G>A, ENST00000566510.5:c.1006G>A, ENST00000566612.5:c.1162G>A, ENST00000611625.4:c.1162G>A, ENST00000612417.4:c.1162G>A, ENST00000621016.4:c.1162G>A, NC_000016.10:g.68813337G>A, CM000678.2:g.68813337G>A, NC_000016.9:g.68847240G>A, CM000678.1:g.68847240G>A, NC_000016.8:g.67404741G>A, NG_008021.1:g.81046G>A, LRG_301:g.81046G>A, NM_004360.4(CDH1):c.1162G>A (p.Glu388Lys)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BP2-Strong [MET], BS2 [MET], PM4 [Unmet], BP4 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.1162G>A (p.Glu388Lys) variant was observed in the homozygous state in an individual without a personal and/or family history of diffuse gastric cancer, lobular breast cancer (BP2_Strong; SCV000254804.3). The variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BP2_Strong, BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA157986/MONDO:0007648/007	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 0, 0] 	1	Uncertain Significance
16	68847375	127910	G	A	NM_004360.4(CDH1):c.1297G>A (p.Asp433Asn)	127910	CA288028	NM_004360.4:c.1297G>A, NM_004360.3:c.1297G>A, LRG_301t1:c.1297G>A, XM_011523488.1:c.562G>A, XM_011523489.1:c.562G>A, NM_001317184.1:c.1137+1209G>A, NM_001317185.1:c.-319G>A, NM_001317186.1:c.-523G>A, ENST00000261769.9:c.1297G>A, ENST00000422392.6:c.1137+1209G>A, ENST00000562836.5:n.1368G>A, ENST00000566510.5:c.1141G>A, ENST00000566612.5:c.1297G>A, ENST00000611625.4:c.1297G>A, ENST00000612417.4:c.1297G>A, ENST00000621016.4:c.1297G>A, NC_000016.10:g.68813472G>A, CM000678.2:g.68813472G>A, NC_000016.9:g.68847375G>A, CM000678.1:g.68847375G>A, NC_000016.8:g.67404876G>A, NG_008021.1:g.81181G>A, LRG_301:g.81181G>A, NM_004360.4(CDH1):c.1297G>A (p.Asp433Asn)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet]	"The c.1297G>A (p.Asp433Asn) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA288028/MONDO:0007648/007	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
16	68849506	127913	C	T	NM_004360.4(CDH1):c.1409C>T (p.Thr470Ile)	127913	CA151518	NM_004360.4:c.1409C>T, NM_004360.3:c.1409C>T, LRG_301t1:c.1409C>T, XM_011523488.1:c.674C>T, XM_011523489.1:c.674C>T, NM_001317184.1:c.1226C>T, NM_001317185.1:c.-140C>T, NM_001317186.1:c.-411C>T, ENST00000261769.9:c.1409C>T, ENST00000422392.6:c.1226C>T, ENST00000562836.5:n.1480C>T, ENST00000566510.5:c.*75C>T, ENST00000566612.5:c.1409C>T, ENST00000611625.4:c.1472C>T, ENST00000612417.4:c.1409C>T, ENST00000621016.4:c.1409C>T, NC_000016.10:g.68815603C>T, CM000678.2:g.68815603C>T, NC_000016.9:g.68849506C>T, CM000678.1:g.68849506C>T, NC_000016.8:g.67407007C>T, NG_008021.1:g.83312C>T, LRG_301:g.83312C>T, NM_004360.4(CDH1):c.1409C>T (p.Thr470Ile)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BP2-Strong [MET], BS2 [MET], PM4 [Unmet], BP4 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.1409C>T (p.Thr470Ile) variant was observed in trans with a known pathogenic CDH1 variant with phase confirmed (BP2_Strong; PMID: 9537325). This variant was observed in the homozygous state in at least 6 individuals without a personal and/or family history of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer (BP2_Strong; internal laboratory contributors). Additionally, this variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BP2_Strong, BS2."	9537325	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA151518/MONDO:0007648/007	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	3	Uncertain Significance
16	68835597	127919	G	A	NM_004360.4(CDH1):c.188G>A (p.Arg63Gln)	127919	CA288048	NM_004360.4:c.188G>A, NM_004360.3:c.188G>A, LRG_301t1:c.188G>A, XM_011523488.1:c.-548G>A, XM_011523489.1:c.-548G>A, NM_001317184.1:c.188G>A, NM_001317185.1:c.-1428G>A, NM_001317186.1:c.-1632G>A, ENST00000261769.9:c.188G>A, ENST00000422392.6:c.188G>A, ENST00000562836.5:n.259G>A, ENST00000564676.5:n.470G>A, ENST00000564745.1:n.183G>A, ENST00000566510.5:c.188G>A, ENST00000566612.5:c.188G>A, ENST00000611625.4:c.188G>A, ENST00000612417.4:c.188G>A, ENST00000621016.4:c.188G>A, NC_000016.10:g.68801694G>A, CM000678.2:g.68801694G>A, NC_000016.9:g.68835597G>A, CM000678.1:g.68835597G>A, NC_000016.8:g.67393098G>A, NG_008021.1:g.69403G>A, LRG_301:g.69403G>A, NM_004360.4(CDH1):c.188G>A (p.Arg63Gln)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP5 [Unmet], BP7 [Unmet], BS1 [MET], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [MET], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.188G>A (p.Arg63Gln) variant has an allele frequency of 0.00109 (0.11%, 6/5486 alleles) in the â€œOtherâ€ subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS1, BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA288048/MONDO:0007648/007	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
16	68863674	127925	G	A	NM_004360.4(CDH1):c.2413G>A (p.Asp805Asn)	127925	CA157966	NM_004360.4:c.2413G>A, NM_004360.3:c.2413G>A, LRG_301t1:c.2413G>A, XM_011523488.1:c.1678G>A, XM_011523489.1:c.1678G>A, NM_001317184.1:c.2230G>A, NM_001317185.1:c.865G>A, NM_001317186.1:c.448G>A, ENST00000261769.9:c.2413G>A, ENST00000422392.6:c.2230G>A, ENST00000562118.1:n.631G>A, ENST00000562836.5:n.2484G>A, ENST00000566510.5:c.*1079G>A, ENST00000566612.5:c.*653G>A, ENST00000611625.4:c.2476G>A, ENST00000612417.4:c.1853+3217G>A, ENST00000621016.4:c.1866-4432G>A, NC_000016.10:g.68829771G>A, CM000678.2:g.68829771G>A, NC_000016.9:g.68863674G>A, CM000678.1:g.68863674G>A, NC_000016.8:g.67421175G>A, NG_008021.1:g.97480G>A, LRG_301:g.97480G>A, NM_004360.4(CDH1):c.2413G>A (p.Asp805Asn)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [MET], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet]	The c.2413G>A (p.Asp805Asn) variant has an allele frequency of 0.00207 (0.21%, 21/10,148 alleles) in the Ashkenazi Jewish subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BA1.	24728327, 25980754, 23197654	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA157966/MONDO:0007648/007	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
16	68842734	127932	C	T	NM_004360.4(CDH1):c.670C>T (p.Arg224Cys)	127932	CA288074	NM_004360.4:c.670C>T, NM_004360.3:c.670C>T, LRG_301t1:c.670C>T, XM_011523488.1:c.-66C>T, XM_011523489.1:c.-66C>T, NM_001317184.1:c.670C>T, NM_001317185.1:c.-946C>T, NM_001317186.1:c.-1150C>T, ENST00000261769.9:c.670C>T, ENST00000422392.6:c.670C>T, ENST00000561751.1:n.437C>T, ENST00000562836.5:n.741C>T, ENST00000564676.5:n.952C>T, ENST00000566510.5:c.531+264C>T, ENST00000566612.5:c.670C>T, ENST00000567320.1:n.180C>T, ENST00000611625.4:c.670C>T, ENST00000612417.4:c.670C>T, ENST00000621016.4:c.670C>T, NC_000016.10:g.68808831C>T, CM000678.2:g.68808831C>T, NC_000016.9:g.68842734C>T, CM000678.1:g.68842734C>T, NC_000016.8:g.67400235C>T, NG_008021.1:g.76540C>T, LRG_301:g.76540C>T, NM_004360.4(CDH1):c.670C>T (p.Arg224Cys)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [MET], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.670C>T (p.Arg224Cys) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS2."	27582386	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA288074/MONDO:0007648/007	0.3246	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	3	Uncertain Significance
12	103246654	133314	G	C	NM_000277.2(PAH):c.781C>G (p.Arg261Gly)	133314	CA269921	NM_000277.2:c.781C>G, NC_000012.12:g.102852876G>C, CM000674.2:g.102852876G>C, NC_000012.11:g.103246654G>C, CM000674.1:g.103246654G>C, NC_000012.10:g.101770784G>C, NG_008690.1:g.69727C>G, NG_008690.2:g.110535C>G, NM_000277.1:c.781C>G, XM_011538422.1:c.781C>G, NM_001354304.1:c.781C>G, NM_000277.3:c.781C>G, ENST00000307000.7:c.766C>G, ENST00000549247.6:n.540C>G, ENST00000553106.5:c.781C>G, NM_000277.2(PAH):c.781C>G (p.Arg261Gly)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP3 [MET]	The c.781C>G (p.Arg261Gly) variant in PAH has not been reported in the literature (to our knowledge). This variant is at extremely low frequency in gnomAD (MAF=0.00006, PM2). A deleterious effect is predicted in SIFT, Polyphen-2, MutationTaster, and REVEL=0.962. In summary, this variant meets criteria to be classified as uncertain significance for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP3.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA269921/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68856080	133846	C	G	NM_004360.4(CDH1):c.1888C>G (p.Leu630Val)	133846	CA157951	NM_004360.4:c.1888C>G, NC_000016.10:g.68822177C>G, CM000678.2:g.68822177C>G, NC_000016.9:g.68856080C>G, CM000678.1:g.68856080C>G, NC_000016.8:g.67413581C>G, NG_008021.1:g.89886C>G, LRG_301:g.89886C>G, NM_004360.3:c.1888C>G, LRG_301t1:c.1888C>G, XM_011523488.1:c.1153C>G, XM_011523489.1:c.1153C>G, NM_001317184.1:c.1705C>G, NM_001317185.1:c.340C>G, NM_001317186.1:c.-78C>G, ENST00000261769.9:c.1888C>G, ENST00000422392.6:c.1705C>G, ENST00000562836.5:n.1959C>G, ENST00000566510.5:c.*554C>G, ENST00000566612.5:c.*128C>G, ENST00000611625.4:c.1951C>G, ENST00000612417.4:c.1830+58C>G, ENST00000621016.4:c.1865+23C>G, NM_004360.4(CDH1):c.1888C>G (p.Leu630Val)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	The c.1888C>G (p.Leu630Val) variant has an allele frequency of 0.00519 (0.52%, 98/18,866 alleles) in the East Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA157951/MONDO:0007648/007	0.1877	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	3	Uncertain Significance
16	68842668	133853	G	A	NM_004360.4(CDH1):c.604G>A (p.Val202Ile)	133853	CA163776	NM_004360.4:c.604G>A, NM_004360.3:c.604G>A, LRG_301t1:c.604G>A, XM_011523488.1:c.-132G>A, XM_011523489.1:c.-132G>A, NM_001317184.1:c.604G>A, NM_001317185.1:c.-1012G>A, NM_001317186.1:c.-1216G>A, ENST00000261769.9:c.604G>A, ENST00000422392.6:c.604G>A, ENST00000561751.1:n.371G>A, ENST00000562836.5:n.675G>A, ENST00000564676.5:n.886G>A, ENST00000566510.5:c.531+198G>A, ENST00000566612.5:c.604G>A, ENST00000567320.1:n.114G>A, ENST00000611625.4:c.604G>A, ENST00000612417.4:c.604G>A, ENST00000621016.4:c.604G>A, NC_000016.10:g.68808765G>A, CM000678.2:g.68808765G>A, NC_000016.9:g.68842668G>A, CM000678.1:g.68842668G>A, NC_000016.8:g.67400169G>A, NG_008021.1:g.76474G>A, LRG_301:g.76474G>A, NM_004360.4(CDH1):c.604G>A (p.Val202Ile)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	The c.604G>A (p.Val202Ile) variant has an allele frequency of 0.00354 (0.35%, 109/30,772 alleles) in the South Asian subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BA1.		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA163776/MONDO:0007648/007	0.4999	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	1	Uncertain Significance
16	68847303	133855	T	C	NM_004360.4(CDH1):c.1225T>C (p.Trp409Arg)	133855	CA157989	NM_004360.4:c.1225T>C, NM_004360.3:c.1225T>C, LRG_301t1:c.1225T>C, XM_011523488.1:c.490T>C, XM_011523489.1:c.490T>C, NM_001317184.1:c.1137+1137T>C, NM_001317185.1:c.-391T>C, NM_001317186.1:c.-595T>C, ENST00000261769.9:c.1225T>C, ENST00000422392.6:c.1137+1137T>C, ENST00000562836.5:n.1296T>C, ENST00000565810.1:n.269T>C, ENST00000566510.5:c.1069T>C, ENST00000566612.5:c.1225T>C, ENST00000611625.4:c.1225T>C, ENST00000612417.4:c.1225T>C, ENST00000621016.4:c.1225T>C, NC_000016.10:g.68813400T>C, CM000678.2:g.68813400T>C, NC_000016.9:g.68847303T>C, CM000678.1:g.68847303T>C, NC_000016.8:g.67404804T>C, NG_008021.1:g.81109T>C, LRG_301:g.81109T>C, NM_004360.4(CDH1):c.1225T>C (p.Trp409Arg)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.1225T>C (p. Trp409Arg) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA157989/MONDO:0007648/007	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	112884118	135112	A	G	NM_002834.4(PTPN11):c.53A>G (p.Asn18Ser)	135112	CA161776	NM_002834.4:c.53A>G, NC_000012.12:g.112446314A>G, CM000674.2:g.112446314A>G, NC_000012.11:g.112884118A>G, CM000674.1:g.112884118A>G, NC_000012.10:g.111368501A>G, NG_007459.1:g.32583A>G, LRG_614:g.32583A>G, NM_002834.3:c.53A>G, LRG_614t1:c.53A>G, NM_080601.1:c.53A>G, XM_006719526.1:c.53A>G, XM_006719527.1:c.53A>G, XM_011538613.1:c.53A>G, NM_001330437.1:c.53A>G, NM_080601.2:c.53A>G, XM_011538613.2:c.53A>G, XM_017019722.1:c.53A>G, ENST00000351677.6:c.53A>G, ENST00000392597.5:c.53A>G, ENST00000635625.1:n.53A>G, NM_002834.4(PTPN11):c.53A>G (p.Asn18Ser)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.53A>G (p.Asn18Ser) variant in the PTPN11 gene is 0.056% (15/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA161776/MONDO:0021060/004	0.025	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
16	68845757	136055	C	T	NM_004360.4(CDH1):c.1003C>T (p.Arg335Ter)	136055	CA166866	NM_004360.4:c.1003C>T, NM_004360.3:c.1003C>T, LRG_301t1:c.1003C>T, XM_011523488.1:c.268C>T, XM_011523489.1:c.268C>T, NM_001317184.1:c.1003C>T, NM_001317185.1:c.-613C>T, NM_001317186.1:c.-817C>T, ENST00000261769.9:c.1003C>T, ENST00000422392.6:c.1003C>T, ENST00000561751.1:n.625C>T, ENST00000562836.5:n.1074C>T, ENST00000566510.5:c.847C>T, ENST00000566612.5:c.1003C>T, ENST00000611625.4:c.1003C>T, ENST00000612417.4:c.1003C>T, ENST00000621016.4:c.1003C>T, NC_000016.10:g.68811854C>T, CM000678.2:g.68811854C>T, NC_000016.9:g.68845757C>T, CM000678.1:g.68845757C>T, NC_000016.8:g.67403258C>T, NG_008021.1:g.79563C>T, LRG_301:g.79563C>T, NM_004360.4(CDH1):c.1003C>T (p.Arg335Ter)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [MET], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PM4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PP1-Strong [MET]	"The c.1003C>T (p.Arg335*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1). This variant was found to co-segregate with disease in multiple affected family members, with >7 meioses observed across at least two families (PP1_Strong; PMID: 16061854, 22723466, 17522512). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1, PP1_Strong."	16061854, 17522512, 22723466, 16061854, 17522512, 22723466	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA166866/MONDO:0007648/007	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	25398229	138061	G	A	NM_004985.4(KRAS):c.90C>T (p.Asp30=)	138061	CA291858	NM_004985.4:c.90C>T, NM_033360.3:c.90C>T, XM_006719069.2:c.90C>T, XM_011520653.1:c.90C>T, XM_006719069.4:c.90C>T, XM_011520653.3:c.90C>T, ENST00000256078.8:c.90C>T, ENST00000311936.7:c.90C>T, ENST00000556131.1:c.90C>T, ENST00000557334.5:c.90C>T, NC_000012.12:g.25245295G>A, CM000674.2:g.25245295G>A, NC_000012.11:g.25398229G>A, CM000674.1:g.25398229G>A, NC_000012.10:g.25289496G>A, NG_007524.1:g.10626C>T, NM_004985.4(KRAS):c.90C>T (p.Asp30=)	KRAS	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.90C>T (p.Asp30=) variant in the KRAS gene is 0.0292% (5/6746) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA291858/MONDO:0021060/004	0.0122	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
19	4101261	138158	C	T	NM_030662.3(MAP2K2):c.546G>A (p.Ala182=)	138158	CA291993	NM_030662.3:c.546G>A, LRG_750t1:c.546G>A, XM_006722799.2:c.546G>A, XM_011528133.1:c.-25G>A, XM_017026989.1:c.546G>A, XM_017026990.1:c.546G>A, XM_017026991.1:c.546G>A, ENST00000262948.9:c.546G>A, ENST00000394867.8:c.255G>A, ENST00000593364.5:n.493G>A, ENST00000597008.5:n.147G>A, ENST00000597263.5:n.10G>A, ENST00000599345.1:n.816G>A, ENST00000601786.5:n.847G>A, ENST00000602167.5:n.266G>A, NC_000019.10:g.4101263C>T, CM000681.2:g.4101263C>T, NC_000019.9:g.4101261C>T, CM000681.1:g.4101261C>T, NC_000019.8:g.4052261C>T, NG_007996.1:g.27866G>A, LRG_750:g.27866G>A, NM_030662.3(MAP2K2):c.546G>A (p.Ala182=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.546G>A (p.Ala182=) variant in the MAP2K2 gene is 0.083% (7/3952) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA291993/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
19	4101032	138159	C	T	NM_030662.3(MAP2K2):c.690G>A (p.Thr230=)	138159	CA291996	NM_030662.3:c.690G>A, LRG_750t1:c.690G>A, XM_006722799.2:c.690G>A, XM_011528133.1:c.120G>A, XM_017026989.1:c.690G>A, XM_017026990.1:c.690G>A, XM_017026991.1:c.690G>A, ENST00000262948.9:c.690G>A, ENST00000394867.8:c.399G>A, ENST00000593364.5:n.637G>A, ENST00000597008.5:n.291G>A, ENST00000597263.5:n.154G>A, ENST00000599021.1:n.14G>A, ENST00000601786.5:n.991G>A, ENST00000602167.5:n.410G>A, NC_000019.10:g.4101034C>T, CM000681.2:g.4101034C>T, NC_000019.9:g.4101032C>T, CM000681.1:g.4101032C>T, NC_000019.8:g.4052032C>T, NG_007996.1:g.28095G>A, LRG_750:g.28095G>A, NM_030662.3(MAP2K2):c.690G>A (p.Thr230=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	The filtering allele frequency of the c.690G>A (p.Thr230=) variant in the MAP2K2 gene is 0.1273% for Latino chromosomes by the Exome Aggregation Consortium (3/642 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1).		None	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	15/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA291996/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
19	4099293	138161	C	T	NM_030662.3(MAP2K2):c.825G>A (p.Leu275=)	138161	CA291999	NM_030662.3:c.825G>A, NC_000019.10:g.4099295C>T, CM000681.2:g.4099295C>T, NC_000019.9:g.4099293C>T, CM000681.1:g.4099293C>T, NC_000019.8:g.4050293C>T, NG_007996.1:g.29834G>A, LRG_750:g.29834G>A, LRG_750t1:c.825G>A, XM_006722799.2:c.705+1724G>A, XM_011528133.1:c.255G>A, XM_017026989.1:c.825G>A, XM_017026990.1:c.705+1724G>A, ENST00000262948.9:c.825G>A, ENST00000394867.8:c.534G>A, ENST00000593364.5:n.772G>A, ENST00000595715.1:n.640G>A, ENST00000597263.5:n.169+1724G>A, ENST00000599021.1:n.29+1724G>A, ENST00000600584.5:n.1385G>A, ENST00000601786.5:n.1126G>A, NM_030662.3(MAP2K2):c.825G>A (p.Leu275=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.825G>A (p.Leu275=) variant in the MAP2K2 gene is 0.142% (14/5968) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA291999/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89725121	138835	T	C	NM_000314.6(PTEN):c.1104T>C (p.Asp368=)	138835	CA000293	NM_000314.6:c.1104T>C, NM_000314.5:c.1104T>C, NM_001304717.2:c.1623T>C, NM_001304718.1:c.513T>C, XM_006717926.2:c.1059T>C, XM_011539982.1:c.1008T>C, XR_945791.1:n.1674T>C, NM_000314.7:c.1104T>C, NM_001304717.5:c.1623T>C, NM_001304718.2:c.513T>C, ENST00000371953.7:c.1104T>C, NC_000010.11:g.87965364T>C, CM000672.2:g.87965364T>C, NC_000010.10:g.89725121T>C, CM000672.1:g.89725121T>C, NC_000010.9:g.89715101T>C, NG_007466.2:g.106926T>C, LRG_311:g.106926T>C, NM_000314.6(PTEN):c.1104T>C (p.Asp368=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP4 [MET], BS1 [MET], BP7 [MET]	"PTEN c.1104T>C (p.D368=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0057 (0.57%, 130/22,966 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/9/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000293/MONDO:0017623/003	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89623200	138836	C	A	NM_000314.6(PTEN):c.-1026C>A	138836	CA000105	NM_000314.6:c.-1026C>A, NM_000314.5:c.-1026C>A, NM_001304717.2:c.-507C>A, NM_001304718.1:c.-1731C>A, ENST00000371953.7:c.-1027C>A, ENST00000610634.1:c.-1129C>A, NC_000010.11:g.87863443C>A, CM000672.2:g.87863443C>A, NC_000010.10:g.89623200C>A, CM000672.1:g.89623200C>A, NC_000010.9:g.89613180C>A, NG_007466.2:g.5006C>A, LRG_311:g.5006C>A, NG_033079.1:g.4995G>T, NM_000314.6(PTEN):c.-1026C>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BS1 [MET], BS2-Supporting [MET], BP5 [MET]	"PTEN c.-1026C>A (NC_000010.10:g.89623200C>A) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.0056 (0.56%, 173/30,898 alleles) in the gnomAD cohort. (PMID 27535533)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000171228.5)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000171228.5)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	9/11/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000105/MONDO:0017623/003	0.0059	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89623323	138837	G	A	NM_000314.6(PTEN):c.-903G>A	138837	CA000628	NM_000314.6:c.-903G>A, NM_000314.5:c.-903G>A, NM_001304717.2:c.-384G>A, NM_001304718.1:c.-1608G>A, ENST00000371953.7:c.-904G>A, ENST00000610634.1:c.-1006G>A, NC_000010.11:g.87863566G>A, CM000672.2:g.87863566G>A, NC_000010.10:g.89623323G>A, CM000672.1:g.89623323G>A, NC_000010.9:g.89613303G>A, NG_007466.2:g.5129G>A, LRG_311:g.5129G>A, NG_033079.1:g.4872C>T, NM_000314.6(PTEN):c.-903G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1 [MET]	"PTEN c.-903G>A (NC_000010.10:g.89623323G>A) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.011 (1.1%, 343/30,808 alleles) in the gnomAD cohort. (PMID 27535533)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/9/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000628/MONDO:0017623/003	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
12	112939998	138843	G	A	NM_002834.4(PTPN11):c.1650G>A (p.Ala550=)	138843	CA292973	NM_002834.4:c.1650G>A, NC_000012.12:g.112502194G>A, CM000674.2:g.112502194G>A, NC_000012.11:g.112939998G>A, CM000674.1:g.112939998G>A, NC_000012.10:g.111424381G>A, NG_007459.1:g.88463G>A, LRG_614:g.88463G>A, NM_002834.3:c.1650G>A, LRG_614t1:c.1650G>A, XM_006719526.1:c.1662G>A, XM_006719527.1:c.1548G>A, XM_011538613.1:c.1659G>A, NM_001330437.1:c.1662G>A, XM_011538613.2:c.1659G>A, XM_017019722.1:c.1647G>A, ENST00000351677.6:c.1650G>A, ENST00000635625.1:n.1662G>A, NM_002834.4(PTPN11):c.1650G>A (p.Ala550=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1650G>A (p.Ala550=) variant in the PTPN11 gene is 0.067% (13/11548) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA292973/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	112724573	139104	C	T	NM_007373.3(SHOC2):c.457C>T (p.Leu153=)	139104	CA333154	NM_007373.3:c.457C>T, NC_000010.11:g.110964815C>T, CM000672.2:g.110964815C>T, NC_000010.10:g.112724573C>T, CM000672.1:g.112724573C>T, NC_000010.9:g.112714563C>T, NG_028922.1:g.50273C>T, LRG_753:g.50273C>T, NM_001269039.1:c.457C>T, LRG_753t1:c.457C>T, XM_011540216.1:c.-380-20813C>T, NM_001269039.2:c.457C>T, NM_001324336.1:c.457C>T, NM_001324337.1:c.457C>T, NR_136749.1:n.116-20813C>T, ENST00000265277.9:c.457C>T, ENST00000369452.8:c.457C>T, ENST00000489390.1:n.56-35600C>T, NM_007373.3(SHOC2):c.457C>T (p.Leu153=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.457C>T (p.Leu153=) variant in the SHOC2 gene is 1.574% (1104/66696) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA333154/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	112769023	139108	C	T	NM_007373.3(SHOC2):c.1302C>T (p.Asn434=)	139108	CA293482	NM_007373.3:c.1302C>T, NC_000010.11:g.111009265C>T, CM000672.2:g.111009265C>T, NC_000010.10:g.112769023C>T, CM000672.1:g.112769023C>T, NC_000010.9:g.112759013C>T, NG_028922.1:g.94723C>T, LRG_753:g.94723C>T, NM_001269039.1:c.1164C>T, LRG_753t1:c.1302C>T, XM_011540216.1:c.219C>T, NM_001269039.2:c.1164C>T, NM_001324336.1:c.1302C>T, NM_001324337.1:c.1302C>T, NR_136749.1:n.714C>T, ENST00000265277.9:c.1164C>T, ENST00000369452.8:c.1302C>T, ENST00000451838.1:n.672C>T, ENST00000489390.1:n.516C>T, NM_007373.3(SHOC2):c.1302C>T (p.Asn434=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP7 [MET], BP5 [MET], BA1 [MET], BP2 [Unmet], BP4 [MET]	"The c.1302C>T (p.Asn434=) variant in the SHOC2 gene has been identified in a patient with an alternate molecular basis for disease (BP5; ClinVar SCV000171633.12). The silent p.Asn434= variant is not predicted by MaxEntScan to impact splicing (BP7, BP4).The filtering allele frequency of the c.1302C>T (p.Asn434=) variant is 0.74% for African chromosomes by the Exome Aggregation Consortium (87/9772 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert panel for autosomal dominant RASopathy variants (BA1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5, BP4, BP7."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA293482/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	112771421	139110	A	G	NM_007373.3(SHOC2):c.1594A>G (p.Ser532Gly)	139110	CA293486	NM_007373.3:c.1594A>G, NM_001269039.1:c.1456A>G, LRG_753t1:c.1594A>G, XM_011540216.1:c.511A>G, NM_001269039.2:c.1456A>G, NM_001324336.1:c.1594A>G, NM_001324337.1:c.1594A>G, NR_136749.1:n.1006A>G, ENST00000265277.9:c.1456A>G, ENST00000369452.8:c.1594A>G, ENST00000451838.1:n.964A>G, ENST00000489390.1:n.808A>G, NC_000010.11:g.111011663A>G, CM000672.2:g.111011663A>G, NC_000010.10:g.112771421A>G, CM000672.1:g.112771421A>G, NC_000010.9:g.112761411A>G, NG_028922.1:g.97121A>G, LRG_753:g.97121A>G, NM_007373.3(SHOC2):c.1594A>G (p.Ser532Gly)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1594A>G (p.Ser532Gly) variant in the SHOC2 gene is 1.147% (138/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA293486/MONDO:0021060/004	0.0007	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	1	Uncertain Significance
2	39249922	139236	T	C	NM_005633.3(SOS1):c.1647A>G (p.Thr549=)	139236	CA293658	NM_005633.3:c.1647A>G, NC_000002.12:g.39022781T>C, CM000664.2:g.39022781T>C, NC_000002.11:g.39249922T>C, CM000664.1:g.39249922T>C, NC_000002.10:g.39103426T>C, NG_007530.1:g.102683A>G, LRG_754:g.102683A>G, LRG_754t1:c.1647A>G, XM_005264515.3:c.1647A>G, XM_011533060.1:c.1740A>G, XM_011533061.1:c.1740A>G, XM_011533062.1:c.1626A>G, XM_011533063.1:c.1623A>G, XM_011533064.1:c.1476A>G, XM_011533065.1:c.1740A>G, XM_011533066.1:c.582A>G, XM_005264515.4:c.1647A>G, XM_011533062.2:c.1626A>G, XM_011533064.2:c.1476A>G, ENST00000395038.6:c.1647A>G, ENST00000402219.6:c.1647A>G, ENST00000426016.5:c.1647A>G, NM_005633.3(SOS1):c.1647A>G (p.Thr549=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.1647A>G (p.Thr549=) variant in the SOS1 gene is 0.0251% (6/10398) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA293658/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89692854	139567	G	T	NM_000314.6(PTEN):c.338G>T (p.Ser113Ile)	139567	CA000405	NM_000314.6:c.338G>T, NC_000010.11:g.87933097G>T, CM000672.2:g.87933097G>T, NC_000010.10:g.89692854G>T, CM000672.1:g.89692854G>T, NC_000010.9:g.89682834G>T, NG_007466.2:g.74659G>T, LRG_311:g.74659G>T, NM_000314.5:c.338G>T, NM_001304717.2:c.857G>T, NM_001304718.1:c.-413G>T, XM_006717926.2:c.293G>T, XM_011539981.1:c.338G>T, XM_011539982.1:c.242G>T, XR_945789.1:n.1050G>T, XR_945790.1:n.1050G>T, XR_945791.1:n.1050G>T, NM_000314.7:c.338G>T, NM_001304717.5:c.857G>T, NM_001304718.2:c.-413G>T, ENST00000371953.7:c.338G>T, ENST00000498703.1:n.164G>T, ENST00000610634.1:c.236G>T, NM_000314.6(PTEN):c.338G>T (p.Ser113Ile)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], BA1 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.338G>T (p.S113I) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350, 25248401	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000405/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
10	89624325	140807	C	G	NM_000314.6(PTEN):c.79+20C>G	140807	CA000575	NM_000314.6:c.79+20C>G, NC_000010.11:g.87864568C>G, CM000672.2:g.87864568C>G, NC_000010.10:g.89624325C>G, CM000672.1:g.89624325C>G, NC_000010.9:g.89614305C>G, NG_007466.2:g.6130C>G, LRG_311:g.6130C>G, NG_033079.1:g.3870G>C, NM_000314.5:c.79+20C>G, NM_001304717.2:c.598+20C>G, NM_001304718.1:c.-627+20C>G, XM_006717926.2:c.79+20C>G, XM_011539981.1:c.79+20C>G, XR_945789.1:n.791+20C>G, XR_945790.1:n.791+20C>G, XR_945791.1:n.791+20C>G, NM_000314.7:c.79+20C>G, NM_001304717.5:c.598+20C>G, NM_001304718.2:c.-627+20C>G, ENST00000371953.7:c.79+20C>G, ENST00000462694.1:n.81+20C>G, ENST00000487939.1:n.100+20C>G, ENST00000610634.1:c.-24+20C>G, ENST00000618586.1:n.68C>G, NM_000314.6(PTEN):c.79+20C>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [MET], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.79+20C>G (IVS1+20C>G) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).BP7: Variant is intronic and at or beyond +7/-21, nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000575/MONDO:0017623/003	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
16	68863657	140871	C	G	NM_004360.4(CDH1):c.2396C>G (p.Pro799Arg)	140871	CA163797	NM_004360.4:c.2396C>G, NM_004360.3:c.2396C>G, LRG_301t1:c.2396C>G, XM_011523488.1:c.1661C>G, XM_011523489.1:c.1661C>G, NM_001317184.1:c.2213C>G, NM_001317185.1:c.848C>G, NM_001317186.1:c.431C>G, ENST00000261769.9:c.2396C>G, ENST00000422392.6:c.2213C>G, ENST00000562118.1:n.614C>G, ENST00000562836.5:n.2467C>G, ENST00000566510.5:c.*1062C>G, ENST00000566612.5:c.*636C>G, ENST00000611625.4:c.2459C>G, ENST00000612417.4:c.1853+3200C>G, ENST00000621016.4:c.1866-4449C>G, NC_000016.10:g.68829754C>G, CM000678.2:g.68829754C>G, NC_000016.9:g.68863657C>G, CM000678.1:g.68863657C>G, NC_000016.8:g.67421158C>G, NG_008021.1:g.97463C>G, LRG_301:g.97463C>G, NM_004360.4(CDH1):c.2396C>G (p.Pro799Arg)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.2396C>G (p.Pro799Arg) variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). There is no other supporting data that meet criteria for consideration. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: PM2."	19268661, 15173255, 22850631	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA163797/MONDO:0007648/007	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711873	141485	A	G	NM_000314.6(PTEN):c.493-2A>G	141485	CA000478	NM_000314.6:c.493-2A>G, NC_000010.11:g.87952116A>G, CM000672.2:g.87952116A>G, NC_000010.10:g.89711873A>G, CM000672.1:g.89711873A>G, NC_000010.9:g.89701853A>G, NG_007466.2:g.93678A>G, LRG_311:g.93678A>G, NM_000314.5:c.493-2A>G, NM_001304717.2:c.1012-2A>G, NM_001304718.1:c.-99-2A>G, XM_006717926.2:c.448-2A>G, XM_011539981.1:c.493-2A>G, XM_011539982.1:c.397-2A>G, XR_945789.1:n.1364-2A>G, XR_945790.1:n.1481-2A>G, XR_945791.1:n.1205-5737A>G, NM_000314.7:c.493-2A>G, NM_001304717.5:c.1012-2A>G, NM_001304718.2:c.-99-2A>G, ENST00000371953.7:c.493-2A>G, NM_000314.6(PTEN):c.493-2A>G	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM6-Strong [MET]	"PTEN c.493-2A>G (IVS5-2A>G) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000222118.9)PM2: Absent in large sequenced populations."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000478/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89624275	141654	CAA	C	NM_000314.6(PTEN):c.50_51delAA (p.Gln17Argfs)	141654	CA000167	NM_000314.6:c.50_51delAA, NM_000314.5:c.50_51del, NM_000314.6:c.50_51del, NM_001304717.2:c.569_570del, NM_001304718.1:c.-656_-655del, XM_006717926.2:c.50_51del, XM_011539981.1:c.50_51del, XR_945789.1:n.762_763del, XR_945790.1:n.762_763del, XR_945791.1:n.762_763del, NM_000314.7:c.50_51del, NM_001304717.5:c.569_570del, NM_001304718.2:c.-656_-655del, ENST00000371953.7:c.50_51del, ENST00000462694.1:n.52_53del, ENST00000487939.1:n.71_72del, ENST00000610634.1:c.-53_-52del, ENST00000618586.1:n.19_20del, NC_000010.11:g.87864519_87864520del, CM000672.2:g.87864519_87864520del, NC_000010.10:g.89624276_89624277del, CM000672.1:g.89624276_89624277del, NC_000010.9:g.89614256_89614257del, NG_007466.2:g.6081_6082del, LRG_311:g.6081_6082del, NG_033079.1:g.3918_3919del, NM_000314.6(PTEN):c.50_51delAA (p.Gln17Argfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PS4-Supporting [MET]	"PTEN c.50_51delAA (p.Q17RfsX26) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 20223021)"	20223021	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000167/MONDO:0017623/003	0.9878	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68847376	141810	A	G	NM_004360.4(CDH1):c.1298A>G (p.Asp433Gly)	141810	CA294197	NM_004360.4:c.1298A>G, NM_004360.3:c.1298A>G, LRG_301t1:c.1298A>G, XM_011523488.1:c.563A>G, XM_011523489.1:c.563A>G, NM_001317184.1:c.1137+1210A>G, NM_001317185.1:c.-318A>G, NM_001317186.1:c.-522A>G, ENST00000261769.9:c.1298A>G, ENST00000422392.6:c.1137+1210A>G, ENST00000562836.5:n.1369A>G, ENST00000566510.5:c.1142A>G, ENST00000566612.5:c.1298A>G, ENST00000611625.4:c.1298A>G, ENST00000612417.4:c.1298A>G, ENST00000621016.4:c.1298A>G, NC_000016.10:g.68813473A>G, CM000678.2:g.68813473A>G, NC_000016.9:g.68847376A>G, CM000678.1:g.68847376A>G, NC_000016.8:g.67404877A>G, NG_008021.1:g.81182A>G, LRG_301:g.81182A>G, NM_004360.4(CDH1):c.1298A>G (p.Asp433Gly)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BP2-Strong [MET], BS2 [MET], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.1298A>G (p.Asp433Gly) variant was observed at least twice in the homozygous state in individuals without a personal and/or family history of diffuse gastric cancer, signet ring cell tumor  or lobular breast cancer (BP2_Strong; SCV000253407.6). This variant has also been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring cell tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BP2_Strong, BS2."	23435907, 20921021	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA294197/MONDO:0007648/007	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89725078	142212	C	T	NM_000314.6(PTEN):c.1061C>T (p.Pro354Leu)	142212	CA000277	NM_000314.6:c.1061C>T, NC_000010.11:g.87965321C>T, CM000672.2:g.87965321C>T, NC_000010.10:g.89725078C>T, CM000672.1:g.89725078C>T, NC_000010.9:g.89715058C>T, NG_007466.2:g.106883C>T, LRG_311:g.106883C>T, NM_000314.5:c.1061C>T, NM_001304717.2:c.1580C>T, NM_001304718.1:c.470C>T, XM_006717926.2:c.1016C>T, XM_011539982.1:c.965C>T, XR_945791.1:n.1631C>T, NM_000314.7:c.1061C>T, NM_001304717.5:c.1580C>T, NM_001304718.2:c.470C>T, ENST00000371953.7:c.1061C>T, NM_000314.6(PTEN):c.1061C>T (p.Pro354Leu)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	PTEN c.1061C>T (p.Pro354Leu) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29706350, 21869887	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000277/MONDO:0017623/003	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89711902	142220	T	A	NM_000314.6(PTEN):c.520T>A (p.Tyr174Asn)	142220	CA000501	NM_000314.6:c.520T>A, NM_000314.5:c.520T>A, NM_001304717.2:c.1039T>A, NM_001304718.1:c.-72T>A, XM_006717926.2:c.475T>A, XM_011539981.1:c.520T>A, XM_011539982.1:c.424T>A, XR_945789.1:n.1391T>A, XR_945790.1:n.1508T>A, XR_945791.1:n.1205-5708T>A, NM_000314.7:c.520T>A, NM_001304717.5:c.1039T>A, NM_001304718.2:c.-72T>A, ENST00000371953.7:c.520T>A, NC_000010.11:g.87952145T>A, CM000672.2:g.87952145T>A, NC_000010.10:g.89711902T>A, CM000672.1:g.89711902T>A, NC_000010.9:g.89701882T>A, NG_007466.2:g.93707T>A, LRG_311:g.93707T>A, NM_000314.6(PTEN):c.520T>A (p.Tyr174Asn)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PP2 [MET], PS3 [MET]	PTEN c.520T>A (p.Y174N)PTEN c.520T>A (p.Y174N) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 10866302)PM2: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000501/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692830	142261	G	A	NM_000314.6(PTEN):c.314G>A (p.Cys105Tyr)	142261	CA000393	NM_000314.6:c.314G>A, NC_000010.11:g.87933073G>A, CM000672.2:g.87933073G>A, NC_000010.10:g.89692830G>A, CM000672.1:g.89692830G>A, NC_000010.9:g.89682810G>A, NG_007466.2:g.74635G>A, LRG_311:g.74635G>A, NM_000314.5:c.314G>A, NM_001304717.2:c.833G>A, NM_001304718.1:c.-437G>A, XM_006717926.2:c.269G>A, XM_011539981.1:c.314G>A, XM_011539982.1:c.218G>A, XR_945789.1:n.1026G>A, XR_945790.1:n.1026G>A, XR_945791.1:n.1026G>A, NM_000314.7:c.314G>A, NM_001304717.5:c.833G>A, NM_001304718.2:c.-437G>A, ENST00000371953.7:c.314G>A, ENST00000498703.1:n.140G>A, ENST00000610634.1:c.212G>A, NM_000314.6(PTEN):c.314G>A (p.Cys105Tyr)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [MET], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP4 [Unmet], PP1 [Unmet], PS4-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.314G>A (p.Cys105Tyr) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (internal laboratory contributor ClinVar Organization ID 26957)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor ClinVar Organization ID 26957)	10400993, 29706350, 15987703, 29706350, 15987703	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000393/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
16	68846147	142285	C	T	NM_004360.4(CDH1):c.1118C>T (p.Pro373Leu)	142285	CA167953	NM_004360.4:c.1118C>T, NC_000016.10:g.68812244C>T, CM000678.2:g.68812244C>T, NC_000016.9:g.68846147C>T, CM000678.1:g.68846147C>T, NC_000016.8:g.67403648C>T, NG_008021.1:g.79953C>T, LRG_301:g.79953C>T, NM_004360.3:c.1118C>T, LRG_301t1:c.1118C>T, XM_011523488.1:c.383C>T, XM_011523489.1:c.383C>T, NM_001317184.1:c.1118C>T, NM_001317185.1:c.-498C>T, NM_001317186.1:c.-702C>T, ENST00000261769.9:c.1118C>T, ENST00000422392.6:c.1118C>T, ENST00000562836.5:n.1189C>T, ENST00000565810.1:n.162C>T, ENST00000566510.5:c.962C>T, ENST00000566612.5:c.1118C>T, ENST00000611625.4:c.1118C>T, ENST00000612417.4:c.1118C>T, ENST00000621016.4:c.1118C>T, NM_004360.4(CDH1):c.1118C>T (p.Pro373Leu)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [MET], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.1118C>T (p.Pro373Leu) variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA167953/MONDO:0007648/007	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
10	89690790	142397	ACTTTT	A	NM_000314.6(PTEN):c.210-7_210-3del5	142397	CA059460	NM_000314.6:c.210-7_210-3delCTTTT, NM_000314.6:c.210-7_210-3del, NC_000010.11:g.87931039_87931043del, CM000672.2:g.87931039_87931043del, NC_000010.10:g.89690796_89690800del, CM000672.1:g.89690796_89690800del, NC_000010.9:g.89680776_89680780del, NG_007466.2:g.72601_72605del, LRG_311:g.72601_72605del, NM_000314.5:c.210-7_210-3del, NM_001304717.2:c.729-7_729-3del, NM_001304718.1:c.-541-7_-541-3del, XM_006717926.2:c.165-7_165-3del, XM_011539981.1:c.210-7_210-3del, XM_011539982.1:c.114-7_114-3del, XR_945789.1:n.922-7_922-3del, XR_945790.1:n.922-7_922-3del, XR_945791.1:n.922-7_922-3del, NM_000314.7:c.210-7_210-3del, NM_001304717.5:c.729-7_729-3del, NM_001304718.2:c.-541-7_-541-3del, ENST00000371953.7:c.210-7_210-3del, ENST00000498703.1:n.36-7_36-3del, ENST00000610634.1:c.108-7_108-3del, NM_000314.6(PTEN):c.210-7_210-3del5	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [MET], BS4 [Unmet], BS3 [MET]	PTEN c.210-7_210-3delCTTTT (IVS3-7_IVS3-3delCTTTT) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS1: Allele frequency of 0.00136 (0.14%, 14/10,306 alleles) in the Ashkenazi Jewish subpopulation of the gnomAD cohort. (PMID 27535533) BS3: Intronic OR synonymous variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID 28677221)	27978560, 22261759, 21659347, 15589575, 16287957, 11156385, 29360161, 26976419, 25669429, 25186627, 28677221, 27443514, 22995991, 28677221	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA059460/MONDO:0017623/003	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89720649	142423	A	T	NM_000314.6(PTEN):c.802-2A>T	142423	CA000591	NM_000314.6:c.802-2A>T, NC_000010.11:g.87960892A>T, CM000672.2:g.87960892A>T, NC_000010.10:g.89720649A>T, CM000672.1:g.89720649A>T, NC_000010.9:g.89710629A>T, NG_007466.2:g.102454A>T, LRG_311:g.102454A>T, NM_000314.5:c.802-2A>T, NM_001304717.2:c.1321-2A>T, NM_001304718.1:c.211-2A>T, XM_006717926.2:c.757-2A>T, XM_011539981.1:c.802-2A>T, XM_011539982.1:c.706-2A>T, XR_945791.1:n.1372-2A>T, NM_000314.7:c.802-2A>T, NM_001304717.5:c.1321-2A>T, NM_001304718.2:c.211-2A>T, ENST00000371953.7:c.802-2A>T, ENST00000472832.2:n.229-2A>T, NM_000314.6(PTEN):c.802-2A>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PS4-Supporting [MET]	"PTEN c.802-2A>T (IVS7-2A>T) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor(s), SCV000222230.9)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000591/MONDO:0017623/003	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692819	142681	C	CAAA	NM_000314.6(PTEN):c.304_306dupAAA (p.Lys102_Pro103insLys)	142681	CA169101	NM_000314.6:c.304_306dupAAA, NM_000314.5:c.304_306dup, NM_000314.6:c.304_306dup, NM_001304717.2:c.823_825dup, NM_001304718.1:c.-447_-445dup, XM_006717926.2:c.259_261dup, XM_011539981.1:c.304_306dup, XM_011539982.1:c.208_210dup, XR_945789.1:n.1016_1018dup, XR_945790.1:n.1016_1018dup, XR_945791.1:n.1016_1018dup, NM_000314.7:c.304_306dup, NM_001304717.5:c.823_825dup, NM_001304718.2:c.-447_-445dup, ENST00000371953.7:c.304_306dup, ENST00000498703.1:n.130_132dup, ENST00000610634.1:c.202_204dup, NC_000010.11:g.87933063_87933065dup, CM000672.2:g.87933063_87933065dup, NC_000010.10:g.89692820_89692822dup, CM000672.1:g.89692820_89692822dup, NC_000010.9:g.89682800_89682802dup, NG_007466.2:g.74625_74627dup, LRG_311:g.74625_74627dup, NM_000314.6(PTEN):c.304_306dupAAA (p.Lys102_Pro103insLys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET]	"PTEN c.304_306dupAAA (p.K102_P103insK) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533)."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	8/11/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA169101/MONDO:0017623/003	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68835596	156496	C	T	NM_004360.4(CDH1):c.187C>T (p.Arg63Ter)	156496	CA333496	NM_004360.4:c.187C>T, NM_004360.3:c.187C>T, LRG_301t1:c.187C>T, XM_011523488.1:c.-549C>T, XM_011523489.1:c.-549C>T, NM_001317184.1:c.187C>T, NM_001317185.1:c.-1429C>T, NM_001317186.1:c.-1633C>T, ENST00000261769.9:c.187C>T, ENST00000422392.6:c.187C>T, ENST00000562836.5:n.258C>T, ENST00000564676.5:n.469C>T, ENST00000564745.1:n.182C>T, ENST00000566510.5:c.187C>T, ENST00000566612.5:c.187C>T, ENST00000611625.4:c.187C>T, ENST00000612417.4:c.187C>T, ENST00000621016.4:c.187C>T, NC_000016.10:g.68801693C>T, CM000678.2:g.68801693C>T, NC_000016.9:g.68835596C>T, CM000678.1:g.68835596C>T, NC_000016.8:g.67393097C>T, NG_008021.1:g.69402C>T, LRG_301:g.69402C>T, NM_004360.4(CDH1):c.187C>T (p.Arg63Ter)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet], PP1 [Unmet], PP3 [Unmet], BS2 [Unmet], PS4-Supporting [MET], PM4 [Unmet], BP2 [Unmet], BP4 [Unmet], BA1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS1 [Unmet]	"The c.187C>T (p.Arg63*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). The variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 9751616). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2, PS4_Supporting."	9751616	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA333496/MONDO:0007648/007	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68863655	156497	TC	T	NM_004360.4(CDH1):c.2398delC (p.Arg800Alafs)	156497	CA281459	NM_004360.4:c.2398delC, NC_000016.10:g.68829756del, CM000678.2:g.68829756del, NC_000016.9:g.68863659del, CM000678.1:g.68863659del, NC_000016.8:g.67421160del, NG_008021.1:g.97465del, LRG_301:g.97465del, NM_004360.3:c.2398del, LRG_301t1:c.2398del, XM_011523488.1:c.1663del, XM_011523489.1:c.1663del, NM_001317184.1:c.2215del, NM_001317185.1:c.850del, NM_001317186.1:c.433del, NM_004360.4:c.2398del, ENST00000261769.9:c.2398del, ENST00000422392.6:c.2215del, ENST00000562118.1:n.616del, ENST00000562836.5:n.2469del, ENST00000566510.5:c.*1064del, ENST00000566612.5:c.*638del, ENST00000611625.4:c.2461del, ENST00000612417.4:c.1853+3202del, ENST00000621016.4:c.1866-4447del, NM_004360.4(CDH1):c.2398delC (p.Arg800Alafs)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP1 [MET], PP3 [Unmet], PM4 [Unmet], PVS1-Strong [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS4 [MET], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet]	"The c.2398delC (p.Arg800Alafs*16) variant is predicted to result in a premature stop codon that leads to a truncated protein. However, it is located within the nonsense mediated decay resistance region upstream of c.2506G>T (p.Glu836*) (PVS1_Strong). The variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID 17545690). This variant was also found to co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed (PP1; PMID: 17545690). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Strong, PM2, PS4, PP1."	17545690, 17545690, 18427545, 17545690	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA281459/MONDO:0007648/007	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68846166	156499	G	A	NM_004360.4(CDH1):c.1137G>A (p.Thr379=)	156499	CA186229	NM_004360.4:c.1137G>A, NM_004360.3:c.1137G>A, LRG_301t1:c.1137G>A, XM_011523488.1:c.402G>A, XM_011523489.1:c.402G>A, NM_001317184.1:c.1137G>A, NM_001317185.1:c.-479G>A, NM_001317186.1:c.-683G>A, ENST00000261769.9:c.1137G>A, ENST00000422392.6:c.1137G>A, ENST00000562836.5:n.1208G>A, ENST00000565810.1:n.181G>A, ENST00000566510.5:c.981G>A, ENST00000566612.5:c.1137G>A, ENST00000611625.4:c.1137G>A, ENST00000612417.4:c.1137G>A, ENST00000621016.4:c.1137G>A, NC_000016.10:g.68812263G>A, CM000678.2:g.68812263G>A, NC_000016.9:g.68846166G>A, CM000678.1:g.68846166G>A, NC_000016.8:g.67403667G>A, NG_008021.1:g.79972G>A, LRG_301:g.79972G>A, NM_004360.4(CDH1):c.1137G>A (p.Thr379=)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM2 [MET], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [MET], PS4 [MET], PS2 [Unmet], PVS1-Moderate [MET]	"The c.1137G>A p.(Thr379=) variant results in a G to non-G change at the last nucleotide of an exon (PVS1_Moderate).  The variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). There is also an RNA assay demonstrating abnormal out-of-frame transcript (PS3; PMID: 15831593). Additionally, this variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 15831593, 17545690, 17221870, 21681551, 27995193). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Moderate, PM2, PS3, PS4."	15831593, 18427545, 15831593, 18427545, 17221870, 15831593, 17545690, 21681551, 27995193	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA186229/MONDO:0007648/007	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763614	158604	A	G	NM_004004.5(GJB2):c.107T>C (p.Leu36Pro)	158604	CA172208	NM_004004.5:c.107T>C, NC_000013.11:g.20189475A>G, CM000675.2:g.20189475A>G, NC_000013.10:g.20763614A>G, CM000675.1:g.20763614A>G, NC_000013.9:g.19661614A>G, NG_008358.1:g.8501T>C, XM_011535049.1:c.107T>C, XM_011535049.2:c.107T>C, NM_004004.6:c.107T>C, ENST00000382844.1:c.107T>C, ENST00000382848.4:c.107T>C, NM_004004.5(GJB2):c.107T>C (p.Leu36Pro)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PVS1 [Unmet], PP3 [MET], PM2-Supporting [MET], BP4 [Unmet], BA1 [Unmet], PS1 [Unmet], PM5 [Unmet], PM3 [MET], BP7 [Unmet], BS1 [Unmet]	"The allele frequency of the p.Leu36Pro variant in the GJB2 gene is 0.01% (2/19954) of East Asian chromosomes by gnomAD, which is a low enough frequency to apply PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_Supporting). The REVEL computational prediction analysis tool produced a score of 0.945, which is above the threshold necessary to apply PP3. This variant has been detected in one patient with hearing loss in trans with 35delG (PM3; PMID:16125251). The variant has also been reported in three individuals with no pathogenic variant found in trans (PMIDs: 17666888, 26043044). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP3, PM3."	16125251, 26043044, 17666888	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA172208/MONDO:0019497/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	73572580	162956	G	A	NM_022124.5(CDH23):c.9566G>A (p.Arg3189Gln)	162956	CA175533	NM_022124.5:c.9566G>A, NM_001171933.1:c.2846G>A, NM_001171934.1:c.2846G>A, NM_001171935.1:c.257G>A, NM_001171936.1:c.257G>A, XM_006717940.2:c.9761G>A, XM_006717942.2:c.9695G>A, XM_011540039.1:c.9758G>A, XM_011540040.1:c.9755G>A, XM_011540041.1:c.9701G>A, XM_011540042.1:c.9671G>A, XM_011540043.1:c.9761G>A, XM_011540044.1:c.9626G>A, XM_011540045.1:c.9761G>A, XM_011540046.1:c.9221G>A, XM_011540047.1:c.8579G>A, XM_011540052.1:c.6089G>A, ENST00000224721.10:c.9581G>A, ENST00000398788.4:c.2846G>A, ENST00000475158.1:n.3102G>A, ENST00000619887.4:c.2846G>A, ENST00000622827.4:c.9566G>A, NC_000010.11:g.71812823G>A, CM000672.2:g.71812823G>A, NC_000010.10:g.73572580G>A, CM000672.1:g.73572580G>A, NC_000010.9:g.73242586G>A, NG_008835.1:g.420877G>A, NM_022124.5(CDH23):c.9566G>A (p.Arg3189Gln)	CDH23	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP4 [Unmet], PP1 [Unmet], BS2 [Unmet], PM2-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], PS2 [Unmet], PS4 [Unmet], PS3 [Unmet], PS1 [Unmet], PM1 [Unmet], PM3 [Unmet], PM4 [Unmet], PM5 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	The c.9566G>A (p.Arg3189Gln) variant in CDH23 has been identified in 1 heterozygous patient with sensorineural hearing loss (Partners LMM internal data, SCV000197429.4). The allele frequency of the variant is 0.023% (7/30608) of South Asian chromosomes by gnomAD, which is a low enough frequency to apply PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : PM2_Supporting.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA175533/MONDO:0019501/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
6	76599951	164639	C	T	NM_004999.3(MYO6):c.2836C>T (p.Arg946Cys)	164639	CA177354	NM_004999.3:c.2836C>T, NC_000006.12:g.75890234C>T, CM000668.2:g.75890234C>T, NC_000006.11:g.76599951C>T, CM000668.1:g.76599951C>T, NC_000006.10:g.76656671C>T, NG_009934.1:g.146043C>T, NG_009934.2:g.146042C>T, NM_001300899.1:c.2836C>T, XM_005248719.2:c.2836C>T, XM_005248720.2:c.2836C>T, XM_005248721.2:c.2836C>T, XM_005248722.2:c.2836C>T, XM_005248724.2:c.2836C>T, XM_005248726.2:c.2836C>T, XM_005248719.4:c.2836C>T, XM_005248720.4:c.2836C>T, XM_005248721.4:c.2836C>T, XM_005248722.4:c.2836C>T, XM_005248724.4:c.2836C>T, XM_005248726.4:c.2836C>T, XM_017010899.2:c.2836C>T, XM_024446447.1:c.2836C>T, XM_024446448.1:c.2836C>T, NM_004999.4:c.2836C>T, ENST00000369975.5:c.2836C>T, ENST00000369977.7:c.2836C>T, ENST00000369981.7:c.2836C>T, ENST00000369985.8:c.2836C>T, ENST00000430435.1:n.25C>T, ENST00000615563.4:c.2836C>T, ENST00000627432.2:c.2836C>T, NM_004999.3(MYO6):c.2836C>T (p.Arg946Cys)	MYO6	nonsyndromic genetic deafness	MONDO:0019497		Likely Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [MET], BS4 [Unmet]	"The filtering allele frequency of the p.Arg946Cys variant in the MYO6 gene is 0.095% (39/30776) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss (BS1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA177354/MONDO:0019497/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
11	121039471	165370	T	C	NM_005422.2(TECTA):c.5836T>C (p.Tyr1946His)	165370	CA178113	NM_005422.2:c.5836T>C, NM_005422.2:n.5836T>C, ENST00000264037.2:n.5836T>C, ENST00000392793.5:c.5836T>C, NC_000011.10:g.121168762T>C, CM000673.2:g.121168762T>C, NC_000011.9:g.121039471T>C, CM000673.1:g.121039471T>C, NC_000011.8:g.120544681T>C, NG_011633.1:g.71097T>C, NM_005422.2(TECTA):c.5836T>C (p.Tyr1946His)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Likely Benign	PP3 [MET], BS1 [MET]	The filtering allele frequency of the c.5836T>C (p.Tyr1946His) variant in the TECTA gene is 0.495% for Ashkenazi Jewish chromosomes by gnomAD (64/10370 with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (HL EP) for autosomal recessive hearing loss variants (BS1). The REVEL computational prediction analysis tool produced a score of 0.8, which is above the threshold necessary to apply PP3. The HL EP allows classification of variants as likely benign with only BS1 if no other criteria are in conflict. The HL EP reviewed the conflicting evidence (PP3) and felt it did not override the Likely Benign classification in this case since computational scores are error prone, especially when predicting pathogenicity. In summary, the HL EP classified this variant as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1, PP3.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA178113/MONDO:0019497/005	0.3246	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	215848748	166435	T	C	NM_206933.2(USH2A):c.12505A>G (p.Thr4169Ala)	166435	CA179513	NM_206933.2:c.12505A>G, NM_206933.3:c.12505A>G, ENST00000307340.7:c.12505A>G, NC_000001.11:g.215675406T>C, CM000663.2:g.215675406T>C, NC_000001.10:g.215848748T>C, CM000663.1:g.215848748T>C, NC_000001.9:g.213915371T>C, NG_009497.1:g.752991A>G, NM_206933.2(USH2A):c.12505A>G (p.Thr4169Ala)	USH2A	Usher syndrome type 2	MONDO:0016484	Autosomal recessive inheritance	Likely Benign	PP3 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [MET], BS1 [MET]	The filtering allele frequency of the p.Thr4169Ala variant in the USH2A gene is 0.32% for African chromosomes by gnomAD (82/24940 with 95% CI) (BS1). Computational predictors for the variant suggest no impact on the gene or gene product (REVEL score: 0.207) (BP4). Of note, this variant was reported in 4 patients with Usher syndrome (PMID:28041643) though without any convincing evidence for pathogenicity (PM3 not met). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss Expert Panel: BS1 and BP4	28041643	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA179513/MONDO:0016484/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	216258168	166499	T	C	NM_206933.2(USH2A):c.5039A>G (p.Lys1680Arg)	166499	CA179559	NM_206933.2:c.5039A>G, NC_000001.11:g.216084826T>C, CM000663.2:g.216084826T>C, NC_000001.10:g.216258168T>C, CM000663.1:g.216258168T>C, NC_000001.9:g.214324791T>C, NG_009497.1:g.343571A>G, NR_125992.1:n.266-1896T>C, NR_125993.1:n.137-1896T>C, NM_206933.3:c.5039A>G, ENST00000307340.7:c.5039A>G, ENST00000463147.1:n.283A>G, ENST00000481786.1:n.281A>G, NM_206933.2(USH2A):c.5039A>G (p.Lys1680Arg)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], PM2-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	"The c.5039A>G (p.Lys1680Arg) variant in USH2A has been observed in the heterozygous state in one individual with hearing loss (PS4 not met; Partners LMM ClinVar SCV000201911.4). The allele frequency of the p.Lys1680Arg variant is 0.05% (20/34286) of Latino chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P).  In summary, this variant meets criteria to be classified as a variant of uncertain clinical significance for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA179559/MONDO:0019501/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
1	216348710	166504	C	CT	NM_206933.2(USH2A):c.4510dupA (p.Arg1504Lysfs)	166504	CA273289	NM_206933.2:c.4510_4511insA, NM_206933.2:c.4510dupA, NM_007123.5:c.4510dup, NM_206933.2:c.4510dup, NM_206933.3:c.4510dup, ENST00000307340.7:c.4510dup, ENST00000366942.3:c.4510dup, NC_000001.11:g.216175371dup, CM000663.2:g.216175371dup, NC_000001.10:g.216348713dup, CM000663.1:g.216348713dup, NC_000001.9:g.214415336dup, NG_009497.1:g.253028dup, NM_206933.2(USH2A):c.4510dupA (p.Arg1504Lysfs)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [MET], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS4 [Unmet], PS3 [Unmet], PS2 [Unmet], PM3-Strong [MET], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.4510dupA (p.Arg1504LysX26) variant in USH2A is predicted to cause a premature stop codon in biologically-relevant-exon 21/72 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected in 2 patients with hearing loss in trans with 2 different pathogenic variants (PM3_S; PMID:22135276). The allele frequency of the p.Arg1504LysX26 variant in the USH2A gene is 0.003% (3/111138) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). At least one patient with a variant in this gene displayed features of retinitis pigmentosa (PP4; PMID: 22135276). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PVS1, PM3_S, PM2, PP4."	22135276, 10729113, 15325563, 28041643, 22135276	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	10/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA273289/MONDO:0019501/005	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
11	76890889	177732	G	A	NM_000260.3(MYO7A):c.2476G>A (p.Ala826Thr)	177732	CA180669	NM_000260.3:c.2476G>A, NC_000011.10:g.77179843G>A, CM000673.2:g.77179843G>A, NC_000011.9:g.76890889G>A, CM000673.1:g.76890889G>A, NC_000011.8:g.76568537G>A, NG_009086.1:g.56580G>A, NM_001127179.2:c.2476G>A, NM_001127180.1:c.2476G>A, XM_005274012.2:c.2476G>A, XM_006718558.2:c.2476G>A, XM_006718559.2:c.2476G>A, XM_006718560.2:c.2476G>A, XM_006718561.2:c.2476G>A, XM_011545044.1:c.2476G>A, XM_011545045.1:c.2476G>A, XM_011545046.1:c.2443G>A, XM_011545047.1:c.2476G>A, XM_011545048.1:c.2368-531G>A, XM_011545049.1:c.2245G>A, XM_011545050.1:c.2218G>A, XM_011545051.1:c.2476G>A, XM_011545052.1:c.2476G>A, XR_949938.1:n.2796G>A, XR_949941.1:n.2796G>A, XR_949942.1:n.2798G>A, XR_949943.1:n.2798G>A, XM_011545044.2:c.2476G>A, XM_011545046.2:c.2566G>A, XM_011545050.2:c.2218G>A, XM_017017778.1:c.2566G>A, XM_017017779.1:c.2566G>A, XM_017017780.1:c.2566G>A, XM_017017781.1:c.2566G>A, XM_017017782.1:c.2566G>A, XM_017017783.1:c.2566G>A, XM_017017784.1:c.2566G>A, XM_017017785.1:c.2335G>A, XM_017017786.1:c.2566G>A, XM_017017787.1:c.2566G>A, XM_017017788.1:c.2566G>A, XR_001747885.1:n.2581G>A, XR_001747886.1:n.2581G>A, XR_001747887.1:n.2581G>A, XR_001747888.1:n.2581G>A, XR_001747889.1:n.2581G>A, NM_000260.4:c.2476G>A, ENST00000409619.6:c.2443G>A, ENST00000409709.7:c.2476G>A, ENST00000409893.5:c.2476G>A, ENST00000458169.2:n.19G>A, ENST00000458637.6:c.2476G>A, ENST00000481328.7:n.19G>A, ENST00000620575.4:c.2476G>A, NM_000260.3(MYO7A):c.2476G>A (p.Ala826Thr)	MYO7A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	BS2 [Unmet], PP3 [Unmet], PP1 [MET], PP4 [MET], BP4 [Unmet], BA1 [MET], PS1 [Unmet], PS4 [Unmet], PM5 [Unmet], PM3 [MET]	"The c.2476G>A (p.Ala826Thr) variant in MYO7A has been detected in 2 patients with Usher syndrome in trans with pathogenic variants, and has been observed as homozygous in at least 9 cases (PM3; PMID:27460420, 29490346, 23770805, 22135276, 18181211, 9382091). It has been reported to segregate with Usher syndrome in at least 12 family members (PP1_Strong; 23770805, 9382091). In most of these cases, the patients were documented to have both hearing loss and retinitis pigmentosa (PP4; PMID:27460420, 29490346, 23770805, 22135276, 9382091). The filtering allele frequency of the p.Ala826Thr variant in the MYO7A gene is 0.55% for South Asian chromosomes by gnomAD, including 1 homozygous observation (144/22680 with 95% CI) and this variant is not statistically enriched in cohorts of Usher (0.8%; Fisherâ€™s exact p value =0.3262) when compared to the South Asian population in gnomAD (0.55%) (PMID:27460420, 29490346, 23770805, 22135276, 18181211, 9382091). Due to the lack of adequately large case-control analyses in the South Asian population, the ClinGen Hearing Loss Expert Panel believes that the evidence for this variant is inconclusive. In summary, this variant meets criteria to be classified as uncertain significance for autosomal recessive Usher syndrome based on the HL EP-specified ACMG/AMP criteria applied: BA1, PM3, PP1, PP4."	23770805, 9382091, 23770805, 9382091, 27460420, 29490346, 22135276, 18181211	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA180669/MONDO:0019501/005	0.025	Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
1	215824001	177913	C	T	NM_206933.2(USH2A):c.14276G>A (p.Gly4759Glu)	177913	CA180987	NM_206933.2:c.14276G>A, NM_206933.3:c.14276G>A, ENST00000307340.7:c.14276G>A, NC_000001.11:g.215650659C>T, CM000663.2:g.215650659C>T, NC_000001.10:g.215824001C>T, CM000663.1:g.215824001C>T, NC_000001.9:g.213890624C>T, NG_009497.1:g.777738G>A, NM_206933.2(USH2A):c.14276G>A (p.Gly4759Glu)	USH2A	Usher syndrome type 2A	MONDO:0010169	Autosomal recessive inheritance	Likely Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP1 [Unmet], PP4 [Unmet], PP3 [Unmet], BS2 [Unmet], BA1 [Unmet], BP2 [Unmet], BP4 [MET], BP3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PS1 [Unmet], PM3 [Unmet], PM1 [Unmet], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [MET], BS4 [Unmet]	"The c.14276G>A (p.Gly4759Glu) variant has been detected in at least 4 heterozygous individuals with clinical features of hearing loss or retinitis pigmentosa (PS4/PM3 not met; Partners LMM internal data, PMID 28041643). However, the filtering allele frequency (the lower threshold of the 95% CI of 102/24022) of the p.Gly4759Glu variant in the USH2A gene is 0.425% for African chromosomes by gnomAD, which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1)."	28041643, 28041643	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA180987/MONDO:0010169/005	0.3246	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	2	Uncertain Significance
11	120984338	178532	A	G	NM_005422.2(TECTA):c.701A>G (p.Gln234Arg)	178532	CA182505	NM_005422.2:c.701A>G, NC_000011.10:g.121113629A>G, CM000673.2:g.121113629A>G, NC_000011.9:g.120984338A>G, CM000673.1:g.120984338A>G, NC_000011.8:g.120489548A>G, NG_011633.1:g.15964A>G, NM_005422.2:n.701A>G, ENST00000264037.2:n.701A>G, ENST00000392793.5:c.701A>G, NM_005422.2(TECTA):c.701A>G (p.Gln234Arg)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Likely Benign	PM2 [Unmet], PVS1 [Unmet], PP3 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PM4 [Unmet], BS1 [MET]	"The filtering allele frequency of the c.701A>G (p.Gln234Arg) variant in the TECTA gene is 0.37% (104/23994) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA182505/MONDO:0019497/005	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
11	121008285	178538	C	T	NM_005422.2(TECTA):c.3097C>T (p.Arg1033Trp)	178538	CA182517	NM_005422.2:c.3097C>T, NM_005422.2:n.3097C>T, ENST00000264037.2:n.3097C>T, ENST00000392793.5:c.3097C>T, NC_000011.10:g.121137576C>T, CM000673.2:g.121137576C>T, NC_000011.9:g.121008285C>T, CM000673.1:g.121008285C>T, NC_000011.8:g.120513495C>T, NG_011633.1:g.39911C>T, NM_005422.2(TECTA):c.3097C>T (p.Arg1033Trp)	TECTA	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Likely Benign	PM2 [Unmet], PVS1 [Unmet], PP3 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM3 [Unmet], BP7 [Unmet], BS1 [MET]	The filtering allele frequency (the lower threshold of the 95% CI of 88/24956) of the p.Arg1033Trp variant in the TECTA gene is 0.29% for African chromosomes by gnomAD, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BS1). The p.Arg1033Trp variant has been identified in one hearing loss patient who carries a second TECTA variant, p.Gln234Arg, that has previously been classified as likely benign by the HL VCEP (PMID 26969326, SCV000840522.3). The variant has also been observed by Partners LMM in one homozygous patient, two heterozygous patients, and two compound heterozygous patients who also carry one or two pathogenic or VUS favor-pathogenic variants. These cases are inconclusive (SCV000204966.4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1.	26969326, 26969326	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA182517/MONDO:0019497/005	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
11	121008680	178539	C	T	NM_005422.2(TECTA):c.3492C>T (p.Thr1164=)	178539	CA182519	NM_005422.2:c.3492C>T, NM_005422.2:n.3492C>T, ENST00000264037.2:n.3492C>T, ENST00000392793.5:c.3492C>T, NC_000011.10:g.121137971C>T, CM000673.2:g.121137971C>T, NC_000011.9:g.121008680C>T, CM000673.1:g.121008680C>T, NC_000011.8:g.120513890C>T, NG_011633.1:g.40306C>T, NM_005422.2(TECTA):c.3492C>T (p.Thr1164=)	TECTA	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Likely Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BP4 [MET], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PS1 [Unmet], PM3 [Unmet], PM1 [Unmet], PM4 [Unmet], PM5 [Unmet], BP7 [MET], BP5 [Unmet], BS1 [MET], BS4 [Unmet]	The filtering allele frequency of the c.3492C>T (p.Thr1164=) variant in the TECTA gene is 0.423% for African chromosomes by gnomAD (123/23960) with 95% CI), which is a high enough frequency to be classified as likely benign based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss variants (BS1). The silent p.Thr1164= variant in TECTA is not predicted by MaxEntScan to impact splicing (BP7, BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1, BP7, BP4.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA182519/MONDO:0019497/005	0.4999	VUS	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
11	120996243	178638	C	T	NM_005422.2(TECTA):c.1436C>T (p.Pro479Leu)	178638	CA182711	NM_005422.2:c.1436C>T, NC_000011.10:g.121125534C>T, CM000673.2:g.121125534C>T, NC_000011.9:g.120996243C>T, CM000673.1:g.120996243C>T, NC_000011.8:g.120501453C>T, NG_011633.1:g.27869C>T, NM_005422.2:n.1436C>T, ENST00000264037.2:n.1436C>T, ENST00000392793.5:c.1436C>T, NM_005422.2(TECTA):c.1436C>T (p.Pro479Leu)	TECTA	nonsyndromic genetic deafness	MONDO:0019497		Benign	BA1 [MET]	"The filtering allele frequency of the c.1436C>T (p.Pro479Leu) variant in the TECTA gene is 0.63% (219/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss variants (BA1)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	17/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA182711/MONDO:0019497/005	0.025	Likely Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
3	12641168	178666	AAAGGGAGGGCCCC	A	NM_002880.3(RAF1):c.1108+9_1108+21delGGGGCCCTCCCTT	178666	CA182757	NM_002880.3:c.1108+9_1108+21del, NM_002880.3:c.1108+9_1108+21delGGGGCCCTCCCTT, NC_000003.12:g.12599673_12599685del, CM000665.2:g.12599673_12599685del, NC_000003.11:g.12641172_12641184del, CM000665.1:g.12641172_12641184del, NC_000003.10:g.12616172_12616184del, NG_007467.1:g.69498_69510del, LRG_413:g.69498_69510del, LRG_413t1:c.1108+9_1108+21del, XM_005265355.1:c.1108+9_1108+21del, XM_005265357.1:c.1009+9_1009+21del, XM_005265358.3:c.865+9_865+21del, XM_005265359.3:c.766+9_766+21del, XM_005265360.1:c.1108+9_1108+21del, XM_011533974.1:c.1108+9_1108+21del, XM_011533975.1:c.865+9_865+21del, NM_001354689.1:c.1168+9_1168+21del, NM_001354690.1:c.1108+9_1108+21del, NM_001354691.1:c.865+9_865+21del, NM_001354692.1:c.865+9_865+21del, NM_001354693.1:c.1009+9_1009+21del, NM_001354694.1:c.925+9_925+21del, NM_001354695.1:c.766+9_766+21del, NR_148940.1:n.1523+9_1523+21del, NR_148941.1:n.1523+9_1523+21del, NR_148942.1:n.1521+9_1521+21del, XM_011533974.3:c.1108+9_1108+21del, XM_017006966.1:c.1009+9_1009+21del, XR_001740227.1:n.1340+9_1340+21del, ENST00000251849.8:c.1108+9_1108+21del, ENST00000423275.5:c.*785+9_*785+21del, ENST00000432427.2:n.745+9_745+21del, ENST00000442415.6:c.1168+9_1168+21del, ENST00000460610.1:n.65+9_65+21del, ENST00000465826.5:n.352+9_352+21del, NM_002880.3(RAF1):c.1108+9_1108+21delGGGGCCCTCCCTT	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BP7 [MET], BP5 [MET], BA1 [MET]	"The c.1108+9_1108+21del variant in the RAF1 gene has been identified in a patient with an alternate molecular basis for disease (BP5; GeneDx, Partners LMM internal data; GTR Lab ID's: 26957, 21766; ClinVar SCV000205113.4, SCV000209007.2). This variant is a synonymous (silent) variant at a nucleotide that is not highly conserved and is not predicted to impact splicing (BP7). The filtering allele frequency of the c.1108+9_1108+21del variant in the RAF1 gene is 0.0637% (54/66698) for European (Non-Finnish) chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel for autosomal dominant RASopathy variants (BA1). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BA1, BP5, BP7."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA182757/MONDO:0021060/004	0.0059	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
6	76538307	178957	C	T	NM_004999.3(MYO6):c.238C>T (p.Arg80Ter)	178957	CA183381	NM_004999.3:c.238C>T, NC_000006.12:g.75828590C>T, CM000668.2:g.75828590C>T, NC_000006.11:g.76538307C>T, CM000668.1:g.76538307C>T, NC_000006.10:g.76595027C>T, NG_009934.1:g.84399C>T, NG_009934.2:g.84398C>T, NM_001300899.1:c.238C>T, XM_005248719.2:c.238C>T, XM_005248720.2:c.238C>T, XM_005248721.2:c.238C>T, XM_005248722.2:c.238C>T, XM_005248724.2:c.238C>T, XM_005248726.2:c.238C>T, XM_005248719.4:c.238C>T, XM_005248720.4:c.238C>T, XM_005248721.4:c.238C>T, XM_005248722.4:c.238C>T, XM_005248724.4:c.238C>T, XM_005248726.4:c.238C>T, XM_017010899.2:c.238C>T, XM_024446447.1:c.238C>T, XM_024446448.1:c.238C>T, NM_004999.4:c.238C>T, ENST00000369975.5:c.238C>T, ENST00000369977.7:c.238C>T, ENST00000369981.7:c.238C>T, ENST00000369985.8:c.238C>T, ENST00000615563.4:c.238C>T, ENST00000627432.2:c.238C>T, NM_004999.3(MYO6):c.238C>T (p.Arg80Ter)	MYO6	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP4 [Unmet], PP1 [Unmet], PP3 [Unmet], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [Unmet], PS2 [Unmet], PS4 [Unmet], PS3 [Unmet], PS1 [Unmet], PM3 [Unmet], PM1 [Unmet], PM5 [Unmet], PM4 [Unmet], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet]	The p.Arg80Ter variant in MYO6 is predicted to cause a premature stop codon in biologically-relevant-exon 4 of a total of 35 exons, and is expected to lead to a truncated or absent protein. Loss of function in MYO6 is an established disease mechanism for autosomal dominant hearing loss (PVS1). The allele frequency of this variant is 0.0009% (1/111322) of European chromosomes by the Genome Aggregation Database ( http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal dominant hearing loss (PM2).  In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant nonsyndromic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: (PVS1, PM2).		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	11/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA183381/MONDO:0019497/005	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	216061814	179542	C	T	NM_206933.2(USH2A):c.8177G>A (p.Gly2726Glu)	179542	CA184631	NM_206933.2:c.8177G>A, NM_206933.3:c.8177G>A, ENST00000307340.7:c.8177G>A, NC_000001.11:g.215888472C>T, CM000663.2:g.215888472C>T, NC_000001.10:g.216061814C>T, CM000663.1:g.216061814C>T, NC_000001.9:g.214128437C>T, NG_009497.1:g.539925G>A, NM_206933.2(USH2A):c.8177G>A (p.Gly2726Glu)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	The p.Gly2726Glu variant in USH2A was identified in 0.003% (3/111282) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel autosomal recessive hearing loss (PM2). In summary, the clinical significance of this variant is uncertain. ACMG/AMG criteria applied: PM2.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA184631/MONDO:0019501/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
7	140501333	180784	A	G	NM_004333.4(BRAF):c.739T>C (p.Phe247Leu)	180784	CA295904	NM_004333.4:c.739T>C, NC_000007.14:g.140801533A>G, CM000669.2:g.140801533A>G, NC_000007.13:g.140501333A>G, CM000669.1:g.140501333A>G, NC_000007.12:g.140147802A>G, NG_007873.3:g.128232T>C, LRG_299:g.128232T>C, LRG_299t1:c.739T>C, XM_005250045.1:c.739T>C, XM_005250046.1:c.739T>C, XM_011516529.1:c.739T>C, XM_011516530.1:c.739T>C, XR_242190.1:n.747T>C, XR_927520.1:n.747T>C, XR_927521.1:n.747T>C, XR_927522.1:n.747T>C, XR_927523.1:n.747T>C, NM_001354609.1:c.739T>C, NM_004333.5:c.739T>C, NR_148928.1:n.1044T>C, XM_017012558.1:c.739T>C, XM_017012559.1:c.739T>C, XR_001744857.1:n.747T>C, XR_001744858.1:n.747T>C, ENST00000288602.10:c.739T>C, ENST00000497784.1:n.774T>C, NM_004333.4(BRAF):c.739T>C (p.Phe247Leu)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Pathogenic	BS2 [Unmet], PP1 [Unmet], PP2 [MET], PP3 [MET], PM1 [MET], PM4 [Unmet], PM5 [Unmet], PS3 [MET], PS2 [Unmet], PS4 [Unmet], PS1 [MET], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM2 [MET], PM6 [MET], BP2 [Unmet], BP3 [Unmet], BP1 [Unmet], BP4 [Unmet], BA1 [Unmet]	"The c.739T>C (p.Phe247Leu) variant in BRAF has been reported in the literature as an unconfirmed de novo occurrence in a patient with clinical features of a RASopathy (PM6; GeneDx internal data; GTR Lab ID: 26957; ClinVar SCV000207748.12). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that the p.Phe247Leu variant may impact protein function (PS3; PMID: 28512244). The c.739T>C variant results in the same amino acid change as the previously established pathogenic c.741T>G (p.Phe247Leu) variant (PS1; ClinVar ID 55793). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of BRAF (PM1; PMID 29493581). The variant is located in the BRAF gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Phe247Leu variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM6, PM2, PS3, PS1, PM1, PP2, PP3."	28512244, 26243863, 22899370	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA295904/MONDO:0021060/004	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
19	4101272	180905	G	A	NM_030662.3(MAP2K2):c.535C>T (p.Arg179Trp)	180905	CA296130	NM_030662.3:c.535C>T, LRG_750t1:c.535C>T, XM_006722799.2:c.535C>T, XM_011528133.1:c.-36C>T, XM_017026989.1:c.535C>T, XM_017026990.1:c.535C>T, XM_017026991.1:c.535C>T, ENST00000262948.9:c.535C>T, ENST00000394867.8:c.244C>T, ENST00000593364.5:n.482C>T, ENST00000597008.5:n.136C>T, ENST00000599345.1:n.805C>T, ENST00000601786.5:n.836C>T, ENST00000602167.5:n.255C>T, NC_000019.10:g.4101274G>A, CM000681.2:g.4101274G>A, NC_000019.9:g.4101272G>A, CM000681.1:g.4101272G>A, NC_000019.8:g.4052272G>A, NG_007996.1:g.27855C>T, LRG_750:g.27855C>T, NM_030662.3(MAP2K2):c.535C>T (p.Arg179Trp)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.535C>T (p.Arg179Trp) variant in the MAP2K2 gene is 0.0362% (3/2258) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA296130/MONDO:0021060/004	0.025	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
3	12633259	181509	C	T	NM_002880.3(RAF1):c.1141G>A (p.Asp381Asn)	181509	CA297118	NM_002880.3:c.1141G>A, LRG_413t1:c.1141G>A, XM_005265355.1:c.1141G>A, XM_005265357.1:c.1042G>A, XM_005265358.3:c.898G>A, XM_005265359.3:c.799G>A, XM_005265360.1:c.1141G>A, XM_011533974.1:c.1141G>A, XM_011533975.1:c.898G>A, NM_001354689.1:c.1201G>A, NM_001354690.1:c.1141G>A, NM_001354691.1:c.898G>A, NM_001354692.1:c.898G>A, NM_001354693.1:c.1042G>A, NM_001354694.1:c.958G>A, NM_001354695.1:c.799G>A, NR_148940.1:n.1669G>A, NR_148941.1:n.1615G>A, NR_148942.1:n.1554G>A, XM_011533974.3:c.1141G>A, XM_017006966.1:c.1042G>A, XR_001740227.1:n.1432G>A, ENST00000251849.8:c.1141G>A, ENST00000423275.5:c.*818G>A, ENST00000432427.2:n.778G>A, ENST00000442415.6:c.1201G>A, ENST00000460610.1:n.98G>A, ENST00000465826.5:n.498G>A, ENST00000475353.1:n.309G>A, ENST00000494557.1:n.157G>A, NC_000003.12:g.12591760C>T, CM000665.2:g.12591760C>T, NC_000003.11:g.12633259C>T, CM000665.1:g.12633259C>T, NC_000003.10:g.12608259C>T, NG_007467.1:g.77420G>A, LRG_413:g.77420G>A, NM_002880.3(RAF1):c.1141G>A (p.Asp381Asn)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1141G>A (p.Asp381Asn) variant in the RAF1 gene is 0.162% (36/16508) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA297118/MONDO:0021060/004	0.0122	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	112724154	181526	A	C	NM_007373.3(SHOC2):c.38A>C (p.Glu13Ala)	181526	CA297169	NM_007373.3:c.38A>C, NC_000010.11:g.110964396A>C, CM000672.2:g.110964396A>C, NC_000010.10:g.112724154A>C, CM000672.1:g.112724154A>C, NC_000010.9:g.112714144A>C, NG_028922.1:g.49854A>C, LRG_753:g.49854A>C, NM_001269039.1:c.38A>C, LRG_753t1:c.38A>C, XM_011540216.1:c.-380-21232A>C, NM_001269039.2:c.38A>C, NM_001324336.1:c.38A>C, NM_001324337.1:c.38A>C, NR_136749.1:n.116-21232A>C, ENST00000265277.9:c.38A>C, ENST00000369452.8:c.38A>C, ENST00000480155.1:n.522A>C, ENST00000489390.1:n.56-36019A>C, ENST00000489783.1:n.416A>C, NM_007373.3(SHOC2):c.38A>C (p.Glu13Ala)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET], BA1 [Unmet]	"The filtering allele frequency of the c.38A>C (p.Glu13Ala) variant in the SHOC2 gene is 0.0484% (10/11206) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA297169/MONDO:0021060/004	0.0028	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	112724635	181528	G	A	NM_007373.3(SHOC2):c.519G>A (p.Met173Ile)	181528	CA199174	NM_007373.3:c.519G>A, NC_000010.11:g.110964877G>A, CM000672.2:g.110964877G>A, NC_000010.10:g.112724635G>A, CM000672.1:g.112724635G>A, NC_000010.9:g.112714625G>A, NG_028922.1:g.50335G>A, LRG_753:g.50335G>A, NM_001269039.1:c.519G>A, LRG_753t1:c.519G>A, XM_011540216.1:c.-380-20751G>A, NM_001269039.2:c.519G>A, NM_001324336.1:c.519G>A, NM_001324337.1:c.519G>A, NR_136749.1:n.116-20751G>A, ENST00000265277.9:c.519G>A, ENST00000369452.8:c.519G>A, ENST00000451838.1:n.27G>A, ENST00000489390.1:n.56-35538G>A, NM_007373.3(SHOC2):c.519G>A (p.Met173Ile)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PS4 [Unmet], PS3 [Unmet], PM2 [MET]	"The c.519G>A (p.Met173Ile) variant in the SHOC2 gene has been observed in a proband with clinical features of a RASopathy (PS4 not met; GeneDx GTR Lab ID:26957 ClinVar SCV000209055.10). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). In vitro functional studies provide some evidence that the p.Met173Ile variant may impact protein function (PS3 not met; PMID: 25137548). In summary, the clinical significance of the p.Met173Ile variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PM2."	25137548	RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	3/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA199174/MONDO:0021060/004	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	112915755	181766	G	A	NM_002834.4(PTPN11):c.1028G>A (p.Arg343Gln)	181766	CA297648	NM_002834.4:c.1028G>A, NC_000012.12:g.112477951G>A, CM000674.2:g.112477951G>A, NC_000012.11:g.112915755G>A, CM000674.1:g.112915755G>A, NC_000012.10:g.111400138G>A, NG_007459.1:g.64220G>A, LRG_614:g.64220G>A, NM_002834.3:c.1028G>A, LRG_614t1:c.1028G>A, NM_080601.1:c.1028G>A, XM_006719526.1:c.1028G>A, XM_006719527.1:c.914G>A, XM_011538613.1:c.1025G>A, NM_001330437.1:c.1028G>A, NM_080601.2:c.1028G>A, XM_011538613.2:c.1025G>A, XM_017019722.1:c.1025G>A, ENST00000351677.6:c.1028G>A, ENST00000392597.5:c.1028G>A, ENST00000635625.1:n.1028G>A, ENST00000635652.1:n.20G>A, NM_002834.4(PTPN11):c.1028G>A (p.Arg343Gln)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1028G>A (p.Arg343Gln) variant in the PTPN11 gene is 0.116% (27/16494) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA297648/MONDO:0021060/004	0.0507	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89720876	183722	G	A	NM_000314.6(PTEN):c.1026+1G>A	183722	CA000103	NM_000314.6:c.1026+1G>A, NM_000314.5:c.1026+1G>A, NM_001304717.2:c.1545+1G>A, NM_001304718.1:c.435+1G>A, XM_006717926.2:c.981+1G>A, XM_011539981.1:c.1026+1G>A, XM_011539982.1:c.930+1G>A, XR_945791.1:n.1596+1G>A, NM_000314.7:c.1026+1G>A, NM_001304717.5:c.1545+1G>A, NM_001304718.2:c.435+1G>A, ENST00000371953.7:c.1026+1G>A, ENST00000472832.2:n.454G>A, NC_000010.11:g.87961119G>A, CM000672.2:g.87961119G>A, NC_000010.10:g.89720876G>A, CM000672.1:g.89720876G>A, NC_000010.9:g.89710856G>A, NG_007466.2:g.102681G>A, LRG_311:g.102681G>A, NM_000314.6(PTEN):c.1026+1G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PS4-Moderate [MET]	"PTEN c.1026+1G>A (IVS8+1G>A) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4) (PMID 28677221).PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 28677221, internal laboratory contributor(s) SCV000212764.4)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000103/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68847213	184346	C	T	NM_004360.4(CDH1):c.1138-3C>T	184346	CA188674	NM_004360.4:c.1138-3C>T, NM_004360.3:c.1138-3C>T, LRG_301t1:c.1138-3C>T, XM_011523488.1:c.403-3C>T, XM_011523489.1:c.403-3C>T, NM_001317184.1:c.1137+1047C>T, NM_001317185.1:c.-478-3C>T, NM_001317186.1:c.-682-3C>T, ENST00000261769.9:c.1138-3C>T, ENST00000422392.6:c.1137+1047C>T, ENST00000562836.5:n.1209-3C>T, ENST00000565810.1:n.182-3C>T, ENST00000566510.5:c.982-3C>T, ENST00000566612.5:c.1138-3C>T, ENST00000611625.4:c.1138-3C>T, ENST00000612417.4:c.1138-3C>T, ENST00000621016.4:c.1138-3C>T, NC_000016.10:g.68813310C>T, CM000678.2:g.68813310C>T, NC_000016.9:g.68847213C>T, CM000678.1:g.68847213C>T, NC_000016.8:g.67404714C>T, NG_008021.1:g.81019C>T, LRG_301:g.81019C>T, NM_004360.4(CDH1):c.1138-3C>T	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Benign	BP7 [Unmet], BP5 [Unmet], BS1 [MET], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BA1 [Unmet], BP4 [MET], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	The c.1138-3C>T variant has an allele frequency of 0.00121 (0.121%, 29/24,036 alleles) in the African subpopulation of the gnomAD cohort (BS1). There are at least 3 in silico predictors in agreement that this variant does not affect splicing (BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS1, BP4.	15322508	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA188674/MONDO:0007648/007	0.3246	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89720690	184466	C	G	NM_000314.6(PTEN):c.841C>G (p.Pro281Ala)	184466	CA000211	NM_000314.6:c.841C>G, NM_000314.5:c.841C>G, NM_001304717.2:c.1360C>G, NM_001304718.1:c.250C>G, XM_006717926.2:c.796C>G, XM_011539981.1:c.841C>G, XM_011539982.1:c.745C>G, XR_945791.1:n.1411C>G, NM_000314.7:c.841C>G, NM_001304717.5:c.1360C>G, NM_001304718.2:c.250C>G, ENST00000371953.7:c.841C>G, ENST00000472832.2:n.268C>G, NC_000010.11:g.87960933C>G, CM000672.2:g.87960933C>G, NC_000010.10:g.89720690C>G, CM000672.1:g.89720690C>G, NC_000010.9:g.89710670C>G, NG_007466.2:g.102495C>G, LRG_311:g.102495C>G, NM_000314.6(PTEN):c.841C>G (p.Pro281Ala)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	PTEN c.841C>G (p.Pro281Ala) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	29785012, 29706350, 29945567	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000211/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89624301	184505	G	A	NM_000314.6(PTEN):c.75G>A (p.Leu25=)	184505	CA000197	NM_000314.6:c.75G>A, NM_000314.5:c.75G>A, NM_001304717.2:c.594G>A, NM_001304718.1:c.-631G>A, XM_006717926.2:c.75G>A, XM_011539981.1:c.75G>A, XR_945789.1:n.787G>A, XR_945790.1:n.787G>A, XR_945791.1:n.787G>A, NM_000314.7:c.75G>A, NM_001304717.5:c.594G>A, NM_001304718.2:c.-631G>A, ENST00000371953.7:c.75G>A, ENST00000462694.1:n.77G>A, ENST00000487939.1:n.96G>A, ENST00000610634.1:c.-28G>A, ENST00000618586.1:n.44G>A, NC_000010.11:g.87864544G>A, CM000672.2:g.87864544G>A, NC_000010.10:g.89624301G>A, CM000672.1:g.89624301G>A, NC_000010.9:g.89614281G>A, NG_007466.2:g.6106G>A, LRG_311:g.6106G>A, NG_033079.1:g.3894C>T, NM_000314.6(PTEN):c.75G>A (p.Leu25=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BP7 [MET], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.75G>A (p.Leu25=) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/12/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000197/MONDO:0017623/003	0.1877	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89717675	184844	C	T	NM_000314.6(PTEN):c.700C>T (p.Arg234Trp)	184844	CA000183	NM_000314.6:c.700C>T, NM_000314.5:c.700C>T, NM_001304717.2:c.1219C>T, NM_001304718.1:c.109C>T, XM_006717926.2:c.655C>T, XM_011539981.1:c.700C>T, XM_011539982.1:c.604C>T, XR_945791.1:n.1270C>T, NM_000314.7:c.700C>T, NM_001304717.5:c.1219C>T, NM_001304718.2:c.109C>T, ENST00000371953.7:c.700C>T, ENST00000472832.2:n.127C>T, NC_000010.11:g.87957918C>T, CM000672.2:g.87957918C>T, NC_000010.10:g.89717675C>T, CM000672.1:g.89717675C>T, NC_000010.9:g.89707655C>T, NG_007466.2:g.99480C>T, LRG_311:g.99480C>T, NM_000314.6(PTEN):c.700C>T (p.Arg234Trp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet]	PTEN c.700C>T (p.R234W) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	30039884	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000183/MONDO:0017623/003	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89717690	184878	A	G	NM_000314.6(PTEN):c.715A>G (p.Met239Val)	184878	CA000189	NM_000314.6:c.715A>G, NC_000010.11:g.87957933A>G, CM000672.2:g.87957933A>G, NC_000010.10:g.89717690A>G, CM000672.1:g.89717690A>G, NC_000010.9:g.89707670A>G, NG_007466.2:g.99495A>G, LRG_311:g.99495A>G, NM_000314.5:c.715A>G, NM_001304717.2:c.1234A>G, NM_001304718.1:c.124A>G, XM_006717926.2:c.670A>G, XM_011539981.1:c.715A>G, XM_011539982.1:c.619A>G, XR_945791.1:n.1285A>G, NM_000314.7:c.715A>G, NM_001304717.5:c.1234A>G, NM_001304718.2:c.124A>G, ENST00000371953.7:c.715A>G, ENST00000472832.2:n.142A>G, NM_000314.6(PTEN):c.715A>G (p.Met239Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP1 [Unmet], PP4 [Unmet], PP3 [Unmet], PP2 [MET], BP2 [Unmet], BP4 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.715A>G (p.Met239Val) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000189/MONDO:0017623/003	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
10	89720813	185213	A	T	NM_000314.6(PTEN):c.964A>T (p.Lys322Ter)	185213	CA000235	NM_000314.6:c.964A>T, NC_000010.11:g.87961056A>T, CM000672.2:g.87961056A>T, NC_000010.10:g.89720813A>T, CM000672.1:g.89720813A>T, NC_000010.9:g.89710793A>T, NG_007466.2:g.102618A>T, LRG_311:g.102618A>T, NM_000314.5:c.964A>T, NM_001304717.2:c.1483A>T, NM_001304718.1:c.373A>T, XM_006717926.2:c.919A>T, XM_011539981.1:c.964A>T, XM_011539982.1:c.868A>T, XR_945791.1:n.1534A>T, NM_000314.7:c.964A>T, NM_001304717.5:c.1483A>T, NM_001304718.2:c.373A>T, ENST00000371953.7:c.964A>T, ENST00000472832.2:n.391A>T, NM_000314.6(PTEN):c.964A>T (p.Lys322Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [MET]	"PTEN c.964A>T (p.K322X) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533)."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000235/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89685275	185713	T	G	NM_000314.6(PTEN):c.170T>G (p.Leu57Trp)	185713	CA000131	NM_000314.6:c.170T>G, NM_000314.5:c.170T>G, NM_001304717.2:c.689T>G, NM_001304718.1:c.-541-5528T>G, XM_006717926.2:c.165-5528T>G, XM_011539981.1:c.170T>G, XM_011539982.1:c.74T>G, XR_945789.1:n.882T>G, XR_945790.1:n.882T>G, XR_945791.1:n.882T>G, NM_000314.7:c.170T>G, NM_001304717.5:c.689T>G, NM_001304718.2:c.-541-5528T>G, ENST00000371953.7:c.170T>G, ENST00000610634.1:c.68T>G, NC_000010.11:g.87925518T>G, CM000672.2:g.87925518T>G, NC_000010.10:g.89685275T>G, CM000672.1:g.89685275T>G, NC_000010.9:g.89675255T>G, NG_007466.2:g.67080T>G, LRG_311:g.67080T>G, NM_000314.6(PTEN):c.170T>G (p.Leu57Trp)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [MET], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.170T>G (p.L57W) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 9256433).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000131/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89685317	185989	A	T	NM_000314.6(PTEN):c.209+3A>T	185989	CA000135	NM_000314.6:c.209+3A>T, NC_000010.11:g.87925560A>T, CM000672.2:g.87925560A>T, NC_000010.10:g.89685317A>T, CM000672.1:g.89685317A>T, NC_000010.9:g.89675297A>T, NG_007466.2:g.67122A>T, LRG_311:g.67122A>T, NM_000314.5:c.209+3A>T, NM_001304717.2:c.728+3A>T, NM_001304718.1:c.-541-5486A>T, XM_006717926.2:c.165-5486A>T, XM_011539981.1:c.209+3A>T, XM_011539982.1:c.113+3A>T, XR_945789.1:n.921+3A>T, XR_945790.1:n.921+3A>T, XR_945791.1:n.921+3A>T, NM_000314.7:c.209+3A>T, NM_001304717.5:c.728+3A>T, NM_001304718.2:c.-541-5486A>T, ENST00000371953.7:c.209+3A>T, ENST00000498703.1:n.35+3A>T, ENST00000610634.1:c.107+3A>T, NM_000314.6(PTEN):c.209+3A>T	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PP3 [MET]	"PTEN c.209+3A>T (IVS3+3A>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP3: At least 2 out of 3 in silico models predict a splicing impact."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	8/11/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000135/MONDO:0017623/003	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692880	186161	A	G	NM_000314.6(PTEN):c.364A>G (p.Ile122Val)	186161	CA000147	NM_000314.6:c.364A>G, NC_000010.11:g.87933123A>G, CM000672.2:g.87933123A>G, NC_000010.10:g.89692880A>G, CM000672.1:g.89692880A>G, NC_000010.9:g.89682860A>G, NG_007466.2:g.74685A>G, LRG_311:g.74685A>G, NM_000314.5:c.364A>G, NM_001304717.2:c.883A>G, NM_001304718.1:c.-387A>G, XM_006717926.2:c.319A>G, XM_011539981.1:c.364A>G, XM_011539982.1:c.268A>G, XR_945789.1:n.1076A>G, XR_945790.1:n.1076A>G, XR_945791.1:n.1076A>G, NM_000314.7:c.364A>G, NM_001304717.5:c.883A>G, NM_001304718.2:c.-387A>G, ENST00000371953.7:c.364A>G, ENST00000498703.1:n.190A>G, ENST00000610634.1:c.262A>G, NM_000314.6(PTEN):c.364A>G (p.Ile122Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PVS1 [Unmet], PM6 [Unmet], PM2 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BS3 [MET], BS4 [Unmet], BS1 [Unmet], BP7 [Unmet], BP5 [Unmet]	PTEN c.364A>G (p.Ile122Val) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3: Missense variants with both lipid phosphatase activity AND results from a second assay appropriate to the protein domain demonstrating no statistically significant difference from wild type. (PMID 21828076, 29706350, 29785012)	21828076, 29785012, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000147/MONDO:0017623/003	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89692820	186427	A	C	NM_000314.6(PTEN):c.304A>C (p.Lys102Gln)	186427	CA000139	NM_000314.6:c.304A>C, NC_000010.11:g.87933063A>C, CM000672.2:g.87933063A>C, NC_000010.10:g.89692820A>C, CM000672.1:g.89692820A>C, NC_000010.9:g.89682800A>C, NG_007466.2:g.74625A>C, LRG_311:g.74625A>C, NM_000314.5:c.304A>C, NM_001304717.2:c.823A>C, NM_001304718.1:c.-447A>C, XM_006717926.2:c.259A>C, XM_011539981.1:c.304A>C, XM_011539982.1:c.208A>C, XR_945789.1:n.1016A>C, XR_945790.1:n.1016A>C, XR_945791.1:n.1016A>C, NM_000314.7:c.304A>C, NM_001304717.5:c.823A>C, NM_001304718.2:c.-447A>C, ENST00000371953.7:c.304A>C, ENST00000498703.1:n.130A>C, ENST00000610634.1:c.202A>C, NM_000314.6(PTEN):c.304A>C (p.Lys102Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [MET], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	PTEN c.304A>C (p.Lys102Gln) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000139/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
16	68863687	187464	AT	A	NM_004360.4(CDH1):c.2430delT (p.Phe810Leufs)	187464	CA197715	NM_004360.4:c.2430delT, NC_000016.10:g.68829788del, CM000678.2:g.68829788del, NC_000016.9:g.68863691del, CM000678.1:g.68863691del, NC_000016.8:g.67421192del, NG_008021.1:g.97497del, LRG_301:g.97497del, NM_004360.3:c.2430del, LRG_301t1:c.2430del, XM_011523488.1:c.1695del, XM_011523489.1:c.1695del, NM_001317184.1:c.2247del, NM_001317185.1:c.882del, NM_001317186.1:c.465del, NM_004360.4:c.2430del, ENST00000261769.9:c.2430del, ENST00000422392.6:c.2247del, ENST00000562118.1:n.648del, ENST00000562836.5:n.2501del, ENST00000566510.5:c.*1096del, ENST00000566612.5:c.*670del, ENST00000611625.4:c.2493del, ENST00000612417.4:c.1853+3234del, ENST00000621016.4:c.1866-4415del, NM_004360.4(CDH1):c.2430delT (p.Phe810Leufs)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BS1 [Unmet], BS4 [Unmet], BP5 [Unmet], BP7 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP1 [Unmet], PP3 [Unmet], PVS1-Strong [MET], PM4 [Unmet], BP2 [Unmet], BP4 [Unmet], BA1 [Unmet], PS2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [MET]	"The c.2430delT (p.Phe810Leufs*6) variant is predicted to result in a premature stop codon that leads to a truncated protein. However, it is located within the nonsense mediated decay resistance region upstream of c.2506G>T (p.Glu836*) (PVS1_Strong). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID 26182300, SCV000261293.4, SCV000218032.4). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Strong, PM2, PS4."	26182300	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA197715/MONDO:0007648/007	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89685269	187590	G	A	NM_000314.6(PTEN):c.165-1G>A	187590	CA000129	NM_000314.6:c.165-1G>A, NM_000314.5:c.165-1G>A, NM_001304717.2:c.684-1G>A, NM_001304718.1:c.-541-5534G>A, XM_006717926.2:c.165-5534G>A, XM_011539981.1:c.165-1G>A, XM_011539982.1:c.69-1G>A, XR_945789.1:n.877-1G>A, XR_945790.1:n.877-1G>A, XR_945791.1:n.877-1G>A, NM_000314.7:c.165-1G>A, NM_001304717.5:c.684-1G>A, NM_001304718.2:c.-541-5534G>A, ENST00000371953.7:c.165-1G>A, ENST00000610634.1:c.63-1G>A, NC_000010.11:g.87925512G>A, CM000672.2:g.87925512G>A, NC_000010.10:g.89685269G>A, CM000672.1:g.89685269G>A, NC_000010.9:g.89675249G>A, NG_007466.2:g.67074G>A, LRG_311:g.67074G>A, NM_000314.6(PTEN):c.165-1G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1 [MET], PM2 [MET]	"PTEN c.165-1G>A (IVS2-1G>A) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533)."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000129/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89720741	187657	C	T	NM_000314.6(PTEN):c.892C>T (p.Gln298Ter)	187657	CA000219	NM_000314.6:c.892C>T, NC_000010.11:g.87960984C>T, CM000672.2:g.87960984C>T, NC_000010.10:g.89720741C>T, CM000672.1:g.89720741C>T, NC_000010.9:g.89710721C>T, NG_007466.2:g.102546C>T, LRG_311:g.102546C>T, NM_000314.5:c.892C>T, NM_001304717.2:c.1411C>T, NM_001304718.1:c.301C>T, XM_006717926.2:c.847C>T, XM_011539981.1:c.892C>T, XM_011539982.1:c.796C>T, XR_945791.1:n.1462C>T, NM_000314.7:c.892C>T, NM_001304717.5:c.1411C>T, NM_001304718.2:c.301C>T, ENST00000371953.7:c.892C>T, ENST00000472832.2:n.319C>T, NM_000314.6(PTEN):c.892C>T (p.Gln298Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PS4-Supporting [MET]	"PTEN c.892C>T (p.Q298X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23470840)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000219/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89725188	187673	C	T	NM_000314.6(PTEN):c.1171C>T (p.Pro391Ser)	187673	CA000118	NM_000314.6:c.1171C>T, NM_000314.5:c.1171C>T, NM_001304717.2:c.1690C>T, NM_001304718.1:c.580C>T, XM_006717926.2:c.1126C>T, XM_011539982.1:c.1075C>T, XR_945791.1:n.1741C>T, NM_000314.7:c.1171C>T, NM_001304717.5:c.1690C>T, NM_001304718.2:c.580C>T, ENST00000371953.7:c.1171C>T, NC_000010.11:g.87965431C>T, CM000672.2:g.87965431C>T, NC_000010.10:g.89725188C>T, CM000672.1:g.89725188C>T, NC_000010.9:g.89715168C>T, NG_007466.2:g.106993C>T, LRG_311:g.106993C>T, NM_000314.6(PTEN):c.1171C>T (p.Pro391Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PP2 [MET]	"PTEN c.1171C>T (p.P391S) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	8/11/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000118/MONDO:0017623/003	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89711927	187827	T	C	NM_000314.6(PTEN):c.545T>C (p.Leu182Ser)	187827	CA000177	NM_000314.6:c.545T>C, NC_000010.11:g.87952170T>C, CM000672.2:g.87952170T>C, NC_000010.10:g.89711927T>C, CM000672.1:g.89711927T>C, NC_000010.9:g.89701907T>C, NG_007466.2:g.93732T>C, LRG_311:g.93732T>C, NM_000314.5:c.545T>C, NM_001304717.2:c.1064T>C, NM_001304718.1:c.-47T>C, XM_006717926.2:c.500T>C, XM_011539981.1:c.545T>C, XM_011539982.1:c.449T>C, XR_945789.1:n.1416T>C, XR_945790.1:n.1533T>C, XR_945791.1:n.1205-5683T>C, NM_000314.7:c.545T>C, NM_001304717.5:c.1064T>C, NM_001304718.2:c.-47T>C, ENST00000371953.7:c.545T>C, NM_000314.6(PTEN):c.545T>C (p.Leu182Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	PTEN c.545T>C (p.Leu182Ser) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).  Of note, this variant may be disease-causing when present in the homozygous state (PMID 26443266), but this expert panel curation is based on presence in the heterozygous state.  PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	28097321, 21194675, 26443266	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000177/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
7	107312637	189148	C	CT	NM_000441.1(SLC26A4):c.365dupT (p.Ile124Tyrfs)	189148	CA274422	NM_000441.1:c.365dupT, NM_000441.1:c.365dup, XM_005250425.1:c.365dup, XM_006716025.2:c.365dup, XM_005250425.2:c.365dup, XM_006716025.3:c.365dup, XM_017012318.1:c.365dup, ENST00000265715.7:c.365dup, ENST00000440056.1:c.365dup, NC_000007.14:g.107672198dup, CM000669.2:g.107672198dup, NC_000007.13:g.107312643dup, CM000669.1:g.107312643dup, NC_000007.12:g.107099879dup, NG_008489.1:g.16564dup, NM_000441.1(SLC26A4):c.365dupT (p.Ile124Tyrfs)	SLC26A4	Pendred syndrome	MONDO:0010134	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], PP3 [Unmet], PP4 [MET], PP1 [Unmet], BS2 [Unmet], BP3 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], PM3-Supporting [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The p.Ile124Tyrfs variant in SLC26A4 is predicted to cause a premature stop codon in biologically-relevant-exon 4/21 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). The allele frequency of the p.Ile124fs variant is in 0.003% (1/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss (PM2). At least one patient with the variant displayed features of enlarged vestibular aqueduct and Mondini malformation which are consistent with Pendred syndrome (PP4; PMID:15679828). This variant has been detected in 2 patients with hearing loss in trans with suspected pathogenic variants (PM3_P, PMID:15679828). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Pendred syndrome based on the ACMG/AMP criteria applied: PVS1, PM2, PP4, PM3_P."	15679828, 15679828, 15679828	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	10/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA274422/MONDO:0010134/005	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692800	189403	C	T	NM_000314.6(PTEN):c.284C>T (p.Pro95Leu)	189403	CA000383	NM_000314.6:c.284C>T, NM_000314.5:c.284C>T, NM_001304717.2:c.803C>T, NM_001304718.1:c.-467C>T, XM_006717926.2:c.239C>T, XM_011539981.1:c.284C>T, XM_011539982.1:c.188C>T, XR_945789.1:n.996C>T, XR_945790.1:n.996C>T, XR_945791.1:n.996C>T, NM_000314.7:c.284C>T, NM_001304717.5:c.803C>T, NM_001304718.2:c.-467C>T, ENST00000371953.7:c.284C>T, ENST00000498703.1:n.110C>T, ENST00000610634.1:c.182C>T, NC_000010.11:g.87933043C>T, CM000672.2:g.87933043C>T, NC_000010.10:g.89692800C>T, CM000672.1:g.89692800C>T, NC_000010.9:g.89682780C>T, NG_007466.2:g.74605C>T, LRG_311:g.74605C>T, NM_000314.6(PTEN):c.284C>T (p.Pro95Leu)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [MET], PVS1 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], PS4-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS2 [Unmet], PS1 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.284C>T (p.Pro95Leu) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 21828076, PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (internal laboratory contributor ClinVar Organization ID 26957)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor ClinVar Organization ID 26957)	25669429, 21659347, 28526761, 21194675, 20600018, 21828076, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000383/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	5	Likely Pathogenic
10	89692923	189406	G	A	NM_000314.6(PTEN):c.407G>A (p.Cys136Tyr)	189406	CA000451	NM_000314.6:c.407G>A, NC_000010.11:g.87933166G>A, CM000672.2:g.87933166G>A, NC_000010.10:g.89692923G>A, CM000672.1:g.89692923G>A, NC_000010.9:g.89682903G>A, NG_007466.2:g.74728G>A, LRG_311:g.74728G>A, NM_000314.5:c.407G>A, NM_001304717.2:c.926G>A, NM_001304718.1:c.-344G>A, XM_006717926.2:c.362G>A, XM_011539981.1:c.407G>A, XM_011539982.1:c.311G>A, XR_945789.1:n.1119G>A, XR_945790.1:n.1119G>A, XR_945791.1:n.1119G>A, NM_000314.7:c.407G>A, NM_001304717.5:c.926G>A, NM_001304718.2:c.-344G>A, ENST00000371953.7:c.407G>A, ENST00000498703.1:n.233G>A, ENST00000610634.1:c.305G>A, NM_000314.6(PTEN):c.407G>A (p.Cys136Tyr)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PP2 [MET], PS4-Supporting [MET], PS2 [MET], PS3 [MET]	"PTEN c.407G>A (p.C136Y) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000222113.9)PS3: Phosphatase activity <50% of wild-type OR RNA, mini-gene, or other assay shows impact on splicing. (PMID 10866302)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Probands with specificity score of 1-1.5. (PMID 9735393, internal laboratory contributor(s) SCV000222113.9)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000451/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	5	Likely Pathogenic
10	89711893	189411	C	T	NM_000314.6(PTEN):c.511C>T (p.Gln171Ter)	189411	CA000494	NM_000314.6:c.511C>T, NM_000314.5:c.511C>T, NM_001304717.2:c.1030C>T, NM_001304718.1:c.-81C>T, XM_006717926.2:c.466C>T, XM_011539981.1:c.511C>T, XM_011539982.1:c.415C>T, XR_945789.1:n.1382C>T, XR_945790.1:n.1499C>T, XR_945791.1:n.1205-5717C>T, NM_000314.7:c.511C>T, NM_001304717.5:c.1030C>T, NM_001304718.2:c.-81C>T, ENST00000371953.7:c.511C>T, NC_000010.11:g.87952136C>T, CM000672.2:g.87952136C>T, NC_000010.10:g.89711893C>T, CM000672.1:g.89711893C>T, NC_000010.9:g.89701873C>T, NG_007466.2:g.93698C>T, LRG_311:g.93698C>T, NM_000314.6(PTEN):c.511C>T (p.Gln171Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PM6 [MET], PS4-Moderate [MET]	"PTEN c.511C>T (p.Q171X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 22595938)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 17043057, PMID 22595938)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000494/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89725230	189424	AT	A	NM_000314.6(PTEN):c.*10delT	189424	CA000290	NM_000314.6:c.*10delT, NC_000010.11:g.87965482del, CM000672.2:g.87965482del, NC_000010.10:g.89725239del, CM000672.1:g.89725239del, NC_000010.9:g.89715219del, NG_007466.2:g.107044del, LRG_311:g.107044del, NM_000314.5:c.*10del, NM_000314.6:c.*10del, NM_001304717.2:c.*10del, NM_001304718.1:c.*10del, XM_006717926.2:c.*10del, XM_011539982.1:c.*10del, XR_945791.1:n.1792del, NM_000314.7:c.*10del, NM_001304717.5:c.*10del, NM_001304718.2:c.*10del, ENST00000371953.7:c.*10del, NM_000314.6(PTEN):c.*10delT	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET]	PTEN c.*10delT (NC_000010.10:g.89725239delT) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	6/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000290/MONDO:0017623/003	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
10	89692876	189426	A	C	NM_000314.6(PTEN):c.360A>C (p.Ala120=)	189426	CA000412	NM_000314.6:c.360A>C, NC_000010.11:g.87933119A>C, CM000672.2:g.87933119A>C, NC_000010.10:g.89692876A>C, CM000672.1:g.89692876A>C, NC_000010.9:g.89682856A>C, NG_007466.2:g.74681A>C, LRG_311:g.74681A>C, NM_000314.5:c.360A>C, NM_001304717.2:c.879A>C, NM_001304718.1:c.-391A>C, XM_006717926.2:c.315A>C, XM_011539981.1:c.360A>C, XM_011539982.1:c.264A>C, XR_945789.1:n.1072A>C, XR_945790.1:n.1072A>C, XR_945791.1:n.1072A>C, NM_000314.7:c.360A>C, NM_001304717.5:c.879A>C, NM_001304718.2:c.-391A>C, ENST00000371953.7:c.360A>C, ENST00000498703.1:n.186A>C, ENST00000610634.1:c.258A>C, NM_000314.6(PTEN):c.360A>C (p.Ala120=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP4 [MET], BP7 [MET]	"PTEN c.360A>C (p.A120=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/12/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000412/MONDO:0017623/003	0.1	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89623026	189433	TGCAAAAGCCGCA	T	NM_000314.6(PTEN):c.-1195_-1184delAAGCCGCAGCAA	189433	CA163819	NC_000010.11:g.87863274_87863285del, CM000672.2:g.87863274_87863285del, NC_000010.10:g.89623031_89623042del, CM000672.1:g.89623031_89623042del, NC_000010.9:g.89613011_89613022del, NG_007466.2:g.4837_4848del, LRG_311:g.4837_4848del, NG_033079.1:g.5157_5168del, NM_001126049.1:c.-794_-783del, ENST00000371953.7:c.-1196_-1185del, ENST00000445946.3:c.-794_-783del, NM_000314.6(PTEN):c.-1195_-1184delAAGCCGCAGCAA	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BP5 [MET], BS1 [Unmet], BS3 [Unmet], BS4-Supporting [MET]	PTEN c.-1195del12 (NC_000010.10:g.89623031_89623042delAAGCCGCAGCAA) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BS4_P: Lack of segregation in affected members of one family. (Internal laboratory contributor SCV SCV000222146.7)BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributors SCV000222146.7, SCV000183826.5)	21194675, 28821472, 21532617, 28495237, 25669429, 28157521, 21532617, 21532617	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA163819/MONDO:0017623/003	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89720832	189441	CAAAT	C	NM_000314.6(PTEN):c.987_990delTAAA (p.Asn329Lysfs)	189441	CA000656	NM_000314.6:c.987_990delTAAA, NM_000314.5:c.987_990del, NM_000314.6:c.987_990del, NM_001304717.2:c.1506_1509del, NM_001304718.1:c.396_399del, XM_006717926.2:c.942_945del, XM_011539981.1:c.987_990del, XM_011539982.1:c.891_894del, XR_945791.1:n.1557_1560del, NM_000314.7:c.987_990del, NM_001304717.5:c.1506_1509del, NM_001304718.2:c.396_399del, ENST00000371953.7:c.987_990del, ENST00000472832.2:n.414_417del, NC_000010.11:g.87961079_87961082del, CM000672.2:g.87961079_87961082del, NC_000010.10:g.89720836_89720839del, CM000672.1:g.89720836_89720839del, NC_000010.9:g.89710816_89710819del, NG_007466.2:g.102641_102644del, LRG_311:g.102641_102644del, NM_000314.6(PTEN):c.987_990delTAAA (p.Asn329Lysfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PVS1 [MET], PM2 [MET], PS4-Supporting [MET]	"PTEN c.987_990delTAAA (p.N329KfsX14) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10232405)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000656/MONDO:0017623/003	0.9971	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89653781	189462	G	C	NM_000314.6(PTEN):c.80-1G>C	189462	CA000586	NM_000314.6:c.80-1G>C, NC_000010.11:g.87894024G>C, CM000672.2:g.87894024G>C, NC_000010.10:g.89653781G>C, CM000672.1:g.89653781G>C, NC_000010.9:g.89643761G>C, NG_007466.2:g.35586G>C, LRG_311:g.35586G>C, NM_000314.5:c.80-1G>C, NM_001304717.2:c.599-1G>C, NM_001304718.1:c.-626-1G>C, XM_006717926.2:c.80-1G>C, XM_011539981.1:c.80-1G>C, XM_011539982.1:c.68+13586G>C, XR_945789.1:n.792-1G>C, XR_945790.1:n.792-1G>C, XR_945791.1:n.792-1G>C, NM_000314.7:c.80-1G>C, NM_001304717.5:c.599-1G>C, NM_001304718.2:c.-626-1G>C, ENST00000371953.7:c.80-1G>C, ENST00000462694.1:n.82-1G>C, ENST00000610634.1:c.-23-1G>C, NM_000314.6(PTEN):c.80-1G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [MET]	"PTEN c.80-1G>C (IVS1-1G>C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533)."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000586/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711899	189500	C	T	NM_000314.6(PTEN):c.517C>T (p.Arg173Cys)	189500	CA000498	NM_000314.6:c.517C>T, NC_000010.11:g.87952142C>T, CM000672.2:g.87952142C>T, NC_000010.10:g.89711899C>T, CM000672.1:g.89711899C>T, NC_000010.9:g.89701879C>T, NG_007466.2:g.93704C>T, LRG_311:g.93704C>T, NM_000314.5:c.517C>T, NM_001304717.2:c.1036C>T, NM_001304718.1:c.-75C>T, XM_006717926.2:c.472C>T, XM_011539981.1:c.517C>T, XM_011539982.1:c.421C>T, XR_945789.1:n.1388C>T, XR_945790.1:n.1505C>T, XR_945791.1:n.1205-5711C>T, NM_000314.7:c.517C>T, NM_001304717.5:c.1036C>T, NM_001304718.2:c.-75C>T, ENST00000371953.7:c.517C>T, NM_000314.6(PTEN):c.517C>T (p.Arg173Cys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PS2-Very Strong [MET], PM2 [MET], PP1 [MET], PP2 [MET], PS3 [MET], PS4-Moderate [MET]	"PTEN c.517C>T (p.R173C) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (PMID 17526800, PMID 22628360, internal laboratory contributor(s) SCV000222220.10)PS3: Phosphatase activity <50% of wild type. (PMID 10866302)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 22628360, PMID 17526800, PMID 17526801)PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 22628360)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA000498/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	5	Likely Pathogenic
10	89623167	189520	C	G	NM_000314.6(PTEN):c.-1059C>G	189520	CA300594	NM_000314.6:c.-1059C>G, NC_000010.11:g.87863410C>G, CM000672.2:g.87863410C>G, NC_000010.10:g.89623167C>G, CM000672.1:g.89623167C>G, NC_000010.9:g.89613147C>G, NG_007466.2:g.4973C>G, LRG_311:g.4973C>G, NG_033079.1:g.5028G>C, NM_001126049.1:c.-923G>C, ENST00000371953.7:c.-1060C>G, ENST00000445946.3:c.-923G>C, NM_000314.6(PTEN):c.-1059C>G	KLLN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Benign	BA1 [MET]	"PTEN c.-1059C>G (NC_000010.10:g.89623167C>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BA1: Allele frequency of 0.0138 (1.38%, 120/8698 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	14/9/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA300594/MONDO:0017623/003	0.025	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
1	216040521	197510	T	C	NM_206933.2(USH2A):c.8682-9A>G	197510	CA275277	NM_206933.2:c.8682-9A>G, NC_000001.11:g.215867179T>C, CM000663.2:g.215867179T>C, NC_000001.10:g.216040521T>C, CM000663.1:g.216040521T>C, NC_000001.9:g.214107144T>C, NG_009497.1:g.561218A>G, NM_206933.3:c.8682-9A>G, ENST00000307340.7:c.8682-9A>G, NM_206933.2(USH2A):c.8682-9A>G	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP1 [Unmet], PP4 [MET], PP3 [MET], PM3-Very Strong [MET], PM2-Supporting [MET], BP2 [Unmet], BP4 [Unmet], BP3 [Unmet], BA1 [Unmet], PS4 [Unmet], PS2 [Unmet], PS3 [Unmet], PM1 [Unmet], PM4 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.8682-9A>G variant in USH2A has been detected in patients with hearing loss in trans with at least 4 pathogenic or suspected-pathogenic variants (PM3_VS; PMID: 27318125, 25425308, 28944237, 23591405). The allele frequency of the c.8682-9A>G variant in the USH2A gene is 0.04% (5/10112) of Ashkenazi Jewish chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). At least one patient with this variant displayed features of retinitis pigmentosa and hearing loss which is consistent with Usher syndrome (PP4; PMID: 27318125, 25425308, 28944237, 23591405). Computational prediction tools and conservation analysis suggest that the c.8682-9A>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM3_VS, PM2_Supporting, PP4, PP3."	25425308, 28944237, 23591405, 27318125, 25425308, 28944237, 23591405, 27318125, 18273898, 27318125	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	24/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA275277/MONDO:0019501/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
2	39281777	197778	T	C	NM_005633.3(SOS1):c.698A>G (p.Asn233Ser)	197778	CA246107	NM_005633.3:c.698A>G, NC_000002.12:g.39054636T>C, CM000664.2:g.39054636T>C, NC_000002.11:g.39281777T>C, CM000664.1:g.39281777T>C, NC_000002.10:g.39135281T>C, NG_007530.1:g.70828A>G, LRG_754:g.70828A>G, LRG_754t1:c.698A>G, XM_005264515.3:c.698A>G, XM_011533060.1:c.791A>G, XM_011533061.1:c.791A>G, XM_011533062.1:c.677A>G, XM_011533063.1:c.674A>G, XM_011533064.1:c.527A>G, XM_011533065.1:c.791A>G, XM_005264515.4:c.698A>G, XM_011533062.2:c.677A>G, XM_011533064.2:c.527A>G, ENST00000395038.6:c.698A>G, ENST00000402219.6:c.698A>G, ENST00000426016.5:c.698A>G, NM_005633.3(SOS1):c.698A>G (p.Asn233Ser)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.698A>G (p.Asn233Ser) variant in the SOS1 gene is 0.0393% (8/10108) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA246107/MONDO:0021060/004	0.025	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
1	215822033	198366	C	T	NM_206933.2(USH2A):c.14419G>A (p.Ala4807Thr)	198366	CA246980	NM_206933.2:c.14419G>A, NC_000001.11:g.215648691C>T, CM000663.2:g.215648691C>T, NC_000001.10:g.215822033C>T, CM000663.1:g.215822033C>T, NC_000001.9:g.213888656C>T, NG_009497.1:g.779706G>A, NM_206933.3:c.14419G>A, ENST00000307340.7:c.14419G>A, NM_206933.2(USH2A):c.14419G>A (p.Ala4807Thr)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Uncertain Significance	PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], PM2-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	"The c.14419G>A (p.Ala4807Thr) variant in USH2A has been observed in at least one individual with hearing loss (Partners LMM ClinVar SCV000272892.2; PS4 not met). The variant has been observed in 0.01% (5/30782) of South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA246980/MONDO:0019501/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103310907	203873	A	G	NM_000277.1(PAH):c.2T>C (p.Met1Thr)	203873	CA312807	NM_000277.1:c.2T>C, XM_011538422.1:c.2T>C, NM_000277.2:c.2T>C, NM_001354304.1:c.2T>C, XM_017019370.2:c.2T>C, NM_000277.3:c.2T>C, ENST00000307000.7:c.-146T>C, ENST00000546844.1:c.2T>C, ENST00000547319.1:n.313T>C, ENST00000549111.5:n.98T>C, ENST00000551337.5:c.2T>C, ENST00000551988.5:n.91T>C, ENST00000553106.5:c.2T>C, ENST00000635500.1:n.29-4231T>C, NC_000012.12:g.102917129A>G, CM000674.2:g.102917129A>G, NC_000012.11:g.103310907A>G, CM000674.1:g.103310907A>G, NC_000012.10:g.101835037A>G, NG_008690.1:g.5474T>C, NG_008690.2:g.46282T>C, NM_000277.1(PAH):c.2T>C (p.Met1Thr)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PVS1 [MET], PP4 [Unmet]	c.2T>C (p.Met1Thr) is a null PAH variant (start loss) where LOF is a known mechanism of disease. There are no known alternative start codons in other transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. This variant has an extremely low frequency in ExAC, ESP, gnomAD. However, it has not been reported in the literature to our knowledge. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA312807/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103288623	208180	G	T	NM_000277.2(PAH):c.242C>A (p.Thr81Asn)	208180	CA275937	NM_000277.2:c.242C>A, NC_000012.12:g.102894845G>T, CM000674.2:g.102894845G>T, NC_000012.11:g.103288623G>T, CM000674.1:g.103288623G>T, NC_000012.10:g.101812753G>T, NG_008690.1:g.27758C>A, NG_008690.2:g.68566C>A, NM_000277.1:c.242C>A, XM_011538422.1:c.242C>A, NM_001354304.1:c.242C>A, XM_017019370.2:c.242C>A, NM_000277.3:c.242C>A, ENST00000307000.7:c.227C>A, ENST00000546844.1:c.242C>A, ENST00000548677.2:n.329C>A, ENST00000548928.1:n.164C>A, ENST00000549111.5:n.338C>A, ENST00000550978.6:n.226C>A, ENST00000551337.5:c.242C>A, ENST00000551988.5:n.331C>A, ENST00000553106.5:c.242C>A, NM_000277.2(PAH):c.242C>A (p.Thr81Asn)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	The c.242C>A (p.Thr81Asn) variant in PAH is reported in 1 PKU patient. PAH and BH4DH genes were sequenced. It was detected with p.V230I which is interpreted as Pathogenic/Likely Pathogenic in ClinVar. (PMID: 23942198) This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, MutationTaster, and Polyphen-2. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3, PP3.	23942198, 23942198	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA275937/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103245482	208182	A	G	NM_000277.2(PAH):c.895T>C (p.Phe299Leu)	208182	CA275941	NM_000277.2:c.895T>C, NC_000012.12:g.102851704A>G, CM000674.2:g.102851704A>G, NC_000012.11:g.103245482A>G, CM000674.1:g.103245482A>G, NC_000012.10:g.101769612A>G, NG_008690.1:g.70899T>C, NG_008690.2:g.111707T>C, NM_000277.1:c.895T>C, XM_011538422.1:c.895T>C, NM_001354304.1:c.895T>C, NM_000277.3:c.895T>C, ENST00000307000.7:c.880T>C, ENST00000549247.6:n.654T>C, ENST00000551114.2:n.557T>C, ENST00000553106.5:c.895T>C, ENST00000635477.1:n.56T>C, NM_000277.2(PAH):c.895T>C (p.Phe299Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [MET], PP3 [MET]	"The c.895T>C (p.Phe299Leu) variant in PAH is reported as Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 208182); no further information is provided. At the time of review (5/25/19), the variant does not appear to be reported in the published literature and/or in the BioPKU database. The variant results in the substitution of a highly conserved Phenylalanine residue with Leucine; the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., predicted deleterious in SIFT, Polyphen2, Mutation Taster; REVEL= 0.96) (PP3). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). Another missense variant at this site, p.Phe299Cys, has been previously reported Pathogenic/Likely Pathogenic by seven submitters in ClinVar (variant ID 613), where it was noted to be a recurrent allele among Norwegian PKU patients and have in-vitro data supporting that it impaired protein function. Another missense variant at this site, Phe299Ser, has also been reported in the BioPKU database (PAH0800). These reports of those variants support use of PM5."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA275941/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36231827	212089	A	T	NM_001754.4(RUNX1):c.557T>A (p.Val186Asp)	212089	CA248819	NM_001754.4:c.557T>A, NC_000021.9:g.34859530A>T, CM000683.2:g.34859530A>T, NC_000021.8:g.36231827A>T, CM000683.1:g.36231827A>T, NC_000021.7:g.35153697A>T, NG_011402.2:g.1130182T>A, LRG_482:g.1130182T>A, NM_001001890.2:c.476T>A, NM_001122607.1:c.476T>A, LRG_482t1:c.557T>A, XM_005261068.3:c.521T>A, XM_005261069.3:c.557T>A, XM_011529766.1:c.557T>A, XM_011529767.1:c.518T>A, XM_011529768.1:c.518T>A, XM_011529770.1:c.557T>A, XR_937576.1:n.736T>A, XM_005261069.4:c.557T>A, XM_011529766.2:c.557T>A, XM_011529767.2:c.518T>A, XM_011529768.2:c.518T>A, XM_011529770.2:c.557T>A, XM_017028487.1:c.404T>A, XR_937576.2:n.783T>A, ENST00000300305.7:c.557T>A, ENST00000344691.8:c.476T>A, ENST00000358356.9:c.476T>A, ENST00000399237.6:c.521T>A, ENST00000399240.5:c.476T>A, ENST00000437180.5:c.557T>A, ENST00000467577.1:n.49T>A, ENST00000482318.5:c.*147T>A, NM_001754.4(RUNX1):c.557T>A (p.Val186Asp)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1-Supporting [MET], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.557T>A (p.Val186Asp) missense variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). It has a REVEL score >0.75 (0.953) (PP3). This variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PM1_Supporting.	28104920	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA248819/MONDO:0011071/008	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
10	89711903	220007	A	G	NM_000314.6(PTEN):c.521A>G (p.Tyr174Cys)	220007	CA349032	NM_000314.6:c.521A>G, NC_000010.11:g.87952146A>G, CM000672.2:g.87952146A>G, NC_000010.10:g.89711903A>G, CM000672.1:g.89711903A>G, NC_000010.9:g.89701883A>G, NG_007466.2:g.93708A>G, LRG_311:g.93708A>G, NM_000314.5:c.521A>G, NM_001304717.2:c.1040A>G, NM_001304718.1:c.-71A>G, XM_006717926.2:c.476A>G, XM_011539981.1:c.521A>G, XM_011539982.1:c.425A>G, XR_945789.1:n.1392A>G, XR_945790.1:n.1509A>G, XR_945791.1:n.1205-5707A>G, NM_000314.7:c.521A>G, NM_001304717.5:c.1040A>G, NM_001304718.2:c.-71A>G, ENST00000371953.7:c.521A>G, NM_000314.6(PTEN):c.521A>G (p.Tyr174Cys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PP2 [MET], PS4-Supporting [MET], PS2 [MET]	"PTEN c.521A>G (p.Y174C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000602123.1)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor(s) SCV000602123.1)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	26/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA349032/MONDO:0017623/003	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68835695	220611	A	G	NM_004360.4(CDH1):c.286A>G (p.Ile96Val)	220611	CA349520	NM_004360.4:c.286A>G, NM_004360.3:c.286A>G, LRG_301t1:c.286A>G, XM_011523488.1:c.-450A>G, XM_011523489.1:c.-450A>G, NM_001317184.1:c.286A>G, NM_001317185.1:c.-1330A>G, NM_001317186.1:c.-1534A>G, ENST00000261769.9:c.286A>G, ENST00000422392.6:c.286A>G, ENST00000561751.1:n.53A>G, ENST00000562836.5:n.357A>G, ENST00000564676.5:n.568A>G, ENST00000564745.1:n.281A>G, ENST00000566510.5:c.286A>G, ENST00000566612.5:c.286A>G, ENST00000611625.4:c.286A>G, ENST00000612417.4:c.286A>G, ENST00000621016.4:c.286A>G, NC_000016.10:g.68801792A>G, CM000678.2:g.68801792A>G, NC_000016.9:g.68835695A>G, CM000678.1:g.68835695A>G, NC_000016.8:g.67393196A>G, NG_008021.1:g.69501A>G, LRG_301:g.69501A>G, NM_004360.4(CDH1):c.286A>G (p.Ile96Val)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Benign	BP5 [Unmet], BP7 [Unmet], BS1 [MET], BS4 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet], BS2 [MET], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.286A>G (p.Ile96Val) variant has an allele frequency of 0.00122 (0.12%, 41/33,578 alleles) in the Latino subpopulation of the gnomAD cohort (BS1). This variant has also been observed in >10 without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BS1, BS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA349520/MONDO:0007648/007	0.6752	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	1	Uncertain Significance
11	534287	222076	G	A	NM_005343.3(HRAS):c.36C>T (p.Gly12=)	222076	CA356960	NM_005343.3:c.36C>T, NC_000011.10:g.534287G>A, CM000673.2:g.534287G>A, NC_000011.9:g.534287G>A, CM000673.1:g.534287G>A, NC_000011.8:g.524287G>A, NG_007666.1:g.6264C>T, NM_001130442.1:c.36C>T, NM_005343.2:c.36C>T, NM_176795.3:c.36C>T, XM_011519875.1:c.-424-4311G>A, XM_011519877.1:c.-161-5293G>A, XR_242795.1:n.235C>T, NM_001130442.2:c.36C>T, NM_001318054.1:c.-284C>T, NM_176795.4:c.36C>T, XM_011519875.2:c.-424-4311G>A, XM_011519877.2:c.-161-5293G>A, XM_017017167.1:c.-499-4236G>A, XM_017017168.1:c.-499-4236G>A, NM_005343.4:c.36C>T, ENST00000311189.7:c.36C>T, ENST00000397594.5:c.36C>T, ENST00000397596.6:c.36C>T, ENST00000417302.5:c.36C>T, ENST00000451590.5:c.36C>T, ENST00000468682.2:n.524C>T, ENST00000482021.1:n.159C>T, ENST00000493230.5:c.36C>T, NM_005343.3(HRAS):c.36C>T (p.Gly12=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.36C>T (p.Gly12=) variant in the HRAS gene is 0.0461% (8/8626) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA356960/MONDO:0021060/004	0.0122	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
10	89717715	223142	T	C	NM_000314.6(PTEN):c.740T>C (p.Leu247Ser)	223142	CA16044135	NM_000314.6:c.740T>C, NC_000010.11:g.87957958T>C, CM000672.2:g.87957958T>C, NC_000010.10:g.89717715T>C, CM000672.1:g.89717715T>C, NC_000010.9:g.89707695T>C, NG_007466.2:g.99520T>C, LRG_311:g.99520T>C, NM_000314.5:c.740T>C, NM_001304717.2:c.1259T>C, NM_001304718.1:c.149T>C, XM_006717926.2:c.695T>C, XM_011539981.1:c.740T>C, XM_011539982.1:c.644T>C, XR_945791.1:n.1310T>C, NM_000314.7:c.740T>C, NM_001304717.5:c.1259T>C, NM_001304718.2:c.149T>C, ENST00000371953.7:c.740T>C, ENST00000472832.2:n.167T>C, NM_000314.6(PTEN):c.740T>C (p.Leu247Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [MET], PVS1 [Unmet], BS2 [Unmet], PP1 [Unmet], PP4 [Unmet], PP2 [MET], PP3 [Unmet], PS4-Supporting [MET], BA1 [Unmet], BP2 [Unmet], BP4 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS4 [Unmet], BS1 [Unmet], BS3 [Unmet], BP5 [Unmet], BP7 [Unmet]	PTEN c.740T>C (p.Leu247Ser) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 28086757)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 28086757)	28086757, 29752200, 28086757, 28086757, 29752200, 28086757, 29752200	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16044135/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103306627	225133	A	G	NM_000277.2(PAH):c.110T>C (p.Leu37Pro)	225133	CA357242	NM_000277.2:c.110T>C, NM_000277.1:c.110T>C, XM_011538422.1:c.110T>C, NM_001354304.1:c.110T>C, XM_017019370.2:c.110T>C, NM_000277.3:c.110T>C, ENST00000307000.7:c.95T>C, ENST00000546844.1:c.110T>C, ENST00000548677.2:n.197T>C, ENST00000548928.1:n.32T>C, ENST00000549111.5:n.206T>C, ENST00000550978.6:n.94T>C, ENST00000551337.5:c.110T>C, ENST00000551988.5:n.199T>C, ENST00000553106.5:c.110T>C, ENST00000635500.1:n.78T>C, NC_000012.12:g.102912849A>G, CM000674.2:g.102912849A>G, NC_000012.11:g.103306627A>G, CM000674.1:g.103306627A>G, NC_000012.10:g.101830757A>G, NG_008690.1:g.9754T>C, NG_008690.2:g.50562T>C, NM_000277.2(PAH):c.110T>C (p.Leu37Pro)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM3 [MET], PP3 [MET], PP4 [MET]	The c.110T>C (p.Leu37Pro) variant in PAH is reported in 1 patient with mild PKU. Assessment of BH4 deficiencies not reported. It was detected with a known pathogenic variant, p.R408W. (PMID: 24350308) This variant is absent from ExAC, gnomAD, 1000G, and ESP. A deleterious effect is predicted in SIFT, Polyphen-2, and MutationTaster. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PP4, PP3.	24350308, 24350308, 24078561	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA357242/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246635	225135	T	A	NM_000277.2(PAH):c.800A>T (p.Gln267Leu)	225135	CA354145	NM_000277.2:c.800A>T, NM_000277.1:c.800A>T, XM_011538422.1:c.800A>T, NM_001354304.1:c.800A>T, NM_000277.3:c.800A>T, ENST00000307000.7:c.785A>T, ENST00000549247.6:n.559A>T, ENST00000553106.5:c.800A>T, NC_000012.12:g.102852857T>A, CM000674.2:g.102852857T>A, NC_000012.11:g.103246635T>A, CM000674.1:g.103246635T>A, NC_000012.10:g.101770765T>A, NG_008690.1:g.69746A>T, NG_008690.2:g.110554A>T, NM_000277.2(PAH):c.800A>T (p.Gln267Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extremely low frequency in ExAC and gnomAD ( 0.00001, 0.000004063); PP3: Predicted deleterious in SIFT, Polyphen2, MutationTaster. REVEL=0.975; PP4_Moderate: Q267L found in 1 Japanese PKU allele and in 1 Chinese PKU patient. Analysis of dihydropteridine reductase activity in red blood cells, biopterin loading test and/or pteridine analysis in urine was performed in the Japanese study. Upgraded per ClinGen Metabolic workgroup. (PMID:21307867; PMID:24078561; PMID:26503515). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate)."	26503515, 21307867, 24078561	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA354145/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
14	31354707	226529	G	A	NM_004086.2(COCH):c.841G>A (p.Asp281Asn)	226529	CA7143202	NM_004086.2:c.841G>A, NC_000014.9:g.30885501G>A, CM000676.2:g.30885501G>A, NC_000014.8:g.31354707G>A, CM000676.1:g.31354707G>A, NC_000014.7:g.30424458G>A, NG_008211.2:g.15967G>A, NM_001135058.1:c.841G>A, NR_038356.1:n.1364C>T, XM_011536539.1:c.841G>A, NM_001347720.1:c.1036G>A, XM_017021071.1:c.1036G>A, XM_024449506.1:c.898G>A, NM_004086.3:c.841G>A, ENST00000216361.8:c.841G>A, ENST00000396618.7:c.841G>A, ENST00000460581.6:c.505G>A, ENST00000468826.2:n.492G>A, ENST00000475087.5:c.841G>A, ENST00000555881.5:c.487G>A, ENST00000557065.1:n.623G>A, NM_004086.2(COCH):c.841G>A (p.Asp281Asn)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1 [MET]	The filtering allele frequency of the c.841G>A (p.Asp281Asn) variant in the COCH gene is 0.5% for African chromosomes by gnomAD (145/24032 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA7143202/MONDO:0019497/005	0.1877	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 1, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
14	31348684	227258	A	G	NM_004086.2(COCH):c.429A>G (p.Pro143=)	227258	CA7143032	NM_004086.2:c.429A>G, NC_000014.9:g.30879478A>G, CM000676.2:g.30879478A>G, NC_000014.8:g.31348684A>G, CM000676.1:g.31348684A>G, NC_000014.7:g.30418435A>G, NG_008211.2:g.9944A>G, NM_001135058.1:c.429A>G, NR_038356.1:n.1618-2926T>C, XM_011536539.1:c.429A>G, NM_001347720.1:c.624A>G, XM_017021071.1:c.624A>G, XM_024449506.1:c.429A>G, NM_004086.3:c.429A>G, ENST00000216361.8:c.429A>G, ENST00000396618.7:c.429A>G, ENST00000460581.6:c.93A>G, ENST00000475087.5:c.429A>G, ENST00000553772.5:c.240-974A>G, ENST00000553833.5:n.583A>G, ENST00000555881.5:c.83-974A>G, ENST00000556908.5:c.381A>G, ENST00000557065.1:n.211A>G, NM_004086.2(COCH):c.429A>G (p.Pro143=)	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1 [MET]	The filtering allele frequency (the lower threshold of the 95% CI of 44/24026) of the c.429A>G (p.Pro143=) variant in the COCH gene is 0.14% for African chromosomes by gnomAD, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA7143032/MONDO:0019497/005	0.4999	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
1	41285030	227469	C	G	NM_004700.3(KCNQ4):c.720C>G (p.Thr240=)	227469	CA10576423	NM_004700.3:c.720C>G, NC_000001.11:g.40819358C>G, CM000663.2:g.40819358C>G, NC_000001.10:g.41285030C>G, CM000663.1:g.41285030C>G, NC_000001.9:g.41057617C>G, NG_008139.1:g.40347C>G, NG_008139.2:g.40347C>G, NM_172163.2:c.720C>G, XM_011542417.1:c.720C>G, XM_011542418.1:c.720C>G, XM_011542419.1:c.720C>G, XM_011542420.1:c.720C>G, XR_946798.1:n.726C>G, XR_946799.1:n.726C>G, XR_946800.1:n.726C>G, XM_017002792.1:c.-298C>G, NM_004700.4:c.720C>G, ENST00000347132.9:c.720C>G, ENST00000443478.3:n.406C>G, ENST00000506017.1:n.39C>G, ENST00000509682.6:n.720C>G, NM_004700.3(KCNQ4):c.720C>G (p.Thr240=)	KCNQ4	hearing loss	MONDO:0005365	Autosomal dominant inheritance	Likely Benign	PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [MET], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [MET], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	The silent p.Thr240= variant in KCNQ4 is not predicted by computational tools to impact splicing (BP7. BP4). The variant is absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org), however this is not considered evidence against a likely benign classification. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied: BP7, BP4.		Hearing Loss EP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	2/10/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10576423/MONDO:0005365/005	0.1877	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
16	68845762	231647	G	A	NM_004700.3(KCNQ4):c.720C>G (p.Thr240=)	227469	CA10576423	NM_004700.3:c.720C>G, NM_172163.2:c.720C>G, XM_011542417.1:c.720C>G, XM_011542418.1:c.720C>G, XM_011542419.1:c.720C>G, XM_011542420.1:c.720C>G, XR_946798.1:n.726C>G, XR_946799.1:n.726C>G, XR_946800.1:n.726C>G, XM_017002792.1:c.-298C>G, NM_004700.4:c.720C>G, ENST00000347132.9:c.720C>G, ENST00000443478.3:n.406C>G, ENST00000506017.1:n.39C>G, ENST00000509682.6:n.720C>G, NC_000001.11:g.40819358C>G, CM000663.2:g.40819358C>G, NC_000001.10:g.41285030C>G, CM000663.1:g.41285030C>G, NC_000001.9:g.41057617C>G, NG_008139.1:g.40347C>G, NG_008139.2:g.40347C>G, NM_004700.3(KCNQ4):c.720C>G (p.Thr240=)	KCNQ4	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Likely Benign	PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [MET], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [MET], BP5 [Unmet]	The silent p.Thr240= variant in KCNQ4 is not predicted by computational tools to impact splicing (BP7. BP4). The variant is absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org), however this is not considered evidence against a likely benign classification. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied: BP7, BP4.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10576423/MONDO:0019497/005	0.4999	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89653805	231916	A	G	NM_004360.4(CDH1):c.1008G>A (p.Glu336=)	231647	CA10580100	NM_004360.4:c.1008G>A, NM_004360.3:c.1008G>A, LRG_301t1:c.1008G>A, XM_011523488.1:c.273G>A, XM_011523489.1:c.273G>A, NM_001317184.1:c.1008G>A, NM_001317185.1:c.-608G>A, NM_001317186.1:c.-812G>A, ENST00000261769.9:c.1008G>A, ENST00000422392.6:c.1008G>A, ENST00000561751.1:n.630G>A, ENST00000562836.5:n.1079G>A, ENST00000566510.5:c.852G>A, ENST00000566612.5:c.1008G>A, ENST00000611625.4:c.1008G>A, ENST00000612417.4:c.1008G>A, ENST00000621016.4:c.1008G>A, NC_000016.10:g.68811859G>A, CM000678.2:g.68811859G>A, NC_000016.9:g.68845762G>A, CM000678.1:g.68845762G>A, NC_000016.8:g.67403263G>A, NG_008021.1:g.79568G>A, LRG_301:g.79568G>A, NM_004360.4(CDH1):c.1008G>A (p.Glu336=)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS1 [Unmet], PS4 [Unmet], PS2 [Unmet], PVS1-Moderate [MET]	"The c.1008G>A p.(Glu336=) variant results in a G to non-G change at the last nucleotide of an exon (PVS1_Moderate). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). There is also an RNA assay demonstrating abnormal out-of-frame transcript (PS3; PMID: 18427545). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Moderate, PM2, PS3."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10580100/MONDO:0007648/007	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89624244	233415	A	G	NM_000314.6(PTEN):c.103A>G (p.Met35Val)	231916	CA10578906	NM_000314.6:c.103A>G, NC_000010.11:g.87894048A>G, CM000672.2:g.87894048A>G, NC_000010.10:g.89653805A>G, CM000672.1:g.89653805A>G, NC_000010.9:g.89643785A>G, NG_007466.2:g.35610A>G, LRG_311:g.35610A>G, NM_000314.5:c.103A>G, NM_001304717.2:c.622A>G, NM_001304718.1:c.-603A>G, XM_006717926.2:c.103A>G, XM_011539981.1:c.103A>G, XM_011539982.1:c.68+13610A>G, XR_945789.1:n.815A>G, XR_945790.1:n.815A>G, XR_945791.1:n.815A>G, NM_000314.7:c.103A>G, NM_001304717.5:c.622A>G, NM_001304718.2:c.-603A>G, ENST00000371953.7:c.103A>G, ENST00000462694.1:n.105A>G, ENST00000610634.1:c.1A>G, NM_000314.6(PTEN):c.103A>G (p.Met35Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PP2 [MET], PS2 [MET], PS4-Moderate [MET]	"PTEN c.103A>G (p.M35V) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000275912.5)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (Internal laboratory contributor(s) SCV000565444.4, SCV000275912.5)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	18/10/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10578906/MONDO:0017623/003	0.1877	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
16	68853296	234554	C	G	NM_000314.6(PTEN):c.18A>G (p.Lys6=)	233415	CA10578903	NM_000314.6:c.18A>G, NM_000314.5:c.18A>G, NM_001304717.2:c.537A>G, NM_001304718.1:c.-688A>G, XM_006717926.2:c.18A>G, XM_011539981.1:c.18A>G, XR_945789.1:n.730A>G, XR_945790.1:n.730A>G, XR_945791.1:n.730A>G, NM_000314.7:c.18A>G, NM_001304717.5:c.537A>G, NM_001304718.2:c.-688A>G, ENST00000371953.7:c.18A>G, ENST00000462694.1:n.20A>G, ENST00000487939.1:n.39A>G, ENST00000610634.1:c.-85A>G, NC_000010.11:g.87864487A>G, CM000672.2:g.87864487A>G, NC_000010.10:g.89624244A>G, CM000672.1:g.89624244A>G, NC_000010.9:g.89614224A>G, NG_007466.2:g.6049A>G, LRG_311:g.6049A>G, NG_033079.1:g.3951T>C, NM_000314.6(PTEN):c.18A>G (p.Lys6=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	BP4 [MET], BP7 [MET]	"PTEN c.18A>G (p.L6=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted."		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	12/10/16	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10578903/MONDO:0017623/003	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
10	89725110	237639	G	A	NM_004360.4(CDH1):c.1679C>G (p.Thr560Arg)	234554	CA10577547	NM_004360.4:c.1679C>G, NM_004360.3:c.1679C>G, LRG_301t1:c.1679C>G, XM_011523488.1:c.944C>G, XM_011523489.1:c.944C>G, NM_001317184.1:c.1496C>G, NM_001317185.1:c.131C>G, NM_001317186.1:c.-254-2608C>G, ENST00000261769.9:c.1679C>G, ENST00000422392.6:c.1496C>G, ENST00000562836.5:n.1750C>G, ENST00000566510.5:c.*345C>G, ENST00000566612.5:c.1566-2608C>G, ENST00000611625.4:c.1742C>G, ENST00000612417.4:c.1679C>G, ENST00000621016.4:c.1679C>G, NC_000016.10:g.68819393C>G, CM000678.2:g.68819393C>G, NC_000016.9:g.68853296C>G, CM000678.1:g.68853296C>G, NC_000016.8:g.67410797C>G, NG_008021.1:g.87102C>G, LRG_301:g.87102C>G, NM_004360.4(CDH1):c.1679C>G (p.Thr560Arg)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS4 [MET], PS1 [Unmet], PS2 [Unmet], PP1-Strong [MET]	"The c.1679C>G (p.Thr560Arg) variant is absent in the gnomAD cohort (PM2;http://gnomad.broadinstitute.org). There are at least 3 in silico predictors in agreement that this variant affects splicing (PP3). There is also an RNA assay demonstrating abnormal out-of-frame transcript (PS3; PMID: 27880784). Additionally, the variant was found to co-segregation with disease in multiple affected family members, with >7 meioses observed across at least 4 families (PP1_Strong; PMID: 27880784, 29769627). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 27880784, 29769627, 23709761 and SCV000580704.2). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PM2, PP3, PS3, PP1_Strong, PS4."	29769627, 29769627, 23709761, 27880784, 29769627	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10577547/MONDO:0007648/007	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	89685300	237643	C	G	NM_000314.7(PTEN):c.1093G>A (p.Val365Ile)	237639	CA059160	NM_000314.7:c.1093G>A, NC_000010.11:g.87965353G>A, CM000672.2:g.87965353G>A, NC_000010.10:g.89725110G>A, CM000672.1:g.89725110G>A, NC_000010.9:g.89715090G>A, NG_007466.2:g.106915G>A, LRG_311:g.106915G>A, NM_000314.5:c.1093G>A, NM_000314.6:c.1093G>A, NM_001304717.2:c.1612G>A, NM_001304718.1:c.502G>A, XM_006717926.2:c.1048G>A, XM_011539982.1:c.997G>A, XR_945791.1:n.1663G>A, NM_001304717.5:c.1612G>A, NM_001304718.2:c.502G>A, ENST00000371953.7:c.1093G>A, NM_000314.7(PTEN):c.1093G>A (p.Val365Ile)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [MET], BS4 [Unmet]	PTEN c.1093G>A (p.Val365Ile) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3: Missense variants with both lipid phosphatase activity AND results from a second assay appropriate to the protein domain demonstrating no statistically significant difference from wild type. (PMID 29785012, 29706350)	29706350, 29785012	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA059160/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36164870	239039	C	A	NM_000314.6(PTEN):c.195C>G (p.Tyr65Ter)	237643	CA10582757	NM_000314.6:c.195C>G, NC_000010.11:g.87925543C>G, CM000672.2:g.87925543C>G, NC_000010.10:g.89685300C>G, CM000672.1:g.89685300C>G, NC_000010.9:g.89675280C>G, NG_007466.2:g.67105C>G, LRG_311:g.67105C>G, NM_000314.5:c.195C>G, NM_001304717.2:c.714C>G, NM_001304718.1:c.-541-5503C>G, XM_006717926.2:c.165-5503C>G, XM_011539981.1:c.195C>G, XM_011539982.1:c.99C>G, XR_945789.1:n.907C>G, XR_945790.1:n.907C>G, XR_945791.1:n.907C>G, NM_000314.7:c.195C>G, NM_001304717.5:c.714C>G, NM_001304718.2:c.-541-5503C>G, ENST00000371953.7:c.195C>G, ENST00000498703.1:n.21C>G, ENST00000610634.1:c.93C>G, NM_000314.6(PTEN):c.195C>G (p.Tyr65Ter)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS2 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.195C>G (p.Y65X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23335809)	21194675, 23335809, 28454995, 29785012, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10582757/MONDO:0017623/003	0.1	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
21	36164771	239040	C	CATGCCG	NM_001754.4(RUNX1):c.1005G>T (p.Gln335His)	239039	CA10014223	NM_001754.4:c.1005G>T, NC_000021.9:g.34792573C>A, CM000683.2:g.34792573C>A, NC_000021.8:g.36164870C>A, CM000683.1:g.36164870C>A, NC_000021.7:g.35086740C>A, NG_011402.2:g.1197139G>T, LRG_482:g.1197139G>T, NM_001001890.2:c.924G>T, LRG_482t1:c.1005G>T, XM_005261068.3:c.969G>T, XM_005261069.3:c.813G>T, XM_011529766.1:c.1005G>T, XM_011529767.1:c.966G>T, XM_011529768.1:c.774G>T, XR_937576.1:n.4609G>T, XM_005261069.4:c.813G>T, XM_011529766.2:c.1005G>T, XM_011529767.2:c.966G>T, XM_011529768.2:c.774G>T, XM_017028487.1:c.852G>T, XR_937576.2:n.4656G>T, ENST00000300305.7:c.1005G>T, ENST00000344691.8:c.924G>T, ENST00000399240.5:c.732G>T, ENST00000437180.5:c.1005G>T, ENST00000482318.5:c.*595G>T, NM_001754.4(RUNX1):c.1005G>T (p.Gln335His)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1 [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP3 [Unmet], PP1 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet]	The NM_001754.4:c.1005G>T (p.Gln335His) variant has a MAF of 0.00357 (0.357%, 15/4,206 alleles) in the East Asian subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This missense variant has a REVEL score 0.4. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014223/MONDO:0011071/008	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36164606	239042	G	A	NM_001754.4(RUNX1):c.1098_1103dupCGGCAT (p.Gly367_Met368insIleGly)	239040	CA10014201	NM_001754.4:c.1098_1103dup6, NM_001754.4:c.1098_1103dupCGGCAT, NC_000021.9:g.34792486_34792491dup, CM000683.2:g.34792486_34792491dup, NC_000021.8:g.36164783_36164788dup, CM000683.1:g.36164783_36164788dup, NC_000021.7:g.35086653_35086658dup, NG_011402.2:g.1197232_1197237dup, LRG_482:g.1197232_1197237dup, NM_001001890.2:c.1017_1022dup, NM_001754.4:c.1098_1103dup, LRG_482t1:c.1098_1103dup, XM_005261068.3:c.1062_1067dup, XM_005261069.3:c.906_911dup, XM_011529766.1:c.1098_1103dup, XM_011529767.1:c.1059_1064dup, XM_011529768.1:c.867_872dup, XM_005261069.4:c.906_911dup, XM_011529766.2:c.1098_1103dup, XM_011529767.2:c.1059_1064dup, XM_011529768.2:c.867_872dup, XM_017028487.1:c.945_950dup, ENST00000300305.7:c.1098_1103dup, ENST00000344691.8:c.1017_1022dup, ENST00000399240.5:c.825_830dup, ENST00000437180.5:c.1098_1103dup, ENST00000482318.5:c.*688_*693dup, NM_001754.4(RUNX1):c.1098_1103dupCGGCAT (p.Gly367_Met368insIleGly)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP2 [Unmet], BP4 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4-Moderate [MET], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS4 [Unmet], BS1 [Unmet], BS3 [Unmet], BP7 [Unmet], PP1 [Unmet], PP3 [Unmet], PM6 [Unmet], PM2 [MET], PVS1 [Unmet]	"The NM_001754.4:c.1098_1103dupCGGCAT (p.Gly367_Met368insIleGly) variant has been reported in two or three probands (two) meeting at least one of the RUNX1-phenotypic criteria (PS4_Moderate; PMID: 27210295, PMID: 28659335). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS4_moderate, PM2."	27210295, 28659335	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014201/MONDO:0011071/008	0.0014	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
21	36259336	239044	A	T	NM_001754.4(RUNX1):c.1269C>T (p.Arg423=)	239042	CA10014189	NM_001754.4:c.1269C>T, NC_000021.9:g.34792309G>A, CM000683.2:g.34792309G>A, NC_000021.8:g.36164606G>A, CM000683.1:g.36164606G>A, NC_000021.7:g.35086476G>A, NG_011402.2:g.1197403C>T, LRG_482:g.1197403C>T, NM_001001890.2:c.1188C>T, LRG_482t1:c.1269C>T, XM_005261068.3:c.1233C>T, XM_005261069.3:c.1077C>T, XM_011529766.1:c.1269C>T, XM_011529767.1:c.1230C>T, XM_011529768.1:c.1038C>T, XM_005261069.4:c.1077C>T, XM_011529766.2:c.1269C>T, XM_011529767.2:c.1230C>T, XM_011529768.2:c.1038C>T, XM_017028487.1:c.1116C>T, ENST00000300305.7:c.1269C>T, ENST00000344691.8:c.1188C>T, ENST00000399240.5:c.996C>T, ENST00000437180.5:c.1269C>T, ENST00000482318.5:c.*859C>T, NM_001754.4(RUNX1):c.1269C>T (p.Arg423=)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4 [MET], BP2 [Unmet], BA1 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM4 [Unmet], PM5 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PM6 [Unmet], PM2 [Unmet], PVS1 [Unmet]	The MAF for the synonymous variant, NM_001754.4:c.1269C>T (p.Arg423=) is 0.00275 (0.2%, 14/5096 alleles) in the non-Finnish European subpopulation of the ExAC cohort, which is â‰¥ 0.0015 (0.15%) (BA1). This variant is predicted by SSF and MES to lead to an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% AND no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014189/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36259324	239045	A	G	NM_001754.4(RUNX1):c.155T>A (p.Met52Lys)	239044	CA10014581	NM_001754.4:c.155T>A, NM_001001890.2:c.74T>A, NM_001122607.1:c.74T>A, LRG_482t1:c.155T>A, XM_005261068.3:c.119T>A, XM_005261069.3:c.155T>A, XM_011529766.1:c.155T>A, XM_011529767.1:c.116T>A, XM_011529768.1:c.116T>A, XM_011529770.1:c.155T>A, XR_937576.1:n.334T>A, XM_005261069.4:c.155T>A, XM_011529766.2:c.155T>A, XM_011529767.2:c.116T>A, XM_011529768.2:c.116T>A, XM_011529770.2:c.155T>A, XM_017028487.1:c.2T>A, XR_937576.2:n.381T>A, ENST00000300305.7:c.155T>A, ENST00000344691.8:c.74T>A, ENST00000358356.9:c.74T>A, ENST00000399237.6:c.119T>A, ENST00000399240.5:c.74T>A, ENST00000437180.5:c.155T>A, ENST00000455571.5:c.116T>A, ENST00000482318.5:c.59-6326T>A, NC_000021.9:g.34887039A>T, CM000683.2:g.34887039A>T, NC_000021.8:g.36259336A>T, CM000683.1:g.36259336A>T, NC_000021.7:g.35181206A>T, NG_011402.2:g.1102673T>A, LRG_482:g.1102673T>A, NM_001754.4(RUNX1):c.155T>A (p.Met52Lys)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [MET], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.155T>A (p.Met52Lys) variant has a MAF of 0.00071 (0.071%, 6/8,456 alleles) in the EA Allele subpopulation of the ESP cohort that is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). This missense variant has a REVEL score >0.75 (0.845) (PP3). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, PP3.	29365323	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014581/MONDO:0011071/008	0.0014	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
21	36206858	239052	G	A	NM_001754.4(RUNX1):c.167T>C (p.Leu56Ser)	239045	CA10014578	NM_001754.4:c.167T>C, NM_001001890.2:c.86T>C, NM_001122607.1:c.86T>C, LRG_482t1:c.167T>C, XM_005261068.3:c.131T>C, XM_005261069.3:c.167T>C, XM_011529766.1:c.167T>C, XM_011529767.1:c.128T>C, XM_011529768.1:c.128T>C, XM_011529770.1:c.167T>C, XR_937576.1:n.346T>C, XM_005261069.4:c.167T>C, XM_011529766.2:c.167T>C, XM_011529767.2:c.128T>C, XM_011529768.2:c.128T>C, XM_011529770.2:c.167T>C, XM_017028487.1:c.14T>C, XR_937576.2:n.393T>C, ENST00000300305.7:c.167T>C, ENST00000344691.8:c.86T>C, ENST00000358356.9:c.86T>C, ENST00000399237.6:c.131T>C, ENST00000399240.5:c.86T>C, ENST00000437180.5:c.167T>C, ENST00000455571.5:c.128T>C, ENST00000482318.5:c.59-6314T>C, NC_000021.9:g.34887027A>G, CM000683.2:g.34887027A>G, NC_000021.8:g.36259324A>G, CM000683.1:g.36259324A>G, NC_000021.7:g.35181194A>G, NG_011402.2:g.1102685T>C, LRG_482:g.1102685T>C, NM_001754.4(RUNX1):c.167T>C (p.Leu56Ser)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4 [Unmet], BP2 [MET], BA1 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [MET], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.167T>C (p.Leu56Ser) variant has a MAF of 0.03259 (3.259%, 518/15,894 alleles) in the South Asian subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (56) in gnomAD population database (BP2). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding, CBFÎ² binding and sub-cellular localization (BS3; PMID: 23817177). Two patients reported in PMID:29365323 with AML. But PS4 can not apply in combined with BA1. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BS3, BP2."	23817177	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014578/MONDO:0011071/008	0.0014	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
16	68771321	239906	G	A	NM_001754.4(RUNX1):c.654C>T (p.Ser218=)	239052	CA10014384	NM_001754.4:c.654C>T, NC_000021.9:g.34834561G>A, CM000683.2:g.34834561G>A, NC_000021.8:g.36206858G>A, CM000683.1:g.36206858G>A, NC_000021.7:g.35128728G>A, NG_011402.2:g.1155151C>T, LRG_482:g.1155151C>T, NM_001001890.2:c.573C>T, NM_001122607.1:c.573C>T, LRG_482t1:c.654C>T, XM_005261068.3:c.618C>T, XM_005261069.3:c.613+24913C>T, XM_011529766.1:c.654C>T, XM_011529767.1:c.615C>T, XM_011529768.1:c.574+24913C>T, XM_011529770.1:c.654C>T, XR_937576.1:n.833C>T, XM_005261069.4:c.613+24913C>T, XM_011529766.2:c.654C>T, XM_011529767.2:c.615C>T, XM_011529768.2:c.574+24913C>T, XM_011529770.2:c.654C>T, XM_017028487.1:c.501C>T, XR_937576.2:n.880C>T, ENST00000300305.7:c.654C>T, ENST00000344691.8:c.573C>T, ENST00000358356.9:c.573C>T, ENST00000399237.6:c.618C>T, ENST00000399240.5:c.532+24913C>T, ENST00000437180.5:c.654C>T, ENST00000469087.1:n.190C>T, ENST00000482318.5:c.*244C>T, NM_001754.4(RUNX1):c.654C>T (p.Ser218=)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP2 [Unmet], BP4 [MET], BA1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS4 [Unmet], PS1 [Unmet], PS3 [Unmet], BP7 [Unmet], BS1 [MET], BS4 [Unmet], BS3 [Unmet], PP1 [Unmet], PP3 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The MAF of the synonymous variant, NM_001754.4:c.654C>T (p.Ser218=), is 0.00105 (0.1%, 36/34418 alleles) in the Latino subpopulation of the gnomAD cohort, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). This synonymous variant is predicted by SSF and MES to lead to an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% AND no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1, BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014384/MONDO:0011071/008	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68844245	239914	G	T	NM_004360.4(CDH1):c.3G>A (p.Met1Ile)	239906	CA10583399	NM_004360.4:c.3G>A, NC_000016.10:g.68737418G>A, CM000678.2:g.68737418G>A, NC_000016.9:g.68771321G>A, CM000678.1:g.68771321G>A, NC_000016.8:g.67328822G>A, NG_008021.1:g.5127G>A, LRG_301:g.5127G>A, NM_004360.3:c.3G>A, LRG_301t1:c.3G>A, NM_001317184.1:c.3G>A, NM_001317185.1:c.-1613G>A, NM_001317186.1:c.-1817G>A, ENST00000261769.9:c.3G>A, ENST00000422392.6:c.3G>A, ENST00000566510.5:c.3G>A, ENST00000566612.5:c.3G>A, ENST00000611625.4:c.3G>A, ENST00000612417.4:c.3G>A, ENST00000621016.4:c.3G>A, NM_004360.4(CDH1):c.3G>A (p.Met1Ile)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Pathogenic	BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PP1-Moderate [MET], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS4-Moderate [MET], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PVS1-Moderate [MET]	"The c.3G>A (p.Met1Ile) variant may cause a truncated or absent protein by altering the start codon of the coding sequence and is predicted to lead to the omission of a critical region of the protein (18726070, 2317870, 20066110) (PVS1_Moderate). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with 5 or 6 meioses observed (PP1_Moderate; PMID:  28202063, 26182300). This variant has also been reported in at least 2 families meeting HDGC clinical criteria (PS4_Moderate; PMID: 26182300, 20719348). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Moderate, PM2, PP1_Moderate, PS4_Moderate."	26182300, 28202063, 26182300, 28202063, 26182300, 20719348, 16061854	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10583399/MONDO:0007648/007	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89717626	255814	C	T	NM_004360.4(CDH1):c.832+1G>T	239914	CA10583412	NM_004360.4:c.832+1G>T, NM_004360.3:c.832+1G>T, LRG_301t1:c.832+1G>T, XM_011523488.1:c.97+1G>T, XM_011523489.1:c.97+1G>T, NM_001317184.1:c.832+1G>T, NM_001317185.1:c.-784+1G>T, NM_001317186.1:c.-988+1G>T, ENST00000261769.9:c.832+1G>T, ENST00000422392.6:c.832+1G>T, ENST00000561751.1:n.455-1342G>T, ENST00000562836.5:n.903+1G>T, ENST00000566510.5:c.676+1G>T, ENST00000566612.5:c.832+1G>T, ENST00000611625.4:c.832+1G>T, ENST00000612417.4:c.832+1G>T, ENST00000621016.4:c.832+1G>T, NC_000016.10:g.68810342G>T, CM000678.2:g.68810342G>T, NC_000016.9:g.68844245G>T, CM000678.1:g.68844245G>T, NC_000016.8:g.67401746G>T, NG_008021.1:g.78051G>T, LRG_301:g.78051G>T, NM_004360.4(CDH1):c.832+1G>T	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM2 [MET], PM6 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PM4 [Unmet], PVS1-Strong [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS4 [MET], PS3 [Unmet], PS2 [Unmet]	"The c.832+G>T variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong). The variant is present in <1/100,000 alleles in the gnomAD cohort. (PM2; http://gnomad.broadinstitute.org).  This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID: 23709761, 23124477, 26182300 and SCV000288497.3). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Strong, PM2, PS4."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10583412/MONDO:0007648/007	0.3246	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
21	36164486	258184	G	C	NM_000314.6(PTEN):c.651C>T (p.Val217=)	255814	CA10587096	NM_000314.6:c.651C>T, NC_000010.11:g.87957869C>T, CM000672.2:g.87957869C>T, NC_000010.10:g.89717626C>T, CM000672.1:g.89717626C>T, NC_000010.9:g.89707606C>T, NG_007466.2:g.99431C>T, LRG_311:g.99431C>T, NM_000314.5:c.651C>T, NM_001304717.2:c.1170C>T, NM_001304718.1:c.60C>T, XM_006717926.2:c.606C>T, XM_011539981.1:c.651C>T, XM_011539982.1:c.555C>T, XR_945791.1:n.1221C>T, NM_000314.7:c.651C>T, NM_001304717.5:c.1170C>T, NM_001304718.2:c.60C>T, ENST00000371953.7:c.651C>T, ENST00000472832.2:n.78C>T, NM_000314.6(PTEN):c.651C>T (p.Val217=)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Benign	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [MET], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [MET], BP5 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.651C>T (p.V217=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact.BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	25/7/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10587096/MONDO:0017623/003	0.0003	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
21	36259125	258185	T	C	NM_001754.4(RUNX1):c.1389C>G (p.Pro463=)	258184	CA10014178	NM_001754.4:c.1389C>G, NM_001001890.2:c.1308C>G, LRG_482t1:c.1389C>G, XM_005261068.3:c.1353C>G, XM_005261069.3:c.1197C>G, XM_011529766.1:c.1389C>G, XM_011529767.1:c.1350C>G, XM_011529768.1:c.1158C>G, XM_005261069.4:c.1197C>G, XM_011529766.2:c.1389C>G, XM_011529767.2:c.1350C>G, XM_011529768.2:c.1158C>G, XM_017028487.1:c.1236C>G, ENST00000300305.7:c.1389C>G, ENST00000344691.8:c.1308C>G, ENST00000399240.5:c.1116C>G, ENST00000437180.5:c.1389C>G, ENST00000482318.5:c.*979C>G, NC_000021.9:g.34792189G>C, CM000683.2:g.34792189G>C, NC_000021.8:g.36164486G>C, CM000683.1:g.36164486G>C, NC_000021.7:g.35086356G>C, NG_011402.2:g.1197523C>G, LRG_482:g.1197523C>G, NM_001754.4(RUNX1):c.1389C>G (p.Pro463=)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1 [MET], BP4 [MET], BP2 [MET], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], BP7 [MET], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PM6 [Unmet], PM2 [Unmet], PVS1 [Unmet]	The MAF for the synonymous variant, NM_001754.4:c.1389C>G (p.Pro463=) is 	0.1206 (12%, 1976/16382 alleles) in the African subpopulation of the gnomAD cohort, which is â‰¥ 0.0015 (0.15%) (BA1). This variant is predicted by SSF and MES to lead to an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% AND no putative cryptic splice sites are created (BP4). This synonymous variant is predicted by evolutionary conservation prediction algorithms that the site is not conserved (PhyloP score -0.503315 <0.1) (BP7). This variant is detected in a homozygous state in 202 individuals in a gnomAD (BP2). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4, BP7.	27106701	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	0.0007	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
21	36206932	258186	G	A	NM_001754.4(RUNX1):c.351+15A>G	258185	CA10014545	NM_001754.4:c.351+15A>G, NM_001001890.2:c.270+15A>G, NM_001122607.1:c.270+15A>G, LRG_482t1:c.351+15A>G, XM_005261068.3:c.315+15A>G, XM_005261069.3:c.351+15A>G, XM_011529766.1:c.351+15A>G, XM_011529767.1:c.312+15A>G, XM_011529768.1:c.312+15A>G, XM_011529770.1:c.351+15A>G, XR_937576.1:n.530+15A>G, XM_005261069.4:c.351+15A>G, XM_011529766.2:c.351+15A>G, XM_011529767.2:c.312+15A>G, XM_011529768.2:c.312+15A>G, XM_011529770.2:c.351+15A>G, XM_017028487.1:c.198+15A>G, XR_937576.2:n.577+15A>G, ENST00000300305.7:c.351+15A>G, ENST00000344691.8:c.270+15A>G, ENST00000358356.9:c.270+15A>G, ENST00000399237.6:c.315+15A>G, ENST00000399240.5:c.270+15A>G, ENST00000437180.5:c.351+15A>G, ENST00000455571.5:c.312+15A>G, ENST00000482318.5:c.59-6115A>G, NC_000021.9:g.34886828T>C, CM000683.2:g.34886828T>C, NC_000021.8:g.36259125T>C, CM000683.1:g.36259125T>C, NC_000021.7:g.35180995T>C, NG_011402.2:g.1102884A>G, LRG_482:g.1102884A>G, NM_001754.4(RUNX1):c.351+15A>G	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1 [MET], BP4 [MET], BP2 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [MET], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.351+15A>G variant has a MAF of 0.00809 (0.809%, 524/64,760 alleles) in the European (Non-Finnish) subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (8) in gnomAD population database (BP2). This intronic variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In addition, evolutionary conservation prediction algorithms predict the site as not being highly conserved (PhyloP score -1.34728 < 0.1) (BP7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4, BP7.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014545/MONDO:0011071/008	0	Benign auto	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=1 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
11	533534	259747	G	A	NM_001754.4(RUNX1):c.614-34C>T	258186	CA10014405	NM_001754.4:c.614-34C>T, NM_001001890.2:c.533-34C>T, NM_001122607.1:c.533-34C>T, LRG_482t1:c.614-34C>T, XM_005261068.3:c.578-34C>T, XM_005261069.3:c.613+24839C>T, XM_011529766.1:c.614-34C>T, XM_011529767.1:c.575-34C>T, XM_011529768.1:c.574+24839C>T, XM_011529770.1:c.614-34C>T, XR_937576.1:n.793-34C>T, XM_005261069.4:c.613+24839C>T, XM_011529766.2:c.614-34C>T, XM_011529767.2:c.575-34C>T, XM_011529768.2:c.574+24839C>T, XM_011529770.2:c.614-34C>T, XM_017028487.1:c.461-34C>T, XR_937576.2:n.840-34C>T, ENST00000300305.7:c.614-34C>T, ENST00000344691.8:c.533-34C>T, ENST00000358356.9:c.533-34C>T, ENST00000399237.6:c.578-34C>T, ENST00000399240.5:c.532+24839C>T, ENST00000437180.5:c.614-34C>T, ENST00000469087.1:n.150-34C>T, ENST00000482318.5:c.*204-34C>T, NC_000021.9:g.34834635G>A, CM000683.2:g.34834635G>A, NC_000021.8:g.36206932G>A, CM000683.1:g.36206932G>A, NC_000021.7:g.35128802G>A, NG_011402.2:g.1155077C>T, LRG_482:g.1155077C>T, NM_001754.4(RUNX1):c.614-34C>T	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1 [MET], BP4 [MET], BP2 [MET], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.614-34C>T variant has a MAF of 1 (100%) in gnomAD cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state in gnomAD population database (BP2). This intronic variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014405/MONDO:0011071/008	0.025	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
19	4094469	261928	C	T	NM_005343.3(HRAS):c.369C>T (p.Arg123=)	259747	CA5779327	NM_005343.3:c.369C>T, NM_001130442.1:c.369C>T, NM_005343.2:c.369C>T, NM_176795.3:c.369C>T, XM_011519875.1:c.-424-5064G>A, XM_011519877.1:c.-162+5197G>A, XR_242795.1:n.568C>T, NM_001130442.2:c.369C>T, NM_001318054.1:c.50C>T, NM_176795.4:c.369C>T, XM_011519875.2:c.-424-5064G>A, XM_011519877.2:c.-162+5197G>A, XM_017017167.1:c.-499-4989G>A, XM_017017168.1:c.-499-4989G>A, NM_005343.4:c.369C>T, ENST00000311189.7:c.369C>T, ENST00000397594.5:c.369C>T, ENST00000397596.6:c.369C>T, ENST00000417302.5:c.369C>T, ENST00000451590.5:c.369C>T, ENST00000462734.1:n.62C>T, ENST00000478324.5:n.79C>T, ENST00000479482.1:n.290C>T, ENST00000493230.5:c.369C>T, NC_000011.10:g.533534G>A, CM000673.2:g.533534G>A, NC_000011.9:g.533534G>A, CM000673.1:g.533534G>A, NC_000011.8:g.523534G>A, NG_007666.1:g.7017C>T, NM_005343.3(HRAS):c.369C>T (p.Arg123=)	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.369C>T (p.Arg123=) variant in the HRAS gene is 0.089% (13/8638) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5779327/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
12	103238196	281073	G	A	NM_030662.3(MAP2K2):c.1074G>A (p.Ala358=)	261928	CA9090706	NM_030662.3:c.1074G>A, NC_000019.10:g.4094471C>T, CM000681.2:g.4094471C>T, NC_000019.9:g.4094469C>T, CM000681.1:g.4094469C>T, NC_000019.8:g.4045469C>T, NG_007996.1:g.34658G>A, LRG_750:g.34658G>A, LRG_750t1:c.1074G>A, XM_006722799.2:c.795G>A, XM_011528133.1:c.504G>A, ENST00000262948.9:c.1074G>A, ENST00000394867.8:c.783G>A, ENST00000597263.5:n.259G>A, ENST00000599021.1:n.184G>A, ENST00000600584.5:n.2523G>A, ENST00000601786.5:n.1375G>A, NM_030662.3(MAP2K2):c.1074G>A (p.Ala358=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1074G>A (p.Ala358=) variant in the MAP2K2 gene is 0.174% (10/3124) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9090706/MONDO:0021060/004	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
14	31349945	281981	C	T	NM_000277.1(PAH):c.983C>T (p.Thr328Ile)	281073	CA10603804	NM_000277.1:c.983C>T, XM_011538422.1:c.926C>T, NM_000277.2:c.983C>T, NM_001354304.1:c.983C>T, NM_000277.3:c.983C>T, ENST00000307000.7:c.968C>T, ENST00000549247.6:n.742C>T, ENST00000551114.2:n.645C>T, ENST00000553106.5:c.983C>T, ENST00000635477.1:n.87C>T, ENST00000635528.1:n.498C>T, NC_000012.12:g.102844418G>A, CM000674.2:g.102844418G>A, NC_000012.11:g.103238196G>A, CM000674.1:g.103238196G>A, NC_000012.10:g.101762326G>A, NG_008690.1:g.78185C>T, NG_008690.2:g.118993C>T, NM_000277.1(PAH):c.983C>T (p.Thr328Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM5 [Unmet], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Predicted deleterious in SIFT, PolyPhen2, Mutation Taster. REVEL=0.952. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10603804/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
1	215802181	282144	G	C	NM_004086.2(COCH):c.629+5C>T	281981	CA7143097	NM_004086.2:c.629+5C>T, NM_001135058.1:c.629+5C>T, NR_038356.1:n.1617+3771G>A, XM_011536539.1:c.629+5C>T, NM_001347720.1:c.824+5C>T, XM_017021071.1:c.824+5C>T, XM_024449506.1:c.629+5C>T, NM_004086.3:c.629+5C>T, ENST00000216361.8:c.629+5C>T, ENST00000396618.7:c.629+5C>T, ENST00000460581.6:c.293+5C>T, ENST00000468826.2:n.148+5C>T, ENST00000475087.5:c.629+5C>T, ENST00000553772.5:c.*189+5C>T, ENST00000555881.5:c.275+5C>T, ENST00000557065.1:n.411+5C>T, NC_000014.9:g.30880739C>T, CM000676.2:g.30880739C>T, NC_000014.8:g.31349945C>T, CM000676.1:g.31349945C>T, NC_000014.7:g.30419696C>T, NG_008211.2:g.11205C>T, NM_004086.2(COCH):c.629+5C>T	COCH	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Benign	BA1 [MET]	The filtering allele frequency of the c.629+5C>T variant in the COCH gene is 0.1% for European chromosomes by gnomAD (162/126474 with 95% CI), which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal dominant hearing loss variants (BA1).		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA7143097/MONDO:0019497/005	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288566	306914	T	C	NM_206933.2(USH2A):c.15494C>G (p.Ala5165Gly)	282144	CA1392668	NM_206933.2:c.15494C>G, NM_206933.3:c.15494C>G, ENST00000307340.7:c.15494C>G, NC_000001.11:g.215628839G>C, CM000663.2:g.215628839G>C, NC_000001.10:g.215802181G>C, CM000663.1:g.215802181G>C, NC_000001.9:g.213868804G>C, NG_009497.1:g.799558C>G, NM_206933.2(USH2A):c.15494C>G (p.Ala5165Gly)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Likely Benign	PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], BS1-Supporting [MET], BA1 [Unmet], BP4 [MET], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS4 [Unmet]	"The filtering allele frequency of the p.Ala5165Gly variant in the USH2A gene is 0.21% (63/24034) of African chromosomes chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org; calculated by using inverse allele frequency at https://www.cardiodb.org/allelefrequencyapp/), which is a higher frequency than would be expected for an autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). Computational prediction tools and conservation analysis suggest that this variant may not impact the protein (BP4). In summary, this variant meets criteria to be classified as likely benign based on the ACMG/AMP criteria applied (BS1_Supporting, BP4)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1392668/MONDO:0019501/005	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	112915678	307226	G	A	NM_000277.2(PAH):c.299A>G (p.His100Arg)	306914	CA6748985	NM_000277.2:c.299A>G, NM_000277.1:c.299A>G, XM_011538422.1:c.299A>G, NM_001354304.1:c.299A>G, XM_017019370.2:c.299A>G, NM_000277.3:c.299A>G, ENST00000307000.7:c.284A>G, ENST00000546844.1:c.299A>G, ENST00000548928.1:n.221A>G, ENST00000549111.5:n.395A>G, ENST00000550978.6:n.283A>G, ENST00000551337.5:c.299A>G, ENST00000551988.5:n.388A>G, ENST00000553106.5:c.299A>G, NC_000012.12:g.102894788T>C, CM000674.2:g.102894788T>C, NC_000012.11:g.103288566T>C, CM000674.1:g.103288566T>C, NC_000012.10:g.101812696T>C, NG_008690.1:g.27815A>G, NG_008690.2:g.68623A>G, NM_000277.2(PAH):c.299A>G (p.His100Arg)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [Unmet], PM3 [MET], PP4 [MET], BP4 [MET]	"PAH-specific ACMG/AMP criteria applied: BP4: In silico overwhelmingly predict benign. REVEL = 0.553; PP4: Detected in a patient with non PKU hyperphe (PMID:11244681); PM3: H100R detected with IVS10 (PMID:11244681). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BP4, PP4, PM3)."	11244681, 11244681	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6748985/MONDO:0009861/006	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
21	36164453	339874	C	A	NM_002834.4(PTPN11):c.951G>A (p.Lys317=)	307226	CA6798691	NM_002834.4:c.951G>A, NM_002834.3:c.951G>A, LRG_614t1:c.951G>A, NM_080601.1:c.951G>A, XM_006719526.1:c.951G>A, XM_006719527.1:c.837G>A, XM_011538613.1:c.948G>A, NM_001330437.1:c.951G>A, NM_080601.2:c.951G>A, XM_011538613.2:c.948G>A, XM_017019722.1:c.948G>A, ENST00000351677.6:c.951G>A, ENST00000392597.5:c.951G>A, ENST00000635625.1:n.951G>A, NC_000012.12:g.112477874G>A, CM000674.2:g.112477874G>A, NC_000012.11:g.112915678G>A, CM000674.1:g.112915678G>A, NC_000012.10:g.111400061G>A, NG_007459.1:g.64143G>A, LRG_614:g.64143G>A, NM_002834.4(PTPN11):c.951G>A (p.Lys317=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.951G>A (p.Lys317=) variant in the PTPN11 gene is 0.231% (49/16480) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6798691/MONDO:0021060/004	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 0, 0] 	2	Uncertain Significance
21	36164520	339875	A	C	NM_001754.4(RUNX1):c.1422G>T (p.Glu474Asp)	339874	CA10652929	NM_001754.4:c.1422G>T, NM_001001890.2:c.1341G>T, LRG_482t1:c.1422G>T, XM_005261068.3:c.1386G>T, XM_005261069.3:c.1230G>T, XM_011529766.1:c.1422G>T, XM_011529767.1:c.1383G>T, XM_011529768.1:c.1191G>T, XM_005261069.4:c.1230G>T, XM_011529766.2:c.1422G>T, XM_011529767.2:c.1383G>T, XM_011529768.2:c.1191G>T, XM_017028487.1:c.1269G>T, ENST00000300305.7:c.1422G>T, ENST00000344691.8:c.1341G>T, ENST00000399240.5:c.1149G>T, ENST00000437180.5:c.1422G>T, ENST00000482318.5:c.*1012G>T, NC_000021.9:g.34792156C>A, CM000683.2:g.34792156C>A, NC_000021.8:g.36164453C>A, CM000683.1:g.36164453C>A, NC_000021.7:g.35086323C>A, NG_011402.2:g.1197556G>T, LRG_482:g.1197556G>T, NM_001754.4(RUNX1):c.1422G>T (p.Glu474Asp)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP2 [Unmet], BP4 [Unmet], PS4 [Unmet], PS1 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], BS3 [Unmet], PP1 [Unmet], PP3 [Unmet], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.1422G>T (p.Glu474Asp) variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score 0.312. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10652929/MONDO:0011071/008	0.3246	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	1	Uncertain Significance
21	36231763	339876	G	A	NM_001754.4(RUNX1):c.1355T>G (p.Val452Gly)	339875	CA10014181	NM_001754.4:c.1355T>G, NM_001001890.2:c.1274T>G, LRG_482t1:c.1355T>G, XM_005261068.3:c.1319T>G, XM_005261069.3:c.1163T>G, XM_011529766.1:c.1355T>G, XM_011529767.1:c.1316T>G, XM_011529768.1:c.1124T>G, XM_005261069.4:c.1163T>G, XM_011529766.2:c.1355T>G, XM_011529767.2:c.1316T>G, XM_011529768.2:c.1124T>G, XM_017028487.1:c.1202T>G, ENST00000300305.7:c.1355T>G, ENST00000344691.8:c.1274T>G, ENST00000399240.5:c.1082T>G, ENST00000437180.5:c.1355T>G, ENST00000482318.5:c.*945T>G, NC_000021.9:g.34792223A>C, CM000683.2:g.34792223A>C, NC_000021.8:g.36164520A>C, CM000683.1:g.36164520A>C, NC_000021.7:g.35086390A>C, NG_011402.2:g.1197489T>G, LRG_482:g.1197489T>G, NM_001754.4(RUNX1):c.1355T>G (p.Val452Gly)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP4 [MET], BP2 [Unmet], BA1 [MET], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], BP7 [Unmet], BS3 [MET], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.1355T>G (p.Val452Gly) variant has a MAF of 0.00177 (0.177%, 22/12,406 alleles) in the East Asian subpopulation of the gnomAD cohort that is â‰¥ 0.0015 (0.15%) (BA1). Transactivation assays demonstrating normal transactivation (80-115% of wt) and data from secondary assays demonstrate normal DNA binding and CBFÎ² binding (BS3; PMID: 25840971). This missense variant has a REVEL score <0.15 (0.046) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BS3, BP4."	25840971	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014181/MONDO:0011071/008	0.0003	Benign	Benign 	 InterVar: Benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	2	Uncertain Significance
21	36252918	339877	G	A	NM_001754.4(RUNX1):c.613+8C>T	339876	CA10014475	NM_001754.4:c.613+8C>T, NC_000021.9:g.34859466G>A, CM000683.2:g.34859466G>A, NC_000021.8:g.36231763G>A, CM000683.1:g.36231763G>A, NC_000021.7:g.35153633G>A, NG_011402.2:g.1130246C>T, LRG_482:g.1130246C>T, NM_001001890.2:c.532+8C>T, NM_001122607.1:c.532+8C>T, LRG_482t1:c.613+8C>T, XM_005261068.3:c.577+8C>T, XM_005261069.3:c.613+8C>T, XM_011529766.1:c.613+8C>T, XM_011529767.1:c.574+8C>T, XM_011529768.1:c.574+8C>T, XM_011529770.1:c.613+8C>T, XR_937576.1:n.792+8C>T, XM_005261069.4:c.613+8C>T, XM_011529766.2:c.613+8C>T, XM_011529767.2:c.574+8C>T, XM_011529768.2:c.574+8C>T, XM_011529770.2:c.613+8C>T, XM_017028487.1:c.460+8C>T, XR_937576.2:n.839+8C>T, ENST00000300305.7:c.613+8C>T, ENST00000344691.8:c.532+8C>T, ENST00000358356.9:c.532+8C>T, ENST00000399237.6:c.577+8C>T, ENST00000399240.5:c.532+8C>T, ENST00000437180.5:c.613+8C>T, ENST00000467577.1:n.105+8C>T, ENST00000482318.5:c.*203+8C>T, NM_001754.4(RUNX1):c.613+8C>T	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BP2 [MET], BP4 [MET], BA1 [MET], PS4 [Unmet], PS1 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [MET], BS4 [Unmet], BS1 [Unmet], BS3 [Unmet], PP1 [Unmet], PP3 [Unmet], PM6 [Unmet], PM2 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.613+8C>T variant has a MAF of 0.00151 (0.151%, 101/66,722 alleles) in the European (Non-Finnish) subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This variant is detected in homozygous state (15) in gnomAD population database (BP2). This intronic variant is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In addition, evolutionary conservation prediction algorithms predict the site as not being highly conserved (PhyloP score -1.2534 < 0.1) (BP7). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4, BP7.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014475/MONDO:0011071/008	0.4999	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
21	36265218	339878	A	C	NM_001754.4(RUNX1):c.444C>T (p.Thr148=)	339877	CA10014514	NM_001754.4:c.444C>T, NM_001001890.2:c.363C>T, NM_001122607.1:c.363C>T, LRG_482t1:c.444C>T, XM_005261068.3:c.408C>T, XM_005261069.3:c.444C>T, XM_011529766.1:c.444C>T, XM_011529767.1:c.405C>T, XM_011529768.1:c.405C>T, XM_011529770.1:c.444C>T, XR_937576.1:n.623C>T, XM_005261069.4:c.444C>T, XM_011529766.2:c.444C>T, XM_011529767.2:c.405C>T, XM_011529768.2:c.405C>T, XM_011529770.2:c.444C>T, XM_017028487.1:c.291C>T, XR_937576.2:n.670C>T, ENST00000300305.7:c.444C>T, ENST00000344691.8:c.363C>T, ENST00000358356.9:c.363C>T, ENST00000399237.6:c.408C>T, ENST00000399240.5:c.363C>T, ENST00000437180.5:c.444C>T, ENST00000455571.5:c.405C>T, ENST00000482318.5:c.*34C>T, NC_000021.9:g.34880621G>A, CM000683.2:g.34880621G>A, NC_000021.8:g.36252918G>A, CM000683.1:g.36252918G>A, NC_000021.7:g.35174788G>A, NG_011402.2:g.1109091C>T, LRG_482:g.1109091C>T, NM_001754.4(RUNX1):c.444C>T (p.Thr148=)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BA1 [Unmet], BP4 [MET], BP2 [Unmet], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [MET], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.444C>T (p.Thr148=) variant is a synonymous variant that is predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In addition, evolutionary conservation prediction algorithms predict the site as not being highly conserved (PhyloP score -4.3832 < 0.1) (BP7). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4, BP7.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014514/MONDO:0011071/008	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
3	12660096	343103	G	A	NM_001754.4(RUNX1):c.97+4T>G	339878	CA10014626	NM_001754.4:c.97+4T>G, NC_000021.9:g.34892921A>C, CM000683.2:g.34892921A>C, NC_000021.8:g.36265218A>C, CM000683.1:g.36265218A>C, NC_000021.7:g.35187088A>C, NG_011402.2:g.1096791T>G, LRG_482:g.1096791T>G, LRG_482t1:c.97+4T>G, XM_005261069.3:c.97+4T>G, XM_011529766.1:c.97+4T>G, XM_011529767.1:c.59-5825T>G, XM_011529768.1:c.59-5825T>G, XM_011529770.1:c.97+4T>G, XR_937576.1:n.276+4T>G, XM_005261069.4:c.97+4T>G, XM_011529766.2:c.97+4T>G, XM_011529767.2:c.59-5825T>G, XM_011529768.2:c.59-5825T>G, XM_011529770.2:c.97+4T>G, XR_937576.2:n.323+4T>G, ENST00000300305.7:c.97+4T>G, ENST00000437180.5:c.97+4T>G, ENST00000455571.5:c.59-5825T>G, ENST00000475045.6:c.97+4T>G, ENST00000482318.5:c.59-12208T>G, NM_001754.4(RUNX1):c.97+4T>G	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP4 [MET], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], BP7 [Unmet], PP3 [Unmet], PP1 [Unmet], PVS1 [Unmet], PM6 [Unmet], PM2 [Unmet]	The NM_001754.4:c.97+4T>G variant is an intronic variant predicted by SSF and MES to lead to either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). The gnomAD Allele Frequency of this variant is 0.00003. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014626/MONDO:0011071/008	0.0028	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103237476	370701	G	A	NM_002880.3(RAF1):c.125C>T (p.Ala42Val)	343103	CA2259832	NM_002880.3:c.125C>T, LRG_413t1:c.125C>T, XM_005265355.1:c.125C>T, XM_005265357.1:c.125C>T, XM_005265358.3:c.-6C>T, XM_005265359.3:c.-6C>T, XM_005265360.1:c.125C>T, XM_011533974.1:c.125C>T, XM_011533975.1:c.-6C>T, NM_001354689.1:c.125C>T, NM_001354690.1:c.125C>T, NM_001354691.1:c.-6C>T, NM_001354692.1:c.-6C>T, NM_001354693.1:c.125C>T, NM_001354694.1:c.-6C>T, NM_001354695.1:c.-6C>T, NR_148940.1:n.540C>T, NR_148941.1:n.540C>T, NR_148942.1:n.540C>T, XM_011533974.3:c.125C>T, XM_017006966.1:c.125C>T, XR_001740227.1:n.456C>T, ENST00000251849.8:c.125C>T, ENST00000416093.1:c.125C>T, ENST00000423275.5:c.125C>T, ENST00000442415.6:c.125C>T, NC_000003.12:g.12618597G>A, CM000665.2:g.12618597G>A, NC_000003.11:g.12660096G>A, CM000665.1:g.12660096G>A, NC_000003.10:g.12635096G>A, NG_007467.1:g.50583C>T, LRG_413:g.50583C>T, NM_002880.3(RAF1):c.125C>T (p.Ala42Val)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.125C>T (p.Ala42Val) variant in the RAF1 gene is 0.026% (25/66738) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA2259832/MONDO:0021060/004	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692836	372481	A	T	NM_000277.2(PAH):c.1147C>T (p.Gln383Ter)	370701	CA16020949	NM_000277.2:c.1147C>T, NM_000277.1:c.1147C>T, XM_011538422.1:c.1090C>T, NM_001354304.1:c.1147C>T, NM_000277.3:c.1147C>T, ENST00000307000.7:c.1132C>T, ENST00000549247.6:n.906C>T, ENST00000551114.2:n.809C>T, ENST00000553106.5:c.1147C>T, ENST00000635477.1:n.251C>T, ENST00000635528.1:n.662C>T, NC_000012.12:g.102843698G>A, CM000674.2:g.102843698G>A, NC_000012.11:g.103237476G>A, CM000674.1:g.103237476G>A, NC_000012.10:g.101761606G>A, NG_008690.1:g.78905C>T, NG_008690.2:g.119713C>T, NM_000277.2(PAH):c.1147C>T (p.Gln383Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PM3 [MET], PP4 [MET]	The c.1147C>T (p.Gln383Ter) variant in PAH is a nonsense variant predicted to undergo NMD, present in all biologically relevant transcripts, absent from all populations databases.  It has been identified in a patient with classic PKU as homozygous, and in trans with a pathogenic variant (R408W), although defect in BH4 metabolism was not excluded in either patient. (PMID: 24350308, 22763404). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PM3, PP4.	24350308, 22763404, 24350308, 22763404	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16020949/MONDO:0009861/006	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89725043	372482	G	A	NM_000314.6(PTEN):c.320A>T (p.Asp107Val)	372481	CA16042748	NM_000314.6:c.320A>T, NM_000314.5:c.320A>T, NM_001304717.2:c.839A>T, NM_001304718.1:c.-431A>T, XM_006717926.2:c.275A>T, XM_011539981.1:c.320A>T, XM_011539982.1:c.224A>T, XR_945789.1:n.1032A>T, XR_945790.1:n.1032A>T, XR_945791.1:n.1032A>T, NM_000314.7:c.320A>T, NM_001304717.5:c.839A>T, NM_001304718.2:c.-431A>T, ENST00000371953.7:c.320A>T, ENST00000498703.1:n.146A>T, ENST00000610634.1:c.218A>T, NC_000010.11:g.87933079A>T, CM000672.2:g.87933079A>T, NC_000010.10:g.89692836A>T, CM000672.1:g.89692836A>T, NC_000010.9:g.89682816A>T, NG_007466.2:g.74641A>T, LRG_311:g.74641A>T, NM_000314.6(PTEN):c.320A>T (p.Asp107Val)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [MET], PVS1 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [MET], PP4 [Unmet], BS2 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS4-Moderate [MET], PS1 [Unmet], PS3 [MET], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], BS3 [Unmet]	PTEN c.320A>T (p.Asp107Val) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type. (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 25418537)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 28526761, PMID 23886400, internal laboratory contributor SCV000490750.2)PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 28526761, PMID 23886400, internal laboratory contributor SCV000490750.2)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	25418537, 23886400, 28526761, 25418537, 23886400, 28526761, 29706350, 29785012, 25418537, 23886400, 28526761	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16042748/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763744	375406	T	G	NM_000314.6(PTEN):c.1027-1G>A	372482	CA16042723	NM_000314.6:c.1027-1G>A, NM_000314.5:c.1027-1G>A, NM_001304717.2:c.1546-1G>A, NM_001304718.1:c.436-1G>A, XM_006717926.2:c.982-1G>A, XM_011539982.1:c.931-1G>A, XR_945791.1:n.1597-1G>A, NM_000314.7:c.1027-1G>A, NM_001304717.5:c.1546-1G>A, NM_001304718.2:c.436-1G>A, ENST00000371953.7:c.1027-1G>A, NC_000010.11:g.87965286G>A, CM000672.2:g.87965286G>A, NC_000010.10:g.89725043G>A, CM000672.1:g.89725043G>A, NC_000010.9:g.89715023G>A, NG_007466.2:g.106848G>A, LRG_311:g.106848G>A, NM_000314.6(PTEN):c.1027-1G>A	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM6 [MET], PM2 [MET], PVS1 [MET], PP2 [Unmet], PP4 [Unmet], PP1 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS2 [Unmet], PS1 [Unmet], PS4 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.1027-1G>A (IVS8-1G>A) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (Internal laboratory contributor SCV000490754.2)	20962022, 20962022, 27477328, 20962022	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16042723/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692904	375958	C	G	NM_004004.5(GJB2):c.-22-2A>C	375406	CA6904346	NM_004004.5:c.-22-2A>C, NC_000013.11:g.20189605T>G, CM000675.2:g.20189605T>G, NC_000013.10:g.20763744T>G, CM000675.1:g.20763744T>G, NC_000013.9:g.19661744T>G, NG_008358.1:g.8371A>C, XM_011535049.1:c.-22-2A>C, XM_011535049.2:c.-22-2A>C, NM_004004.6:c.-22-2A>C, ENST00000382844.1:c.-24A>C, ENST00000382848.4:c.-22-2A>C, NM_004004.5(GJB2):c.-22-2A>C	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PS3-Supporting [MET], PP1-Moderate [MET], PM2 [Unmet], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], PM3-Supporting [MET], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BS1 [MET], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	"The filtering allele frequency of the c.-22-2A>C variant in the GJB2 gene is 0.35% for Ashkenazi Jewish chromosomes in the Genome Aggregation Database (46/10134 with 95% CI), which meets the allele frequency threshold defined by the ClinGen Hearing Loss Expert Panel for considering strong evidence against pathogenicity for autosomal recessive hearing loss variants (BS1). However, the c.-22-2A>C variant in the GJB2 gene has been detected in 2 patients with hearing loss in trans with the pathogenic c.35delG variant (PM3_S; PMID: 25401782, 24039984). This variant has been reported to segregate with hearing loss in at least 2 family members (PP1_M; PMID: 24039984). It was also identified in the heterozygous state without a second variant in 4 individuals with hearing loss, and in the biallelic state (with 35delG) in one individual with reportedly normal hearing (GeneDx, ARUP, unpublished data). RNA analysis showed that patients with the -22-2A>C variant express a novel GJB2 transcript with a slightly longer 5â€™UTR but otherwise normal coding region. The alternate transcript was shown to have reduced expression but it is not clear if the lower expression is sufficient to lead to a phenotype (PS3_Supporting; PMID: 24039984). In summary, due to its high allele frequency, insufficient case observations and insufficient functional evidence, this variant has been classified as uncertain clinical significance for autosomal recessive hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM3_Supporting, PP1_Moderate, PS3_Supporting, BS1"	24039984, 24039984, 25401782, 24039984, 25401782, 24039984, 24039984	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	25/10/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6904346/MONDO:0019497/005	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
10	89692993	375959	G	T	NM_000314.6(PTEN):c.388C>G (p.Arg130Gly)	375958	CA16602437	NM_000314.6:c.388C>G, NC_000010.11:g.87933147C>G, CM000672.2:g.87933147C>G, NC_000010.10:g.89692904C>G, CM000672.1:g.89692904C>G, NC_000010.9:g.89682884C>G, NG_007466.2:g.74709C>G, LRG_311:g.74709C>G, NM_000314.5:c.388C>G, NM_001304717.2:c.907C>G, NM_001304718.1:c.-363C>G, XM_006717926.2:c.343C>G, XM_011539981.1:c.388C>G, XM_011539982.1:c.292C>G, XR_945789.1:n.1100C>G, XR_945790.1:n.1100C>G, XR_945791.1:n.1100C>G, NM_000314.7:c.388C>G, NM_001304717.5:c.907C>G, NM_001304718.2:c.-363C>G, ENST00000371953.7:c.388C>G, ENST00000498703.1:n.214C>G, ENST00000610634.1:c.286C>G, NM_000314.6(PTEN):c.388C>G (p.Arg130Gly)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM4 [Unmet], PM1 [MET], PM5 [MET]	PTEN c.388C>G (p.Arg130Gly) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 10866302, PMID 21828076, PMID 29706350)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations (PMID 27535533).PM5: Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic and with equal or lesser BLOSUM62 score has been seen before (ClinVar Variation ID 7829, SCV000840465.2).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	10866302, 29706350, 29785012, 21828076, 19457929, 20926450, 21659347, 24778394, 19457929, 20926450, 25669429	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16602437/MONDO:0017623/003	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	4	Uncertain Significance
21	36231783	376018	G	A	NM_000314.6(PTEN):c.477G>T (p.Arg159Ser)	375959	CA16602438	NM_000314.6:c.477G>T, NC_000010.11:g.87933236G>T, CM000672.2:g.87933236G>T, NC_000010.10:g.89692993G>T, CM000672.1:g.89692993G>T, NC_000010.9:g.89682973G>T, NG_007466.2:g.74798G>T, LRG_311:g.74798G>T, NM_000314.5:c.477G>T, NM_001304717.2:c.996G>T, NM_001304718.1:c.-274G>T, XM_006717926.2:c.432G>T, XM_011539981.1:c.477G>T, XM_011539982.1:c.381G>T, XR_945789.1:n.1189G>T, XR_945790.1:n.1189G>T, XR_945791.1:n.1189G>T, NM_000314.7:c.477G>T, NM_001304717.5:c.996G>T, NM_001304718.2:c.-274G>T, ENST00000371953.7:c.477G>T, ENST00000498703.1:n.303G>T, ENST00000610634.1:c.375G>T, NM_000314.6(PTEN):c.477G>T (p.Arg159Ser)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [MET], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.477G>T (p.Arg159Ser) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.	29617666, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16602438/MONDO:0017623/003	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89717673	376510	G	A	NM_001754.4(RUNX1):c.601C>T (p.Arg201Ter)	376018	CA16602487	NM_001754.4:c.601C>T, NC_000021.9:g.34859486G>A, CM000683.2:g.34859486G>A, NC_000021.8:g.36231783G>A, CM000683.1:g.36231783G>A, NC_000021.7:g.35153653G>A, NG_011402.2:g.1130226C>T, LRG_482:g.1130226C>T, NM_001001890.2:c.520C>T, NM_001122607.1:c.520C>T, LRG_482t1:c.601C>T, XM_005261068.3:c.565C>T, XM_005261069.3:c.601C>T, XM_011529766.1:c.601C>T, XM_011529767.1:c.562C>T, XM_011529768.1:c.562C>T, XM_011529770.1:c.601C>T, XR_937576.1:n.780C>T, XM_005261069.4:c.601C>T, XM_011529766.2:c.601C>T, XM_011529767.2:c.562C>T, XM_011529768.2:c.562C>T, XM_011529770.2:c.601C>T, XM_017028487.1:c.448C>T, XR_937576.2:n.827C>T, ENST00000300305.7:c.601C>T, ENST00000344691.8:c.520C>T, ENST00000358356.9:c.520C>T, ENST00000399237.6:c.565C>T, ENST00000399240.5:c.520C>T, ENST00000437180.5:c.601C>T, ENST00000467577.1:n.93C>T, ENST00000482318.5:c.*191C>T, NM_001754.4(RUNX1):c.601C>T (p.Arg201Ter)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [MET], PM5 [Unmet], PM1 [Unmet], PM4 [Unmet], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], BP7 [Unmet], PP1-Strong [MET], PP3 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet]	"The NM_001754.4:c.601C>T (p.Arg201Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant has been reported in four probands meeting at least one of the RUNX1-phenotypic criteria (PS4; PMIDs: 10508512; 19387465; 20549580; 28513614). The variant was found to co-segregate with disease in multiple affected family members, with 14 meioses observed in across 4 families (PP1_Strong; PMID: 10508512; 19387465; 20549580; 28513614). The variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PS4, PP1_Strong, PM2."	10508512, 28513614, 20549580, 19387465, 10508512, 28513614, 20549580, 19387465, 10508512, 28513614, 20549580, 19387465	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16602487/MONDO:0011071/008	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
12	103288576	376937	T	G	NM_000314.6(PTEN):c.698G>A (p.Arg233Gln)	376510	CA060404	NM_000314.6:c.698G>A, NC_000010.11:g.87957916G>A, CM000672.2:g.87957916G>A, NC_000010.10:g.89717673G>A, CM000672.1:g.89717673G>A, NC_000010.9:g.89707653G>A, NG_007466.2:g.99478G>A, LRG_311:g.99478G>A, NM_000314.5:c.698G>A, NM_001304717.2:c.1217G>A, NM_001304718.1:c.107G>A, XM_006717926.2:c.653G>A, XM_011539981.1:c.698G>A, XM_011539982.1:c.602G>A, XR_945791.1:n.1268G>A, NM_000314.7:c.698G>A, NM_001304717.5:c.1217G>A, NM_001304718.2:c.107G>A, ENST00000371953.7:c.698G>A, ENST00000472832.2:n.125G>A, NM_000314.6(PTEN):c.698G>A (p.Arg233Gln)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP2 [MET], PP3 [Unmet], PP1 [Unmet], BA1 [Unmet], BS3-Supporting [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	PTEN c.698G>A (p.R233Q) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350)	27147599, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA060404/MONDO:0017623/003	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
19	4099305	378108	G	A	NM_000277.2(PAH):c.289A>C (p.Ile97Leu)	376937	CA6748987	NM_000277.2:c.289A>C, NC_000012.12:g.102894798T>G, CM000674.2:g.102894798T>G, NC_000012.11:g.103288576T>G, CM000674.1:g.103288576T>G, NC_000012.10:g.101812706T>G, NG_008690.1:g.27805A>C, NG_008690.2:g.68613A>C, NM_000277.1:c.289A>C, XM_011538422.1:c.289A>C, NM_001354304.1:c.289A>C, XM_017019370.2:c.289A>C, NM_000277.3:c.289A>C, ENST00000307000.7:c.274A>C, ENST00000546844.1:c.289A>C, ENST00000548928.1:n.211A>C, ENST00000549111.5:n.385A>C, ENST00000550978.6:n.273A>C, ENST00000551337.5:c.289A>C, ENST00000551988.5:n.378A>C, ENST00000553106.5:c.289A>C, NM_000277.2(PAH):c.289A>C (p.Ile97Leu)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Uncertain Significance	PM2 [Unmet], PP4 [MET], BP4 [MET]	"PAH-specific ACMG/AMP criteria applied: BP4: Tolerated in SIFT, benign in Polyphen-2, Polymorphism in MutationTaster. REVEL=0.511; PP4: Seen in patient with mild HPA (PMID:17627389). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BP4, PP4)."	17627389	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	7/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6748987/MONDO:0009861/006	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
19	4117480	378913	C	T	NM_030662.3(MAP2K2):c.813C>T (p.Asp271=)	378108	CA9090826	NM_030662.3:c.813C>T, LRG_750t1:c.813C>T, XM_006722799.2:c.705+1712C>T, XM_011528133.1:c.243C>T, XM_017026989.1:c.813C>T, XM_017026990.1:c.705+1712C>T, ENST00000262948.9:c.813C>T, ENST00000394867.8:c.522C>T, ENST00000593364.5:n.760C>T, ENST00000595715.1:n.628C>T, ENST00000597263.5:n.169+1712C>T, ENST00000599021.1:n.29+1712C>T, ENST00000600584.5:n.1373C>T, ENST00000601786.5:n.1114C>T, NC_000019.10:g.4099307G>A, CM000681.2:g.4099307G>A, NC_000019.9:g.4099305G>A, CM000681.1:g.4099305G>A, NC_000019.8:g.4050305G>A, NG_007996.1:g.29822C>T, LRG_750:g.29822C>T, NM_030662.3(MAP2K2):c.813C>T (p.Asp271=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.813C>T (p.Asp271=) variant in the MAP2K2 gene is 0.0045% (1/7096) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9090826/MONDO:0021060/004	0.0002	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
10	89624270	404147	G	A	NM_030662.3(MAP2K2):c.240G>A (p.Ala80=)	378913	CA9091070	NM_030662.3:c.240G>A, NC_000019.10:g.4117482C>T, CM000681.2:g.4117482C>T, NC_000019.9:g.4117480C>T, CM000681.1:g.4117480C>T, NC_000019.8:g.4068480C>T, NG_007996.1:g.11647G>A, LRG_750:g.11647G>A, LRG_750t1:c.240G>A, XM_006722799.2:c.240G>A, XM_017026989.1:c.240G>A, XM_017026990.1:c.240G>A, XM_017026991.1:c.240G>A, ENST00000262948.9:c.240G>A, ENST00000394867.8:c.-52G>A, ENST00000599345.1:n.437G>A, NM_030662.3(MAP2K2):c.240G>A (p.Ala80=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.240G>A (p.Ala80=) variant in the MAP2K2 gene is 0.0284% (9/16506) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9091070/MONDO:0021060/004	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68862107	406663	G	A	NM_000314.6(PTEN):c.44G>A (p.Arg15Lys)	404147	CA16613142	NM_000314.6:c.44G>A, NM_000314.5:c.44G>A, NM_001304717.2:c.563G>A, NM_001304718.1:c.-662G>A, XM_006717926.2:c.44G>A, XM_011539981.1:c.44G>A, XR_945789.1:n.756G>A, XR_945790.1:n.756G>A, XR_945791.1:n.756G>A, NM_000314.7:c.44G>A, NM_001304717.5:c.563G>A, NM_001304718.2:c.-662G>A, ENST00000371953.7:c.44G>A, ENST00000462694.1:n.46G>A, ENST00000487939.1:n.65G>A, ENST00000610634.1:c.-59G>A, ENST00000618586.1:n.13G>A, NC_000010.11:g.87864513G>A, CM000672.2:g.87864513G>A, NC_000010.10:g.89624270G>A, CM000672.1:g.89624270G>A, NC_000010.9:g.89614250G>A, NG_007466.2:g.6075G>A, LRG_311:g.6075G>A, NG_033079.1:g.3925C>T, NM_000314.6(PTEN):c.44G>A (p.Arg15Lys)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Uncertain Significance	PM2 [MET], PP2 [MET], PS3-Supporting [MET]	"PTEN c.44G>A (p.R15K) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 25875300)"		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	3/1/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16613142/MONDO:0017623/003	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36259139	409822	C	G	NM_004360.4(CDH1):c.2195G>A (p.Arg732Gln)	406663	CA16615410	NM_004360.4:c.2195G>A, NC_000016.10:g.68828204G>A, CM000678.2:g.68828204G>A, NC_000016.9:g.68862107G>A, CM000678.1:g.68862107G>A, NC_000016.8:g.67419608G>A, NG_008021.1:g.95913G>A, LRG_301:g.95913G>A, NM_004360.3:c.2195G>A, LRG_301t1:c.2195G>A, XM_011523488.1:c.1460G>A, XM_011523489.1:c.1460G>A, NM_001317184.1:c.2012G>A, NM_001317185.1:c.647G>A, NM_001317186.1:c.230G>A, ENST00000261769.9:c.2195G>A, ENST00000422392.6:c.2012G>A, ENST00000562118.1:n.413G>A, ENST00000562836.5:n.2266G>A, ENST00000566510.5:c.*861G>A, ENST00000566612.5:c.*435G>A, ENST00000611625.4:c.2258G>A, ENST00000612417.4:c.1853+1650G>A, ENST00000621016.4:c.1866-5999G>A, NM_004360.4(CDH1):c.2195G>A (p.Arg732Gln)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Likely Pathogenic	BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [MET], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS4-Moderate [MET], PS3 [MET], PS1 [Unmet], PS2 [Unmet]	"The c.2195G>A (p.Arg732Gln) variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant is predicted to affect splicing by at least 3 in silico splicing predictors in agreement (PP3). Additionally, there is an RNA assay demonstrating an abnormal out-of-frame transcript for this variant (PS3; PMID: 17545690 15235021). This variant has also been reported in at least 2 families meeting HDGC clinical criteria (PS4_Moderate; PMID: 17545690 15235021). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PM2, PP3, PS3, PS4_Moderate."	17545690, 17545690, 15235021, 17545690, 15235021, 26580448	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16615410/MONDO:0007648/007	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36206814	415832	C	T	NM_001754.4(RUNX1):c.351+1G>C	409822	CA16616270	NM_001754.4:c.351+1G>C, NC_000021.9:g.34886842C>G, CM000683.2:g.34886842C>G, NC_000021.8:g.36259139C>G, CM000683.1:g.36259139C>G, NC_000021.7:g.35181009C>G, NG_011402.2:g.1102870G>C, LRG_482:g.1102870G>C, NM_001001890.2:c.270+1G>C, NM_001122607.1:c.270+1G>C, LRG_482t1:c.351+1G>C, XM_005261068.3:c.315+1G>C, XM_005261069.3:c.351+1G>C, XM_011529766.1:c.351+1G>C, XM_011529767.1:c.312+1G>C, XM_011529768.1:c.312+1G>C, XM_011529770.1:c.351+1G>C, XR_937576.1:n.530+1G>C, XM_005261069.4:c.351+1G>C, XM_011529766.2:c.351+1G>C, XM_011529767.2:c.312+1G>C, XM_011529768.2:c.312+1G>C, XM_011529770.2:c.351+1G>C, XM_017028487.1:c.198+1G>C, XR_937576.2:n.577+1G>C, ENST00000300305.7:c.351+1G>C, ENST00000344691.8:c.270+1G>C, ENST00000358356.9:c.270+1G>C, ENST00000399237.6:c.315+1G>C, ENST00000399240.5:c.270+1G>C, ENST00000437180.5:c.351+1G>C, ENST00000455571.5:c.312+1G>C, ENST00000482318.5:c.59-6129G>C, NM_001754.4(RUNX1):c.351+1G>C	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP3 [Unmet], PP1 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet]	The NM_001754.4(RUNX1):c.351+1G>C variant is a canonical splice site variant that is predicted to introduce a frameshift and a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16616270/MONDO:0011071/008	0.025	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 1, 0, 0] 	1	Uncertain Significance
7	140500166	417225	T	C	NM_001754.4(RUNX1):c.698G>A (p.Arg233His)	415832	CA10014373	NM_001754.4:c.698G>A, NM_001001890.2:c.617G>A, NM_001122607.1:c.617G>A, LRG_482t1:c.698G>A, XM_005261068.3:c.662G>A, XM_005261069.3:c.613+24957G>A, XM_011529766.1:c.698G>A, XM_011529767.1:c.659G>A, XM_011529768.1:c.574+24957G>A, XM_011529770.1:c.698G>A, XR_937576.1:n.877G>A, XM_005261069.4:c.613+24957G>A, XM_011529766.2:c.698G>A, XM_011529767.2:c.659G>A, XM_011529768.2:c.574+24957G>A, XM_011529770.2:c.698G>A, XM_017028487.1:c.545G>A, XR_937576.2:n.924G>A, ENST00000300305.7:c.698G>A, ENST00000344691.8:c.617G>A, ENST00000358356.9:c.617G>A, ENST00000399237.6:c.662G>A, ENST00000399240.5:c.532+24957G>A, ENST00000437180.5:c.698G>A, ENST00000469087.1:n.234G>A, ENST00000482318.5:c.*288G>A, NC_000021.9:g.34834517C>T, CM000683.2:g.34834517C>T, NC_000021.8:g.36206814C>T, CM000683.1:g.36206814C>T, NC_000021.7:g.35128684C>T, NG_011402.2:g.1155195G>A, LRG_482:g.1155195G>A, NM_001754.4(RUNX1):c.698G>A (p.Arg233His)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [MET], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.698G>A (p.Arg233His) variant has a MAF of 0.00142 (0.142%, 34/23,970 alleles) in the African subpopulation of the gnomAD cohort that is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). We allow a variant to reach a likely benign classification based on BS1 alone if there is no contradictory evidence supporting pathogenicity. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014373/MONDO:0011071/008	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 0, 0] 	2	Uncertain Significance
21	36252865	417961	C	T	NM_004333.4(BRAF):c.976A>G (p.Ile326Val)	417225	CA4516861	NM_004333.4:c.976A>G, LRG_299t1:c.976A>G, XM_005250045.1:c.976A>G, XM_005250046.1:c.976A>G, XM_011516529.1:c.976A>G, XM_011516530.1:c.976A>G, XR_242190.1:n.984A>G, XR_927520.1:n.984A>G, XR_927521.1:n.984A>G, XR_927522.1:n.984A>G, XR_927523.1:n.984A>G, NM_001354609.1:c.976A>G, NM_004333.5:c.976A>G, NR_148928.1:n.1281A>G, XM_017012558.1:c.976A>G, XM_017012559.1:c.976A>G, XR_001744857.1:n.984A>G, XR_001744858.1:n.984A>G, ENST00000288602.10:c.976A>G, ENST00000497784.1:n.1011A>G, NC_000007.14:g.140800366T>C, CM000669.2:g.140800366T>C, NC_000007.13:g.140500166T>C, CM000669.1:g.140500166T>C, NC_000007.12:g.140146635T>C, NG_007873.3:g.129399A>G, LRG_299:g.129399A>G, NM_004333.4(BRAF):c.976A>G (p.Ile326Val)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1772A>G (p.Asn591Ser) variant in the SOS1 gene is 0.054% (11/11524) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA4516861/MONDO:0021060/004	0.8999	Likely Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68862157	418841	C	T	NM_001754.4(RUNX1):c.497G>A (p.Arg166Gln)	417961	CA16616941	NM_001754.4:c.497G>A, NC_000021.9:g.34880568C>T, CM000683.2:g.34880568C>T, NC_000021.8:g.36252865C>T, CM000683.1:g.36252865C>T, NC_000021.7:g.35174735C>T, NG_011402.2:g.1109144G>A, LRG_482:g.1109144G>A, NM_001001890.2:c.416G>A, NM_001122607.1:c.416G>A, LRG_482t1:c.497G>A, XM_005261068.3:c.461G>A, XM_005261069.3:c.497G>A, XM_011529766.1:c.497G>A, XM_011529767.1:c.458G>A, XM_011529768.1:c.458G>A, XM_011529770.1:c.497G>A, XR_937576.1:n.676G>A, XM_005261069.4:c.497G>A, XM_011529766.2:c.497G>A, XM_011529767.2:c.458G>A, XM_011529768.2:c.458G>A, XM_011529770.2:c.497G>A, XM_017028487.1:c.344G>A, XR_937576.2:n.723G>A, ENST00000300305.7:c.497G>A, ENST00000344691.8:c.416G>A, ENST00000358356.9:c.416G>A, ENST00000399237.6:c.461G>A, ENST00000399240.5:c.416G>A, ENST00000437180.5:c.497G>A, ENST00000482318.5:c.*87G>A, NM_001754.4(RUNX1):c.497G>A (p.Arg166Gln)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS4-Moderate [MET], PS1 [Unmet], PS3 [MET], PM5 [Unmet], PM4 [Unmet], PM1 [MET], BP7 [Unmet], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], PM6-Supporting [MET], PP3 [MET], PP1 [MET], PM2 [MET], PVS1 [Unmet]	"Transactivation assays demonstrate altered transactivation (<20% of wt) for the NM_001754.4:c.497G>A (p.Arg166Gln) variant and data from a secondary assays demonstrate altered DNA binding, CBFÎ² binding and sub-cellular localization (PS3; PMID: 11830488,  25840971, 23848403). This variant affects one of the hotspot residues established by the MM-VCEP for RUNX1 (PM1). This variant has been reported in three probands meeting at least one of the RUNX1-phenotypic criteria (PS4_Moderate; PMID: 10508512, 28960434, 26175287). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). It has a REVEL score >0.75 (0.962) (PP3). There are two unrelated probands meeting at least one of the RUNX1- phenotypic criteria with assumed de novo occurrence (without confirmation of maternity and paternity) (PM6_ Supporting; PMID: 8960434, 26175287). This variant was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 10508512). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM1, PS4_Moderate, PM2, PP3,  PM6_Supporting, PP1."	10508512, 28960434, 26175287, 11830488, 25840971, 23848403, 10508512, 28960434, 26175287, 10508512	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16616941/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89712021	427623	G	C	NM_004360.4(CDH1):c.2245C>T (p.Arg749Trp)	418841	CA8130235	NM_004360.4:c.2245C>T, NC_000016.10:g.68828254C>T, CM000678.2:g.68828254C>T, NC_000016.9:g.68862157C>T, CM000678.1:g.68862157C>T, NC_000016.8:g.67419658C>T, NG_008021.1:g.95963C>T, LRG_301:g.95963C>T, NM_004360.3:c.2245C>T, LRG_301t1:c.2245C>T, XM_011523488.1:c.1510C>T, XM_011523489.1:c.1510C>T, NM_001317184.1:c.2062C>T, NM_001317185.1:c.697C>T, NM_001317186.1:c.280C>T, ENST00000261769.9:c.2245C>T, ENST00000422392.6:c.2062C>T, ENST00000562118.1:n.463C>T, ENST00000562836.5:n.2316C>T, ENST00000566510.5:c.*911C>T, ENST00000566612.5:c.*485C>T, ENST00000611625.4:c.2308C>T, ENST00000612417.4:c.1853+1700C>T, ENST00000621016.4:c.1866-5949C>T, NM_004360.4(CDH1):c.2245C>T (p.Arg749Trp)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet]	"The c.2245C>T (p.Arg749Trp) variant is present in <1/100,000 alleles in the ExAC cohort (PM2; http://exac.broadinstitute.org). There is no other supporting data that meet criteria for consideration. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: PM2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA8130235/MONDO:0007648/007	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89711893	428206	C	CA	NM_000314.6(PTEN):c.634+5G>C	427623	CA645509438	NM_000314.6:c.634+5G>C, NM_000314.5:c.634+5G>C, NM_001304717.2:c.1153+5G>C, NM_001304718.1:c.43+5G>C, XM_006717926.2:c.589+5G>C, XM_011539981.1:c.634+5G>C, XM_011539982.1:c.538+5G>C, XR_945791.1:n.1205-5589G>C, NM_000314.7:c.634+5G>C, NM_001304717.5:c.1153+5G>C, NM_001304718.2:c.43+5G>C, ENST00000371953.7:c.634+5G>C, ENST00000472832.2:n.61+5G>C, NC_000010.11:g.87952264G>C, CM000672.2:g.87952264G>C, NC_000010.10:g.89712021G>C, CM000672.1:g.89712021G>C, NC_000010.9:g.89702001G>C, NG_007466.2:g.93826G>C, LRG_311:g.93826G>C, NM_000314.6(PTEN):c.634+5G>C	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], BS2 [Unmet], PS4-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [MET], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.634+5G>C (IVS6+5G>C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: RNA, mini-gene, or other assay shows impact on splicing. (PMID 28677221)PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 28677221)	21659347, 28677221, 28677221	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA645509438/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692957	428216	GG	A	NM_000314.6(PTEN):c.512dup (p.Arg172Glufs)	428206	CA645369422	NM_000314.6:c.512dup, NM_000314.5:c.512dup, NM_001304717.2:c.1031dup, NM_001304718.1:c.-80dup, XM_006717926.2:c.467dup, XM_011539981.1:c.512dup, XM_011539982.1:c.416dup, XR_945789.1:n.1383dup, XR_945790.1:n.1500dup, XR_945791.1:n.1205-5716dup, NM_000314.7:c.512dup, NM_001304717.5:c.1031dup, NM_001304718.2:c.-80dup, ENST00000371953.7:c.512dup, NC_000010.11:g.87952137dup, CM000672.2:g.87952137dup, NC_000010.10:g.89711894dup, CM000672.1:g.89711894dup, NC_000010.9:g.89701874dup, NG_007466.2:g.93699dup, LRG_311:g.93699dup, NM_000314.6(PTEN):c.512dup (p.Arg172Glufs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], BS2 [Unmet], PS4-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.512dup (p.R172Efs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 17526801)	27477328, 22261759, 25669429, 21659347, 17526801, 21190448, 20962022, 21956414, 21194675, 20600018	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA645369422/MONDO:0017623/003	0.4999	VUS	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89692782	428271	C	CT	NM_000314.6(PTEN):c.441_442delGGinsA (p.Ala148Hisfs)	428216	CA645369482	NM_000314.6:c.441_442delGGinsA, NC_000010.11:g.87933200_87933201delinsA, CM000672.2:g.87933200_87933201delinsA, NC_000010.10:g.89692957_89692958delinsA, CM000672.1:g.89692957_89692958delinsA, NC_000010.9:g.89682937_89682938delinsA, NG_007466.2:g.74762_74763delinsA, LRG_311:g.74762_74763delinsA, NM_000314.5:c.441_442delinsA, NM_000314.6:c.441_442delinsA, NM_001304717.2:c.960_961delinsA, NM_001304718.1:c.-310_-309delinsA, XM_006717926.2:c.396_397delinsA, XM_011539981.1:c.441_442delinsA, XM_011539982.1:c.345_346delinsA, XR_945789.1:n.1153_1154delinsA, XR_945790.1:n.1153_1154delinsA, XR_945791.1:n.1153_1154delinsA, NM_000314.7:c.441_442delinsA, NM_001304717.5:c.960_961delinsA, NM_001304718.2:c.-310_-309delinsA, ENST00000371953.7:c.441_442delinsA, ENST00000498703.1:n.267_268delinsA, ENST00000610634.1:c.339_340delinsA, NM_000314.6(PTEN):c.441_442delGGinsA (p.Ala148Hisfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.441_442delGGinsA (p.Ala148Hisfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).	22261759, 27477328, 10400993, 25669429	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA645369482/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	89720733	428274	TATGTGATCAAGAAATC	G	NM_000314.6(PTEN):c.270dup (p.Glu91Terfs)	428271	CA645369474	NM_000314.6:c.270dup, NM_000314.5:c.270dup, NM_001304717.2:c.789dup, NM_001304718.1:c.-481dup, XM_006717926.2:c.225dup, XM_011539981.1:c.270dup, XM_011539982.1:c.174dup, XR_945789.1:n.982dup, XR_945790.1:n.982dup, XR_945791.1:n.982dup, NM_000314.7:c.270dup, NM_001304717.5:c.789dup, NM_001304718.2:c.-481dup, ENST00000371953.7:c.270dup, ENST00000498703.1:n.96dup, ENST00000610634.1:c.168dup, NC_000010.11:g.87933029dup, CM000672.2:g.87933029dup, NC_000010.10:g.89692786dup, CM000672.1:g.89692786dup, NC_000010.9:g.89682766dup, NG_007466.2:g.74591dup, LRG_311:g.74591dup, NM_000314.6(PTEN):c.270dup (p.Glu91Terfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PVS1 [MET], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PS1 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet]	PTEN c.270dup (p.Glu91Terfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA645369474/MONDO:0017623/003	0.4999	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36252995	429813	C	G	NM_000314.6(PTEN):c.884_900del17insG (p.Leu295Argfs)	428274	CA645369469	NM_000314.6:c.884_900del17insG, NM_000314.5:c.884_900delinsG, NM_000314.6:c.884_900delinsG, NM_001304717.2:c.1403_1419delinsG, NM_001304718.1:c.293_309delinsG, XM_006717926.2:c.839_855delinsG, XM_011539981.1:c.884_900delinsG, XM_011539982.1:c.788_804delinsG, XR_945791.1:n.1454_1470delinsG, NM_000314.7:c.884_900delinsG, NM_001304717.5:c.1403_1419delinsG, NM_001304718.2:c.293_309delinsG, ENST00000371953.7:c.884_900delinsG, ENST00000472832.2:n.311_327delinsG, NC_000010.11:g.87960976_87960992delinsG, CM000672.2:g.87960976_87960992delinsG, NC_000010.10:g.89720733_89720749delinsG, CM000672.1:g.89720733_89720749delinsG, NC_000010.9:g.89710713_89710729delinsG, NG_007466.2:g.102538_102554delinsG, LRG_311:g.102538_102554delinsG, NM_000314.6(PTEN):c.884_900del17insG (p.Leu295Argfs)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PVS1 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP2 [Unmet], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet]	PTEN c.884_900del17insG (p.Leu295Argfs) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5â€™ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).		PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf	28/11/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA645369469/MONDO:0017623/003	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 1, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	112920006	436446	A	G	NM_001754.4(RUNX1):c.367G>C (p.Asp123His)	429813	CA10014524	NM_001754.4:c.367G>C, NM_001001890.2:c.286G>C, NM_001122607.1:c.286G>C, LRG_482t1:c.367G>C, XM_005261068.3:c.331G>C, XM_005261069.3:c.367G>C, XM_011529766.1:c.367G>C, XM_011529767.1:c.328G>C, XM_011529768.1:c.328G>C, XM_011529770.1:c.367G>C, XR_937576.1:n.546G>C, XM_005261069.4:c.367G>C, XM_011529766.2:c.367G>C, XM_011529767.2:c.328G>C, XM_011529768.2:c.328G>C, XM_011529770.2:c.367G>C, XM_017028487.1:c.214G>C, XR_937576.2:n.593G>C, ENST00000300305.7:c.367G>C, ENST00000344691.8:c.286G>C, ENST00000358356.9:c.286G>C, ENST00000399237.6:c.331G>C, ENST00000399240.5:c.286G>C, ENST00000437180.5:c.367G>C, ENST00000455571.5:c.328G>C, ENST00000482318.5:c.74G>C, NC_000021.9:g.34880698C>G, CM000683.2:g.34880698C>G, NC_000021.8:g.36252995C>G, CM000683.1:g.36252995C>G, NC_000021.7:g.35174865C>G, NG_011402.2:g.1109014G>C, LRG_482:g.1109014G>C, NM_001754.4(RUNX1):c.367G>C (p.Asp123His)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PM1-Supporting [MET], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PS4-Supporting [MET], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.367G>C (p.Asp123His) missense variant has a REVEL score >0.75 (0.943) (PP3). This variant affects one of the other residues (AA 105-204; not established as a hot spot by the MM-VCEP) within the RHD PM1_Supporting). The variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 18723428). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP3, PM1_Supporting, PS4_Supporting."	18723428, 18723428, 18723428	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014524/MONDO:0011071/008	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 1, 1, 0] 	2	Uncertain Significance
21	36164618	436611	C	T	NM_002834.4(PTPN11):c.1221A>G (p.Gly407=)	436446	CA6798737	NM_002834.4:c.1221A>G, NM_002834.3:c.1221A>G, LRG_614t1:c.1221A>G, NM_080601.1:c.1221A>G, XM_006719526.1:c.1221A>G, XM_006719527.1:c.1107A>G, XM_011538613.1:c.1218A>G, NM_001330437.1:c.1221A>G, NM_080601.2:c.1221A>G, XM_011538613.2:c.1218A>G, XM_017019722.1:c.1218A>G, ENST00000351677.6:c.1221A>G, ENST00000392597.5:c.1221A>G, ENST00000635625.1:n.1221A>G, ENST00000635652.1:n.213A>G, NC_000012.12:g.112482202A>G, CM000674.2:g.112482202A>G, NC_000012.11:g.112920006A>G, CM000674.1:g.112920006A>G, NC_000012.10:g.111404389A>G, NG_007459.1:g.68471A>G, LRG_614:g.68471A>G, NM_002834.4(PTPN11):c.1221A>G (p.Gly407=)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1221A>G (p.Gly407=) variant in the PTPN11 gene is 0.115% (27/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6798737/MONDO:0021060/004	0.3246	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
21	36253011	436616	C	T	NM_001754.4(RUNX1):c.1257G>A (p.Val419=)	436611	CA512341177	NM_001754.4:c.1257G>A, NC_000021.9:g.34792321C>T, CM000683.2:g.34792321C>T, NC_000021.8:g.36164618C>T, CM000683.1:g.36164618C>T, NC_000021.7:g.35086488C>T, NG_011402.2:g.1197391G>A, LRG_482:g.1197391G>A, NM_001001890.2:c.1176G>A, LRG_482t1:c.1257G>A, XM_005261068.3:c.1221G>A, XM_005261069.3:c.1065G>A, XM_011529766.1:c.1257G>A, XM_011529767.1:c.1218G>A, XM_011529768.1:c.1026G>A, XM_005261069.4:c.1065G>A, XM_011529766.2:c.1257G>A, XM_011529767.2:c.1218G>A, XM_011529768.2:c.1026G>A, XM_017028487.1:c.1104G>A, ENST00000300305.7:c.1257G>A, ENST00000344691.8:c.1176G>A, ENST00000399240.5:c.984G>A, ENST00000437180.5:c.1257G>A, ENST00000482318.5:c.*847G>A, NM_001754.4(RUNX1):c.1257G>A (p.Val419=)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], BP7 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PVS1 [Unmet], PM6 [Unmet]	Even though the NM_001754.4:c.1257G>A (p.Val419=) variant is predicted to create alternative splice acceptor sites, MES and SSF are not predicted to abolish any existing consensus sites and it is too far away from either end of the exon for a prediction regarding the affect on the consensus acceptor or donor sites. The allele Frequency of this variant in gnomAD is 0.00003. In summary, the clinical significance of this variant is uncertain (VUS). None of the ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA512341177/MONDO:0011071/008	0.9986	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36259175	436617	A	T	NM_001754.4(RUNX1):c.352-1G>A	436616	CA410202793	NM_001754.4:c.352-1G>A, NM_001001890.2:c.271-1G>A, NM_001122607.1:c.271-1G>A, LRG_482t1:c.352-1G>A, XM_005261068.3:c.316-1G>A, XM_005261069.3:c.352-1G>A, XM_011529766.1:c.352-1G>A, XM_011529767.1:c.313-1G>A, XM_011529768.1:c.313-1G>A, XM_011529770.1:c.352-1G>A, XR_937576.1:n.531-1G>A, XM_005261069.4:c.352-1G>A, XM_011529766.2:c.352-1G>A, XM_011529767.2:c.313-1G>A, XM_011529768.2:c.313-1G>A, XM_011529770.2:c.352-1G>A, XM_017028487.1:c.199-1G>A, XR_937576.2:n.578-1G>A, ENST00000300305.7:c.352-1G>A, ENST00000344691.8:c.271-1G>A, ENST00000358356.9:c.271-1G>A, ENST00000399237.6:c.316-1G>A, ENST00000399240.5:c.271-1G>A, ENST00000437180.5:c.352-1G>A, ENST00000455571.5:c.313-1G>A, ENST00000482318.5:c.59-1G>A, NC_000021.9:g.34880714C>T, CM000683.2:g.34880714C>T, NC_000021.8:g.36253011C>T, CM000683.1:g.36253011C>T, NC_000021.7:g.35174881C>T, NG_011402.2:g.1108998G>A, LRG_482:g.1108998G>A, NM_001754.4(RUNX1):c.352-1G>A	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [MET], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [MET]	"The NM_001754.4:c.352-1G>A variant is a canonical splice site variant that is predicted to introduce a frameshift and premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 26175287). This variant was found to co-segregate with disease in multiple affected family members, with three meioses observed in one family (PP1; PMID: 26175287). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2, PS4_Supporting, PP1."	26175287, 26175287, 26175287	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410202793/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36259232	436618	C	A	NM_001754.4(RUNX1):c.316T>A (p.Trp106Arg)	436617	CA410203508	NM_001754.4:c.316T>A, NC_000021.9:g.34886878A>T, CM000683.2:g.34886878A>T, NC_000021.8:g.36259175A>T, CM000683.1:g.36259175A>T, NC_000021.7:g.35181045A>T, NG_011402.2:g.1102834T>A, LRG_482:g.1102834T>A, NM_001001890.2:c.235T>A, NM_001122607.1:c.235T>A, LRG_482t1:c.316T>A, XM_005261068.3:c.280T>A, XM_005261069.3:c.316T>A, XM_011529766.1:c.316T>A, XM_011529767.1:c.277T>A, XM_011529768.1:c.277T>A, XM_011529770.1:c.316T>A, XR_937576.1:n.495T>A, XM_005261069.4:c.316T>A, XM_011529766.2:c.316T>A, XM_011529767.2:c.277T>A, XM_011529768.2:c.277T>A, XM_011529770.2:c.316T>A, XM_017028487.1:c.163T>A, XR_937576.2:n.542T>A, ENST00000300305.7:c.316T>A, ENST00000344691.8:c.235T>A, ENST00000358356.9:c.235T>A, ENST00000399237.6:c.280T>A, ENST00000399240.5:c.235T>A, ENST00000437180.5:c.316T>A, ENST00000455571.5:c.277T>A, ENST00000482318.5:c.59-6165T>A, NM_001754.4(RUNX1):c.316T>A (p.Trp106Arg)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [MET], PS4 [Unmet], PM1-Supporting [MET], PM5 [Unmet], PM4 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP3 [MET], PP1 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet]	"The NM_001754.4:c.316T>A (p.Trp106Arg) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). Transactivation assays demonstrating altered transactivation (<20% of wt, and/or reduced to levels similar to well-established pathogenic variants such as R201Q or R166Q) AND data from secondary assay demonstrate altered DNA binding. (PS3; PMID: 25840971). This missense variant has a REVEL score >0.75 (0.976) (PP3). All patients reported in literature with this variant were not confirmed as germline variants (PMID: 21828118, PMID: 19282830, PMID: 25840971). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3, PM2, PP3, PM1_supporting."	25840971	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410203508/MONDO:0011071/008	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246589	439228	T	C	NM_001754.4(RUNX1):c.259G>T (p.Gly87Cys)	436618	CA10014559	NM_001754.4:c.259G>T, NC_000021.9:g.34886935C>A, CM000683.2:g.34886935C>A, NC_000021.8:g.36259232C>A, CM000683.1:g.36259232C>A, NC_000021.7:g.35181102C>A, NG_011402.2:g.1102777G>T, LRG_482:g.1102777G>T, NM_001001890.2:c.178G>T, NM_001122607.1:c.178G>T, LRG_482t1:c.259G>T, XM_005261068.3:c.223G>T, XM_005261069.3:c.259G>T, XM_011529766.1:c.259G>T, XM_011529767.1:c.220G>T, XM_011529768.1:c.220G>T, XM_011529770.1:c.259G>T, XR_937576.1:n.438G>T, XM_005261069.4:c.259G>T, XM_011529766.2:c.259G>T, XM_011529767.2:c.220G>T, XM_011529768.2:c.220G>T, XM_011529770.2:c.259G>T, XM_017028487.1:c.106G>T, XR_937576.2:n.485G>T, ENST00000300305.7:c.259G>T, ENST00000344691.8:c.178G>T, ENST00000358356.9:c.178G>T, ENST00000399237.6:c.223G>T, ENST00000399240.5:c.178G>T, ENST00000437180.5:c.259G>T, ENST00000455571.5:c.220G>T, ENST00000482318.5:c.59-6222G>T, NM_001754.4(RUNX1):c.259G>T (p.Gly87Cys)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.259G>T (p.Gly87Cys) variant is a missense variant has a REVEL score >0.75 (0.918) (PP3). AMR Subpopulation of 1000 Genomes Allele frequency 0.00144 with 1 allele out of 694 alleles. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP3.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014559/MONDO:0011071/008	0.3246	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
10	73464800	444219	G	A	NM_000277.1:c.842+4A>G	439228	CA16020870	NM_000277.1:c.842+4A>G, NC_000012.12:g.102852811T>C, CM000674.2:g.102852811T>C, NC_000012.11:g.103246589T>C, CM000674.1:g.103246589T>C, NC_000012.10:g.101770719T>C, NG_008690.1:g.69792A>G, NG_008690.2:g.110600A>G, XM_011538422.1:c.842+4A>G, NM_000277.2:c.842+4A>G, NM_001354304.1:c.842+4A>G, NM_000277.3:c.842+4A>G, ENST00000307000.7:c.827+4A>G, ENST00000549247.6:n.601+4A>G, ENST00000553106.5:c.842+4A>G, ENST00000635477.1:n.3+4A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"PAH-specific ACMG/AMP criteria applied: PP3: HSF: Broken WT Donor Site, New Donor Site. MaxEnt: Broken WT Donor Site.; PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP4_Moderate: IVS7+4A>G seen in 2 PKU patients. BH4 deficiency was ruled out. Upgraded per ClinGen PAH EP. (PMID:21147011); PM3: Detected in trans with A300S, pathogenic in ClinVar (PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PM2, PP4_Moderate, PM3)."	21147011, 21147011	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	12/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16020870/MONDO:0009861/006	0.8999	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763044	447450	A	C	NM_022124.5(CDH23):c.2866G>A (p.Glu956Lys)	444219	CA5544361	NM_022124.5:c.2866G>A, NM_001171930.1:c.2866G>A, NM_001171931.1:c.2866G>A, XM_006717940.2:c.3061G>A, XM_006717942.2:c.2995G>A, XM_011540039.1:c.3061G>A, XM_011540040.1:c.3055G>A, XM_011540041.1:c.3001G>A, XM_011540042.1:c.3061G>A, XM_011540043.1:c.3061G>A, XM_011540044.1:c.2926G>A, XM_011540045.1:c.3061G>A, XM_011540046.1:c.2521G>A, XM_011540047.1:c.1879G>A, XM_011540048.1:c.3061G>A, XM_011540049.1:c.3061G>A, XM_011540050.1:c.3061G>A, XM_011540051.1:c.3061G>A, XM_011540053.1:c.3061G>A, XM_011540054.1:c.3001G>A, XR_945796.1:n.3304G>A, XR_946052.1:n.83-448C>T, ENST00000224721.10:c.2881G>A, ENST00000299366.11:c.2866G>A, ENST00000398809.8:c.2866G>A, ENST00000442677.3:n.1641G>A, ENST00000466757.7:n.2297G>A, ENST00000616684.4:c.2866G>A, ENST00000622827.4:c.2866G>A, NC_000010.11:g.71705043G>A, CM000672.2:g.71705043G>A, NC_000010.10:g.73464800G>A, CM000672.1:g.73464800G>A, NC_000010.9:g.73134806G>A, NG_008835.1:g.313097G>A, NM_022124.5(CDH23):c.2866G>A (p.Glu956Lys)	CDH23	sensorineural hearing loss disorder	MONDO:0020678	Autosomal recessive inheritance	Likely Pathogenic	PP3 [MET], PM2-Supporting [MET], BP4 [Unmet], PM3-Strong [MET]	"The allele frequency of the c.2866G>A (p.Glu956Lys) variant in the CDH23 gene is 0.025% (6/23706) of African chromosomes by gnomAD, which is a low enough frequency to apply PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_Supporting). This variant has been reported in five probands with hearing loss without evidence of retinal disease (PMID 25963016, 22899989). Four of these individuals also harbored the p.Pro240Leu pathogenic variant in CDH23; however, only three were confirmed in trans (PM3_Strong, PMID 25963016, 22899989). The fifth individual also harbored  the p.Asp645Gly variant in CDH23, but phasing was not performed (PMID 25963016). The REVEL computational prediction analysis tool produced a score of 0.616, which was just below the threshold to automatically apply PP3, but the Expert Panel decided to apply PP3 based upon manual review of alignments to examine homology. In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: PM3_Strong, PM2_Supporting, PP3."	26763877, 25963016, 22899989	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5544361/MONDO:0020678/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
7	140487375	448924	T	C	NM_004004.5(GJB2):c.677T>G (p.Val226Gly)	447450	CA6904209	NM_004004.5:c.677T>G, XM_011535049.1:c.677T>G, XM_011535049.2:c.677T>G, NM_004004.6:c.677T>G, ENST00000382844.1:c.677T>G, ENST00000382848.4:c.677T>G, NC_000013.11:g.20188905A>C, CM000675.2:g.20188905A>C, NC_000013.10:g.20763044A>C, CM000675.1:g.20763044A>C, NC_000013.9:g.19661044A>C, NG_008358.1:g.9071T>G, NM_004004.5(GJB2):c.677T>G (p.Val226Gly)	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], PP3 [Unmet], PP4 [Unmet], PP1 [Unmet], BS2 [Unmet], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.677T>G (p.Val226Gly) variant has been identified in the heterozygous state in one individual with sensorineural hearing loss and one individual with breast or ovarian cancer in the literature (PS4 not met; 17666888 27153395). The  allele frequency of the p.Val226Gly variant in the GJB2 gene is 0.003% (1/343458) of Latino chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). In summary, this variant meets criteria to be classified as a variant of uncertain clinical significance for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2."	25388846, 25388846, 17666888, 27153395	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	14/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6904209/MONDO:0019497/005	0.0059	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
11	533618	448926	A	C	NM_004333.5(BRAF):c.1150A>G (p.Arg384Gly)	448924	CA4516796	NM_004333.5:c.1150A>G, NM_004333.4:c.1150A>G, LRG_299t1:c.1150A>G, XM_005250045.1:c.1150A>G, XM_005250046.1:c.1150A>G, XM_011516529.1:c.1150A>G, XM_011516530.1:c.1150A>G, XR_242190.1:n.1158A>G, XR_927520.1:n.1158A>G, XR_927521.1:n.1158A>G, XR_927522.1:n.1158A>G, XR_927523.1:n.1158A>G, NM_001354609.1:c.1150A>G, NR_148928.1:n.1455A>G, XM_017012558.1:c.1150A>G, XM_017012559.1:c.1150A>G, XR_001744857.1:n.1158A>G, XR_001744858.1:n.1158A>G, ENST00000288602.10:c.1150A>G, ENST00000497784.1:n.1185A>G, NC_000007.14:g.140787575T>C, CM000669.2:g.140787575T>C, NC_000007.13:g.140487375T>C, CM000669.1:g.140487375T>C, NC_000007.12:g.140133844T>C, NG_007873.3:g.142190A>G, LRG_299:g.142190A>G, NM_004333.5(BRAF):c.1150A>G (p.Arg384Gly)	BRAF	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.1150A>G (p.Arg384Gly) variant in the BRAF gene is 0.116% (16/8646) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA4516796/MONDO:0021060/004	0.025	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
3	12626660	448927	C	T	NM_005343.3(HRAS):c.291-6T>G	448926	CA5779338	NM_005343.3:c.291-6T>G, NC_000011.10:g.533618A>C, CM000673.2:g.533618A>C, NC_000011.9:g.533618A>C, CM000673.1:g.533618A>C, NC_000011.8:g.523618A>C, NG_007666.1:g.6933T>G, NM_001130442.1:c.291-6T>G, NM_005343.2:c.291-6T>G, NM_176795.3:c.291-6T>G, XM_011519875.1:c.-424-4980A>C, XM_011519877.1:c.-162+5281A>C, XR_242795.1:n.490-6T>G, NM_001130442.2:c.291-6T>G, NM_001318054.1:c.-29-6T>G, NM_176795.4:c.291-6T>G, XM_011519875.2:c.-424-4980A>C, XM_011519877.2:c.-162+5281A>C, XM_017017167.1:c.-499-4905A>C, XM_017017168.1:c.-499-4905A>C, NM_005343.4:c.291-6T>G, ENST00000311189.7:c.291-6T>G, ENST00000397594.5:c.291-6T>G, ENST00000397596.6:c.291-6T>G, ENST00000417302.5:c.291-6T>G, ENST00000451590.5:c.291-6T>G, ENST00000479482.1:n.212-6T>G, ENST00000493230.5:c.291-6T>G, NM_005343.3(HRAS):c.291-6T>G	LRRC56	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.291-6T>G variant in the HRAS gene is 0.051% (14/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5779338/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
3	12641734	448928	T	C	NM_002880.3(RAF1):c.1629G>A (p.Thr543=)	448927	CA2259460	NM_002880.3:c.1629G>A, LRG_413t1:c.1629G>A, XM_005265355.1:c.1629G>A, XM_005265357.1:c.1530G>A, XM_005265358.3:c.1386G>A, XM_005265359.3:c.1287G>A, XM_011533974.1:c.1629G>A, XM_011533975.1:c.1386G>A, NM_001354689.1:c.1689G>A, NM_001354690.1:c.1629G>A, NM_001354691.1:c.1386G>A, NM_001354692.1:c.1386G>A, NM_001354693.1:c.1530G>A, NM_001354694.1:c.1446G>A, NM_001354695.1:c.1287G>A, NR_148940.1:n.2157G>A, NR_148941.1:n.2103G>A, NR_148942.1:n.2042G>A, XM_011533974.3:c.1629G>A, XM_017006966.1:c.1530G>A, ENST00000251849.8:c.1629G>A, ENST00000423275.5:c.*1306G>A, ENST00000432427.2:n.1266G>A, ENST00000442415.6:c.1689G>A, ENST00000471449.1:n.318G>A, NC_000003.12:g.12585161C>T, CM000665.2:g.12585161C>T, NC_000003.11:g.12626660C>T, CM000665.1:g.12626660C>T, NC_000003.10:g.12601660C>T, NG_007467.1:g.84019G>A, LRG_413:g.84019G>A, NM_002880.3(RAF1):c.1629G>A (p.Thr543=)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.438+8A>T variant in the MAP2K1 gene is 0.075% (19/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA2259460/MONDO:0021060/004	0.0028	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
3	12660097	448930	C	T	NM_002880.3(RAF1):c.907A>G (p.Thr303Ala)	448928	CA2259632	NM_002880.3:c.907A>G, LRG_413t1:c.907A>G, XM_005265355.1:c.907A>G, XM_005265357.1:c.808A>G, XM_005265358.3:c.664A>G, XM_005265359.3:c.565A>G, XM_005265360.1:c.907A>G, XM_011533974.1:c.907A>G, XM_011533975.1:c.664A>G, NM_001354689.1:c.967A>G, NM_001354690.1:c.907A>G, NM_001354691.1:c.664A>G, NM_001354692.1:c.664A>G, NM_001354693.1:c.808A>G, NM_001354694.1:c.724A>G, NM_001354695.1:c.565A>G, NR_148940.1:n.1322A>G, NR_148941.1:n.1322A>G, NR_148942.1:n.1322A>G, XM_011533974.3:c.907A>G, XM_017006966.1:c.808A>G, XR_001740227.1:n.1139A>G, ENST00000251849.8:c.907A>G, ENST00000423275.5:c.*584A>G, ENST00000432427.2:n.544A>G, ENST00000442415.6:c.967A>G, ENST00000465826.5:n.151A>G, ENST00000491290.1:n.536A>G, NC_000003.12:g.12600235T>C, CM000665.2:g.12600235T>C, NC_000003.11:g.12641734T>C, CM000665.1:g.12641734T>C, NC_000003.10:g.12616734T>C, NG_007467.1:g.68945A>G, LRG_413:g.68945A>G, NM_002880.3(RAF1):c.907A>G (p.Thr303Ala)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.907A>G (p.Thr303Ala) variant in the RAF1 gene is 0.0284% (7/11568) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA2259632/MONDO:0021060/004	0.0014	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	112724479	448931	G	A	NM_002880.3(RAF1):c.124G>A (p.Ala42Thr)	448930	CA2259833	NM_002880.3:c.124G>A, NC_000003.12:g.12618598C>T, CM000665.2:g.12618598C>T, NC_000003.11:g.12660097C>T, CM000665.1:g.12660097C>T, NC_000003.10:g.12635097C>T, NG_007467.1:g.50582G>A, LRG_413:g.50582G>A, LRG_413t1:c.124G>A, XM_005265355.1:c.124G>A, XM_005265357.1:c.124G>A, XM_005265358.3:c.-7G>A, XM_005265359.3:c.-7G>A, XM_005265360.1:c.124G>A, XM_011533974.1:c.124G>A, XM_011533975.1:c.-7G>A, NM_001354689.1:c.124G>A, NM_001354690.1:c.124G>A, NM_001354691.1:c.-7G>A, NM_001354692.1:c.-7G>A, NM_001354693.1:c.124G>A, NM_001354694.1:c.-7G>A, NM_001354695.1:c.-7G>A, NR_148940.1:n.539G>A, NR_148941.1:n.539G>A, NR_148942.1:n.539G>A, XM_011533974.3:c.124G>A, XM_017006966.1:c.124G>A, XR_001740227.1:n.455G>A, ENST00000251849.8:c.124G>A, ENST00000416093.1:c.124G>A, ENST00000423275.5:c.124G>A, ENST00000442415.6:c.124G>A, NM_002880.3(RAF1):c.124G>A (p.Ala42Thr)	RAF1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.124G>A (p.Ala42Thr) variant in the RAF1 gene is 0.026% (25/66738) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA2259833/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
10	112724493	448932	C	T	NM_007373.3(SHOC2):c.363G>A (p.Glu121=)	448931	CA5689580	NM_007373.3:c.363G>A, NC_000010.11:g.110964721G>A, CM000672.2:g.110964721G>A, NC_000010.10:g.112724479G>A, CM000672.1:g.112724479G>A, NC_000010.9:g.112714469G>A, NG_028922.1:g.50179G>A, LRG_753:g.50179G>A, NM_001269039.1:c.363G>A, LRG_753t1:c.363G>A, XM_011540216.1:c.-380-20907G>A, NM_001269039.2:c.363G>A, NM_001324336.1:c.363G>A, NM_001324337.1:c.363G>A, NR_136749.1:n.116-20907G>A, ENST00000265277.9:c.363G>A, ENST00000369452.8:c.363G>A, ENST00000489390.1:n.56-35694G>A, ENST00000489783.1:n.741G>A, NM_007373.3(SHOC2):c.363G>A (p.Glu121=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.363G>A (p.Glu121=) variant in the SHOC2 gene is 0.0384% (8/10350) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5689580/MONDO:0021060/004	0.025	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	112724729	448933	A	G	NM_007373.3(SHOC2):c.377C>T (p.Thr126Ile)	448932	CA5689584	NM_007373.3:c.377C>T, NC_000010.11:g.110964735C>T, CM000672.2:g.110964735C>T, NC_000010.10:g.112724493C>T, CM000672.1:g.112724493C>T, NC_000010.9:g.112714483C>T, NG_028922.1:g.50193C>T, LRG_753:g.50193C>T, NM_001269039.1:c.377C>T, LRG_753t1:c.377C>T, XM_011540216.1:c.-380-20893C>T, NM_001269039.2:c.377C>T, NM_001324336.1:c.377C>T, NM_001324337.1:c.377C>T, NR_136749.1:n.116-20893C>T, ENST00000265277.9:c.377C>T, ENST00000369452.8:c.377C>T, ENST00000489390.1:n.56-35680C>T, NM_007373.3(SHOC2):c.377C>T (p.Thr126Ile)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.377C>T (p.Thr126Ile) variant in the SHOC2 gene is 0.0384% (8/10346) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5689584/MONDO:0021060/004	0.0122	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
10	112760217	448934	C	T	NM_007373.3(SHOC2):c.613A>G (p.Thr205Ala)	448933	CA5689601	NM_007373.3:c.613A>G, NC_000010.11:g.110964971A>G, CM000672.2:g.110964971A>G, NC_000010.10:g.112724729A>G, CM000672.1:g.112724729A>G, NC_000010.9:g.112714719A>G, NG_028922.1:g.50429A>G, LRG_753:g.50429A>G, NM_001269039.1:c.613A>G, LRG_753t1:c.613A>G, XM_011540216.1:c.-380-20657A>G, NM_001269039.2:c.613A>G, NM_001324336.1:c.613A>G, NM_001324337.1:c.613A>G, NR_136749.1:n.116-20657A>G, ENST00000265277.9:c.613A>G, ENST00000369452.8:c.613A>G, ENST00000451838.1:n.121A>G, ENST00000489390.1:n.56-35444A>G, NM_007373.3(SHOC2):c.613A>G (p.Thr205Ala)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.613A>G (p.Thr205Ala) variant in the SHOC2 gene is 0.0328% (10/16502) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5689601/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
10	112760225	448935	A	C	NM_007373.3(SHOC2):c.886C>T (p.Leu296=)	448934	CA5689679	NM_007373.3:c.886C>T, NC_000010.11:g.111000459C>T, CM000672.2:g.111000459C>T, NC_000010.10:g.112760217C>T, CM000672.1:g.112760217C>T, NC_000010.9:g.112750207C>T, NG_028922.1:g.85917C>T, LRG_753:g.85917C>T, NM_001269039.1:c.748C>T, LRG_753t1:c.886C>T, XM_011540216.1:c.-198C>T, NM_001269039.2:c.748C>T, NM_001324336.1:c.886C>T, NM_001324337.1:c.886C>T, NR_136749.1:n.298C>T, ENST00000265277.9:c.748C>T, ENST00000369452.8:c.886C>T, ENST00000451838.1:n.256C>T, ENST00000489390.1:n.100C>T, NM_007373.3(SHOC2):c.886C>T (p.Leu296=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.886C>T (p.Leu296=) variant in the SHOC2 gene is 0.08% (15/11572) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5689679/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39213309	448938	C	T	NM_007373.3(SHOC2):c.894A>C (p.Ala298=)	448935	CA5689680	NM_007373.3:c.894A>C, NC_000010.11:g.111000467A>C, CM000672.2:g.111000467A>C, NC_000010.10:g.112760225A>C, CM000672.1:g.112760225A>C, NC_000010.9:g.112750215A>C, NG_028922.1:g.85925A>C, LRG_753:g.85925A>C, NM_001269039.1:c.756A>C, LRG_753t1:c.894A>C, XM_011540216.1:c.-190A>C, NM_001269039.2:c.756A>C, NM_001324336.1:c.894A>C, NM_001324337.1:c.894A>C, NR_136749.1:n.306A>C, ENST00000265277.9:c.756A>C, ENST00000369452.8:c.894A>C, ENST00000451838.1:n.264A>C, ENST00000489390.1:n.108A>C, NM_007373.3(SHOC2):c.894A>C (p.Ala298=)	SHOC2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.894A>C (p.Ala298=) variant in the SHOC2 gene is 0.054% (9/8648) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA5689680/MONDO:0021060/004	0.0028	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
2	39213415	448939	A	C	NM_005633.3(SOS1):c.3658G>A (p.Val1220Met)	448938	CA1624132	NM_005633.3:c.3658G>A, LRG_754t1:c.3658G>A, XM_005264515.3:c.3613G>A, XM_011533060.1:c.3751G>A, XM_011533061.1:c.3706G>A, XM_011533062.1:c.3637G>A, XM_011533063.1:c.3634G>A, XM_011533064.1:c.3487G>A, XM_011533065.1:c.3604-805G>A, XM_011533066.1:c.2593G>A, XM_005264515.4:c.3613G>A, XM_011533062.2:c.3637G>A, XM_011533064.2:c.3487G>A, ENST00000395038.6:c.3613G>A, ENST00000402219.6:c.3658G>A, ENST00000426016.5:c.3658G>A, ENST00000469581.1:n.401G>A, NC_000002.12:g.38986168C>T, CM000664.2:g.38986168C>T, NC_000002.11:g.39213309C>T, CM000664.1:g.39213309C>T, NC_000002.10:g.39066813C>T, NG_007530.1:g.139296G>A, LRG_754:g.139296G>A, NM_005633.3(SOS1):c.3658G>A (p.Val1220Met)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.3658G>A (p.Val1220Met) variant in the SOS1 gene is 0.0328% (10/16512) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624132/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39222280	448940	C	G	NM_005633.3(SOS1):c.3552T>G (p.Pro1184=)	448939	CA1624148	NM_005633.3:c.3552T>G, LRG_754t1:c.3552T>G, XM_005264515.3:c.3507T>G, XM_011533060.1:c.3645T>G, XM_011533061.1:c.3600T>G, XM_011533062.1:c.3531T>G, XM_011533063.1:c.3528T>G, XM_011533064.1:c.3381T>G, XM_011533065.1:c.3604-911T>G, XM_011533066.1:c.2487T>G, XM_005264515.4:c.3507T>G, XM_011533062.2:c.3531T>G, XM_011533064.2:c.3381T>G, ENST00000395038.6:c.3507T>G, ENST00000402219.6:c.3552T>G, ENST00000426016.5:c.3552T>G, ENST00000469581.1:n.295T>G, NC_000002.12:g.38986274A>C, CM000664.2:g.38986274A>C, NC_000002.11:g.39213415A>C, CM000664.1:g.39213415A>C, NC_000002.10:g.39066919A>C, NG_007530.1:g.139190T>G, LRG_754:g.139190T>G, NM_005633.3(SOS1):c.3552T>G (p.Pro1184=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.3552T>G (p.Pro1184=) variant in the SOS1 gene is 0.126% (17/8594) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624148/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39224072	448941	G	A	NM_005633.3(SOS1):c.3330G>C (p.Ser1110=)	448940	CA1624221	NM_005633.3:c.3330G>C, LRG_754t1:c.3330G>C, XM_005264515.3:c.3330G>C, XM_011533060.1:c.3423G>C, XM_011533061.1:c.3423G>C, XM_011533062.1:c.3309G>C, XM_011533063.1:c.3306G>C, XM_011533064.1:c.3159G>C, XM_011533065.1:c.3423G>C, XM_011533066.1:c.2265G>C, XM_005264515.4:c.3330G>C, XM_011533062.2:c.3309G>C, XM_011533064.2:c.3159G>C, ENST00000395038.6:c.3330G>C, ENST00000402219.6:c.3330G>C, ENST00000426016.5:c.3330G>C, NC_000002.12:g.38995139C>G, CM000664.2:g.38995139C>G, NC_000002.11:g.39222280C>G, CM000664.1:g.39222280C>G, NC_000002.10:g.39075784C>G, NG_007530.1:g.130325G>C, LRG_754:g.130325G>C, NM_005633.3(SOS1):c.3330G>C (p.Ser1110=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.3330G>C (p.Ser1110=) variant in the SOS1 gene is 0.0382% (8/10406) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624221/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39241061	448942	C	G	NM_005633.3(SOS1):c.3072C>T (p.Leu1024=)	448941	CA1624273	NM_005633.3:c.3072C>T, LRG_754t1:c.3072C>T, XM_005264515.3:c.3072C>T, XM_011533060.1:c.3165C>T, XM_011533061.1:c.3165C>T, XM_011533062.1:c.3051C>T, XM_011533063.1:c.3048C>T, XM_011533064.1:c.2901C>T, XM_011533065.1:c.3165C>T, XM_011533066.1:c.2007C>T, XM_005264515.4:c.3072C>T, XM_011533062.2:c.3051C>T, XM_011533064.2:c.2901C>T, ENST00000395038.6:c.3072C>T, ENST00000402219.6:c.3072C>T, ENST00000426016.5:c.3072C>T, NC_000002.12:g.38996931G>A, CM000664.2:g.38996931G>A, NC_000002.11:g.39224072G>A, CM000664.1:g.39224072G>A, NC_000002.10:g.39077576G>A, NG_007530.1:g.128533C>T, LRG_754:g.128533C>T, NM_005633.3(SOS1):c.3072C>T (p.Leu1024=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.3072C>T (p.Leu1024=) variant in the SOS1 gene is 0.075% (19/16510) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624273/MONDO:0021060/004	0.0122	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
2	39285865	448944	C	T	NM_005633.3(SOS1):c.2010G>C (p.Leu670Phe)	448942	CA1624490	NM_005633.3:c.2010G>C, LRG_754t1:c.2010G>C, XM_005264515.3:c.2010G>C, XM_011533060.1:c.2103G>C, XM_011533061.1:c.2103G>C, XM_011533062.1:c.1989G>C, XM_011533063.1:c.1986G>C, XM_011533064.1:c.1839G>C, XM_011533065.1:c.2103G>C, XM_011533066.1:c.945G>C, XM_005264515.4:c.2010G>C, XM_011533062.2:c.1989G>C, XM_011533064.2:c.1839G>C, ENST00000395038.6:c.2010G>C, ENST00000402219.6:c.2010G>C, ENST00000426016.5:c.2010G>C, NC_000002.12:g.39013920C>G, CM000664.2:g.39013920C>G, NC_000002.11:g.39241061C>G, CM000664.1:g.39241061C>G, NC_000002.10:g.39094565C>G, NG_007530.1:g.111544G>C, LRG_754:g.111544G>C, NM_005633.3(SOS1):c.2010G>C (p.Leu670Phe)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.2010G>C (p.Leu670Phe) variant in the SOS1 gene is 0.055% (9/8572) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624490/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39285879	448945	T	C	NM_005633.3(SOS1):c.294G>A (p.Lys98=)	448944	CA1624823	NM_005633.3:c.294G>A, NC_000002.12:g.39058724C>T, CM000664.2:g.39058724C>T, NC_000002.11:g.39285865C>T, CM000664.1:g.39285865C>T, NC_000002.10:g.39139369C>T, NG_007530.1:g.66740G>A, LRG_754:g.66740G>A, LRG_754t1:c.294G>A, XM_005264515.3:c.294G>A, XM_011533060.1:c.387G>A, XM_011533061.1:c.387G>A, XM_011533062.1:c.273G>A, XM_011533063.1:c.270G>A, XM_011533064.1:c.123G>A, XM_011533065.1:c.387G>A, XM_005264515.4:c.294G>A, XM_011533062.2:c.273G>A, XM_011533064.2:c.123G>A, ENST00000395038.6:c.294G>A, ENST00000402219.6:c.294G>A, ENST00000426016.5:c.294G>A, ENST00000451331.1:c.123G>A, NM_005633.3(SOS1):c.294G>A (p.Lys98=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.294G>A (p.Lys98=) variant in the SOS1 gene is 0.0284% (9/16504) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624823/MONDO:0021060/004	0.025	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
2	39285934	448946	T	C	NM_005633.3(SOS1):c.280A>G (p.Ile94Val)	448945	CA1624825	NM_005633.3:c.280A>G, LRG_754t1:c.280A>G, XM_005264515.3:c.280A>G, XM_011533060.1:c.373A>G, XM_011533061.1:c.373A>G, XM_011533062.1:c.259A>G, XM_011533063.1:c.256A>G, XM_011533064.1:c.109A>G, XM_011533065.1:c.373A>G, XM_005264515.4:c.280A>G, XM_011533062.2:c.259A>G, XM_011533064.2:c.109A>G, ENST00000395038.6:c.280A>G, ENST00000402219.6:c.280A>G, ENST00000426016.5:c.280A>G, ENST00000451331.1:c.109A>G, NC_000002.12:g.39058738T>C, CM000664.2:g.39058738T>C, NC_000002.11:g.39285879T>C, CM000664.1:g.39285879T>C, NC_000002.10:g.39139383T>C, NG_007530.1:g.66726A>G, LRG_754:g.66726A>G, NM_005633.3(SOS1):c.280A>G (p.Ile94Val)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.280A>G (p.Ile94Val) variant in the SOS1 gene is 0.0253% (6/10300) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624825/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
2	39294841	448947	A	G	NM_005633.3(SOS1):c.225A>G (p.Gln75=)	448946	CA1624827	NM_005633.3:c.225A>G, NC_000002.12:g.39058793T>C, CM000664.2:g.39058793T>C, NC_000002.11:g.39285934T>C, CM000664.1:g.39285934T>C, NC_000002.10:g.39139438T>C, NG_007530.1:g.66671A>G, LRG_754:g.66671A>G, LRG_754t1:c.225A>G, XM_005264515.3:c.225A>G, XM_011533060.1:c.318A>G, XM_011533061.1:c.318A>G, XM_011533062.1:c.204A>G, XM_011533063.1:c.201A>G, XM_011533064.1:c.54A>G, XM_011533065.1:c.318A>G, XM_005264515.4:c.225A>G, XM_011533062.2:c.204A>G, XM_011533064.2:c.54A>G, ENST00000395038.6:c.225A>G, ENST00000402219.6:c.225A>G, ENST00000426016.5:c.225A>G, ENST00000451331.1:c.54A>G, NM_005633.3(SOS1):c.225A>G (p.Gln75=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.225A>G (p.Gln75=) variant in the SOS1 gene is 0.042% (12/16448) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624827/MONDO:0021060/004	0.0059	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
15	66782869	448949	T	C	NM_005633.3(SOS1):c.141T>C (p.Tyr47=)	448947	CA1624855	NM_005633.3:c.141T>C, NC_000002.12:g.39067700A>G, CM000664.2:g.39067700A>G, NC_000002.11:g.39294841A>G, CM000664.1:g.39294841A>G, NC_000002.10:g.39148345A>G, NG_007530.1:g.57764T>C, LRG_754:g.57764T>C, LRG_754t1:c.141T>C, XM_005264515.3:c.141T>C, XM_011533060.1:c.234T>C, XM_011533061.1:c.234T>C, XM_011533062.1:c.120T>C, XM_011533063.1:c.117T>C, XM_011533064.1:c.-31T>C, XM_011533065.1:c.234T>C, XM_005264515.4:c.141T>C, XM_011533062.2:c.120T>C, XM_011533064.2:c.-31T>C, ENST00000395038.6:c.141T>C, ENST00000402219.6:c.141T>C, ENST00000426016.5:c.141T>C, ENST00000451331.1:c.-31T>C, NM_005633.3(SOS1):c.141T>C (p.Tyr47=)	SOS1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.141T>C (p.Tyr47=) variant in the SOS1 gene is 0.116% (16/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	18/4/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1624855/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
19	4099271	448950	C	A	NM_002755.3(MAP2K1):c.1098T>C (p.Ala366=)	448949	CA7624163	NM_002755.3:c.1098T>C, NC_000015.10:g.66490531T>C, CM000677.2:g.66490531T>C, NC_000015.9:g.66782869T>C, CM000677.1:g.66782869T>C, NC_000015.8:g.64569923T>C, NG_008305.1:g.108659T>C, LRG_725:g.108659T>C, NG_051234.1:g.12285A>G, LRG_725t1:c.1098T>C, NM_006049.2:c.*208A>G, XM_011521783.1:c.1032T>C, NM_006049.3:c.*208A>G, NR_138061.1:n.727A>G, XM_011521783.3:c.1032T>C, XM_017022411.2:c.1020T>C, XM_017022412.1:c.954T>C, XM_017022413.1:c.570T>C, ENST00000307102.9:c.1098T>C, ENST00000395589.6:c.*208A>G, ENST00000563480.6:c.*208A>G, ENST00000566326.1:c.570T>C, NM_002755.3(MAP2K1):c.1098T>C (p.Ala366=)	MAP2K1	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.1098T>C (p.Ala366=) variant in the MAP2K1 gene is 0.0459% (8/8654) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA7624163/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 0, 0] 	1	Uncertain Significance
19	4117495	448952	G	A	NM_030662.3(MAP2K2):c.847G>T (p.Val283Leu)	448950	CA9090817	NM_030662.3:c.847G>T, LRG_750t1:c.847G>T, XM_006722799.2:c.705+1746G>T, XM_011528133.1:c.277G>T, XM_017026989.1:c.847G>T, XM_017026990.1:c.705+1746G>T, ENST00000262948.9:c.847G>T, ENST00000394867.8:c.556G>T, ENST00000593364.5:n.794G>T, ENST00000595715.1:n.662G>T, ENST00000597263.5:n.169+1746G>T, ENST00000599021.1:n.29+1746G>T, ENST00000600584.5:n.1407G>T, ENST00000601786.5:n.1148G>T, NC_000019.10:g.4099273C>A, CM000681.2:g.4099273C>A, NC_000019.9:g.4099271C>A, CM000681.1:g.4099271C>A, NC_000019.8:g.4050271C>A, NG_007996.1:g.29856G>T, LRG_750:g.29856G>T, NM_030662.3(MAP2K2):c.847G>T (p.Val283Leu)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.847G>T (p.Val283Leu) variant in the MAP2K2 gene is 0.0448% (6/5824) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9090817/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
19	4117579	448953	G	A	NM_030662.3(MAP2K2):c.225C>T (p.Ile75=)	448952	CA9091075	NM_030662.3:c.225C>T, LRG_750t1:c.225C>T, XM_006722799.2:c.225C>T, XM_017026989.1:c.225C>T, XM_017026990.1:c.225C>T, XM_017026991.1:c.225C>T, ENST00000262948.9:c.225C>T, ENST00000394867.8:c.-67C>T, ENST00000599345.1:n.422C>T, NC_000019.10:g.4117497G>A, CM000681.2:g.4117497G>A, NC_000019.9:g.4117495G>A, CM000681.1:g.4117495G>A, NC_000019.8:g.4068495G>A, NG_007996.1:g.11632C>T, LRG_750:g.11632C>T, NM_030662.3(MAP2K2):c.225C>T (p.Ile75=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.225C>T (p.Ile75=) variant in the MAP2K2 gene is 0.08% (20/16508) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9091075/MONDO:0021060/004	0.0003	Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
19	4123828	448954	G	A	NM_030662.3(MAP2K2):c.141C>T (p.Asp47=)	448953	CA9091086	NM_030662.3:c.141C>T, NC_000019.10:g.4117581G>A, CM000681.2:g.4117581G>A, NC_000019.9:g.4117579G>A, CM000681.1:g.4117579G>A, NC_000019.8:g.4068579G>A, NG_007996.1:g.11548C>T, LRG_750:g.11548C>T, LRG_750t1:c.141C>T, XM_006722799.2:c.141C>T, XM_017026989.1:c.141C>T, XM_017026990.1:c.141C>T, XM_017026991.1:c.141C>T, ENST00000262948.9:c.141C>T, ENST00000394867.8:c.-151C>T, ENST00000599345.1:n.338C>T, NM_030662.3(MAP2K2):c.141C>T (p.Asp47=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Benign	BA1 [MET]	"The filtering allele frequency of the c.141C>T (p.Asp47=) variant in the MAP2K2 gene is 0.054% (9/8646) of East Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9091086/MONDO:0021060/004	0.0028	Likely Benign	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance
10	89653795	449088	CATT	C	NM_030662.3(MAP2K2):c.45C>T (p.Asn15=)	448954	CA9091108	NM_030662.3:c.45C>T, LRG_750t1:c.45C>T, XM_006722799.2:c.45C>T, XM_017026989.1:c.45C>T, XM_017026990.1:c.45C>T, XM_017026991.1:c.45C>T, ENST00000262948.9:c.45C>T, ENST00000394867.8:c.-231-16C>T, ENST00000599345.1:n.242C>T, NC_000019.10:g.4123831G>A, CM000681.2:g.4123831G>A, NC_000019.9:g.4123828G>A, CM000681.1:g.4123828G>A, NC_000019.8:g.4074828G>A, NG_007996.1:g.5299C>T, LRG_750:g.5299C>T, NM_030662.3(MAP2K2):c.45C>T (p.Asn15=)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Benign	BS1 [MET]	"The filtering allele frequency of the c.45C>T (p.Asn15=) variant in the MAP2K2 gene is 0.0295% (6/8856) of South Asian chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as likely benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1; PMID:29493581)"		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf	9/5/17	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9091108/MONDO:0021060/004	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 1, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68835692	463775	C	T	NM_000314.6(PTEN):c.97_99delATT (p.Ile33del)	449088	CA645559009	NM_000314.6:c.97_99delATT, NC_000010.11:g.87894042_87894044del, CM000672.2:g.87894042_87894044del, NC_000010.10:g.89653799_89653801del, CM000672.1:g.89653799_89653801del, NC_000010.9:g.89643779_89643781del, NG_007466.2:g.35604_35606del, LRG_311:g.35604_35606del, NM_000314.5:c.97_99del, NM_000314.6:c.97_99del, NM_001304717.2:c.616_618del, NM_001304718.1:c.-609_-607del, XM_006717926.2:c.97_99del, XM_011539981.1:c.97_99del, XM_011539982.1:c.68+13604_68+13606del, XR_945789.1:n.809_811del, XR_945790.1:n.809_811del, XR_945791.1:n.809_811del, NM_000314.7:c.97_99del, NM_001304717.5:c.616_618del, NM_001304718.2:c.-609_-607del, ENST00000371953.7:c.97_99del, ENST00000462694.1:n.99_101del, ENST00000610634.1:c.-6_-4del, NM_000314.6(PTEN):c.97_99delATT (p.Ile33del)	PTEN	PTEN hamartoma tumor syndrome	MONDO:0017623	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [MET], PVS1 [Unmet], BS2 [Unmet], PP2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], PS4-Supporting [MET], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [MET], PS2 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet]	PTEN c.97_99delATT (p.I33del) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the â€œPTEN ACMG Specifications Summaryâ€ document (assertion method column).PS3: Phosphatase activity <50% of wild type OR RNA, mini-gene, or other assay shows impact on splicing. (PMID 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (Internal laboratory contributor SCV000616838.1)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor SCV000616838.1)	10234502, 29706350	PTEN VCEP	https://www.clinicalgenome.org/site/assets/files/10250/pten_acmg_specifications_summary_v1_0_2018.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA645559009/MONDO:0017623/003	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36259274	463988	T	TCC	NM_004360.4(CDH1):c.283C>T (p.Gln95Ter)	463775	CA8129823	NM_004360.4:c.283C>T, NM_004360.3:c.283C>T, LRG_301t1:c.283C>T, XM_011523488.1:c.-453C>T, XM_011523489.1:c.-453C>T, NM_001317184.1:c.283C>T, NM_001317185.1:c.-1333C>T, NM_001317186.1:c.-1537C>T, ENST00000261769.9:c.283C>T, ENST00000422392.6:c.283C>T, ENST00000561751.1:n.50C>T, ENST00000562836.5:n.354C>T, ENST00000564676.5:n.565C>T, ENST00000564745.1:n.278C>T, ENST00000566510.5:c.283C>T, ENST00000566612.5:c.283C>T, ENST00000611625.4:c.283C>T, ENST00000612417.4:c.283C>T, ENST00000621016.4:c.283C>T, NC_000016.10:g.68801789C>T, CM000678.2:g.68801789C>T, NC_000016.9:g.68835692C>T, CM000678.1:g.68835692C>T, NC_000016.8:g.67393193C>T, NG_008021.1:g.69498C>T, LRG_301:g.69498C>T, NM_004360.4(CDH1):c.283C>T (p.Gln95Ter)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP1 [Unmet], PP3 [Unmet], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS1 [Unmet], PS2 [Unmet], PS4-Moderate [MET]	"The c.283C>T (p.Gln95*) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1). The variant is present in <1/100,000 alleles in the gnomAD cohort. (PM2; http://gnomad.broadinstitute.org).  This variant has been reported in at least 2 families meeting HDGC clinical criteria (PS4_Moderate; PMID: 17545690, internal laboratory contributor). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2, PS4_Moderate."	17545690	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA8129823/MONDO:0007648/007	0.9971	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36421179	463989	T	C	NM_001754.4(RUNX1):c.215_216dup (p.Ser73Glyfs)	463988	CA658656806	NM_001754.4:c.215_216dup, NM_001754.4:c.215_216dupGG, NM_001001890.2:c.134_135dup, NM_001122607.1:c.134_135dup, LRG_482t1:c.215_216dup, XM_005261068.3:c.179_180dup, XM_005261069.3:c.215_216dup, XM_011529766.1:c.215_216dup, XM_011529767.1:c.176_177dup, XM_011529768.1:c.176_177dup, XM_011529770.1:c.215_216dup, XR_937576.1:n.394_395dup, XM_005261069.4:c.215_216dup, XM_011529766.2:c.215_216dup, XM_011529767.2:c.176_177dup, XM_011529768.2:c.176_177dup, XM_011529770.2:c.215_216dup, XM_017028487.1:c.62_63dup, XR_937576.2:n.441_442dup, ENST00000300305.7:c.215_216dup, ENST00000344691.8:c.134_135dup, ENST00000358356.9:c.134_135dup, ENST00000399237.6:c.179_180dup, ENST00000399240.5:c.134_135dup, ENST00000437180.5:c.215_216dup, ENST00000455571.5:c.176_177dup, ENST00000482318.5:c.59-6266_59-6265dup, NC_000021.9:g.34886978_34886979dup, CM000683.2:g.34886978_34886979dup, NC_000021.8:g.36259275_36259276dup, CM000683.1:g.36259275_36259276dup, NC_000021.7:g.35181145_35181146dup, NG_011402.2:g.1102733_1102734dup, LRG_482:g.1102733_1102734dup, NM_001754.4(RUNX1):c.215_216dup (p.Ser73Glyfs)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [MET]	"The NM_001754.4:c.215_216dup (p.Ser73Glyfs) variant is a frameshift variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; SCV000638134.1). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2, PS4_Supporting."		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA658656806/MONDO:0011071/008	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
21	36252971	463994	T	C	NM_001754.4(RUNX1):c.18A>G (p.Ile6Met)	463989	CA10014733	NM_001754.4:c.18A>G, NC_000021.9:g.35048882T>C, CM000683.2:g.35048882T>C, NC_000021.8:g.36421179T>C, CM000683.1:g.36421179T>C, NC_000021.7:g.35343049T>C, NG_011402.2:g.940830A>G, LRG_482:g.940830A>G, LRG_482t1:c.18A>G, XM_005261069.3:c.18A>G, XM_011529766.1:c.18A>G, XM_011529767.1:c.18A>G, XM_011529768.1:c.18A>G, XM_011529770.1:c.18A>G, XR_937576.1:n.197A>G, XM_005261069.4:c.18A>G, XM_011529766.2:c.18A>G, XM_011529767.2:c.18A>G, XM_011529768.2:c.18A>G, XM_011529770.2:c.18A>G, XR_937576.2:n.244A>G, ENST00000300305.7:c.18A>G, ENST00000416754.1:c.18A>G, ENST00000437180.5:c.18A>G, ENST00000455571.5:c.18A>G, ENST00000475045.6:c.18A>G, ENST00000482318.5:c.18A>G, NM_001754.4(RUNX1):c.18A>G (p.Ile6Met)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Benign	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [MET], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	MAF for NM_001754.4:c.18A>G (p.Ile6Met) variant is 0.00025 (0.02%, 17/66732 Alleles) in the non-Finnish European subpopulation of ExAC database, which is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). Note: The variant is classified as likely benign based on BS1 alone with no contradictory evidence supporting pathogenicity. In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the  Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014733/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36265254	464002	A	T	NM_001754.4(RUNX1):c.391A>G (p.Thr131Ala)	463994	CA410202714	NM_001754.4:c.391A>G, NM_001001890.2:c.310A>G, NM_001122607.1:c.310A>G, LRG_482t1:c.391A>G, XM_005261068.3:c.355A>G, XM_005261069.3:c.391A>G, XM_011529766.1:c.391A>G, XM_011529767.1:c.352A>G, XM_011529768.1:c.352A>G, XM_011529770.1:c.391A>G, XR_937576.1:n.570A>G, XM_005261069.4:c.391A>G, XM_011529766.2:c.391A>G, XM_011529767.2:c.352A>G, XM_011529768.2:c.352A>G, XM_011529770.2:c.391A>G, XM_017028487.1:c.238A>G, XR_937576.2:n.617A>G, ENST00000300305.7:c.391A>G, ENST00000344691.8:c.310A>G, ENST00000358356.9:c.310A>G, ENST00000399237.6:c.355A>G, ENST00000399240.5:c.310A>G, ENST00000437180.5:c.391A>G, ENST00000455571.5:c.352A>G, ENST00000482318.5:c.98A>G, NC_000021.9:g.34880674T>C, CM000683.2:g.34880674T>C, NC_000021.8:g.36252971T>C, CM000683.1:g.36252971T>C, NC_000021.7:g.35174841T>C, NG_011402.2:g.1109038A>G, LRG_482:g.1109038A>G, NM_001754.4(RUNX1):c.391A>G (p.Thr131Ala)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PM1-Supporting [MET], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PM4 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.391A>G (p.Thr131Ala) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.942) (PP3). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PM1_supporting.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410202714/MONDO:0011071/008	0.1877	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
21	36171741	464009	G	A	NM_001754.4(RUNX1):c.65T>A (p.Ile22Lys)	464002	CA10014634	NM_001754.4:c.65T>A, LRG_482t1:c.65T>A, XM_005261069.3:c.65T>A, XM_011529766.1:c.65T>A, XM_011529767.1:c.59-5861T>A, XM_011529768.1:c.59-5861T>A, XM_011529770.1:c.65T>A, XR_937576.1:n.244T>A, XM_005261069.4:c.65T>A, XM_011529766.2:c.65T>A, XM_011529767.2:c.59-5861T>A, XM_011529768.2:c.59-5861T>A, XM_011529770.2:c.65T>A, XR_937576.2:n.291T>A, ENST00000300305.7:c.65T>A, ENST00000416754.1:c.65T>A, ENST00000437180.5:c.65T>A, ENST00000455571.5:c.59-5861T>A, ENST00000475045.6:c.65T>A, ENST00000482318.5:c.59-12244T>A, NC_000021.9:g.34892957A>T, CM000683.2:g.34892957A>T, NC_000021.8:g.36265254A>T, CM000683.1:g.36265254A>T, NC_000021.7:g.35187124A>T, NG_011402.2:g.1096755T>A, LRG_482:g.1096755T>A, NM_001754.4(RUNX1):c.65T>A (p.Ile22Lys)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1 [MET], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.65T>A (p.Ile22Lys) variant has an MAF of 0.00201 (0.2%, 23/11436 alleles) in the Latino subpopulation of the ExAC cohort which is â‰¥ 0.0015 (0.15%) (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014634/MONDO:0011071/008	0.0122	Likely Benign	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 1, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	112888151	477669	T	C	NM_001754.4(RUNX1):c.824C>T (p.Pro275Leu)	464009	CA10014287	NM_001754.4:c.824C>T, NC_000021.9:g.34799444G>A, CM000683.2:g.34799444G>A, NC_000021.8:g.36171741G>A, CM000683.1:g.36171741G>A, NC_000021.7:g.35093611G>A, NG_011402.2:g.1190268C>T, LRG_482:g.1190268C>T, NM_001001890.2:c.743C>T, LRG_482t1:c.824C>T, XM_005261068.3:c.788C>T, XM_005261069.3:c.632C>T, XM_011529766.1:c.824C>T, XM_011529767.1:c.785C>T, XM_011529768.1:c.593C>T, XR_937576.1:n.1003C>T, XM_005261069.4:c.632C>T, XM_011529766.2:c.824C>T, XM_011529767.2:c.785C>T, XM_011529768.2:c.593C>T, XM_017028487.1:c.671C>T, XR_937576.2:n.1050C>T, ENST00000300305.7:c.824C>T, ENST00000344691.8:c.743C>T, ENST00000399240.5:c.551C>T, ENST00000437180.5:c.824C>T, ENST00000482318.5:c.*414C>T, NM_001754.4(RUNX1):c.824C>T (p.Pro275Leu)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Benign	BA1 [MET], BP4 [MET], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP3 [Unmet], PP1 [Unmet], PVS1 [Unmet], PM2 [Unmet], PM6 [Unmet]	The NM_001754.4:c.824C>T (p.Pro275Leu) variant has an MAF of 0.00225 (0.2%, 26/11566 alleles) in the Latino subpopulation of the ExAC cohort that is â‰¥ 0.0015 (0.15%) (BA1). This missense variant has a REVEL score <0.15 (0.146) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP4.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA10014287/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68842699	479488	G	T	NM_002834.4(PTPN11):c.167T>C (p.Ile56Thr)	477669	CA243707917	NM_002834.4:c.167T>C, NM_002834.3:c.167T>C, LRG_614t1:c.167T>C, NM_080601.1:c.167T>C, XM_006719526.1:c.167T>C, XM_006719527.1:c.167T>C, XM_011538613.1:c.164T>C, NM_001330437.1:c.167T>C, NM_080601.2:c.167T>C, XM_011538613.2:c.164T>C, XM_017019722.1:c.164T>C, ENST00000351677.6:c.167T>C, ENST00000392597.5:c.167T>C, ENST00000635625.1:n.167T>C, NC_000012.12:g.112450347T>C, CM000674.2:g.112450347T>C, NC_000012.11:g.112888151T>C, CM000674.1:g.112888151T>C, NC_000012.10:g.111372534T>C, NG_007459.1:g.36616T>C, LRG_614:g.36616T>C, NM_002834.4(PTPN11):c.167T>C (p.Ile56Thr)	PTPN11	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Likely Pathogenic	PP2 [MET], PP3 [MET], PP1 [Unmet], BS2 [Unmet], PS4-Supporting [MET], PM5 [MET], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS2 [Unmet], PS3 [Unmet], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], BS3 [Unmet], PM2 [MET], PM6 [Unmet], BP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet]	"The c.167T>C (p.Ile56Thr) variant in PTPN11 has been identified in 2 related patients with clinical features of a RASopathy (PS4_Supporting, PP1; Invitae internal data; GTR Lab ID 500031; ClinVar SCV000659038.1). A different pathogenic missense variant (p.Ile56Val) has been previously identified at this codon of PTPN11 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 40485). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). The variant is located in the PTPN11 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Ile56Thr variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for RASopathies in an autosomal dominant manner. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS4_Supporting, PP1, PM2, PM5, PP2, PP3."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA243707917/MONDO:0021060/004	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
16	68867259	479504	G	T	NM_004360.4(CDH1):c.635G>T (p.Gly212Val)	479488	CA396458057	NM_004360.4:c.635G>T, NM_004360.3:c.635G>T, LRG_301t1:c.635G>T, XM_011523488.1:c.-101G>T, XM_011523489.1:c.-101G>T, NM_001317184.1:c.635G>T, NM_001317185.1:c.-981G>T, NM_001317186.1:c.-1185G>T, ENST00000261769.9:c.635G>T, ENST00000422392.6:c.635G>T, ENST00000561751.1:n.402G>T, ENST00000562836.5:n.706G>T, ENST00000564676.5:n.917G>T, ENST00000566510.5:c.531+229G>T, ENST00000566612.5:c.635G>T, ENST00000567320.1:n.145G>T, ENST00000611625.4:c.635G>T, ENST00000612417.4:c.635G>T, ENST00000621016.4:c.635G>T, NC_000016.10:g.68808796G>T, CM000678.2:g.68808796G>T, NC_000016.9:g.68842699G>T, CM000678.1:g.68842699G>T, NC_000016.8:g.67400200G>T, NG_008021.1:g.76505G>T, LRG_301:g.76505G>T, NM_004360.4(CDH1):c.635G>T (p.Gly212Val)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet]	"The c.635G>T (p.Gly212Val) variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; SCV000661629.1). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: PM2, PS4_Supporting."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA396458057/MONDO:0007648/007	0.9986	Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68846113	483264	GT	G	NM_004360.4(CDH1):c.2506G>T (p.Glu836Ter)	479504	CA396472215	NM_004360.4:c.2506G>T, NM_004360.3:c.2506G>T, LRG_301t1:c.2506G>T, XM_011523488.1:c.1771G>T, XM_011523489.1:c.1771G>T, NM_001317184.1:c.2323G>T, NM_001317185.1:c.958G>T, NM_001317186.1:c.541G>T, ENST00000261769.9:c.2506G>T, ENST00000422392.6:c.2323G>T, ENST00000562118.1:n.724G>T, ENST00000562836.5:n.2577G>T, ENST00000566510.5:c.*1172G>T, ENST00000566612.5:c.*746G>T, ENST00000611625.4:c.2569G>T, ENST00000612417.4:c.1854-835G>T, ENST00000621016.4:c.1866-847G>T, NC_000016.10:g.68833356G>T, CM000678.2:g.68833356G>T, NC_000016.9:g.68867259G>T, CM000678.1:g.68867259G>T, NC_000016.8:g.67424760G>T, NG_008021.1:g.101065G>T, LRG_301:g.101065G>T, NM_004360.4(CDH1):c.2506G>T (p.Glu836Ter)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PVS1-Strong [MET], PM4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS2 [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet]	"The c.2506G>T (p.Glu836*) variant results in a premature stop codon that leads to a truncated protein. While it is located within the nonsense mediated decay resistance region,it is recognized as the most c-terminal pathogenic variant in CDH1 (PVS1_Strong, PMID: 29798843). This variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). There is one known de novo observation with parental confirmation in a patient with diffuse gastric cancer and/or lobular breast cancer (PS2; PMID: 29798843). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1_Strong, PM2, PS2."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA396472215/MONDO:0007648/007	0.9971	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68835787	486824	GC	G	NM_004360.4(CDH1):c.1085delT (p.Val362Glyfs)	483264	CA658658486	NM_004360.4:c.1085delT, NC_000016.10:g.68812211del, CM000678.2:g.68812211del, NC_000016.9:g.68846114del, CM000678.1:g.68846114del, NC_000016.8:g.67403615del, NG_008021.1:g.79920del, LRG_301:g.79920del, NM_004360.3:c.1085del, LRG_301t1:c.1085del, XM_011523488.1:c.350del, XM_011523489.1:c.350del, NM_001317184.1:c.1085del, NM_001317185.1:c.-531del, NM_001317186.1:c.-735del, NM_004360.4:c.1085del, ENST00000261769.9:c.1085del, ENST00000422392.6:c.1085del, ENST00000561751.1:n.707del, ENST00000562836.5:n.1156del, ENST00000565810.1:n.129del, ENST00000566510.5:c.929del, ENST00000566612.5:c.1085del, ENST00000611625.4:c.1085del, ENST00000612417.4:c.1085del, ENST00000621016.4:c.1085del, NM_004360.4(CDH1):c.1085delT (p.Val362Glyfs)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BS4 [Unmet], BS1 [Unmet], BP7 [Unmet], BP5 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP1 [Unmet], PP3 [Unmet], PS4-Supporting [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet]	"The c.1085delT (p.Val362Glyfs*31) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1). The variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; SCV000669065.1). Therefore, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2, PS4_Supporting."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA658658486/MONDO:0007648/007	0.9971	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
16	68842599	496233	A	G	NM_004360.4(CDH1):c.382delC (p.His128Ilefs)	486824	CA496152715	NM_004360.4:c.382delC, NM_004360.3:c.382del, LRG_301t1:c.382del, XM_011523488.1:c.-354del, XM_011523489.1:c.-354del, NM_001317184.1:c.382del, NM_001317185.1:c.-1234del, NM_001317186.1:c.-1438del, NM_004360.4:c.382del, ENST00000261769.9:c.382del, ENST00000422392.6:c.382del, ENST00000561751.1:n.149del, ENST00000562836.5:n.453del, ENST00000564676.5:n.664del, ENST00000564745.1:n.377del, ENST00000566510.5:c.382del, ENST00000566612.5:c.382del, ENST00000611625.4:c.382del, ENST00000612417.4:c.382del, ENST00000621016.4:c.382del, NC_000016.10:g.68801888del, CM000678.2:g.68801888del, NC_000016.9:g.68835791del, CM000678.1:g.68835791del, NC_000016.8:g.67393292del, NG_008021.1:g.69597del, LRG_301:g.69597del, NM_004360.4(CDH1):c.382delC (p.His128Ilefs)	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Pathogenic	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [MET], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet]	"The c.382delC (p.His128Ilefs*87) variant is predicted to result in a premature stop codon that leads to a truncated or absent protein (PVS1). The variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant has been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; PMID: 15235021). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel: PVS1, PM2, PS4_Supporting."	19269290	CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	21/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA496152715/MONDO:0007648/007	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	41285135	505302	G	C	NM_004360.3:c.535A>G	496233	CA396457842	NM_004360.3:c.535A>G, LRG_301t1:c.535A>G, XM_011523488.1:c.-201A>G, XM_011523489.1:c.-201A>G, NM_001317184.1:c.535A>G, NM_001317185.1:c.-1081A>G, NM_001317186.1:c.-1285A>G, NM_004360.4:c.535A>G, ENST00000261769.9:c.535A>G, ENST00000422392.6:c.535A>G, ENST00000561751.1:n.302A>G, ENST00000562836.5:n.606A>G, ENST00000564676.5:n.817A>G, ENST00000564745.1:n.530A>G, ENST00000566510.5:c.531+129A>G, ENST00000566612.5:c.535A>G, ENST00000567320.1:n.45A>G, ENST00000611625.4:c.535A>G, ENST00000612417.4:c.535A>G, ENST00000621016.4:c.535A>G, NC_000016.10:g.68808696A>G, CM000678.2:g.68808696A>G, NC_000016.9:g.68842599A>G, CM000678.1:g.68842599A>G, NC_000016.8:g.67400100A>G, NG_008021.1:g.76405A>G, LRG_301:g.76405A>G	CDH1	hereditary diffuse gastric cancer	MONDO:0007648	Autosomal dominant inheritance	Uncertain Significance	BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP1 [MET], PS4-Supporting [MET], PM4 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS2 [Unmet]	"The c.535A>G (p.Lys179Glu) variant is absent in the gnomAD cohort (PM2; http://gnomad.broadinstitute.org). This variant was found to co-segregate with disease in multiple affected family members, with 3 or 4 meioses observed (PP1; internal laboratory contributor). This variant has also been reported in at least one family meeting HDGC clinical criteria (PS4_Supporting; internal laboratory contributor). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: PM2, PP1, PS4_Supporting."		CDH1 VCEP	https://www.clinicalgenome.org/site/assets/files/8816/clingen_cdh1_acmg_specifications_v1.pdf	22/11/18	7/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA396457842/MONDO:0007648/007	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
1	215932085	506273	G	T	NM_004700.3(KCNQ4):c.825G>C (p.Trp275Cys)	505302	CA21112664	NM_004700.3:c.825G>C, NC_000001.11:g.40819463G>C, CM000663.2:g.40819463G>C, NC_000001.10:g.41285135G>C, CM000663.1:g.41285135G>C, NC_000001.9:g.41057722G>C, NG_008139.1:g.40452G>C, NG_008139.2:g.40452G>C, NM_172163.2:c.825G>C, XM_011542417.1:c.825G>C, XM_011542418.1:c.825G>C, XM_011542419.1:c.825G>C, XM_011542420.1:c.825G>C, XR_946798.1:n.831G>C, XR_946799.1:n.831G>C, XR_946800.1:n.831G>C, XM_017002792.1:c.-193G>C, NM_004700.4:c.825G>C, ENST00000347132.9:c.825G>C, ENST00000443478.3:n.511G>C, ENST00000506017.1:n.144G>C, ENST00000509682.6:n.825G>C, NM_004700.3(KCNQ4):c.825G>C (p.Trp275Cys)	KCNQ4	nonsyndromic genetic deafness	MONDO:0019497	Autosomal dominant inheritance	Likely Pathogenic	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP1 [Unmet], PP4 [Unmet], PP3 [MET], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], PS4 [Unmet], PS3 [Unmet], PS2 [Unmet], PS1 [Unmet], PM5 [MET], PM3 [Unmet], PM4 [Unmet], PM1 [MET], BS1 [Unmet], BS4 [Unmet], BP5 [Unmet], BP7 [Unmet]	"The c.825G>C (p.Trp275Cys) variant was found in one patient with hearing loss (PS4 not met; Partners LMM ClinVar SCV000712456.1). The p.Trp275Cys variant in the KCNQ4 gene was absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org) (PM2). A different pathogenic missense variant (p.Trp275Arg) and a likely pathogenic missense variant (p.Trp275Ser) have been previously identified at this codon of KCNQ4 which may indicate that this residue is critical to the function of the protein (PM5; ClinVar Variation ID 6242, PMID: 25116015, 20301388; ClinVar Variation ID 372951). Furthermore, the variant is in a location that has been defined by the ClinGen Hearing Loss Expert Panel to be a mutational hotspot or domain of KCNQ4 (PM1; PMID: 23717403 https://www.uniprot.org/uniprot/P56696). Computational prediction tools and conservation analysis suggest that the p.Trp275Cys variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant non-syndromic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: (PM2, PM5, PM1, PP3)."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	10/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA21112664/MONDO:0019497/005	0.9971	Pathogenic	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
11	76883813	517357	G	A	NM_206933.2(USH2A):c.11241C>A (p.Tyr3747Ter)	506273	CA1393780	NM_206933.2:c.11241C>A, NC_000001.11:g.215758743G>T, CM000663.2:g.215758743G>T, NC_000001.10:g.215932085G>T, CM000663.1:g.215932085G>T, NC_000001.9:g.213998708G>T, NG_009497.1:g.669654C>A, NM_206933.3:c.11241C>A, ENST00000307340.7:c.11241C>A, NM_206933.2(USH2A):c.11241C>A (p.Tyr3747Ter)	USH2A	Usher syndrome	MONDO:0019501	Autosomal recessive inheritance	Pathogenic	PM6 [Unmet], PVS1 [MET], BS2 [Unmet], PP3 [Unmet], PP1 [Unmet], PP4 [Unmet], PM2-Supporting [MET], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3-Supporting [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	The p.Tyr3747X variant in USH2A is predicted to cause a premature stop codon in biologically-relevant-exon 58/72 that leads to a truncated or absent protein in a gene in which loss-of-function is an established mechanism (PVS1). The allele frequency of the p.Tyr3747X variant in the Ush2A gene is 0.017% (4/24020) of African chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for  autosomal recessive hearing loss ( PM2_Supporting). This variant has been detected in 1 patient with hearing loss in trans with a suspected pathogenic variant (PM3_Supporting, Partners LMM internal data SCV000713838.1). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied: PVS1,  PM2_Supporting, PM3_Supporting.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	17/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA1393780/MONDO:0019501/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36231821	532659	G	C	NM_000260.3(MYO7A):c.1817G>A (p.Arg606His)	517357	CA6197622	NM_000260.3:c.1817G>A, NM_001127179.2:c.1817G>A, NM_001127180.1:c.1817G>A, XM_005274012.2:c.1817G>A, XM_006718558.2:c.1817G>A, XM_006718559.2:c.1817G>A, XM_006718560.2:c.1817G>A, XM_006718561.2:c.1817G>A, XM_011545044.1:c.1817G>A, XM_011545045.1:c.1817G>A, XM_011545046.1:c.1784G>A, XM_011545047.1:c.1817G>A, XM_011545048.1:c.1817G>A, XM_011545049.1:c.1586G>A, XM_011545050.1:c.1559G>A, XM_011545051.1:c.1817G>A, XM_011545052.1:c.1817G>A, XR_949938.1:n.2137G>A, XR_949941.1:n.2137G>A, XR_949942.1:n.2139G>A, XR_949943.1:n.2139G>A, XM_011545044.2:c.1817G>A, XM_011545046.2:c.1907G>A, XM_011545050.2:c.1559G>A, XM_017017778.1:c.1907G>A, XM_017017779.1:c.1907G>A, XM_017017780.1:c.1907G>A, XM_017017781.1:c.1907G>A, XM_017017782.1:c.1907G>A, XM_017017783.1:c.1907G>A, XM_017017784.1:c.1907G>A, XM_017017785.1:c.1676G>A, XM_017017786.1:c.1907G>A, XM_017017787.1:c.1907G>A, XM_017017788.1:c.1907G>A, XR_001747885.1:n.1922G>A, XR_001747886.1:n.1922G>A, XR_001747887.1:n.1922G>A, XR_001747888.1:n.1922G>A, XR_001747889.1:n.1922G>A, NM_000260.4:c.1817G>A, ENST00000409619.6:c.1784G>A, ENST00000409709.7:c.1817G>A, ENST00000409893.5:c.1817G>A, ENST00000458637.6:c.1817G>A, ENST00000620575.4:c.1817G>A, NC_000011.10:g.77172767G>A, CM000673.2:g.77172767G>A, NC_000011.9:g.76883813G>A, CM000673.1:g.76883813G>A, NC_000011.8:g.76561461G>A, NG_009086.1:g.49504G>A, NM_000260.3(MYO7A):c.1817G>A (p.Arg606His)	MYO7A	nonsyndromic genetic deafness	MONDO:0019497		Uncertain Significance	PM6 [Unmet], PVS1 [Unmet], PP3 [MET], PP1 [Unmet], PP4 [MET], BS2 [Unmet], PM2-Supporting [MET], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [MET], BP7 [Unmet], BP5 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The allele frequency of the p.Arg505His variant in MYO7A is 0.035% (8/23150) South Asian chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2_P). This variant has been detected in 1 patient with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3; Partners LMM internal data SCV000731600.1). Computational prediction tools and conservation analysis suggest that the p.Arg606His variant may impact the protein (PP3). One patient with a variant in this gene displayed features of sensorineural hearing loss and delayed walking (PP4; Partners LMM internal data SCV000731600.1). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_P, PM3, PP3, PP4."		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	28/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6197622/MONDO:0019497/005	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
21	36164715	532662	C	G	NM_001754.4(RUNX1):c.563C>G (p.Thr188Ser)	532659	CA410208042	NM_001754.4:c.563C>G, NM_001001890.2:c.482C>G, NM_001122607.1:c.482C>G, LRG_482t1:c.563C>G, XM_005261068.3:c.527C>G, XM_005261069.3:c.563C>G, XM_011529766.1:c.563C>G, XM_011529767.1:c.524C>G, XM_011529768.1:c.524C>G, XM_011529770.1:c.563C>G, XR_937576.1:n.742C>G, XM_005261069.4:c.563C>G, XM_011529766.2:c.563C>G, XM_011529767.2:c.524C>G, XM_011529768.2:c.524C>G, XM_011529770.2:c.563C>G, XM_017028487.1:c.410C>G, XR_937576.2:n.789C>G, ENST00000300305.7:c.563C>G, ENST00000344691.8:c.482C>G, ENST00000358356.9:c.482C>G, ENST00000399237.6:c.527C>G, ENST00000399240.5:c.482C>G, ENST00000437180.5:c.563C>G, ENST00000467577.1:n.55C>G, ENST00000482318.5:c.*153C>G, NC_000021.9:g.34859524G>C, CM000683.2:g.34859524G>C, NC_000021.8:g.36231821G>C, CM000683.1:g.36231821G>C, NC_000021.7:g.35153691G>C, NG_011402.2:g.1130188C>G, LRG_482:g.1130188C>G, NM_001754.4(RUNX1):c.563C>G (p.Thr188Ser)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PM1-Supporting [MET], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.563C>G (p.Thr188Ser) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.922) (PP3). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PM1_supporting.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410208042/MONDO:0011071/008	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
21	36164461	532664	G	GGC	NM_001754.4(RUNX1):c.1160G>C (p.Gly387Ala)	532662	CA410147917	NM_001754.4:c.1160G>C, NC_000021.9:g.34792418C>G, CM000683.2:g.34792418C>G, NC_000021.8:g.36164715C>G, CM000683.1:g.36164715C>G, NC_000021.7:g.35086585C>G, NG_011402.2:g.1197294G>C, LRG_482:g.1197294G>C, NM_001001890.2:c.1079G>C, LRG_482t1:c.1160G>C, XM_005261068.3:c.1124G>C, XM_005261069.3:c.968G>C, XM_011529766.1:c.1160G>C, XM_011529767.1:c.1121G>C, XM_011529768.1:c.929G>C, XM_005261069.4:c.968G>C, XM_011529766.2:c.1160G>C, XM_011529767.2:c.1121G>C, XM_011529768.2:c.929G>C, XM_017028487.1:c.1007G>C, ENST00000300305.7:c.1160G>C, ENST00000344691.8:c.1079G>C, ENST00000399240.5:c.887G>C, ENST00000437180.5:c.1160G>C, ENST00000482318.5:c.*750G>C, NM_001754.4(RUNX1):c.1160G>C (p.Gly387Ala)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP2 [Unmet], BP4 [MET], BA1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PS1 [Unmet], PS3 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet], BS3 [Unmet], PP1 [Unmet], PP3 [Unmet], PS4-Supporting [MET], PM2 [Unmet], PM6 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.1160G>C (p.Gly387Ala) variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 27210295). This missense variant has a REVEL score <0.15 (0.141) and SSF and MES predict either an increase in the canonical splice site score or a decrease of the canonical splice site score by no more than 10% and no putative cryptic splice sites are created (BP4). The gnomAD Allele Frequency of this variant is 0.00001. In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS4_ supporting, BP4."	27210295	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410147917/MONDO:0011071/008	0.9941	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36259160	532671	T	C	NM_001754.4(RUNX1):c.1412_1413dup (p.Leu472Alafs)	532664	CA658799413	NM_001754.4:c.1412_1413dupGC, NM_001754.4:c.1412_1413dup, NC_000021.9:g.34792170_34792171dup, CM000683.2:g.34792170_34792171dup, NC_000021.8:g.36164467_36164468dup, CM000683.1:g.36164467_36164468dup, NC_000021.7:g.35086337_35086338dup, NG_011402.2:g.1197546_1197547dup, LRG_482:g.1197546_1197547dup, NM_001001890.2:c.1331_1332dup, LRG_482t1:c.1412_1413dup, XM_005261068.3:c.1376_1377dup, XM_005261069.3:c.1220_1221dup, XM_011529766.1:c.1412_1413dup, XM_011529767.1:c.1373_1374dup, XM_011529768.1:c.1181_1182dup, XM_005261069.4:c.1220_1221dup, XM_011529766.2:c.1412_1413dup, XM_011529767.2:c.1373_1374dup, XM_011529768.2:c.1181_1182dup, XM_017028487.1:c.1259_1260dup, ENST00000300305.7:c.1412_1413dup, ENST00000344691.8:c.1331_1332dup, ENST00000399240.5:c.1139_1140dup, ENST00000437180.5:c.1412_1413dup, ENST00000482318.5:c.*1002_*1003dup, NM_001754.4(RUNX1):c.1412_1413dup (p.Leu472Alafs)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP1-Strong [MET], PVS1-Strong [MET], PP3 [Unmet], PS4-Supporting [MET], PS3-Moderate [MET], PM2 [MET], PM6 [Unmet]	"The NM_001754.4:c.1412_1413dup (p.Leu472Alafs) variant is a frameshift variant that is not expected to result in nonsense-mediated mRNA decay, but the predicted truncated/altered region (removes aa 472-480, including the VWRPY motif) is critical to protein function (PVS1_Strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 24353905). This variant was found to co-segregate with disease in multiple affected family members, with seven meioses observed in one family (PP1_Strong; PMID: 24353905). There is evidence of abnormal protein expression of this variant allele as a functional consequence of incorrect protein products (PS3_Moderate; PMID: 24353905). PS3_Moderate is applied because the variant meets PVS1_Strong. In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_strong, PP1_strong, PS3_moderate, PM2, PS4_supporting."	24353905, 24353905, 24353905, 24353905	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA658799413/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
19	4101030	543999	C	T	NM_001754.4(RUNX1):c.331A>G (p.Thr111Ala)	532671	CA410203415	NM_001754.4:c.331A>G, NM_001001890.2:c.250A>G, NM_001122607.1:c.250A>G, LRG_482t1:c.331A>G, XM_005261068.3:c.295A>G, XM_005261069.3:c.331A>G, XM_011529766.1:c.331A>G, XM_011529767.1:c.292A>G, XM_011529768.1:c.292A>G, XM_011529770.1:c.331A>G, XR_937576.1:n.510A>G, XM_005261069.4:c.331A>G, XM_011529766.2:c.331A>G, XM_011529767.2:c.292A>G, XM_011529768.2:c.292A>G, XM_011529770.2:c.331A>G, XM_017028487.1:c.178A>G, XR_937576.2:n.557A>G, ENST00000300305.7:c.331A>G, ENST00000344691.8:c.250A>G, ENST00000358356.9:c.250A>G, ENST00000399237.6:c.295A>G, ENST00000399240.5:c.250A>G, ENST00000437180.5:c.331A>G, ENST00000455571.5:c.292A>G, ENST00000482318.5:c.59-6150A>G, NC_000021.9:g.34886863T>C, CM000683.2:g.34886863T>C, NC_000021.8:g.36259160T>C, CM000683.1:g.36259160T>C, NC_000021.7:g.35181030T>C, NG_011402.2:g.1102849A>G, LRG_482:g.1102849A>G, NM_001754.4(RUNX1):c.331A>G (p.Thr111Ala)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS1 [Unmet], PS4 [Unmet], PM1-Supporting [MET], PM4 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	The NM_001754.4:c.331A>G (p.Thr111Ala) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.939) (PP3). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PM1_supporting.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410203415/MONDO:0011071/008	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36206833	545522	C	A	NM_030662.3(MAP2K2):c.692G>A (p.Arg231His)	543999	CA9090854	NM_030662.3:c.692G>A, LRG_750t1:c.692G>A, XM_006722799.2:c.692G>A, XM_011528133.1:c.122G>A, XM_017026989.1:c.692G>A, XM_017026990.1:c.692G>A, XM_017026991.1:c.692G>A, ENST00000262948.9:c.692G>A, ENST00000394867.8:c.401G>A, ENST00000593364.5:n.639G>A, ENST00000597008.5:n.293G>A, ENST00000597263.5:n.156G>A, ENST00000599021.1:n.16G>A, ENST00000601786.5:n.993G>A, ENST00000602167.5:n.412G>A, NC_000019.10:g.4101032C>T, CM000681.2:g.4101032C>T, NC_000019.9:g.4101030C>T, CM000681.1:g.4101030C>T, NC_000019.8:g.4052030C>T, NG_007996.1:g.28097G>A, LRG_750:g.28097G>A, NM_030662.3(MAP2K2):c.692G>A (p.Arg231His)	MAP2K2	RASopathy	MONDO:0021060	Autosomal dominant inheritance	Uncertain Significance	PP1 [Unmet], PP2 [MET], PP3 [MET], BS2 [Unmet], PM1 [Unmet], PM4 [Unmet], PM5 [Unmet], PS4 [Unmet], PS3 [Unmet], PS2 [Unmet], PS1 [Unmet], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS3 [Unmet], BS4 [Unmet], PM2 [Unmet], PM6 [Unmet], BP1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], BA1 [Unmet]	"The c.692G>A (p.Arg231His) variant in MAP2K2 has been identified in a patient with clinical features consistent with cardiomyopathy (PS4 not met; Invitae internal data, GTR Lab ID 500031; ClinVar SCV000776886.1). The variant is located in the MAP2K2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Computational prediction tools and conservation analysis suggest that the p.Arg231His variant may impact the protein (PP3). In summary, the clinical significance of the p.Arg231His variant is uncertain. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): PP2, PP3."		RASopathy VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/pdyydcyt/acmg_variant_classification_rasopathy_.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA9090854/MONDO:0021060/004	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103234208	551555	G	T	NM_001001890.2(RUNX1):c.598G>T (p.Glu200Ter)	545522	CA410206910	NM_001001890.2:c.598G>T, NM_001122607.1:c.598G>T, NM_001754.4:c.679G>T, LRG_482t1:c.679G>T, XM_005261068.3:c.643G>T, XM_005261069.3:c.613+24938G>T, XM_011529766.1:c.679G>T, XM_011529767.1:c.640G>T, XM_011529768.1:c.574+24938G>T, XM_011529770.1:c.679G>T, XR_937576.1:n.858G>T, XM_005261069.4:c.613+24938G>T, XM_011529766.2:c.679G>T, XM_011529767.2:c.640G>T, XM_011529768.2:c.574+24938G>T, XM_011529770.2:c.679G>T, XM_017028487.1:c.526G>T, XR_937576.2:n.905G>T, ENST00000300305.7:c.679G>T, ENST00000344691.8:c.598G>T, ENST00000358356.9:c.598G>T, ENST00000399237.6:c.643G>T, ENST00000399240.5:c.532+24938G>T, ENST00000437180.5:c.679G>T, ENST00000469087.1:n.215G>T, ENST00000482318.5:c.*269G>T, NC_000021.9:g.34834536C>A, CM000683.2:g.34834536C>A, NC_000021.8:g.36206833C>A, CM000683.1:g.36206833C>A, NC_000021.7:g.35128703C>A, NG_011402.2:g.1155176G>T, LRG_482:g.1155176G>T, NM_001001890.2(RUNX1):c.598G>T (p.Glu200Ter)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Pathogenic	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS3 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [MET]	"The NM_001001890.2:c.598G>T (p.Glu200Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; PMID: 30990344). In summary, this variant meets criteria to be classified as pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2, PS4_Supporting."	30990344	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410206910/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	1	Uncertain Significance
12	103234275	552907	T	C	NM_000277.1:c.1285C>A	551555	CA6748701	NM_000277.1:c.1285C>A, XM_011538422.1:c.1228C>A, NM_000277.2:c.1285C>A, NM_001354304.1:c.1285C>A, NM_000277.3:c.1285C>A, ENST00000307000.7:c.1270C>A, ENST00000551114.2:n.947C>A, ENST00000553106.5:c.1285C>A, ENST00000635477.1:n.389C>A, ENST00000635528.1:n.800C>A, NC_000012.12:g.102840430G>T, CM000674.2:g.102840430G>T, NC_000012.11:g.103234208G>T, CM000674.1:g.103234208G>T, NC_000012.10:g.101758338G>T, NG_008690.1:g.82173C>A, NG_008690.2:g.122981C>A	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [Unmet]	The c.1285C>A (p.Gln429Lys) variant in PAH is reported in a patient with mild PKU (Phe level 720). BH4 cofactor deficiency was excluded. It was detected with a known pathogenic variant, EX6-96A>G (VarID 590). (PMID: 26503515, 28982351) This variant has a low frequency in gnomAD and ExAC (MAF=0.00002), and absent in 1000G. Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PP4_Moderate, PM3.	26503515, 28982351, 28982351	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6748701/MONDO:0009861/006	0.6752	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103288698	555212	T	C	NM_000277.1:c.1218A>G	552907	CA6748708	NM_000277.1:c.1218A>G, NC_000012.12:g.102840497T>C, CM000674.2:g.102840497T>C, NC_000012.11:g.103234275T>C, CM000674.1:g.103234275T>C, NC_000012.10:g.101758405T>C, NG_008690.1:g.82106A>G, NG_008690.2:g.122914A>G, XM_011538422.1:c.1161A>G, NM_000277.2:c.1218A>G, NM_001354304.1:c.1218A>G, NM_000277.3:c.1218A>G, ENST00000307000.7:c.1203A>G, ENST00000551114.2:n.880A>G, ENST00000553106.5:c.1218A>G, ENST00000635477.1:n.322A>G, ENST00000635528.1:n.733A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PM5 [MET], PM3 [MET], PP3 [Unmet], PP4 [MET]	The c.1218A>G (p.Ile406Met) variant in PAH is reported in 2 individuals with non-PKU HPA. BH4 assessment was not stated. It was detected with a known pathogenic variant, p.Arg408Trp. (PMID: 23357515) This variant has a low allele frequency in gnomAD and ExAC (MAF=0.00003) and is absent in 1000G. Computational evidence is discordant. Another missense change at this amino acid is interpreted as likely pathogenic by the PAH VCEP (p.I406T). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PM3, PM5, PP4.	23357515, 23357515	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	9/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6748708/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103249097	555366	G	A	NM_000277.2(PAH):c.523C>T (p.Pro175Ser)	555366	CA16020810	NM_000277.2:c.523C>T, NM_000277.1:c.523C>T, XM_011538422.1:c.523C>T, NM_001354304.1:c.523C>T, XM_017019370.2:c.523C>T, NM_000277.3:c.523C>T, ENST00000307000.7:c.508C>T, ENST00000549111.5:n.619C>T, ENST00000551988.5:n.544C>T, ENST00000553106.5:c.523C>T, NC_000012.12:g.102855319G>A, CM000674.2:g.102855319G>A, NC_000012.11:g.103249097G>A, CM000674.1:g.103249097G>A, NC_000012.10:g.101773227G>A, NG_008690.1:g.67284C>T, NG_008690.2:g.108092C>T, NM_000277.2(PAH):c.523C>T (p.Pro175Ser)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PP4-Moderate [MET], PM3 [MET], PP3 [MET]	"The c.523C>T (p.Pro175Ser) variant in PAH has been reported in 1 individual with classic PKU (BH4 deficiency excluded) in trans with pathogenic variant p.R413P (PP4_Moderate, PM3; PMID: 26322415). This variant is absent in population databases (PM2). Computational evidence support a deleterious effect (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PP3."	26322415, 26322415	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16020810/MONDO:0009861/006	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763047	555720	G	A	NM_004004.5:c.674C>T	555720	CA387460667	NM_004004.5:c.674C>T, NC_000013.11:g.20188908G>A, CM000675.2:g.20188908G>A, NC_000013.10:g.20763047G>A, CM000675.1:g.20763047G>A, NC_000013.9:g.19661047G>A, NG_008358.1:g.9068C>T, XM_011535049.1:c.674C>T, XM_011535049.2:c.674C>T, NM_004004.6:c.674C>T, ENST00000382844.1:c.674C>T, ENST00000382848.4:c.674C>T	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [Unmet], PP4 [Unmet], PP1 [Unmet], BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], BP3 [Unmet], PS3 [Unmet], PS2 [Unmet], PS4 [Unmet], PS1 [Unmet], PM3 [MET], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	"The p.Pro225Leu variant in GJB2 is absent from the Genome Aggregation Database  (http://gnomad.broadinstitute.org) (PM2). This variant has been detected in 1 patient with hearing loss in trans with pathogenic or suspected-pathogenic variants (PM3; PMID:21112098). In summary, this variant meets criteria to be classified as a variant of uncertain clinical significance for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel:  PM2, PM3."	21112098, 21112098	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	20/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA387460667/MONDO:0019497/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246635	556296	T	C	NM_000277.1:c.800A>G	556296	CA16020862	NM_000277.1:c.800A>G, NC_000012.12:g.102852857T>C, CM000674.2:g.102852857T>C, NC_000012.11:g.103246635T>C, CM000674.1:g.103246635T>C, NC_000012.10:g.101770765T>C, NG_008690.1:g.69746A>G, NG_008690.2:g.110554A>G, XM_011538422.1:c.800A>G, NM_000277.2:c.800A>G, NM_001354304.1:c.800A>G, NM_000277.3:c.800A>G, ENST00000307000.7:c.785A>G, ENST00000549247.6:n.559A>G, ENST00000553106.5:c.800A>G	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PP4-Moderate [MET], PM5 [Unmet], PM3 [MET], PP3 [MET], PS3 [MET]	"The c.800A>G (p.Gln267Arg) variant in PAH has been reported in 1 individual with Classic PKU (BH4 deficiency excluded) and was detected with G257V which is pathogenic per the ClinGen PAH VCEP (PP4_Moderate, PM3; PMID: 24401910). This variant is absent in population databases (PM2). This variant has 1.1% enzyme activity (PS3; PMID: 24401910). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM2, PM3, PP3."	24401910, 24401910, 24401910	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	10/12/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16020862/MONDO:0009861/006	0.8121	VUS	Likely pathogenic 	 InterVar: Likely pathogenic PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 1, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103306610	557124	C	A	NM_000277.2(PAH):c.127G>T (p.Glu43Ter)	557124	CA16020729	NM_000277.2:c.127G>T, NM_000277.1:c.127G>T, XM_011538422.1:c.127G>T, NM_001354304.1:c.127G>T, XM_017019370.2:c.127G>T, NM_000277.3:c.127G>T, ENST00000307000.7:c.112G>T, ENST00000546844.1:c.127G>T, ENST00000548677.2:n.214G>T, ENST00000548928.1:n.49G>T, ENST00000549111.5:n.223G>T, ENST00000550978.6:n.111G>T, ENST00000551337.5:c.127G>T, ENST00000551988.5:n.216G>T, ENST00000553106.5:c.127G>T, ENST00000635500.1:n.95G>T, NC_000012.12:g.102912832C>A, CM000674.2:g.102912832C>A, NC_000012.11:g.103306610C>A, CM000674.1:g.103306610C>A, NC_000012.10:g.101830740C>A, NG_008690.1:g.9771G>T, NG_008690.2:g.50579G>T, NM_000277.2(PAH):c.127G>T (p.Glu43Ter)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Pathogenic	PM2 [MET], PVS1 [MET], PP4 [MET]	"The c.127G>T (p.Glu43*) variant is a nonsense variant in exon 2 of 13 in PAH, predicted to undergo nonsense mediated decay with the truncated region critical to protein function. It has been reported in 2 individuals with PKU (BH4 deficiency not excluded). (PP4; PMID: 26503515). This variant is absent from population databases (PM2). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PVS1, PM2, PP4."	26503515	PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA16020729/MONDO:0009861/006	0.9971	Pathogenic	Pathogenic 	 InterVar: Pathogenic PVS1=1 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36164712	561222	G	T	NM_001754.4(RUNX1):c.1163C>A (p.Ser388Ter)	561222	CA410147908	NM_001754.4:c.1163C>A, NC_000021.9:g.34792415G>T, CM000683.2:g.34792415G>T, NC_000021.8:g.36164712G>T, CM000683.1:g.36164712G>T, NC_000021.7:g.35086582G>T, NG_011402.2:g.1197297C>A, LRG_482:g.1197297C>A, NM_001001890.2:c.1082C>A, LRG_482t1:c.1163C>A, XM_005261068.3:c.1127C>A, XM_005261069.3:c.971C>A, XM_011529766.1:c.1163C>A, XM_011529767.1:c.1124C>A, XM_011529768.1:c.932C>A, XM_005261069.4:c.971C>A, XM_011529766.2:c.1163C>A, XM_011529767.2:c.1124C>A, XM_011529768.2:c.932C>A, XM_017028487.1:c.1010C>A, ENST00000300305.7:c.1163C>A, ENST00000344691.8:c.1082C>A, ENST00000399240.5:c.890C>A, ENST00000437180.5:c.1163C>A, ENST00000482318.5:c.*753C>A, NM_001754.4(RUNX1):c.1163C>A (p.Ser388Ter)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PM4 [Unmet], PM1 [Unmet], PM5 [Unmet], BP7 [Unmet], BS3 [Unmet], BS4 [Unmet], BS1 [Unmet], PS3-Supporting [MET], PVS1-Strong [MET], PP3 [Unmet], PP1 [Unmet], PS4-Supporting [MET], PM6 [Unmet], PM2 [MET]	"The NM_001754.4:c.1163C>A (p.Ser388Ter) variant is a nonsense variant that is predicted to introduce a premature stop codon and expected to result in nonsense-mediated mRNA decay (PVS1). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). Transactivation assays demonstrate enhanced transactivation (>115% of wt) (PS3_Supporting; PMID: 20846103). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_Supporting; PMID: 20846103). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1, PM2, PS3_Supporting, PS4_Supporting."	20846103, 20846103, 20846103, 20846103	Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410147908/MONDO:0011071/008	0.9941	Likely Pathogenic	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36259177	561233	T	G	NM_001754.4(RUNX1):c.314A>C (p.His105Pro)	561233	CA410203519	NM_001754.4:c.314A>C, NM_001001890.2:c.233A>C, NM_001122607.1:c.233A>C, LRG_482t1:c.314A>C, XM_005261068.3:c.278A>C, XM_005261069.3:c.314A>C, XM_011529766.1:c.314A>C, XM_011529767.1:c.275A>C, XM_011529768.1:c.275A>C, XM_011529770.1:c.314A>C, XR_937576.1:n.493A>C, XM_005261069.4:c.314A>C, XM_011529766.2:c.314A>C, XM_011529767.2:c.275A>C, XM_011529768.2:c.275A>C, XM_011529770.2:c.314A>C, XM_017028487.1:c.161A>C, XR_937576.2:n.540A>C, ENST00000300305.7:c.314A>C, ENST00000344691.8:c.233A>C, ENST00000358356.9:c.233A>C, ENST00000399237.6:c.278A>C, ENST00000399240.5:c.233A>C, ENST00000437180.5:c.314A>C, ENST00000455571.5:c.275A>C, ENST00000482318.5:c.59-6167A>C, NC_000021.9:g.34886880T>G, CM000683.2:g.34886880T>G, NC_000021.8:g.36259177T>G, CM000683.1:g.36259177T>G, NC_000021.7:g.35181047T>G, NG_011402.2:g.1102832A>C, LRG_482:g.1102832A>C, NM_001754.4(RUNX1):c.314A>C (p.His105Pro)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Likely Pathogenic	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PM1-Supporting [MET], PS1 [Unmet], PS3 [Unmet], PM4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PM5-Supporting [MET], PP3 [MET], PP1 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.314A>C (p.His105Pro) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.953) (PP3). This variant is a missense change at the same residue (p.His105Pro) where a different missense change has been previously established as a likely pathogenic variant (NM_001754.4:c.315C>A (p.His105Glu)) based on MM-VCEP rules for RUNX1 and RNA data or agreement in splicing predictors (SSF and MES) show no splicing effects (PM5_Supporting). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; SCV000807773.1). In summary, this variant meets criteria to be classified as likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PM1_supporting, PM5_supporting, PS4_supporting."		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410203519/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36252860	561243	C	T	NM_001754.4(RUNX1):c.502G>A (p.Gly168Arg)	561243	CA410202479	NM_001754.4:c.502G>A, NC_000021.9:g.34880563C>T, CM000683.2:g.34880563C>T, NC_000021.8:g.36252860C>T, CM000683.1:g.36252860C>T, NC_000021.7:g.35174730C>T, NG_011402.2:g.1109149G>A, LRG_482:g.1109149G>A, NM_001001890.2:c.421G>A, NM_001122607.1:c.421G>A, LRG_482t1:c.502G>A, XM_005261068.3:c.466G>A, XM_005261069.3:c.502G>A, XM_011529766.1:c.502G>A, XM_011529767.1:c.463G>A, XM_011529768.1:c.463G>A, XM_011529770.1:c.502G>A, XR_937576.1:n.681G>A, XM_005261069.4:c.502G>A, XM_011529766.2:c.502G>A, XM_011529767.2:c.463G>A, XM_011529768.2:c.463G>A, XM_011529770.2:c.502G>A, XM_017028487.1:c.349G>A, XR_937576.2:n.728G>A, ENST00000300305.7:c.502G>A, ENST00000344691.8:c.421G>A, ENST00000358356.9:c.421G>A, ENST00000399237.6:c.466G>A, ENST00000399240.5:c.421G>A, ENST00000437180.5:c.502G>A, ENST00000482318.5:c.*92G>A, NM_001754.4(RUNX1):c.502G>A (p.Gly168Arg)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BA1 [Unmet], BP4 [Unmet], BP2 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PM1-Supporting [MET], PM5 [Unmet], PM4 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], PP3 [MET], PP1 [Unmet], PVS1 [Unmet], PM2 [MET], PM6 [Unmet]	The NM_001754.4:c.502G>A (p.Gly168Arg) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.947) (PP3). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PM1_supporting.		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410202479/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
21	36231852	561246	T	G	NM_001754.4(RUNX1):c.532A>C (p.Thr178Pro)	561246	CA410208110	NM_001754.4:c.532A>C, NM_001001890.2:c.451A>C, NM_001122607.1:c.451A>C, LRG_482t1:c.532A>C, XM_005261068.3:c.496A>C, XM_005261069.3:c.532A>C, XM_011529766.1:c.532A>C, XM_011529767.1:c.493A>C, XM_011529768.1:c.493A>C, XM_011529770.1:c.532A>C, XR_937576.1:n.711A>C, XM_005261069.4:c.532A>C, XM_011529766.2:c.532A>C, XM_011529767.2:c.493A>C, XM_011529768.2:c.493A>C, XM_011529770.2:c.532A>C, XM_017028487.1:c.379A>C, XR_937576.2:n.758A>C, ENST00000300305.7:c.532A>C, ENST00000344691.8:c.451A>C, ENST00000358356.9:c.451A>C, ENST00000399237.6:c.496A>C, ENST00000399240.5:c.451A>C, ENST00000437180.5:c.532A>C, ENST00000467577.1:n.24A>C, ENST00000482318.5:c.*122A>C, NC_000021.9:g.34859555T>G, CM000683.2:g.34859555T>G, NC_000021.8:g.36231852T>G, CM000683.1:g.36231852T>G, NC_000021.7:g.35153722T>G, NG_011402.2:g.1130157A>C, LRG_482:g.1130157A>C, NM_001754.4(RUNX1):c.532A>C (p.Thr178Pro)	RUNX1	hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome	MONDO:0011071	Autosomal dominant inheritance	Uncertain Significance	BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PM1-Supporting [MET], PM5 [Unmet], PM4 [Unmet], BP7 [Unmet], BS3 [Unmet], BS1 [Unmet], BS4 [Unmet], PP3 [MET], PP1 [Unmet], PS4-Supporting [MET], PM2 [MET], PM6 [Unmet], PVS1 [Unmet]	"The NM_001754.4:c.532A>C (p.Thr178Pro) variant affects one of the residues (AA 105-204) within the RHD (PM1_Supporting). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2). This missense variant has a REVEL score >0.75 (0.971) (PP3). This variant has been reported in one proband meeting at least one of the RUNX1-phenotypic criteria (PS4_ Supporting; SCV000807789.1). In summary, the clinical significance of this variant is uncertain (VUS). ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2, PP3, PS4_ supporting, PM1_supporting."		Myeloid Malignancy VCEP	https://www.clinicalgenome.org/site/assets/files/3833/clingen_myelomalig_acmg_specifications_v1.pdf			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA410208110/MONDO:0011071/008	0.8121	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[1, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103310906	585206	C	G	NM_000277.2(PAH):c.3G>C (p.Met1Ile)	585206	CA386303909	NM_000277.2:c.3G>C, NC_000012.12:g.102917128C>G, CM000674.2:g.102917128C>G, NC_000012.11:g.103310906C>G, CM000674.1:g.103310906C>G, NC_000012.10:g.101835036C>G, NG_008690.1:g.5475G>C, NG_008690.2:g.46283G>C, NM_000277.1:c.3G>C, XM_011538422.1:c.3G>C, NM_001354304.1:c.3G>C, XM_017019370.2:c.3G>C, NM_000277.3:c.3G>C, ENST00000307000.7:c.-145G>C, ENST00000546844.1:c.3G>C, ENST00000547319.1:n.314G>C, ENST00000549111.5:n.99G>C, ENST00000551337.5:c.3G>C, ENST00000551988.5:n.92G>C, ENST00000553106.5:c.3G>C, ENST00000635500.1:n.29-4230G>C, NM_000277.2(PAH):c.3G>C (p.Met1Ile)	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Pathogenic	PM2 [MET], PVS1 [MET], PM5 [Unmet], PP4 [Unmet], PS1 [Unmet]	The c.3G>C (p.Met1Ile) variant in PAH is a null variant (start loss) where LOF is a known mechanism of disease. There are no known alternative start codons in other transcripts. The next in-frame Met is at amino acid 180 in exon 6. There are 49 pathogenic variants in ClinVar upstream of aa 180. The p.Met1Val variant has <3% enzyme activity as compared to wild type (PMID: 9450897), confirming start loss variants lead to loss of function of the PAH enzyme without re-initiation. This variant is absent in population databases (PM2).  This variant has not been reported in an affected individual in the literature to our knowledge. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM2, PVS1.		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/			FALSE	https://erepo.genome.network/evrepo/ui/classification/CA386303909/MONDO:0009861/006	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	3	Uncertain Significance
13	20763044	585322	A	T	NM_004004.5:c.677T>A	585322	CA387460663	NM_004004.5:c.677T>A, NC_000013.11:g.20188905A>T, CM000675.2:g.20188905A>T, NC_000013.10:g.20763044A>T, CM000675.1:g.20763044A>T, NC_000013.9:g.19661044A>T, NG_008358.1:g.9071T>A, XM_011535049.1:c.677T>A, XM_011535049.2:c.677T>A, NM_004004.6:c.677T>A, ENST00000382844.1:c.677T>A, ENST00000382848.4:c.677T>A	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PM6 [Unmet], PVS1 [Unmet], BS2 [Unmet], PP1 [Unmet], PP4 [Unmet], PP3 [Unmet], BP3 [Unmet], BP4 [Unmet], BP2 [Unmet], BA1 [Unmet], PS1 [Unmet], PS3 [Unmet], PS4 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM3 [Unmet], PM1 [Unmet], BP5 [Unmet], BP7 [Unmet], BS1 [Unmet], BS4 [Unmet]	"The c.677T>A (p.Val226Asp) variant in GJB2 has been identified in a heterozygous state in one Mongolian individual with sensorineural hearing loss (PS4 not met; PMID: 20201936). This variant was absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org) (PM2). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2."	20201936	Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	27/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA387460663/MONDO:0019497/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
13	20763068	585327	C	T	NM_004004.5:c.653G>A	585327	CA6904216	NM_004004.5:c.653G>A, NC_000013.11:g.20188929C>T, CM000675.2:g.20188929C>T, NC_000013.10:g.20763068C>T, CM000675.1:g.20763068C>T, NC_000013.9:g.19661068C>T, NG_008358.1:g.9047G>A, XM_011535049.1:c.653G>A, XM_011535049.2:c.653G>A, NM_004004.6:c.653G>A, ENST00000382844.1:c.653G>A, ENST00000382848.4:c.653G>A	GJB2	nonsyndromic genetic deafness	MONDO:0019497	Autosomal recessive inheritance	Uncertain Significance	PM2 [MET], PVS1 [Unmet], PM6 [Unmet], BS2 [Unmet], PP3 [MET], PP1 [Unmet], PP4 [Unmet], BA1 [Unmet], BP4 [Unmet], BP3 [Unmet], BP2 [Unmet], PS1 [Unmet], PS4 [Unmet], PS3 [Unmet], PS2 [Unmet], PM5 [Unmet], PM4 [Unmet], PM1 [Unmet], PM3 [Unmet], BS1 [Unmet], BS4 [Unmet], BP7 [Unmet], BP5 [Unmet]	The p.Cys218Tyr variant in GJB2 was identified in 0.002% (2/109924) of European chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). Computational prediction tools and conservation analysis suggest that the p.Cys218Tyr variant may impact the protein (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied: PM2, PP3.		Hearing Loss VCEP	https://submit.ncbi.nlm.nih.gov/ft/byid/vroiax8b/hearing_loss_acmg_specifications_v1_2018.pdf	10/9/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6904216/MONDO:0019497/005	0.4999	VUS	Uncertain significance 	 InterVar: Uncertain significance PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 1, 0, 0, 0, 0, 0] PP=[0, 0, 1, 0, 0, 0] BA1=0 BS=[0, 0, 0, 0, 0] BP=[0, 0, 0, 0, 0, 0, 0, 0] 	2	Uncertain Significance
12	103246663	590340	G	A	NM_000277.1:c.772C>T	590340	CA6748843	NM_000277.1:c.772C>T, NC_000012.12:g.102852885G>A, CM000674.2:g.102852885G>A, NC_000012.11:g.103246663G>A, CM000674.1:g.103246663G>A, NC_000012.10:g.101770793G>A, NG_008690.1:g.69718C>T, NG_008690.2:g.110526C>T, XM_011538422.1:c.772C>T, NM_000277.2:c.772C>T, NM_001354304.1:c.772C>T, NM_000277.3:c.772C>T, ENST00000307000.7:c.757C>T, ENST00000549247.6:n.531C>T, ENST00000553106.5:c.772C>T	PAH	phenylketonuria	MONDO:0009861	Autosomal recessive inheritance	Likely Benign	BP7 [MET], BS1 [MET], PM2 [Unmet]	"PAH-specific ACMG/AMP criteria applied: BS1: > PAH specific guidelines of AF-0.0002 (0.02%); BP7: No deleterious effect predicted.. In summary this variant meets criteria to be classified as likely benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BP7)."		PAH VCEP	https://www.clinicalgenome.org/working-groups/clinical-domain/inborn-errors-of-metabolism-clinical-domain-working-group/pah-variant-curation-expert-panel/	13/8/18	10/12/18	FALSE	https://erepo.genome.network/evrepo/ui/classification/CA6748843/MONDO:0009861/006	0.025	VUS	Likely benign 	 InterVar: Likely benign PVS1=0 PS=[0, 0, 0, 0, 0] PM=[0, 0, 0, 0, 0, 0, 0] PP=[0, 0, 0, 0, 0, 0] BA1=0 BS=[1, 0, 0, 0, 0] BP=[0, 0, 0, 1, 0, 0, 1, 0] 	2	Uncertain Significance